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Results: 86 clinical supervisors finished the training (participation rate 
95%). Preliminary results show that participants’ satisfaction with the 
training was similar in both groups. There was no change in motivation 
to teach or give feedback after training among both groups (sum of 
means – traditional: pre 37.97 (SD 3.64) vs post 37.19 (SD 4.73) p = 
0.28; experiential: pre 37.8 (SD 4.19) vs post 37.8 (SD 3.18) p = 1.00). 
Both groups expressed higher self-efficacy regarding their ability to 
teach or give feedback in the post-intervention phase (sum of means 
– traditional: pre 94.86 (SD 17.44) vs 106.71 (14.27) p <0.001; 
experiential: 90.85 (SD 19.92) vs 103.94 (SD 10.33), p <0.001). 
Objective analysis of participants’ teaching skills is still ongoing and 
the final results will be presented at the conference. 
Discussion: Training junior clinical supervisors on how to supervise 
and give feedback is effective. The additional impact of individual 
coaching versus simple workshops is still uncertain. 
FM230
Do early handoffs in internal medicine wards affect  
the quality and cost of care?
Christophe Fehlmann1, Martine Louis Simonet1, Christophe  
Gaudet-Blavignac2, Jérôme Stirnemann1, Katherine Blondon1,3 
1Service de Médecine Interne Générale, DMIRG, HUG; 2Service des 
Sciences de l’Information Médicale, DISIM, HUG; 3Direction Médicale, 
HUG, Genève, Switzerland
Introduction: Continuity of care is a key feature for high quality of 
care. To maintain the continuity of care of patients in the hospital, 
physicians conduct clinical handoffs to transfer both patient information 
and accountability from one provider or team to another. Prior studies 
show that handoffs are associated with an increased risk of 
complications and an increased length of stay. We were interested in 
studying the association between early handoffs (handoffs occurring 
between residents within the first 72 hours of a patient’s admission) 
and length of stay (LOS), use of resources (number of blood tests  
and procedures) and incidence of serious adverse events (transfers  
to ICU/ intermediate care unit or death). 
Methods: This is a retrospective cohort study of adult patients 
admitted to the General Internal Medicine Ward of Geneva University 
Hospital between 2012 and 2014, with a LOS >72 hours. We compared 
patients admitted by physicians other than the usual day team with 
patients who were admitted by the primary day team in univariate and 
multivariate linear and logistic regression models. Our outcomes were 
LOS, use of resources and incidence of serious adverse events. We 
adjusted the models for potential cofounders. 
Results: We included 11’948 patients, 38% of whom were in the early 
handoff group. Our preliminary analyses show that an early handoff, in 
particular with a change of attending, is independently associated with 
an increase of LOS (+6.4%, 3.5–9.5, p <0.01 and +17.9, 14.6–21.2, 
p <0.01 respectively). Although early handoffs are not significantly 
associated with a higher use of resources, it was associated with more 
serious adverse events (OR = 1.3, 1.1–1.7, p <0.5) in the early handoffs 
group. Our subgroup analyses show that the association between 
early handoff and LOS loses significance when the patients are 
admitted on a public holiday.
Conclusion: Early handoffs affected the quality of care, especially the 
length of stay for patients admitted during weekdays. This emphasizes 
the importance of identifying and handing off pertinent and essential 
key information to enable care continuity when the medical team in 
charge of the patient changes. As restricting the number of handoffs is 
unrealistic, we should aim to improve the handoff training for both 
residents and supervisors, by standardizing the process and content, 
to maintain the continuity, safety and effectiveness of care for 
hospitalized patients. 
FM231
Should we stop to care about the transition because  
it’s not cost-effective?
Antoine Garnier1, Carole Nachar2, Pierre Voirol2,  
Anne-Claude Griesser3, Gérard Waeber1, Olivier Lamy1 
1Internal Medicine Department, University Hospital of Lausanne; 
2Pharmacy Department; 3Medical Directorate, University Hospital of 
Lausanne (CHUV), Lausanne, Switzerland
Background: Patients hospitalized with heart failure (HF) present the 
highest rate of readmission within 30 days, above 20%. Reduction of 
early readmission is a major concern as quality and cost control 
indicator. Parts of these are potentially avoidable (PARE) and 
algorithms can estimate an adjusted expected range based on 
FM228
Rates, delays and completeness of general  
practitioners’ responses to a postal versus  
web-based survey: a randomized trial
Paul Sebo1, Hubert Maisonneuve1, Bernard Cerutti2,  
Jean Pascal Fournier3, Nicolas Senn4, Dagmar M Haller Esther1 
1Unité des Internistes Généralistes et Pédiatres / Université de 
Genève; 2Unité de Développement et de Recherche en Éducation 
Médicale, Faculté de Médecine, Genève, Switzerland; 3Département 
de Médecine Générale, Faculté de Médecine, Université de Nantes, 
Nantes, France; 4Institut Universitaire de Médecine de Famille, 
Lausanne, Switzerland
Background: Web-based surveys became a new and popular method 
for collecting data, but only few studies directly compared postal and 
web-based surveys among physicians, and none to our knowledge 
among general practitioners (GPs).
Objective: To compare two modes of survey delivery (postal and 
web-based) in terms of participation rates, response times and 
completeness of questionnaires in a study assessing GPs’ preventive 
practices.
Methods: This randomized study was conducted in Western 
Switzerland (Geneva and Vaud) and in France (Alsace and Pays de la 
Loire) in 2015. A random selection of community-based GPs (1000 
GPs in Switzerland and 2400 GPs in France) were randomly allocated 
to receive a questionnaire about preventive care activities either by 
post (n = 700 in Switzerland, n = 400 in France) or by e-mail (n = 300 
in Switzerland, n = 2000 in France). Reminder messages were sent 
once in the postal and twice in the web-based group. GPs practicing 
only complementary and alternative medicine (CAM) were excluded 
from the study.
Results: Overall, 764 GPs (22.5%) returned the questionnaire. 
Compared to the postal group, participation rate in the web-based 
group was more than four times lower (10.7% vs 47.1%), but median 
response time was much shorter (1 day vs. 1–3 weeks) and the 
number of GPs having fully completed the questionnaire was twice  
as high (63.8% vs. 34.6%).
Conclusions: Web-based surveys offer many advantages such as 
reduced response time, higher completeness of data and large cost 
savings, but our findings suggest that postal surveys can be still 
considered for GP research. The use of mixed-mode approaches is 
probably a good strategy to increase GPs’ participation to surveys 
whilst reducing costs. 
FM229
Faculty development program for clinical supervision: 
comparison of two training formats
Noelle Junod Perron1,2, Nadia Bajwa1,2, Jehanne de Grasset1,  
Nicole Jastrow-Meyer1, Hélène Richard1, Marie-Claude Audétat2,3, 
Mathieu Nendaz1,2 
1Hôpitaux Universitaires de Genève; 2Unité de Développement et de 
Recherche en Éducation Médicale, Faculté de Médecine; 3Unité des 
Internistes Généralistes et Pédiatres, Faculté de Médecine, Université 
de Genève, Genève, Switzerland
Introduction: The Swiss Institute of postgraduate and continuous 
training (ISFM/SIWF) now requires residents’ performance to be 
assessed in clinical practice through the use of mini-CEX and DOPS. 
However, junior clinical supervisors often feel uncomfortable in 
supervising and giving feedback to residents by lack of effective 
teaching skills, especially in domains such as clinical reasoning, 
professionalism, communication or interprofessional collaboration.  
The aim of the project was to evaluate whether a discipline-related  
and personalized coaching faculty development program was more 
effective than a more traditional program on supervisors’ teaching skills 
in such domains. 
Methods: We conducted a randomized, controlled, intervention study. 
Clinical supervisors from 5 departments (including hospital and 
ambulatory general internal medicine) were invited to attend a 6-month 
faculty development program at the Geneva University Hospitals.  
They were randomly assigned to one of two formats: (1) traditional 
with 3 workshops (7 hrs); (2) experiential with 2 workshops and 3 
individualized one-hour video-based coaching (8 hrs). Outcome 
measures were self-perceptions of participants’ motivation (6 item 
questionnaire; 1–7 Likert scale) and self-efficacy (13 item 
questionnaire; 1–10 Likert scale) and objective analysis of participants’ 
teaching skills during 4 objective structured teaching encounters 
conducted before and after the training. 
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give consent. On average, a transition plan needed 3:16 hours per 
patient. The medication reconciliation was the most time-consuming 
task. Moreover, overhead time like administration or screening 
accounted for 5–6 hours per day. Despite efforts to fulfill a complex 
transition plan, we did not observed a significant reduction of 
outcomes. Readmission rate even increased between pre-intervention 
and intervention periods (19.2% vs 21.1%, p-value 0.368). Conclusive 
results were seen in a sensitivity analysis: patients who received 
transition plan had lower rate of days spent for readmission and PARE 
compared to non-completers (19.2% vs 16.1%, p-value 0.002).
Conclusion: Our multidisciplinary transition plan got positive feedback 
of patients and stakeholders but failed to reduce readmission rate.  
It could be applied only to 32% of patients. However, this kind of 
intervention is time- and money-consuming. Further studies about 
transition care should look for benefit in other quality indicators like 
adverse drugs event, communication issue, or adherence to treatment. 
medical-administrative data. To reduce readmission, a multidisciplinary 
transition plan is more effective than any single intervention. We aimed 
to assess the effectiveness of a transition plan to reduce early 
readmission among HF-patients.
Methods: We conducted a before-and-after study in a tertiary general 
internal medicine department. We included all consecutive HF-patients 
discharged to home during the 13 months of intervention (2013–2014) 
and compared them to medical records from 2011 to 2013. The 
transition plan consisted of 11 interventions performed by a nurse, a 
pharmacist and a physician. Outcomes were rate of days spent for 
30-days readmission, rate of days spent for PARE according to 
SQLape®, and rate of readmission.
Results: We included 1’441 records in the pre-intervention period and 
431 in the intervention period. 138 patients (mean age 77.8 years old, 
SD 10.7) received the transition plan while 293 were non-completers 
(mean age 78.32 years old, SD 11.8). 130 were diagnosed for HF after 
screening; 111 were discharged before enrolment; and 52 refused to 
FM232
Prescription of homeopathy in outpatient care:  
what physicians believe and what they intend 
Stefan Markun, Thomas Rosemann, Marc Maeder, Sima Djalali 
IHAMZ, Institut für Hausarztmedizin Zürich, Universität Zürich 
(Institute of Primary Care, University of Zurich), Zürich, Switzerland
Background: Homeopathy is a highly controversial topic. Postulated 
mechanisms explaining homeopathy’s mode of action remain 
unconvincing for natural scientist and non-surprisingly, the aggregated 
evidence from rigorous randomized controlled trials suggests that 
homeopathy is merely a placebo. Still, homeopathy continues to be 
prescribed also by physicians educated in academic medicine. 
Whether prescribing physicians believe in specific effects despite their 
education in natural sciences or whether they knowingly prescribe 
homeopathy to exploit non-specific/placebo effects and what might 
cause such homeopathy prescriptions is largely unknown. These 
issues, however, have important educational and ethical implications.
Methods: In 2015, we performed a cross-sectional survey among all 
physicians working in outpatient care in the Swiss Canton of Zurich. 
We assessed their prescription behaviour; believes in mode of action 
and accordable intentions behind the prescriptions. Furthermore, 
associations with prescribing homeopathy were investigated.
Results: From 4072 approached physicians in outpatient care 1531 
responded (response rate 38%). Homeopathy was prescribed by 345 
(23%) of the physicians. Prescribers’ believed modes of action were 
“the law of similars” (42%), placebo effect- and other interpersonal 
effects (up to 35%), “Water memory” (19%) and “quantum physics” 
(19%). Unambiguously accordable intentions behind prescriptions 
were achievement of specific effects in 50% and non-specific/placebo 
effects in 21%. Among all physicians (prescribers and non-prescribers 
included) only 55% thought that the available evidence rather 
disproves efficacy of homeopathy. Perception of patient requests for 
homeopathy and certain medical specializations were among factors 
strongly associated with prescribing homeopathy.
Conclusion: One in five physicians in outpatient care prescribed 
homeopathic remedies. Half of the homeopathy prescribing physicians 
intended specific effects, questioning the sustainability of their 
education in natural sciences. One in five prescribing physicians made 
use of homeopathy as a non-specific/placebo treatment and are 
therefore transgressing ethical directives. To explain why physicians 
prescribe homeopathy we need to better understand social and 
educational factors as well as homeopathy’s attractiveness in different 
medical specializations. 
FM233
Informed decision making in colorectal cancer screening: 
influence of decision Aids and primary care physician on 
participants’ intention to screen and preference for 
colonoscopy or faecal immunochemical tests (FIT)
Allan Relecom1, Jean-Marc Theler2, Cyril Ducroz3,  
Jacques Cornuz4, Beatrice Arzel5, Idris Guessous6,7 
1Service d’Oncologie; 2Department of Community Medicine, Primary 
Care and Emergency Medicine, Hôpitaux Universitaires de Genève, 
Genève; 3Vaud Foundation for Cancer Screening; 4University of 
Lausanne, Lausanne; 5Geneva Foundation for Breast Cancer 
Screening; 6Department of Community Medicine, Primary Care  
and Emergency Medicine, Geneva University Hospitals, Geneva; 
7Department of Ambulatory Care and Community Medicine,  
University of Lausanne, Lausanne, Switzerland
Introduction: Colorectal cancer (CRC) screening reduces CRC 
mortality and incidence. Faecal immunochemical tests (FIT) and 
colonoscopy are both recommended but vary greatly in their attributes. 
Primary care physicians (PCP) were shown to favour colonoscopy as a 
screening test for their patients in a recent study conducted in the 
French-speaking region of Switzerland. In the perspective of a CRC 
screening programme in the canton of Geneva (Switzerland) that 
would offer both tests through informed decision via the PCP, we 
aimed to investigate the a priori influence of written and visual decision 
aids and PCP counselling in the choices of individuals regarding CRC 
screening. 
Method: We conducted a population-based survey using a self-
reported questionnaire sent in 2016 to 4500 randomly selected 
Geneva residents aged between 50 and 69. Participants were 
provided with written and visual decision aid tools used in the ongoing 
CRC screening programme of the adjacent canton (Vaud) illustrating 
the potential benefit of CRC screening and the pros and cons of FIT 
and colonoscopy. Intention to screen and choice of screening test after 
the consideration of the aids was assessed. Influence of the PCP on 
the decision of the participant was also evaluated. 
Results: Overall, 1517 participants were included in the analyses. A 
majority of participants (73%) considered that the decision aids clearly 
illustrated the benefit of CRC screening, and 53% were incited by the 
latter to undertake CRC screening. Based on the decision aids 
provided, 41% of the participants chose FIT as the preferred screening 
test, 46% favoured colonoscopy and 13% were undecided. A large 
proportion of participants (84%) stated that their decision to undertake 
CRC screening would be influenced by their PCP, and 85% reported 
that their choice of the test would be influenced by what their PCP 
would recommend. 
Conclusion: Written and visual aid tools provide useful information for 
CRC screening decision-making. The participants were quite balanced 
in their preference for colonoscopy and FIT after considering the 
decision aids. This should be considered by PCPs when counselling 
patients about CRC screening, given their significant influence on 
screening decisions, in order to avoid a shift towards colonoscopy. 
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Use of corticosteroids for subacute cough in  
primary care
Tiziana Straessle1, Andreas Zeller1, Christoph Merlo2, Stefan Essig2,3 
1Centre for Primary Health Care, University of Basel, Basel; 2Institute 
of Primary and Community Care, Luzern, Luzern; 3Swiss Paraplegic 
Research, Nottwil, Nottwil, Switzerland
Introduction: Subacute cough (lasting 3–8 weeks) as a symptom  
of upper respiratory tract infections is very common in primary care 
consultations. Many colleagues reported that they often prescribe 
corticosteroids for subacute cough. However, the basis for an 
evidence-based decision for or against corticosteroids is weak. We 
aimed to determine the proportion of general practitioners (GPs) using 
corticosteroids for subacute cough.
Methods: All GPs registered with the Institutes of Primary Care Basel 
or Lucerne could participate in an online survey. They received an 
invite by e-mail containing the case vignette of a 32-year old, healthy 
non-smoker without asthma, who has had dry cough for 4 weeks.  
They were then asked if they would prescribe steroids, followed up  
by six (if yes) or two (if no) questions.
Results: 183 of 472 (39%) GPs replied. 141 of 183 (77%) prescribed 
steroids for subacute cough. 99% of those GPs replying to the 
follow-up questions used inhaled steroids, 18% used oral steroids. 
Symbicort 200/6µg twice per day for 2 weeks was the most common 
inhaled steroid, Prednisone 20 mg per day for 5 days was the most 
common oral steroid. 42% and 21% also prescribed codeine and 
dextromethorphan, respectively. These proportions were similar among 
those GPs who did not prescribe steroids (43% and 16%). Overall, 94 
GPs would like to participate in an intervention study on the efficacy  
of corticosteroids on subacute cough.
Conclusion: Despite weak evidence corticosteroids are frequently 
used for subacute cough in the course of upper respiratory tract 
infections in primary care. An intervention study on the efficacy of 
corticosteroids for subacute cough should be planned. 
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Association between alcohol and caffeine  
consumption and nocturnal leg cramps in patients  
over 60 years old: a case-control study
Choé Delacour1, Juliette Chambe1, François Lefebvre2,  
Dagmar M. Haller3, Hubert Maisonneuve3 
1Département de Médecine Générale, Faculté de médecine, 
Université de Strasbourg; 2Département de Santé Publique, Faculté 
de Médecine, Université de Strasbourg, Strasbourg, France; 3Unité 
des Internistes Généralistes et Pédiatres / Université de Genève, 
Genève, Switzerland
Introduction: Nocturnal leg cramps are a specific kind of cramps 
affecting almost half of patients over 60 years old. They reduce 
patients’ quality of sleep and have a negative impact on their quality  
of life. The aim of this study was to evaluate the association between 
nocturnal leg cramps and the consumption of alcoholic beverages and 
caffeine in patients over 60 years old attending general practices.
Methods: Case-control study with a Bayesian approach for sensitivity 
analysis. Participants were volontary ambulatory patients over 60 
years old consulting their family doctor. Cases, i.e. patients suffering 
from cramps, were matched with controls (free from cramps) for age, 
sex, medical history and medications known to trigger cramps. Alcohol 
and caffeine consumption were assessed through the E3N Food 
frequency questionnaire. 
Results: We found an association between the global consumption of 
alcoholic beverages and nocturnal leg cramps (OR 6.5 95% credibility 
interval [1.68; 38.05], posterior probability 99.82%). Caffeine 
consumption was not significantly associated with nocturnal leg 
cramps. 
Conclusion: We identified an association between alcohol 
consumption and nocturnal leg cramps among patients over 60 years 
old attending general practices. These findings have implication for the 
prevention of cramps. They also open new avenues for the further 
exploration of the as yet uncertain pathophysiology of cramps, 
considering effects of ageing and alcohol on muscular fibres. 
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From practice employee to (co-)owner:  
young general practitioners predict their future  
careers. A cross-sectional survey
Luzia Birgit Gisler1, Marius Bachofner2,  
Cora Nina Moser-Bucher3, Nathalie Scherz4,5, Sven Streit1 
1Institute of Primary Health Care (BIHAM), University of Bern, Bern; 
2Family Practice, Nottwil; 3Center for Primary Care Medicine, 
University of Basel, Basel, 4Institute of Primary Care, University 
Hospital Zurich, University of Zurich; 5Arud Centres for Addiction 
Medicine, Zurich, Switzerland
Introduction: In Switzerland, the mean age of general practitioners 
(GPs) in 1993 was 46. In 2015, it had increased to 55, and GPs over 
65 made up 15% of the workforce. As more and more older, self-
employed GPs retire, young doctors will be needed to fill their positions 
and eventually take over their practices. Some stakeholders blamed 
the increasing shortage of GPs on the feminisation of the medical 
profession, arguing women preferred part-time work. We set out to 
determine what employment status young GPs wanted, if their 
preference would change over time, and which working conditions and 
factors were most important in their choice of practice.
Methods: We administered a cross-sectional online survey to 
members of the Swiss Young General Practitioners Association 
(JHaS). Our survey captured participants’ characteristics, and their 
preferred type of practice and working conditions by closed questions, 
ratings of attractiveness of fictional job ads, and an open question.
 
Results: Surveys were returned by 270 JHaS members (61%). 
Women made up 71% of respondents. Overall mean age was 32.9. 
Most participants were GPs or residents; less than 10% were medical 
students. Most wanted to work in the suburbs or countryside in small 
GP-owned group practices, with up to five colleagues. French-
speaking participants preferred larger practices. Most respondents 
intended to work part-time: mean desired workload was 78% for men 
and 66% for women. Positive working climate was a major factor in 
choosing a GP practice. Dispensing medications made a practice 
more attractive for over a third of respondents. Most respondents 
intended to make house calls outside regular on-call hours. A large 
majority wanted to be employees in their first GP job. But most wanted 
to become owners or co-owners of a practice within five years; only 
7–9% preferred to remain employees.
Conclusion: Young and future GPs in Switzerland prefer to work in 
small, GP-owned group practices. Feminisation of the GP profession 
explains only part of the increase in desire for part-time work, as both 
genders want to work part-time. Our study demonstrates that the large 
majority of young GPs project a career arc that begins as an 
employee, but transitions to self-employment within five years. Future 
practice models should take these wishes of young GPs into account if 
they want to attract them as employees and potential future (co-)
owners. 
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Introduction: Sepsis, according to the new definition, is a life-
threatening organ dysfunction with high mortality. In order to promptly 
identify septic patients with the worst prognosis outside the intensive 
care unit (ICU), a new bedside score was proposed: the quick SOFA 
score (qSOFA). It remains relatively untested in emergency settings. 
We measured the performance of the qSOFA and 2 other clinical 
scores at the emergency department’s triage to identify the most 
severely infected patients among a population of patients transported 
by emergency medical services (EMS) to our emergency department 
(ED).
Methods: We performed a retrospective study of all patients 
transported to the Lausanne University Hospital, from January 1st to 
December 31st 2012. All patients with a suspected or proven infection 
through the ED stay were included. qSOFA, SIRS and Sepsis scores 
were retrospectively calculated upon arrival to the ED. End points 
were: ICU admission, ICU stay >3 days and mortality at 48 hours. 
Definitions: qSOFA score: ≥ two of the following criteria: systolic blood 
pressure (SBP) ≤100 mm Hg, respiratory rate (RR) ≥22/min, and 
altered mental status (Glasgow Coma Scale (GCS) <15). SIRS score: 
≥ two of the following criteria: heart rate >90/min, RR >20/min, 
temperature <36 °C or ≥38.3 °C). Sepsis score: SIRS score plus one 
sign of organ dysfunction or hypoperfusion (GCS <15, oxygen 
saturation <90% or SBP <90 mm Hg).
Results: Among the 11’411 patients transported to the University 
hospital, 890 patients fulfilled the criteria of a final diagnosis of 
infection; four had missing data and were excluded. 886 (7.8%) 
patients were included; 454 had an infection without organ failure after 
the ED stay, and 442 had a sepsis with organ failure. Sensitivity of the 
qSOFA and sepsis scores for mortality at 48h reached 60%, and 80% 
for the SIRS score. For ICU admission, the sensitivity of the qSOFA 
score was 31.3%, 42.5% for the sepsis score, and 58.8% for the SIRS 
score. The sensitivities were practically identical for the stay in ICU  
≥3 days: 30.5 % for the qSOFA score, 42.4% for the sepsis score,  
and 57.6% for the SIRS score.
Conclusion: The qSOFA score, as well as existing clinical scores, 
perform poorly to early identify upon arrival to the ED, the most 
seriously infected patients. 
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Introduction: Inspired by the US Choosing Wisely® campaign, the 
Swiss Society of General Internal Medicine (SSGIM) released in May 
2016 a list of 5 treatments or diagnostic tests frequently used in the 
Hospital and considered as unnecessary, since not improving patient 
care and increasing health care costs. The Swiss initiative was called 
“smarter medicine”. “Smarter medicine” recommendations were 
implemented on our Department on August 9th 2016. They were 
supported by lectures to the physicians, weekly emails 
communications and were discussed during every Chief and 
Consultant visit. We retrospectively analysed the count of blood draws 
before and after implementation of the recommendation aiming at 
reducing unnecessary blood tests.
Methods: Retrospective single centre analysis conducted on the 
Department of Internal Medicine, Uster Hospital, Switzerland. Patient 
hospitalized in the three months before and after recommendation 
implementation (May to November 2016) were analysed. Data were 
anonymous and retrieved from a quality data base.
Results: Of the 2023 patients included in the analysis, 997 patients 
were hospitalized before and 1026 after “smarter medicine” was 
implemented. There was a significant decrease in the count of blood 
draws after recommendation implementation (median count of blood 
draws per patient in the first group 4 (interquartile range (IQR) 2–7), 
median count in the group after recommendation 4 (IQR 2–6), P = 
0.002) (fig. 1). Indeed, since 46% of the patients in the 1st group had 
>4 blood tests, this ratio decreased to 39% after “smarter medicine”. 
Volume of blood drawn was also significant lower in the three months 
after (median blood volume drawn per patient 56 mL, IQR 27–99) than 
before recommendation (median 65 mL, IQR 68–108, P = 0.01) (fig. 2).
Conclusions: Inappropriate blood draws may lead to anemia, patient 
discomfort and false positive results. The simple and low-cost 
interventions used to implement the “smarter medicine” seem to have 
changed physician behaviour by reducing the count of blood orders. 
These results are promising and we need a wide implementation of 
the “smarter medicine” recommendation to reduce resource wasting. 
Whether the “smarter medicine” will impact patient and clinical 
outcome remains however unknown and further studies are needed  
to clarify this issue. 
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Introduction: Computed tomography pulmonary angiography (CTPA) 
has not only become the method of choice for diagnosing acute 
pulmonary embolism (PE), it also allows for risk stratification of 
patients with PE. To date, no study has specifically examined the 
predictive value of CTPA findings to assess short-term prognosis in 
Figure 1
Figure 2
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elderly patients with acute PE who are particularly vulnerable to 
adverse outcomes.
Methods: We aimed to evaluate the prognostic performance of the 
computed tomography obstruction index (CTOI) and right ventricular 
dysfunction (right ventricular [RV] to left ventricular [LV] diameter ratio 
>0.9) in elderly patients with PE. We studied 291 patients aged ≥65 
years with acute symptomatic PE in a prospective multicenter Swiss 
cohort study. CTPA was performed at each participating study center 
and then anonymously sent to Lausanne University Hospital, where 
the images were independently evaluated by two board-certified 
radiologists. Outcomes were 90-day overall and PE-related mortality, 
and recurrent venous thromboembolism (VTE) during the whole 
follow-up period. We examined associations of the CTOI and the RV/
LV diameter ratio with mortality and VTE recurrence using survival 
analysis, adjusting for provoked VTE, the Pulmonary Embolism 
Severity Index, and anticoagulation as a time-varying covariate.
Results: Overall, 15 patients died within 90 days (6 from definite or 
possible PE). While the CTOI was not associated with 90-day overall 
mortality (adjusted hazard ratio [HR] per 10% CTOI increase 0.92; 
95% confidence interval [CI] 0.70–1.21; P = 0.54), it was significantly 
associated with PE-related 90-day mortality (adjusted sub-hazard ratio 
[SHR] per 10% CTOI increase 1.36; 95% CI 1.03-1.81; P = 0.03). The 
RV/LV diameter ratio was neither associated with overall nor PE-
related 90-day mortality. The CTOI (adjusted SHR per 10% CTOI 
increase 1.27; 95% CI 1.12-1.45; P <0.001) and the RV/LV diameter 
ratio (adjusted SHR per unit increase 2.74; 95% CI 1.26-5.95; P = 0.01) 
were both significantly associated with VTE recurrence. 
Conclusion: In elderly patients with acute PE, the CTOI was 
associated with PE-related 90-day mortality but not with overall 
mortality. The RV/LV diameter ratio did not predict mortality. Both 
measures predicted VTE recurrence. 
Association of predictors with 90-day mortality
  Crude HR  
or SHR (95% CI)
P value Adjusted HR  
or SHR (95% CI)
P value
Overall mortality
CTOI (per 
10%)
0.90 (0.70; 1.14) 0.37 0.92 (0.70; 1.21)a 0.54
RV/LV diam-
eter ratio 
(per unit)
0.27 (0.03; 2.16) 0.22 0.35 (0.06; 2.18)a 0.26
PE-related mortality
CTOI (per 
10%)
1.33 (1.00; 1.78) 0.05 1.36 (1.03; 1.81)a 0.03
RV/LV diam-
eter ratio 
(per unit)
0.61 (0.17; 2.25) 0.46 0.69 (0.23; 2.07)a 0.51
aAdjustment was done for provoked VTE, the Pulmonary Embolism Se-
verity Index, and anticoagulation treatment as a time-varying covariate. 
HR: Hazard ratio from Cox regression. 
SHR: Subhazard ratio from competing risk regression accounting for 
non-PE-related death as a competing event.
Association of predictors with VTE recurrence
  Crude SHR  
(95% CI)
P value Adjusted SHR 
(95% CI)
P 
value
VTE recurrence
CTOI  
(per 10%)
1.21 (1.07; 1.38) 0.003 1.27 (1.12; 1.45)a <0.001
RV/LV diam-
eter ratio 
(per unit)
1.56 (0.67; 3.67) 0.31 2.74 (1.26; 5.95)a 0.01
aAdjustment was done for provoked VTE, the Pulmonary Embolism Se-
verity Index, and anticoagulation treatment as a time-varying covariate. 
SHR: Subhazard ratio from competing risk regression accounting for 
non-PE-related death as a competing event.
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Introduction: Elevated N-terminal pro-brain natriuretic peptide 
(NT-pro-BNP) levels are associated with in-hospital morbidity and 
mortality. We aimed to compare in-hospital mortality in adult patients 
with different levels of NT-pro-BNP.
Method: We studied 3833 adult patients (median age: 72 years) 
hospitalized between June 2013 and April 2015 in a Swiss university 
hospital. All patients had at least one NT-pro-BNP measurement. 
Patients were categorized in quintiles (Q) according to their highest 
NT-pro-BNP level (Q1: 5-243; Q2: 244-819; Q3: 820-2271; Q4: 
2272-6095 and Q5: ≥6096 ng/l). Mortality and length of stay (LOS) of 
Q5 was compared to the others (Q1-4); comparisons between all 
quintiles were also performed.
Results: Almost eight out of ten (79.9%) patients were hospitalized  
in a medical ward; 10.7% in a surgical ward and 9.4% in the intensive 
care unit. Approximately one out of seven (12.4%) had a main 
diagnosis of heart failure (HF), and 2.2% had stage 5 renal failure. 
Patients in the highest quintile (Q5) were older (78.3 ± 12.8 vs. 70.3 ± 
16 years, respectively, p <0.001), had more frequently a main 
diagnosis of HF (26% vs. 9%, p <0.001), presented more frequently 
with stage 5 renal failure (7.6% vs. 0.8%, p <0.001), and were more 
likely to be admitted through emergency room (79% vs 73%, p <0.001) 
than patients in Q1–4. Patients in Q5 had higher in-hospital mortality 
than patients in Q1–4 (9.7 vs. 4.3 deaths per 1000 patients*day, 
respectively, p <0.001). This difference persisted after adjusting for age, 
gender, principal diagnoses (heart failure, other heart disease, 
pneumonia, chronic obstructive pulmonary disease and other), stage 5 
renal failure, hospital ward and stay in emergency room: Hazard ratio 
and (95% confidence interval): 1.97 (1.57–2.46), p <0.001. Using 
individual quintiles led to similar conclusions, with a multivariate-
adjusted test for trend: p <0.001.
Figure 1: Kaplan-Meyer survival curves.
Patients in Q5 also had a longer LOS: median and (interquartile 
range): 15 (7–26) vs. 9 (2–18) days, respectively, p <0.001; this 
difference persisted after multivariate adjustment (p <0.001 on 
log-transformed data). 
Conclusion: Patients with high NT-pro-BNP levels are at higher risk  
of in-hospital mortality and longer LOS. NT-pro-BNP levels can be a 
helpful tool for predicting in-hospital patient outcome. 
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Background: The characteristics of patients admitted to internal 
medicine change with time. Patients are increasingly older and present 
with more comorbidities, which impacts prescription patterns. We 
aimed to measure the trends in the pattern of medications prescribed 
at discharged from a department of Internal Medicine of a university 
hospital.
Methods: Retrospective study including 18’075 adult patients 
discharged between 2009 and 2015. Drugs prescribed at discharge 
were coded according to the anatomical therapeutic chemical (ATC) 
nomenclature of the World Health Organization.
Results: The three most commonly classes of drugs prescribed were 
“alimentary tract and metabolism (including insulins);”; “nervous 
system”, and A “blood and blood forming organs” (table). The five most 
prescribed drugs were analgesics (8.4% of all drugs prescribed); 
antithrombotic agents (ATC code B01, 8.0%); psycholeptics (including 
hypnotics and sedatives, 7.2%); drugs for constipation (7.0%) and 
drugs for acid related disorders (6.0%). Most prescribed groups 
increased during the study period, excepting ATC group B “blood and 
blood forming organs”, “cardiovascular system”, and “dermatologicals”. 
In 2015, over eight out of ten patients discharged received at least one 
drug from”alimentary tract and metabolism” or “nervous system” 
(figure; all trends are significant at p <0.001). 
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Introduction: Hyperthyroidism is associated with an increased risk of 
osteoporosis and fractures. However, it is not clear whether high 
thyroid-stimulation hormone (TSH) within its reference range and low 
free thyroxine (FT4) levels lead to increased fracture risk. Furthermore, 
the target TSH to reach with levothyroxine treatment of hypothyroidism 
remains controversial. We aimed to evaluate the association between 
TSH within the reference range, FT4, and incident fractures. 
Methods: We performed an individual participant data analysis of 
thirteen prospective cohort studies across three continents with a 
median follow-up of 12.1 years (interquartile range 8.5–12.9). We 
included adults with baseline serum TSH within the reference range 
(0.45–4.49 mIU/L). The primary outcome was incident hip fracture. 
Secondary outcomes were incident clinical vertebral, non-vertebral, 
and any fractures. For clinical relevance, we categorized participants’ 
TSH as: 0.45-0.99mIU/L; 1.00–1.49 mIU/L; 1.50–2.49 mIU/L; 2.50–3.49 
mIU/L; and, 3.50–4.49 mIU/L (reference group). FT4 was assessed as 
one standard deviation increase within each study, because FT4 
assay methodology differed between cohorts. Analyses were stratified 
by sex and age. 
 
EPIDEMIOLOGIE  
Figure 1: Trends for the major groups of drugs.
Conclusion: The pattern of drug prescription has changed, with an 
increase in drugs for alimentary tract and metabolism and nervous 
system. The reasons for and the consequences of the very high 
prevalence of drugs for the nervous system should be further 
investigated.
Keywords: Prescribed drugs; Hospital; discharge 
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Results: During a follow-up of 659,059 person-years of 61,959 
participants euthyroid at baseline, 2,565 had hip fracture (4.6%; from 
12 cohorts with hip fracture data). Compared with the reference group, 
the pooled age- and sex-adjusted hazard ratio (HR) (95%CI) for hip 
fractures was 1.25 (1.05–1.49) for TSH 0.45-0.99 mIU/L, 1.19 (1.01–
1.41) for TSH 1.00–1.49 mIU/L, 1.09 (0.93–1.28) for TSH 1.50–2.49 
mIU/L, and 1.12 (0.94–1.33) for TSH 2.50–3.49 mIU/L (P for trend = 
0.004). The risk of hip fractures also increased according to FT4 levels 
(HR 1.22 [95%CI 1.11–1.35] per one standard deviation increase in 
FT4). FT4, but not TSH, was significantly associated with non-
vertebral and any fractures, but not with vertebral fractures. Results 
remained similar in sensitivity analyses that excluded participants 
taking thyroxine at baseline, or that included only participants with 
TSH remaining within the reference range during follow-up, as well as 
in analyses stratified by sex or age (figure). 
Conclusions: Lower levels of TSH within the reference range and 
higher levels of FT4 are associated with increased risk of hip fractures. 
These findings are relevant to the definition of optimal thyroid function 
and raise questions about treatment targets for hypothyroidism. 
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Background and aims: Treatment of type 2 diabetes mellitus (T2DM) 
evolves with time, but little information is available regarding its 
determinants in the general population. We aimed to assess changes 
and determinants associated to antidiabetic treatment in a Swiss 
population-based sample.
Methods: Two hundred and ten participants with T2DM from the 
CoLaus study. Antidiabetic drug treatment was assessed at baseline 
(2003–2006) and follow-up (2009–2012), and categorized into 
maintainers, changers and reducers/quitters.
Results: At baseline, 146 (69.5%) of the 210 participants received 
antidiabetic treatment. Of the 146 participants treated, 124 (84.9%) 
received oral antidiabetics alone, 8 (5.5%) insulin alone and 14 (9.6%) 
insulin and oral antidiabetics. During the 5.5 year follow-up, 108 
(74.0%) patients maintained, 27 (18.5%) changed and 11 (7.5%) 
reduced or stopped treatment. Patients who changed therapy had 
higher baseline fasting plasma glucose (FPG) levels than the others 
(10.3 ± 3.7 vs. 7.8 ± 2.0 and 7.6 ± 2.0 mmol/L for maintainers and 
reducers/quitters, respectively, p <0.001) and also lower levels of FPG 
<7.0 mmol/L (7.4%, vs. 39.8% and 45.5% for maintainers and reducers/
quitters, respectively, p = 0.002). At follow-up, patients who changed 
therapy had the highest prevalence of FPG decrease relative to 
baseline (55.6%, vs. 46.3% and 9.1% for maintainers and reducers/
quitters, respectively, p = 0.025).
Conclusion: During a 5.5 year follow-up, less than one fifth of patients 
with T2DM had his/her drug treatment changed. Changes in T2DM 
treatment lead to an improvement of the unfavourable FPG status. The 
reasons and impact of quitting or reducing treatment should be further 
explored.
Keywords: Type 2 diabetes; antidiabetic drugs; treatment; 
epidemiology; trends 
FM244
Hip and knee replacements in Switzerland:  
variation in regional utilizasation patterns
Sabrina N. Jegerlehner1, Judith M. Schlapbach1, Maria M. Wertli1, 
Claudia Scheuter1, Radoslaw Panczak2, Alan G. Haynes2,3,  
Arnaud Chiolero4,5, Nicolas Rodondi1,6, Drahomir A. Aujesky1 
1Allgemeine Innere Medizin, Inselspital, University Hospital and 
University of Bern; 2Universität Bern, Institut für Sozial- und 
Präventivmedizin ISPM; 3Universität Bern, Clinicals Trials Unit, Bern; 
4Institut Universitaire de Médecine Sociale et Préventive, Lausanne, 
Switzerland; 5Department of Epidemiology, McGill University, 
Montreal, QC, Canada; 6Universität Bern, Berner Institut für 
Hausarztmedizin BIHAM, Bern, Switzerland
Introduction: Compared to other OECD countries, Switzerland has 
the highest hip replacement (HR) and one of the highest knee 
replacement (KR) rates. However, previous data on HR and KR use in 
Switzerland date back to the year 2008, and no recent data on the use 
of HR/KR are available. We assessed the regional variation in the use 
of HR/KR in Switzerland. 
Methods: We conducted a population-based small area-variation 
analysis. We used procedure codes to identify HR/KR from routinely 
collected patient discharge data from all Swiss hospitals during 
2012/13. We derived hospital service areas (HSAs) by analyzing 
patient flows to determine where the majority of residents were 
hospitalized, merging areas served by the same hospital into HSAs. 
We calculated age/sex-standardized utilization rates per 10,000 
persons for each HSA. We determined 2 measures of regional 
variation, the extremal quotient (EQ, highest HR/KR rate divided by 
lowest rate) and the systemic component of variation (SCV). We 
estimated the reduction in variation of crude HR/KR rates in multi-level 
negative binomial regression models, adjusting for age/sex, 
socioeconomic factors (language area, urbanization, socioeconomic 
position), and the number of orthopedic surgeons as a proxy for care 
availability. 
Results: Overall, 34,638 HR and 19,333 KR were electively performed 
in 2012/13. The age/sex-adjusted mean HR rate was 28/10,000 
persons, with a range from 19 to 50/10,000 persons across HSAs 
(fig. A). The age/sex-adjusted mean KR rate was 16/10,000 persons, 
with a range from 7 to 31/10,000 persons across HSAs (fig. B). For KR, 
the variation was large with an EQ of 4.5 and a SCV of 17.8; age/
sex-adjustment only minimally changed variation, whereas additional 
adjustment for socioeconomic factors and surgeon number reduced 
the variation by 10% and an additional 2%, respectively. For HR, the 
variation was low, with an EQ of 2.6 and a SCV of 2.9. While age/
sex-adjustment increased variation; additional adjustment for 
socioeconomic factors and surgeon number reduced the variation by 
9.2% and an additional 6.4%, respectively. 
Conclusion: We found a substantial variation in KR rates that could 
not be explained by differences in age/sex, socioeconomic factors, or 
care availability, while the variation in HR rates was modest. The 
variation in KR rates is unlikely to be explained by regional differences 
in incidence or severity of osteoarthritis and more likely indicates 
regional over- and underuse. 
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Dietary behaviors influence inflammatory markers:  
results from the CoLaus study
Eva Piccand, Peter Vollenweider, Pedro Manuel Marques-Vidal 
Department of Medicine, Internal Medicine, Lausanne University 
Hospital (CHUV), Lausanne, Switzerland
Introduction: Our aim is to assess the impact of dietary intake (single 
foods, macro and micronutrients, dietary patterns and scores) on 
inflammatory markers (CRP, IL-6, TNF-α and leucocyte count).
Methods: Data from 3774 participants of the population-based 
CoLaus study. Dietary intake was assessed using a semi-quantitative 
food frequency questionnaire. Single foods, nutrients, three naive 
(using principal components analysis) and four oriented 
(Mediterranean, Alternative Healthy Eating Index) dietary scores were 
used. Associations with inflammatory markers were assessed using 
spearman correlation and robust linear regression. 
Results: CRP was positively associated (p <0.01, table 1) with the 
“meat and chips” pattern, and negatively associated with the “fruits and 
vegetables” pattern, the Mediterranean and the Alternative Healthy 
Eating Index (AHEI) scores, fruits, carrots, tofu and carotene. After 
adjusting for age, body mass index (BMI), gender, smoking habits, 
education, sedentarity, total calories intake and diabetes, the negative 
associations with the “fruits and vegetables” pattern, the 
Mediterranean and the Alternative Healthy Eating Index scores, and 
fruits remained significant (p <0.01, table 2). Leucocyte count was 
positively associated (p <0.01, table 1) with the “meat and chips” 
pattern and negatively associated with the “fruits and vegetables” 
pattern, the AHEI scores, a high intake of fiber, carotene, carrots, 
salad, tofu, fruits, bananas, apples and kiwis. After multivariate 
adjustment, only the associations with the “meat and chips” and the 
“fruits and vegetables” patterns remained significant (p <0.01, table 2).
Conversely, no significant associations were found between all dietary 
markers and TNF-α and IL-6 after multivariate adjustment. 
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Conclusions: (un)healthy dietary behaviors have a small but 
significant impact on inflammatory markers in the general population. 
The effect of individual nutrients or foods appears to be of less clinical 
importance. 
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Legislative changes and 22-year trends in individual  
alcohol consumption in a Swiss adult population
Shireen Dumont1, Pedro Marques-Vidal2, Thierry Favrod-Coune1, 
Jean-Marc Theler1, Jean-Michel Gaspoz1, Barbara Broers1,  
Idris Guessous1 
1Hôpitaux Universitaires de Genève, Genève;  
2Lausanne University Hospital (CHUV), Lausanne, Switzerland
Introduction: Alcohol misuse is an important determinant of health 
and a major contributor to the burden of disease worldwide. With 
regard to alcohol use regulations, Switzerland has a long history of 
efforts to regulate alcohol production, sale and use, at the cantonal 
and federal levels. Evidence on the impact of legislative changes on 
individual alcohol consumption is limited. Using an observational study 
design, we assessed trends in individual alcohol consumption of a 
Swiss adult population following the public policy changes that took 
place between 1993 and 2014, while considering individual 
characteristics and secular trends.
Method: We used data from the “Bus Santé” study, an annual health 
survey conducted in random samples of the adult population in the 
State of Geneva, Switzerland. Individual alcohol intake was assessed 
using a validated food frequency questionnaire. Individual 
characteristics including education were self-reported. Seven policy 
changes (six about alcohol and one about tobacco) that occurred 
between 1993 and 2014 defined 6 different periods. We predicted 
alcohol intake using quantile regression with multivariate analysis for 
each period adjusting for participant characteristics and tested 
significance periods. Sensitivity analysis was performed including 
drinkers only, the 10th percentile of highest drinkers and smoker’s 
status.
Results: The study included data from 18,963 participants (aged 
18–75 years). Between 1992 and 2014, participants’ individual alcohol 
intake decreased from 7.3 to 5.4 g/day (26% reduction, p <0.001). Men 
decreased their alcohol intake by 35% compared to 31% for women 
(p <0.001). The decrease in alcohol intake remained significant when 
considering drinkers only (30% decrease, p <0.001) and the 10th 
percentile highest drinkers (24% decrease, p <0.001). Consumption of 
all alcoholic beverages decreased between 1993 and 2014 except for 
the moderate consumption of beer, which increased. After adjustment 
for participants’ characteristics and secular trends, no independent 
association between alcohol legislative changes and individual alcohol 
intake was found.
Conclusion: Between 1993 and 2014, alcohol consumption 
decreased in the Swiss adult population independently of policy 
changes. 
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Sleep disorders are associated with trabecular bone  
score and osteoporotic fracture, not with bone mineral  
density
Nadege Lambert1, Didier Hans2, Raphael Heinzer3,  
José Haba-Rubio3, Pedro Marques-Vidal1, Olivier Lamy2 
1Internal Medicine Unit, Internal Medicine Department; 2Center of 
Bone Diseases, Rheumatology Unit, Bone and Joint Department; 
3Center for Investigation and Research in Sleep, CHUV, University 
Hospital and University of Lausanne, Lausanne, Switzerland
Context: Sleep disorders and osteoporosis increase with age and are 
associated with high morbidity, mortality and economic burden. The 
prevalence of sleep-disordered breathing in Swiss women is 23% 
above 40 years and the remaining lifetime risk of osteoporotic (OP) 
fracture at 50 years is >50%. Poor sleep quality is associated with 
increased risk of fall and inconsistently with low bone mineral density 
(BMD), but the effect sizes were small and the mechanisms are 
unknown. Our study aimed to assess if sleep characteristics are 
associated with markers of bone health: BMD, microarchitecture 
assessed indirectly by trabecular bone score (TBS), and OP and non 
OP fractures. 
Methods: OsteoLaus is a population-based cohort of 1500 randomly 
selected Caucasian women (50 to 80 y old) living in Lausanne, 
Switzerland. All women had lumbar spine BMD and TBS, hip BMD, 
vertebral fracture assessment, and questionnaire about OP and non 
OP fractures. A random selection of 660 women was included in the 
HypnoLaus Sleep cohort study and had a polysomnography. Total 
sleep time (TST), sleep onset latency (SOL), slow-wave sleep and 
rapid eye movement sleep (REM) quantity, apnoea-hypopnoea index 
(AHI), oxygen desaturation index (ODI) and sleep efficiency were 
evaluated. 
Results: After adjustment, sleep parameters were not associated with 
BMD, AHI and ODI were inversely associated with TBS. All the results 
for fractures were adjusted for age, BMI and psychoactive drugs. Sleep 
onset latency was associated with OP fractures (p <0.001). REM was 
associated with OP and non OP fractures (p <0.05). We create a score 
of “sleep quality” including 6 parameters: total sleep time, sleep onset 
latency, slow-wave sleep, REM sleep, AHI, and sleep efficiency. This 
score was significantly lower only for women with prevalent OP 
fracture: women with OP fracture vs women without fracture (–0.25 ± 
0.09 vs. 0.05 ± 0.04, P <0.03). 
Conclusion: Our study demonstrates for the first time that TBS is 
altered in women with high AHI or high ODI. We found however no 
relevant association between BMD and sleep characteristics. The 
sleep quality score was lower for women with OP fracture. Further 
studies are needed to: 1) explain how some sleep characteristics affect 
TBS; and 2) validate the score of “sleep quality” in other studies. 
FM248
Use of polypill components in a swiss population- 
based study
Julien Castioni, Nazanin Abolhassani, Peter Vollenweider,  
Gérard Waeber, Pedro Marques-Vidal 
Medicine, Lausanne University Hospital (CHUV), Lausanne, 
Switzerland
Background: Cardiovascular diseases (CVD) are the first cause  
of mortality and morbidity worldwide. Insufficient adherence to 
cardiovascular therapy could explain in part this finding despite 
tremendous progress in CVD treatment. Lack of adherence could be 
prevented by a fixed combined dose of efficient medications for CVD 
prevention, the so-called polypill. We aimed to assess the prevalence 
of participants in a large population-based study in Lausanne already 
taking simultaneously individual components of polypills approved 
either worldwide or in Switzerland. 
Methods: Cross-sectional study conducted between 2009 and 2012  
in a sample of 5064 participants aged 40–80 years. Medications taken 
and associated medical conditions were assessed by questionnaire 
and confirmed by interview. Two major types of polypill equivalents 
were defined based on commercially available polypills. Polypill 
equivalent A contains aspirin, a statin and any antihypertensive drug 
and equivalent B a statin and any antihypertensive drug. In addition we 
further assessed two combinations that correspond to Swissmedic’s 
approved polypills: equivalent C contains a statin and a calcium 
channel blocker and equivalent D a statin, a calcium channel blockers 
and an angiotensin-converting-enzyme inhibitors. 
Results: Equivalent A was the most frequent (5.5%) and was more 
prevalent among men (7.8% vs. 3.6% in women), in the elderly (16.1% 
in ≥70 vs. 1.1% in 40–50 age group) in low educated people (6.7% vs. 
4.2% in high educated) and in participants with a history of CVD 
(38.5% vs. 2.8% in those without). Equivalent B was taken by 5.2% of 
the participants and was more prevalent among men (6.1% vs. 4.4%) 
the elderly (11.1 in ≥70 vs. 0.9% in 40–50 age group); participants with 
lower education levels (6.9% vs. 2.3% in high educated) and 
participants with a history of CVD (8.9% vs. 4.9% in those without). 
Equivalent C was taken by 2.6% of the participants and equivalent D 
by 0.8% of the participants, both with similar distribution (table 1). 
Conclusion: In the population older than 40y in Lausanne, 
approximately one in 38 subjects could take a Swissmedic approved 
polypill, instead of receiving separate drugs; and up to one in 18 
subjects for worldwide approved polypills. A larger choice of polypill 
may increase the number of the population taking polypills. However, 
the potential impact of better drug adherence with a polypill 
prescription remains to be evaluated in randomised studies. 
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Effect of thyroid hormone replacement among  
untreated older adults with subclinical hypothyroidism;  
a randomised placebo-controlled trial (TRUST)
Nicolas Rodondi, for the TRUST Investigators 
Universitätsklinik und Poliklinik für Allgemeine Innere Medizin, 
Universität Bern, Bern, Switzerland
Background: Subclinical hypothyroidism is a common disorder among 
older adults, occurring in 10–15% of those over 65. Guidelines on how 
to treat are not precise and interpretable in various ways, leading to 
large variation in treatment of subclinical hypothyroidism. Underlying 
trial data on thyroid hormone replacement are scarce and limited. The 
small overall sample size (32–120 participants), the relatively young 
patient, the short duration of follow-up (4–12 months) and the limited 
quality of the included trials (three out of 12 rated as “good” by the 
USPSTF) yielded only limited evidence on the benefits of thyroxine 
replacement. To contribute to the body of evidence, we set out to a 
large international trial of thyroxine replacement among older adults. 
Methods: We randomly assigned older adults aged ≥65 years with 
untreated persistent subclinical hypothyroidism into a double-blind 
placebo-controlled parallel group trial of levothyroxine to assess its 
multi-modal effects. Persistent subclinical hypothyroidism was 
diagnosed on the basis of persistently elevated TSH levels between 
4.6 and 19.9 mU/L, measured on ≥2 occasions, at least 3 months 
apart, to avoid treating transient abnormal TSH based on a single 
TSH. Levothyroxine starting dose was 50 µg daily (or 25 µg if weight 
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<50 Kg or coronary heart disease), with blinded dose titration to reach 
a TSH <4.6 mU/L. The primary outcome was thyroid related quality of 
life. Secondary outcomes were general quality of life, change in 
muscular function with handgrip strength, measured using isometric 
dynamometry, change in executive cognitive function, activities of daily 
living and total mortality. 
Results: At the close of recruitment, we enrolled 738 patients into the 
TRUST trial in 4 European countries. Participants were followed up for 
1 to 3 years. Results are under embargo until presentation early April 
for meeting presentation in US, but will be fully presented at SGAIM 
national meeting in May. 
Conclusions: This trial is by far the largest and longest RCT of 
treatment of subclinical hypothyroidism and is the first study which is 
powered to detect a meaningful change in symptoms / quality of life, 
over a realistic and appropriate clinical time-frame, to give definitive 
answers on the impact of thyroxine therapy among older adults with 
subclinical hypothyroidism. Results will provide the necessary 
evidence to properly inform best practice for treatment of subclinical 
hypothyroidism in older people. 
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Effect of vitamin D3 on self-perceived fatigue:  
a double-blind randomized placebo-controlled trial
Albina Nowak1, Lukas Boesch1, Erik Andres1, Edouard Battegay1, 
Thorsten Hornemann2, Christoph Schmid3, Heike Bischoff-Ferrari4, 
Paolo Suter1, Pierre-Alexandre Krayenbuehl5 
1Innere Medizin; 2Institut für Klinische Chemie; 3Klinik für 
Endokrinologie; 4Klinik für Geriatrie, Universitätsspital Zürich, Zürich; 
5Innere Medizin, Spital Linth, Uznach, Switzerland
Introduction: Vitamin D deficiency is frequent and has been 
associated with fatigue in uncontrolled trials. 
Methods: This is the first double-blind placebo-controlled clinical trial 
to investigate the efficacy of per os vitamin D3 (cholecalciferol) in 
treating fatigue among otherwise healthy persons with low serum 
25-hydroxyvitamin D (25(OH)D) levels. We enrolled 120 individuals 
(mean age 29 ± 6 years, 53% female) presenting with fatigue and 
vitamin D deficiency (serum 25(OH)D <20 µg/l). Participants were 
randomized to a single oral dose of 100,000 units of vitamin D or 
placebo. The primary endpoint was intra-individual change in the 
Fatigue Assessment Scale (FAS) at 4 weeks after treatment. 
Results: The mean age of the participants was 29 ± 6 years, 53% 
were female. Mean FAS decreased significantly more in the vitamin D 
group (–3.3 ± 5.3; 95% confidence interval for change –14.1 to 4.1) 
compared with placebo (–0.8 ± 5.3; 95% confidence interval for 
change –9.0 to 8.7); (p-value = 0.01). FAS improved significantly only 
in the vitamin D (p-value <0.001) but not in the placebo (p-value = 
0.24) Group.
Amelioration of fatigue was reported more frequently in vitamin D than 
in placebo group (42 (72%) vs 31 (50%); p-value = 0.01; Odds Ratio 
(OR) 2.63, 95% confidence interval for OR 1.23–5.62). Among all 
participants, improvement in fatigue score correlated with the rise in 
25(OH)D level (R = –0.22, p-value = 0.02). 
Conclusion: Vitamin D treatment significantly improved fatigue in 
otherwise healthy persons with vitamin D deficiency. 
This study was registered at the www.ClinicalTrials.gov Protocol ID 
NCT02022475. 
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Lung cancer: sex difference in the lifetime risk and  
10-year risk between 1995 and 2013 in a Swiss population
Christina Bruder1, Jean-Luc Bulliard1, Simon Germann1, Isabelle 
Konzelmann2, Murielle Bochud1, Magali Leyvraz1, Arnaud Chiolero1,2 
1Institut Universitaire de Médecine Sociale et Préventive (IUMSP), 
CHUV, Lausanne; 2Registre Valaisan des Tumeurs (RVsT), 
Observatoire Valaisan de la Santé (OVS), Sion, Switzerland
Introduction: In Switzerland, lung cancer is a leading cause of cancer 
death. Because smoking is the major cause of lung cancer, trends in 
lung cancer incidence are following trends in smoking habits in the 
population, with a latency time of about 30 years. In Switzerland, there 
was a peak in men’s lung cancer incidence in the 1980s, followed by a 
decrease until now. Among women, the incidence has increased since 
the 1970s and, apparently, has not yet reached a peak. Because 
cancers are feared diseases, an adequate communication about the 
individual risk of developing cancer is important. Mortality and 
incidence are traditionally used to assess cancer burden. However, 
these metrics are difficult to interpret at the individual level. Providing 
the lifetime and 10-year risk of cancer could improve risk 
communication for patients and health professionals. Our aim was to 
estimate trends in the lifetime and 10-year risk of lung cancer, in men 
and women, between 1995 and 2013.
Methods: We used data from all lung cancer cases recorded between 
1995 and 2013 by the Registre Valaisan des tumeurs (RVsT) and the 
Registre Vaudois des tumeurs (RVT). These two population-based 
registries collect data on all new cancer cases of women and men 
living in Valais and Vaud. Data on mortality were provided by the 
Federal Statistical Office. We estimated sex-specific lifetime risk and 
10-year risk of lung cancer using the current probability method, which 
estimates cumulative risk of any condition accounting for competing 
risk and death.
Results: Between 1995 and 2013, 10453 cases of lung cancer were 
recorded. The lifetime risk of developing lung cancer decreased in men 
from 8.1% in 1995–1998 to 6.8% in 2009–2013 (fig. 1). During this 
same period, it increased in women from 2.8% to 4.1% (fig. 1). In both 
sexes, the 10-year risk of lung cancer increased with age until the age 
of 70 and decreased thereafter. Between 1995 and 2013, the 10-year 
risk of lung cancer decreased in men at all ages, excepted in men over 
80 years of age in whom the risk increased. Among women, the 
10-year risk increased in women above 50 years of age.
Figure 1: Fatigue before 
and after vitamin D 
treatment.
Conclusion: Lifetime and 10-year risk of cancer can improve cancer 
risk communication. Between 1995 and 2013, the lifetime risk of lung 
cancer decreased in men and increased among women. 
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Statins and risk of Alzheimer’s disease:  
evidence from Mendelian randomization
Julien Vaucher1, Michael V. Holmes2,3 
1Department of Internal Medicine, University Hospital of Lausanne 
(CHUV), Lausanne, Switzerland; 2Clinical Trial Service Unit & 
Epidemiological Studies Unit, Nuffield Department of Population 
Health; 3Medical Research Council Population Health Research Unit 
at the University of Oxford, Oxford, United Kingdom
Background: Observational studies suggest that statin use is 
inversely associated with risk of Alzheimer disease (AD). Thus, it is 
important to investigate whether any statin impact on risk of AD 
represents an on-target effect (i.e., due to a specific inhibition of the 
3-hydro-3-méthylglutaryl coenzyme A reductase (HMGCR)). Since 
known genetic variants recapitulate the effect of statins (inhibition of 
HMGCR), we used single-nucleotide polymorphisms (SNPs) in/near 
HMGCR gene to estimate the association between statin use and risk 
of AD. 
Methods: Using the properties of genetic variants (presence from 
conception and inalterable nature), we applied a “Mendelian 
randomization” (MR) approach to estimate the causal effect of HMGCR 
inhibition on risk of AD, a form of drug target exploratory analysis. We 
used 3 independent (r2 <0.25) SNPs in/near HMGCR (rs16872526, 
rs12916, rs5744707) and retrieved their association estimates with 
LDL-cholesterol, as reported in up to 183,465 individuals in the Global 
Lipids Genetic Consortium. We retrieved the same SNPs and their 
association estimates with AD from a large AD GWAS (including 
17,008 cases and 37,154 controls). We then estimated a causal effect 
and a corresponding standard error (SE) for each SNP derived by the 
Wald and delta methods, respectively. Individual causal effect 
estimates were pooled using random-effects meta-analysis. Since 
APOE gene, which encodes apolipoprotein E (ApoE; found in 
chylomicrons and some lipoproteins), influence the odds of AD, we 
complemented the analysis by testing whether an ApoE-associated 
variant (rs7412) was related to risk of AD as a positive control. Analysis 
for APOE rs7412 was performed as described above. 
Results: In Mendelian randomization analysis based on 17,008 AD 
cases and 37,154 controls, statin use (instrumented using HMGCR-
related variants) was not associated with risk of AD (OR for AD: 1.00; 
95% CI, 0.66–1.52). Using APOE rs7412 as a positive control, and 
scaling the results to the same difference in LDL-C, the odds of AD 
was strongly reduced (OR for AD: 0.49; 95% CI, 0.42–0.56). 
Conclusions: This study shows that pharmacological inhibition of 
HMGCR (i.e., the on-target effect of statins) is unlikely to reduce the 
risk of AD. These findings provide evidence to make inferences about 
the clinical effect of statins and to help orientate research on any 
relationship between statin use and risk of AD. 
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Anti-apolipoprotein A-1 IgG as predictors of coronary  
heart disease and all-cause mortality in the general  
population: results from the CoLaus study
Panagiotis Antiochos1, Pedro Marques-Vidal1, Julien Virzi2,  
Sabrina Pagano2, Nathalie Satta2, Oliver Hartley2, Fabrizio 
Montecucco2, François Mach2, Zoltan Kutalik3, Gérard Waeber1,  
Peter Vollenweider1, Nicolas Vuilleumier2 
1CHUV, University Hospital and University of Lausanne, Lausanne; 
2Hôpitaux Universitaires de Genève, Genève; 3Institut Universitaire de 
Médecine Sociale et Préventive, Lausanne, Switzerland
Introduction: Autoantibodies against apolipoprotein A-1 (anti-apoA-1 
IgG) have emerged as an independent biomarker for cardiovascular 
disease in selected settings, but their associations with incident 
coronary heart disease and mortality in the general population is 
unknown. We aimed to determine whether anti-apoA-1 IgG: a) predict 
incident CHD and all-cause mortality in the general population, and 
b) are associated with single-nucleotide polymorphisms (SNPs) in a 
genome-wide association study (GWAS). 
Methods: Clinical, biological and genetic data were obtained from 
the population-based, prospective CoLaus study, including 5220 
participants (mean age 52.6 years, 47.3% men) followed over a 
median duration of 5.6 years. The primary study outcome was 
adjudicated incident CHD, defined as adjudicated incident myocardial 
infarction, angina, percutaneous coronary revascularization or bypass 
grafting. 
Results: In subjects positive vs. negative for anti-apoA-1 IgG, total 
CHD rate was 3.9% vs. 2.8% (p = 0.077), while nonfatal CHD rate was 
3.6% vs. 2.3% (p = 0.018). Multivariate-adjusted Hazard ratios (aHR) 
and (95% confidence intervals) were 1.58 (0.96; 2.60), and 1.53 (1.03; 
2.26), for total and nonfatal CHD, respectively. The association was 
modulated by a significant interaction between anti-apoA-1 IgG and  
a functional SNP in the CD14 receptor gene (rs2569190), with 
anti-apoA-1 IgG conferring the highest risk for CHD in non-TT 
rs2569190 carriers (aHRs = 1.73 (1.10; 2.73)), whereas being 
associated with the lowest risk in TT homozygotes (p-for-interaction = 
0.015). After multivariate adjustment, anti-apoA-1 IgG positivity 
independently predicted all-cause mortality (aHR = 1.54, (1.11-2.13), 
P = 0.01), with each standard deviation of logarithmically transformed 
anti-apoA-1 IgG being associated with a 15% increase in mortality risk. 
Our GWAS yielded 9 SNPs belonging to the Fc receptor like-3 
(FCRL3) gene that were significantly associated with anti-apoA-1 IgG 
levels, with the lead SNP (rs6427397, P = 1.54×10–9) explaining 0.67% 
of anti-apoA-1 IgG level variation. 
Conclusion: Anti-apoA-1 IgG independently predict nonfatal incident 
CHD in the general population, the strength of this association being 
dependent on a functional polymorphism of the CD14 receptor gene. 
Our findings further indicate that preclinical autoimmunity to anti-
apoA-1 IgG is linked to FCRL3, a susceptibility gene for autoimmune 
diseases, and may as well represent a novel mortality risk factor in the 
community. 
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Cannabis use and risk of schizophrenia:  
a Mendelian randomization study
Julien Vaucher1, Brendan J. Keating2, Aurélie M. Lasserre3, Wei 
Gan4,5, Donald M. Lyall6, Joey Ward6, Daniel J. Smith6, Jill P. Pell6, 
Naveed Sattar7, Guillaume Paré8,9,10, Michael V. Holmes11,12 
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2Department of Surgery, University of Pennsylvania, Philadelphia, PA, 
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Psychopathology (CEPP), University Hospital of Lausanne (CHUV), 
Prilly, Switzerland; 4Wellcome Trust Centre for Human Genetics; 
5Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill 
Hospital Campus, University of Oxford, Oxford; 6Institute of Health & 
Wellbeing; 7Institute of Cardiovascular and Medical Science, 
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Background: Cannabis use is observationally associated with an 
increased risk of schizophrenia, however whether the relationship is 
causal is not known. Observational studies cannot clarify causality and 
a randomized trial would be unethical. 
Methods: We took 10 independent genetic variants previously 
identified to associate with cannabis use in 32,330 individuals to 
determine the nature of the association between cannabis use and 
risk of schizophrenia. Genetic variants were employed as instruments 
to recapitulate a randomized controlled trial involving two groups 
(cannabis users vs nonusers) to estimate the causal effect of cannabis 
use on risk of schizophrenia in 34,241 cases and 45,604 controls from 
predominantly European descent. Genetically-derived estimates were 
compared with a meta-analysis of observational studies reporting ever 
use of cannabis and risk of schizophrenia or related disorders. We 
conducted additional tests accounting for unmeasured pleiotropy of 
the genetic instrument and for tobacco exposure. Sensitivity analyses 
included exploring the influence of the causal summary estimate to 
individual genetic variant and restricting to putative functional variants. 
Findings: Based on the genetic approach, use of cannabis was 
associated with increased risk of schizophrenia (OR of schizophrenia 
for users vs. non-users of cannabis: 1.37; 95%CI, 1.09 to 1.67; P-value 
= 0.007). The corresponding estimate from observational analysis was 
1.43 (95% CI, 1.19 to 1.67; P-value for heterogeneity = 0.76). The 
genetic instrument did not show evidence of pleiotropy nor when 
accounting for tobacco exposure (OR of schizophrenia for users vs. 
non-users of cannabis, adjusted for ever vs. never smoker: 1.41; 95% 
CI, 1.09 to 1.83). Furthermore, the causal estimate remained robust to 
sensitivity analyses. 
Interpretation: These findings add to the substantial evidence base 
that showed that association between use of cannabis and risk of 
schizophrenia is likely to be causal. Such robust evidence may inform 
public health message about the risks of cannabis use, especially 
regarding its potential mental health consequences. 
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Smartphone-app compared to standard blood pressure 
measurement – trial design and pilot data of the iPARR trial
Jens Eckstein1,2, Thilo Burkard3,4, Clemens Winterhalder1, Licia 
Leonardi1, Emanuel Thommen1, Ralf Birkemeyer5, Stefan Weber6, 
Andrea Seeck7, Nicole König7, Marcus Dörr8 
1Klinik Innere Medizin, Universitätsspital Basel; 2CMIO Office; 
3Medizinische Poliklinik, Universitätsspital BaselBasel; 4Klinik für 
Kardiologie, Universitätsspital Basel, Basel, Switzerland; 5Medizin, 
Universitätsklinikum Ulm, Ulm; 6Medizin, Universitätsklinikum 
Regensburg, Regensburg; 7Preventicus, Jena, 8Medizin, 
Universitätsklinikum Greifswald, Greifswald, Germany
Introduction: Smartphones and smartwatches allow to measure and 
track vital signs traditionally assessed with dedicated equipment. As 
these devices and health-related apps become increasingly used by 
the general population, it is essential to assess the accuracy of new 
measuring methods. A recently developed algorithm calculates systolic 
blood pressure (SBP) from the pulse wave recorded with a 
smartphone camera. This app is the only smartphone based tool 
worldwide that works without calibration measurement or additional 
peripheral devices to estimate SBP, but works with a large database  
of pulse wave curves with varying data for gender, size, weight, age, 
tobacco use and systolic blood pressure. The iPARR trial compared 
the accuracy of this method with a traditional professional blood 
pressure monitor. 
Methods: In this prospective, blind, single-center trial, 1000 adult 
subjects were recruited. Seven sequential blood pressure 
measurements were performed after five minutes of rest in a quiet 
room in a sitting position. The series started with a standard device 
(Omron HBP-1300 professional blood pressure monitor, appropriate 
cuff size) alternating with the tested smartphone app (Preventicus®, 
iPhone 4s). The photoplethysmographic signal was recorded by 
placing the finger on the smartphone camera for 3 minutes. Based on 
the pulse wave morphology and five additional parameters (age, size, 
weight, sex, tobacco use) the pulse wave files were analysed by 
Preventicus® without knowledge of the oscillometric values. Data is 
merged with external monitoring end of February 2017 and will be 
present for the SGAIM meeting. 
Results: (Pilot data)In a retrospective analysis pilot data of 500 
patients showed a correlation of r = 0.81 and mean error of <10 mm 
Hg between the SBP measured with a standard device and a 
smartphone. A first pilot validation cohort of 85 subjects confirms the 
proof of concept with a correlation of r = 0.76 and a mean error of  
13.6 mm Hg 
Conclusion: Pilot data of an ongoing prospective blinded validation 
trial (iPARR) shows that SBP estimation with a smartphone app is a 
promising innovative tool that will be tested and developed further to 
be implemented in a smartwatch or suitable wristband. A validation 
cohort following ESH criteria will follow. 
The iPARR trial data will be available for the SGAIM Meeting 2017. 
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Introduction: Higher educational attainment is observationally 
associated with a lower risk of coronary artery disease, however it is 
not known whether this association is causal. We used Mendelian 
randomization, a method where genetic data are used to provide 
causal estimates to make inferences about the role of an exposure on 
the risk of a disease outcome. 
Methods: We used 162 genetic variants previously associated with 
education to assess whether a genetic predisposition towards higher 
education is associated with risk of coronary artery disease in public 
datasets with 589,377 participants of predominantly Caucasian origin 
and living in developed countries. The primary outcome was combined 
fatal and nonfatal coronary artery disease. Genetically-derived 
estimates were compared with updated observational estimates of the 
association between education and incidence of coronary artery 
disease from several large observational studies. Sensitivity analyses 
included checking for potential pleiotropic effects of the genetic 
variants (i.e., when genetic variants associate directly with coronary 
artery disease via pathways that bypass education) and testing 
whether genetic liabilities for coronary artery disease is associated 
with educational outcomes. 
Results: A one standard deviation increase in the genetic 
predisposition towards higher education (i.e. 3.6 years of additional 
schooling) lowered the risk of coronary artery disease by a third (odds 
ratio [OR] = 0.67, 95% confidence interval [CI], 0.59 to 0.77), 
consistent with observational estimates. Equivalent increases in 
education were also causally associated with reductions in smoking, 
BMI and improvements in blood lipid profiles. Genetic variants did not 
present pleiotropic effects based on various sensitivity approaches 
(Egger and weighted median Mendelian randomization analyses). The 
reverse investigation, of whether genetic liabilities for risk of CAD are 
associated with educational outcomes, showed an absence of 
association (standard deviation difference in education per 1-log unit 
increase in coronary artery disease = 0.002; 95% CI, –0.013 to 0.016). 
Conclusions: Higher educational attainment is causally associated 
with a reduced risk of coronary artery disease. This may be partly 
explained by changes to smoking, BMI and blood lipids. These findings 
offer support for policy interventions that increase education in order to 
improve population health. 
Figure 1: Repeated measurements of the same patients with a  
smartphone are reproducible.
Figure 2
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What are the challenges for the management  
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Introduction: The prevalence of residents in difficulty is 7–15% and is 
a major concern in medical education. Remediation plans have shown 
a good efficacy, but residents in difficulty are often detected too late in 
their academic cursus. Difficulties concern mainly cognitive and clinical 
reasoning (85%), professionalism (51%), communication (49%) and 
collaborative problems (20%) and may occur simultaneously. 
Nowadays most training hospitals in Switzerland do not have specific 
processes to identify and manage residents in difficulty. The aim of the 
study was to explore the challenges perceived by physicians at 
different hierarchical levels (residents (R), senior residents (SR), 
attendings (A), physician in chief (PC)) regarding the process of 
identifying, diagnosing and supporting residents in difficulty in a 
structured and programmatic way.
Methods: We conducted an exploratory qualitative study. Participants 
were volunteers from the Primary Care Division of the Geneva 
University Hospitals. Between December 2015 and July 2016, we 
conducted three focus groups (with SR, A, R) and one interview with 
the division’s PC. Focus groups and the interview were transcribed, 
coded, and analyzed qualitatively using a content thematic approach 
and Fishbein’s conceptual Framework.
Results: We identified similar and divergent factors regarding the 
implementation of such a programmatic approach among physicians 
of different hierarchical levels. Major findings show: – Supervisors (SR, 
A, PC) usually identified correctly residents in difficulty but they did not 
set up systematic remediation strategies. – Supervisors (SR, A) felt 
concerned about residents in difficulty and the possible adverse effect 
on patient care, but were afraid to harm their career by writing up a 
poor institutional assessment. – Residents feared that sharing their 
own difficulties with their supervisors would impact negatively on their 
career. – Environmental constraints (lack of money, lack of time and 
resources…) were reported by the four levels.
Conclusion: We identified a lack of a programmatic approach for the 
management of residents in difficulty. Thus, this process depends on 
residents’ attitudes regarding their own performance, the type of 
difficulties identified, and both on hierarchical involvement and 
institutional support. Similar and divergent factors regarding the 
implementation of such a programmatic approach are present at the 
different hierarchical levels and need to be addressed specifically. 
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Does patients’ satisfaction change under team care  
in a chronic care management program instead of  
usual care by the family physician alone?
Adrian O. Goeldlin, Marc Jungi 
Sanacare Gruppenpraxis, Bern, Switzerland
Introduction: Interprofessional chronic care management (CCM) 
programs in teams of doctors and coaches (medical practice 
coordinators, specially trained medical assistants) look promising to 
face the lack of primary care physicians. They offer an evidence-based 
high quality of care. But there are still doubts about patients’ 
acceptance. Our aim is to find, whether these evidence-based 
programs have an influence on patient’s perception of care.
Methods: We evaluated 12 Swiss primary health care group practices 
offering interprofessional CCM programs by teams of doctors and 
coaches (medical practice coordinators, specially trained medical 
assistants). These programs are offered to patients with progressed 
arterial hypertension, type 2 diabetes mellitus, chronic obstructive 
pulmonary disease and combinations of these conditions. Between 
May 2013 and December 2015, 564 consecutive patients entered the 
programs. 559 (99%) of them completed a patient’s satisfaction 
questionnaire about their family physician with 9 items derived from 
the European Practice Assessment (EPA). Items had to be rated on a 
5-point Likert scale between 1 (bad) and 5 (excellent). After a one-year 
program cycle, patients were asked to answer the same questionnaire 
regarding their team (coach and doctor). We collected all of these 
evaluation data available at January 4th, 2017. The “before-and-after” 
ratings were compared using paired sample t tests, applying 
Bonferroni correction for single item testing.
Results: 396 of the 559 patients (71%) answered the second 
questionnaire. There was a statistically significant difference in overall 
rating of family physicians alone (M = 4.63; SD = 0.42) and teams of 
doctors and coaches (M = 4.72; SD = 0.41); t(395) = 4.38, p <0.001. 
Results of single item testing are displayed in table 1.
Conclusion: In our setting, CCM programs run by teams of doctors 
and coaches further improved an already high satisfaction of patients 
with chronic conditions. Patients seem particularly better informed 
about symptoms and disease and feel better supported in dealing with 
emotional problems by this team approach. 
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Background: Since the subjection of residents in Swiss hospitals to 
the federal labour law, the worktime limit of 50 hours/week applies, but 
several cases became public in which the declaration of extra hours 
was unprecise. In 2015, the first Swiss resident time-motion study 
performed at the CHUV discovered that as many as 75% of extra 
hours were not reported with a self-declaration system. Therefore, we 
wanted to assess whether a time clock system prevents residents from 
not reporting extra hours. 
Method: We compared working hours from residents working at the 
Cantonal Hospital Baden (KSB) and the Lausanne University Hospital 
(CHUV). To assess actual working time, data was extracted from the 
Medical Day study at each center in which trained observers followed 
residents during normal day shifts. To ensure comparability the same 
protocol, tablet software and instruction of observers was used. Actual 
worktime was defined as duration from entering to leaving the office. At 
KSB, residents registered their working hours at dedicated spots with 
individual badges. At CHUV, working hours were self-reported with 
monthly cards. Extra hours were defined as more than 660 min per 
day at KSB and 600 min at CHUV (including 60 respectively 30 
minutes lunchbreak). Statistical testing was performed with two-sided, 
untailed t-test. 
Results: Demographic baseline characteristics are shown in table 1.
Table 1: Baseline characteristics of residents.
  KSB CHUV  
  mean SD mean SD p value
Age (years) 29.6 3.19 28.8 1.7 0.15
Months postgraduate 20.9 17.7 31.2 11.9 0.002
Months experience  
in internal medicine
16.1 11.3 27.0 10.4 <0.001
Swiss diploma 66.7%   60.70%    
Female gender 57%   63%    
SD = standard deviation
RECHERCHE, FORMATION, ORGANISATION ET SYSTÈME DE SANTÉ II / FORSCHUNG, FORTBILDUNG, ORGANISATION 
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Conclusions: Compared to a 6-month period with one full-time 
attending physician, a 6-months job-sharing period with two attending 
physicians had no effect on the number of prescriptions and LOS of 
the patients, and was associated with a similar coworkers’ self-rated 
satisfaction. Conversely, it increased the delay of discharge letters. 
Conclusion: 1) Using time clocks to report working hour is more 
precise than self-reporting. 2) Self declaration is associated with 
underreporting. 3) Our study may have implications for working hour 
reporting policies in hospitals. 4) The cold numbers must be balanced 
with “overall considerations” of research and education “invested” in 
trainees by mentors and institutions. 
FM260
Effects of two job-sharing physicians versus a full 
timeattending physician on quality of care and coworkers’ 
satisfactionin a Swiss hospital
Marie Méan, Pedro Marques-Vidal, Julien Castioni, Nathalie Wenger, 
Gérard Waeber 
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Introduction: An increasing number of physicians choose to work 
part-time and consider job-sharing as an alternative to the traditional 
hospital practice model. Whether two part-time, job-sharing physicians 
provide the same output as a single one working full-time has seldom 
been assessed. We therefore aimed to compare the effects of two 
job-sharing physicians versus a full time physician on quality of 
inpatients care and coworkers’ satisfaction. 
Methods: Intervention study conducted between 2014 and 2016 in an 
internal medicine ward of a Swiss teaching hospital. Patients (n = 549) 
were evaluated regarding quality of care; coworkers (30 house staff 
and 12 residents) were queried regarding satisfaction at work. A 
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486.4 hours of observation (43 shifts) were collected in KSB and 568.2 
hours (49 shifts) in CHUV. At KSB, the length of a shift determined by 
time clock was very similar to observation (684.0 ± 65.6 min vs 678.6 
± 65.6 min, p-value 0.7). At CHUV, the length of shift determined by 
self-reported timecards was lower than observation (695.7 ± 80.1 min 
vs 635.3 ± 53.7 min, p-value <0.001). At KSB the difference is not 
significant, while at CHUV the system misses on average 60.4 minutes 
of daily work. Mean extra hours per shift was lower at KSB than at 
CHUV (18.6 ± 65.6 min vs 95.7 ± 80.1 min, p-value <0.001). 
Summarized, there were no unreported hours in KSB (–3.83h), but 
49.3 hours unregistered extra hours at CHUV during observation.
6-month job-sharing period (1.6.2015–30.11.2015) with two attending 
physicians (Monday-Wednesday and Wednesday-Friday) was 
compared to a 6-month period (1.12.2014–31.5.2015) with one 
attending physician working full-time. Patients’ outcomes were: 1) the 
number of biological or X-ray exams prescribed; 2) the time to send 
out the discharge letter, and 3) length of stay (LOS). Coworkers’ 
outcome was self-rated satisfaction at work, assessed using validated 
questionnaires (COPSOQ and SAPHORA). 
Results: Among the 549 patients, average LOS was shorter during 
the job-sharing period but a similar trend was also found for the entire 
hospital. Biological prescriptions were lower during the job-sharing 
period, X-ray prescriptions did not differ but the time needed to send 
out the discharge letter increased 
Table 2: Shift durations depending on method of measurement.
Table 1: Patients’ outcome after each study period.
Coworkers’ satisfaction scores were similar before and after the job-sharing 
period.
Table 2: Coworkers’ satisfaction at work.
MÉDECINE SPECIALISÉE I / FACHMEDIZIN I  
FM261
Sudden cardiac death in the young: coronary smooth  
muscle cells of plaque and media exhibit a contractile 
phenotype
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Introduction: Coronary artery disease is the leading cause of sudden 
cardiac death (SCD) in non-athletes. The histopathologic features of 
atherosclerotic plaques in young SCD victims are strikingly different 
from those of elderly patients: plaques of young adults are 
characterized by extensive smooth muscle cell (SMC) hyperplasia, 
scanty lipid core and small inflammation (hence the misnomer 
“non-atheromatous atherosclerosis”). These lesions are characterized 
by a lower rate of acute thrombosis compared to fibroatheromatous 
plaques. Thus, SCD triggered by “non-atheromatous atherosclerosis” 
is likely not ascribable to fibrous cap rupture. Other causes, and 
particularly coronary artery spasm, are rather invoked. In this study we 
aimed at characterizing the SMC phenotype in the intima and media of 
coronary atherosclerotic plaques from SCD victims.
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Methods: Among 652 young (<40 years old) victims in the SCD 
Registry of Northeast Italy, 125 (19%) were due to coronary 
atherosclerosis. 33 coronary artery specimens taken at autopsy were 
included in this study: (a) 6 “control” non-atherosclerotic coronary 
arteries from young patients died of cardiovascular-unrelated causes; 
(b) 18 atherosclerotic coronary arteries from young SCD victims 
(7 fibroatheromathous and 11 “non-atheromatous atherosclerosis” 
lesions); (c) 9 atherosclerotic coronary arteries from old cardiovascular 
patients. The expression of a-smooth muscle actin (a-SMA), smooth 
muscle myosin heavy chains (SMMHCs), heavy-caldesmon (h-CaD) 
and S100A4 were detected by means of immunohistochemistry and 
quantified morphometrically.
Results: The expression of a-SMA, SMMHCs and h-CaD was higher 
in the intima of non-atherosclerotic arteries from young patients and  
in atherosclerotic plaques from young SCD victims compared to 
atherosclerotic plaques from old patients. The expression of S100A4 
was significantly lower in the intima of non-atherosclerotic arteries 
from young patients compared to atherosclerotic plaques from young 
SCD victims and old patients. Unlike old patients, the coronary media 
underlying atherosclerotic plaques from young SCD victims exhibited  
a strong positivity for a-SMA, SMMHCs and h-CaD.
Conclusions: Plaque and media SMCs from young SCD victims 
exhibit a contractile phenotype characterized by increased expression 
of a-SMA, SMMHCs and h-CaD. In the setting of critical stenosis, 
intima and media SMC contractility might contribute to coronary 
spasm and myocardial ischemia, precipitating SCD. 
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Background: Pneumonia ranks high among causes of morbimortality 
in the elderly. Its diagnosis is challenging because of the poor 
sensitivity and specificity of signs and symptoms and pittfalls in 
interpretation of chest x-rays (CXR). A recent study showed the value 
of CT in the diagnosis of pneumonia in the emergency room. Our 
objective was to assess whether low-dose CT modified the 
management of pneumonia in elderly patients and enabled 
discontinuation of empirical antimicrobial therapy.
Material and methods: Monocentric prospective interventional study 
conducted from May 2015 to April 2016, including patients more than 
65 years old, hospitalized in internal medicine for a clinical diagnosis 
of pneumonia and who were prescribed antibiotic therapy. Patients 
treated for pneumonia during the last 6 months, having already 
undergone a CT or having received antimicrobial therapy for more 
than 48 hours were excluded. All patients had CXR and native 
low-dose CT within 72h after the hospitalization. The probability of 
pneumonia was assessed by the clinician on a 5 levels Likert scale 
before and after CT. The main outcome was the number of diagnoses 
that were changed after CT (upgraded or downgraded diagnosis).
Results: Among 898 screened patients, 203 were included: 98 women 
(48.3%), median age 84 years (65-103); 154 (75.9%) had community 
acquired pneumonia, 72 (35.5%) had been hospitalized during the 
previous 6 months. The median CURB-65 score was 2. There was an 
infiltrate on the CXR according to the clinician with a certain/high 
probability in 85 patients (41.9%). The 30-days mortality was 5.4%. 
Among 200 patients with available data, the probability of pneumonia 
before and after the CT is depicted in the table. The probability of the 
diagnosis was altered after CT in 134 (67%) patients: 67 were 
downgraded and 67 upgraded. Antibiotics were discontinued in 18 
patients (9%) after CT.
Conclusions: To our knowledge, this is the first study assessing the 
use of thoracic CT in a geriatric population hospitalized for pneumonia. 
CT altered the diagnosis of pneumonia in 26% of patients and led to 
discontinuation of antimicrobial therapy in 9%. These results should be 
confirmed in a randomized clinical trial comparing usual management 
versus systematic CT. 
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Introduction: Systemic sclerosis (SSc) can involve the urinary tract. 
However, the prevalence and disease specific risk factors for urinary 
incontinence (UI) are unknown. Our goal was to assess the prevalence 
of UI, explore the association with the main clinical and serological 
subsets and evaluate the impact of UI on quality of life in SSc.
Methods: 334 consecutive patients with SSc were included in five 
European tertiary centers. UI and quality of life were assessed through 
self-administered questionnaires. Logistic regressions models were 
performed to test the association between clinical forms, serologic 
status and UI. Multivariable logistic regressions were performed to 
adjust for confounders (age, sex, disability, diabetes, body mass index, 
caffeine consumption, dyspnea and pulmonary hypertension) and test 
further independent predefined SSc risk factors for UI. 
Results: The prevalence of UI was 63% (95%CI: 60–68%). Limited 
cutaneous SSc (lcSSc) and anti-centromere antibodies (ACA) were 
both significantly associated with UI (adjusted OR 2.0; 95%CI: 
1.1–3.7). Patients positive for ACA or suffering from lcSSc had frequent 
and heavy urinary leaks compared to other SSc patients. In 
multivariable model, ACA (OR 2.8; 95%CI: 1.4-5.6), lcSSc (OR 2.2; 
95%CI: 1.1–4.4), female sex (OR 11.3; 95%CI: 3.6–35.1), worsening of 
dyspnea (OR 8.8; 95%CI: 1.6–49.3), lower HAQ-DI (OR 3.3; 95%CI: 
1.6–6.6), finger-skin thickening (OR 2.0; 95%CI: 1.1–3.8), and active 
finger ulceration (OR 0.3; 95%CI: 0.1–0.9), were independently 
associated with UI. Patients suffering from UI had decreased quality of 
life. Failure to include the calculated number of subject and the use of 
a self-administered questionnaire rather than an objective measure to 
assess UI are the main limitations of this study. 
Conclusions: Self-reported UI is frequent in SSc and disproportionally 
affects lcSSc and patients positive for ACA. SSc patients with UI have 
low quality of life. 
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Diagnostic accuracy of undernutrition in hospital  
discharge data: improvements needed
Saman Khalatbari-Soltani, Gérard Waeber, Pedro Marques-Vidalb 
Department of Internal Medicine, Lausanne University Hospital 
(CHUV), Lausanne, Switzerland
Background and aims: Prevalence of undernutrition among 
hospitalized patients is high, ranging between 20 to 60%. 
Undernutrition is associated with increased morbidity and mortality, 
longer hospital stay, decreased quality of life, and increasing health 
care costs. Hospital administrative databases are widely used for 
disease monitoring and health policies planning. Hence, adequate 
reporting of undernourished patients is necessary and its diagnostic 
accuracy should be high. To our knowledge, the diagnostic accuracy of 
undernutrition reporting in administrative data is poorly known. We 
aimed to examine the diagnostic accuracy of undernutrition reporting 
in a Swiss university hospital.
Probability of the diagnosis before and after CT
  Probability 
after CT
           
Probability 
before CT
Excluded Low Intermediary High Certain   Change of 
probability
Excluded  0  0  0  1  0   1   1 (100%)
Low  6  4  3  1  1  15  11 (73%)
Intermediary 11 23 13 14  9  70  57 (81%)
High  3  8 11 32 38  92  60 (65%)
Certain  1  1  2  1 17  22   5 (23%)
  21 36 29 49 65 200 134 (67%)
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Methods: Retrospective cross-sectional study using administrative 
data for years 2013-14 from the Internal medicine unit of the Lausanne 
university hospital (n = 2509). Two reference diagnoses were defined: 
1) ‘confirmed’ undernutrition by a nutrition risk screening-2002 
(NRS-2002) score ≥3 plus a body mass index (BMI) <18.5 kg/m2, and 
2) ‘probable’ undernutrition by a NRS-2002 ≥3 plus any prescription of 
nutritional management/support plus a BMI ≥18.5 and <20 kg/m2 if 
age <70 years (<22 kg/m2 if age≥70 years). Missing BMI values were 
imputed.
Results: Of the 2509 eligible patients, 262 (10.4%) were classified as 
‘confirmed’ and 631 (25.2%) as ‘probable’ undernutrition. Sensitivity, 
specificity, negative and positive predictive values (and corresponding 
95% confidence intervals) for undernutrition reporting using ‘confirmed’ 
undernutrition were 43.0 (37.0–49.3); 87.2 (85.8–88.6); 92.9 (91.7–
94.0) and 28.2 (23.8–32.8), respectively. The corresponding values 
using both ‘confirmed’ and ‘probable’ undernutrition were 30.0 
(27.2-32.9); 93.4 (92.0–94.6); 66.7 (64.7–68.7) and 75.1 (70.6–79.3), 
respectively. Similar findings were obtained after stratifying for gender 
or for age group, or restricting the analysis to patients with non-missing 
BMI data.
Conclusion: Undernutrition reporting in hospital discharge data has 
good specificity but its sensitivity and positive predictive values are 
low. 
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Introduction: Because symptoms of thyroid dysfunction are not 
specific, laboratory confirmation by measuring thyroid-stimulating 
hormone (TSH) and free thyroxine (fT4) is essential. As small changes 
in fT4 result in large changes in TSH, TSH alone is a sensitive marker 
of thyroid dysfunction. Therefore, most guidelines for thyroid function 
evaluation recommend testing TSH first, with fT4 assessment only if 
TSH is outside the reference range (two-step) or if an abnormality of 
TSH secretion is suspected. However, the acceptance of these 
recommendations varies, even among experts and national thyroid 
associations, with several recommending that both TSH and fT4 
should be measured simultaneously (one-step), despite the up to 
two-fold higher costs. We aimed to compare the diagnostic 
concordance of the two-step vs. the one-step approach and to assess 
whether fT4 testing could be reduced.
Methods: In a cross-sectional analysis of participants in the 
population-based Busselton Health Study in Australia, we calculated 
diagnostic concordance between the two-step and the one-step 
approach. Results were deemed concordant when normal TSH 
matched normal fT4, increased TSH matched decreased fT4, and 
decreased TSH matched increased fT4. All other combinations, as well 
as subclinical thyroid dysfunction, were not considered concordant. 
Reference ranges were defined as between 0.45 and 4.49 mU/l for 
TSH, and between 11.2 and 20.8 pmol/l for fT4.
Results: Of the 4471 participants (age 17–97 years, 55% women), 
4156 (93%) were euthyroid, 35 (0.7%) had overt hypothyroidism, 86 
(1.9%) had subclinical hypothyroidism, 170 (3.8%) had subclinical 
hyperthyroidism, and 23 (0.5%) had overt hyperthyroidism. Using the 
two-step approach, TSH alone was sufficient to correctly diagnose 
euthyroidism in 89.2% of individuals. Of the remaining 10.8%, 7.0% 
had subclinical (5.8%) or overt thyroid dysfunction (1.2%) and 3.8% 
had a normal TSH but a fT4 outside the reference range. In most of 
these cases (85%), fT4 was within 2 pmol/l of the fT4 reference range 
limits, consistent with healthy outliers.
Conclusions: A two-step approach (fT4 assessment only in the case 
of an abnormal TSH) may prevent unnecessary fT4 measurement in 
up to 93% individuals. Simultaneous measurement of thyroid function 
with TSH and fT4 does not appear to be medically justified. 
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Background: It has recently been discovered that Neutrophil 
Extracellular Traps (NETs) are formed as an antimicrobial mechanism 
upon activation of neutrophil granulocytes, leading to an effective 
entrapment and killing of a wide variety of bacteria and other 
microbes. Neutrophil activation plays a major role in the 
pathophysiological cascades of community-acquired pneumonia (CAP) 
which is the leading cause of infectious death worldwide. However,  
to date there are no clinical data on NETs in pneumonia.
Methods: This is a secondary analysis of a randomised, placebo-
controlled, double-blind, multicenter trial. Patients aged >18 years with 
CAP were enrolled from seven tertiary care hospitals in Switzerland 
within 24 h of presentation. Patients were randomised (1:1 ratio) to 
receive either 50 mg of prednisone or placebo daily for 7 days. The 
primary endpoint was time-to clinical stability (TTCS); secondary 
endpoints were length of stay, mortality, duration of antibiotic 
treatment, CAP complications. NETs were assessed by measurement 
of cell-free nucleosomes in serum and plasma by sandwich ELISA. 
Multivariate regression models adjusted for severity (pneumonia 
severity index, age, gender, metabolic factors, cardiovascular diseases 
and other comorbidities) were performed in order to analyze 
associations with TTCS, length of hospital-stay, mortality, duration  
of antibiotic treatment and CAP complications. 
Results: A total of 310 randomised patients were included in the 
analysis. Overall, levels of NETs were significantly increased at time  
of emergency admission and declined over 7 days (2.67 vs. 1.18 
absorbance units (AU), p = 0.01). Baseline levels of NETs were 
associated with disease severity as well as reduced hazards of clinical 
stability [HR 0.97 (95% CI 0.94, 0.99), p = 0.041] and consecutive 
hospital discharge [HR of 0.90 (95% CI 0.82, 0.99), p = 0.012]. NETs 
were associated with a 3.81-fold odds ratio of 30-day mortality [(95% 
CI 1.39, 10.4), p = 0.009] and prolonged duration of intravenous 
antibiotic treatment by 0.5 days (95% CI 0.1, 0.94, p = 0.015). NETs 
were significantly increased after 5 days in the prednisone group  
(1.19 vs. 0.79 AU, p <0.0005).
Conclusion: NETs are considerably increased in community-acquired 
pneumonia and represent a novel biomarker for outcome prediction, 
i.e. for staging of disease severity and identification of patients at risk. 
Effects of prednisone may partly be explained by modulation of NET 
formation. 
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Background: Screening for prostate cancer is frequently performed in 
many western countries, including Switzerland. Various organizations 
have recently recommended against routine screening, notably due  
to the high risk of overdiagnosis or overtreatment. Our aim was to 
examine whether recent changes in secular trends in the incidence 
and mortality of prostate cancer, as well as prostatectomy rates have 
been observed in Switzerland. 
Methods: We assessed all cases of invasive prostate cancer, deaths 
from prostate cancer, and prostatectomy from 1998 to 2012 using data 
from the Swiss cancer registries, the Swiss Federal Statistical Office, 
and the Swiss Hospital Medical Statistics. We estimated age-
standardized incidence by tumor stage (early, advanced), prostate 
cancer-specific mortality, and prostatectomy, and stratified these rates 
by age group (<50 years, 50–69 years, ≥70 years). We calculated 
absolute and relative annual changes in rates. 
Results: Figure 1 illustrates the results. The age-standardized 
incidence of prostate cancer increased greatly in men aged 50–69 
years (absolute mean annual change +4.6/100’000 men, 95%CI: +2.9 
to +6.2) between 1998 and 2002, and stabilized afterwards. In men 
aged ≥70 years, the incidence decreased slightly between 1998 and 
2002, and more substantially since 2003. The incidence of early tumor 
stages increased between 1998 and 2002 in men aged 50–69 years 
only, then stabilized, while the incidence of advanced stages remained 
stable across all age strata. Since 1998, the annual age-standardized 
mortality rate of prostate cancer slightly declined in men aged 50–69 
years (absolute mean annual change –0.1/100’000, 95%CI: –0.2 to 
–0.1) and in men aged ≥70 years (absolute mean annual change 
–0.5/100’000, 95% CI: –0.7 to –0.3). The rate of prostatectomy 
increased until 2008, more so among men aged 50 to 69 years old 
than among men aged ≥70 years; it remained stable after 2008 in both 
age strata. 
Conclusions: The increase in the incidence of prostate cancer and in 
prostatectomy observed until recently in Switzerland, potentially 
revealing a growing frequency of overdiagnosis and overtreatment, 
has leveled off. This may reflect recent changes in screening and 
clinical workup practices. 
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Background: Acute chest pain is one of the leading causes for 
emergency room visits. In more than 70 percent no cardiac etiology is 
found. Recently derived prediction rules, the Troponin-only Manchester 
Acute Coronary Syndromes (T-MACS) and the Vancouver Chest pain 
rule 2014 (VCP 2014) included the high sensitive Troponin T-assay 
(hs-Trop-T) to identify low risk patients and demonstrated good 
sensitivity. However, for many rules patients with a moderate to high 
pretest probability were included and few external validation studies 
exist. The aim of the study was to externally validate currently available 
chest pain rules in patients presenting with non-cardiac (NCCP) and 
cardiac chest pain (CP) to the emergency department of the 
Kantonsspital Winterthur. 
Methods: Retrospective chart review of patient seeking care for acute 
chest pain of non-cardiac and cardiac origin at the emergency 
department between December 1, 2009 and December 31, 2011. 
Patients were identified using ICD-10 codes for NCCP and CP. Data 
was extracted in a predefined form. The quality of the data extraction 
was very good (<10% extraction errors). Missing values were multiply 
imputed. Using the cut-off of <2% Risk to miss a CP the sensitivity and 
specificity for the T-MACS rule and the VCP 2014 rule were calculated. 
Results: In total 1467 patients were included of whom 245 (16.7%) a 
CP was diagnosed (104 STEMI, 125 NSTEMI, 4 ACS). The VCP 2014 
correctly identified 245 (100%) CP and 578 (47%) NCCP cases, 
misdiagnosed 0 CP and 644 (53%) NCCP. The MACS-T rule was 
applied to a subset of 766 patients in whom hs-Trop-T were available. 
The MACS-T rule correctly identified (Risk <2% for ACS) 112 (77%) 
CP and 344 (55%) NCCP cases, misdiagnosed 33 CP (23%) and 277 
(45%) NCCP. The sensitivity for the MACS-T rule was 71%, for the 
Vancouver Chest Pain Rule 100%. The specificity was 62% and 56%, 
respectively. 
Conclusion: The external validation in a low risk population for 
cardiac chest pain demonstrated a high sensitivity for the VCP 2014 
rule whereas the sensitivity for the MACS-T rule was poor. Both rules 
showed poor specificity. 
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Introduction: Thyroid-stimulating hormone (TSH) measurement is 
recommended in etiologic dementia work-up. However, data on the 
association between subclinical thyroid dysfunction (SCTD) and 
dementia are limited, because well-performed prospective cohorts with 
long follow-up are lacking. We prospectively assessed the association 
of SCTD with incident dementia and decline in Modified Mini-Mental 
state (3MS) in a large cohort of older adults. 
Methods: We studied participants from the Health, Aging, Body and 
Composition Study, with thyroid function measurement but no 
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Objective: Four strategies for very early rule-out of acute myocardial 
infarction (AMI) using high-sensitivity cardiac troponin I (hs-cTnI) have 
been identified. It remains unclear which strategy is most attractive for 
clinical application. 
Methods: We prospectively enrolled unselected patients presenting to 
the emergency department (ED) with symptoms suggestive of AMI. 
The final diagnosis was adjudicated by two independent cardiologists. 
Hs-cTnI levels were measured at presentation and after 1h in a blinded 
fashion. We directly compared all four hs-cTnI-based rule-out 
strategies: limit of detection (LOD, hs-cTnI <2 ng/L), single cut-off 
(hs-cTnI <5 ng/L), 1h-algorithm (hs-cTnI <5 ng/L and 1h-change  
dementia at baseline, and 3MS at baseline and follow-up. Dementia 
was adjudicated based on: 1) race-stratified 3MS change ≥1.5SD; 2) 
dementia diagnosis on hospital records and 3MS ≤90; 3) dementia 
drug. Subclinical hyperthyroidism (SHyper, TSH <0.45 mIU/L, free 
thyroxine [FT4] normal) and subclinical hypothyroidism (SHypo, TSH 
4.50–19.99 mIU/L, FT4 normal) were compared with euthyroidism 
(TSH 0.45–4.49mIU/L). Dementia risk was assessed by competing-
risk Cox regression and 3MS change over time by mixed-effects 
models, adusting for age, race, education and baseline 3MS in the 
main analysis, and then further for cardiovascular risk factors. 
Results: Among 2558 participants, mean age was 75.1 (SD 2.8); 52% 
were women, 85% were euthyroid, 3% had SHyper and 12% SHypo. 
Over 9 years, 22% participants developed dementia. Among men, 
incidence of dementia was 38% for SHyper, 22% for euthyroidism and 
17% for SHypo. Among women, it was 20% for SHyper, 24% for 
euthyroidism and 21% for SHypo. Compared to euthyroids, risk of 
dementia was increased in men with SHyper (adjusted HR 2.02 
[95%CI 1.03;3.96]), but not in women (adjusted HR 0.73 [95%CI 
0.40;1.35], P = 0.02 for interaction by gender). On average, men with 
SHyper had larger (–4.59 [95%CI –7.96; –1.22]) decline in 3MS than 
euthyroid men, while it did not differ in women with SHyper or SHypo 
participants. All results were similar after adjusting for cardiovascular 
risk factors. SHypo was not associated with dementia (adjusted HR 
0.91 [95%CI 0.70;1.19]).
Conclusion: Among older adults, men with SHyper had increased risk 
of dementia and larger decrease in cognition, whereas women with 
SHyper and SHypo participants did not. Checking TSH among 
patients with dementia seems appropriate. Clinical trials are needed to 
assess if treating SHyper in older men reduces incidence and 
progression of cognitive impairment. 
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Introduction: Not all patients carry the same risk of developing a 
post-thrombotic syndrome (PTS) after a first lower limb deep vein 
thrombosis (DVT) event. We sought to derive a clinical prediction 
model for prognosis to estimate the risk of PTS development within 
24 months of an index DVT.
Methods: We used data from 276 patients with a first acute 
symptomatic DVT included in a prospective cohort as our derivation 
sample. We derived our prediction rule using logistic regression with 
backward selection, with the occurrence of the PTS within 24 months 
of an index DVT based on the Villalta scale as the outcome, and 12 
candidate variables as predictors. We used bootstrapping methods for 
internal validation.
Results: Analyzed patients had a median age of 74 years, 46% were 
women, 32% had a concomitant PE, and 18% presented an isolated 
distal DVT as the initial DVT event. The majority (60%) of DVT events 
was unprovoked and 17% of DVTs were cancer-related. Overall, 161 
patients (58.3%) developed a PTS within 24 months of an index DVT 
based on the Villalta scale. Our prediction rule is based on 6 clinical 
risk factors (age ≥75 years, presence of peripheral arterial disease, 
prior varicose vein surgery, multilevel thrombosis, concomitant 
antiplatelet or NSAID therapy, and the number of leg symptoms and 
signs). 
Overall, 16.3%, 30.8%, and 52.9% of patients were classified as low 
(score 0–3), moderate (score 4–5), and high-risk (score ≥6) for 
developing a PTS, respectively. Within 24 months of an index DVT, 
24.4% of the patients in the low-risk category developed a PTS, 38.8% 
in the moderate-risk category, and 80.1% in the high-risk category. 
Table 2 shows the predictive accuracy for risk category ≥6 points  
(high vs medium/low risk). 
The prediction model had a good discriminatory power (AUC 0.79; 
95% confidence interval 0.74–0.84) and a good fit (P = 0.12).  
Internal validation showed similar results.
Conclusions: This easy to use clinical prediction rule accurately 
identifies patients with acute symptomatic DVT who are at high risk of 
developing a PTS within 24 months. This particular group of patients 
may benefit from specific educational and therapeutical options to 
prevent PTS. Further validation of the score is important before its 
implementation into practice. 
Table 1: Risk factors of PTS within 24 months.
  Odds Ratio 
(95%-CI)
β-Coefficient** 
(95%-CI)
Points 
assigned
Age ≥75 years 1.61 (0.91–2.85) 0.48 (-0.10–1.05) +1
Concomitant 
antiplatelet/NSAID 
therapy
1.98 (1.05–3.70) 0.68 (0.05–1.31) +1
Multilevel thrombosis 1.66 (0.93–2.98) 0.51 (–0.07–1.09) +1
Peripheral arterial 
disease
2.50 (0.73–8.60) 0.91 (–0.32–2.15) +1
Prior varicose vein 
surgery
2.81 (1.04–7.65) 1.04 (0.04–2.03) +1
Number of signs  
and symptoms*
1.65 (1.40–1.95) 0.50 (0.34–0.67) +1 each
Abbreviations: CI : confidence interval ; NSAID : non steroidal anti-
inflammatory drug, *including pain, cramps, heaviness, pruritus, paresthesia, 
edema, skin induration, hyperpigmentation, venous ectasia, redness, pain 
during calf compression. **from multivariable model
Table 2: Predictive accuracy for risk category ≥6 points.
PTS Sensitivity % (95%-CI)
Specificity % 
(95%-CI)
PPV % 
(95%-CI)
NPV % 
(95%-CI)
within 3 
months
76.9 
(68.1–83.8)
62.5 
(55.0–69.5)
56.8 
(48.7–64.6)
80.8 
(73.2–86.6)
within 12 
months
72.9 
(65.0–79.5)
67.6 
(59.4–74.9)
69.9 
(62.0–76.7)
70.8 
(62.4–77.9)
within 24 
months
72.7 
(65.3–79.0)
74.8 
(66.1–81.8)
80.1 
(72.9–85.8)
66.2 
(57.7–73.7)
Abbreviation: PTS: post-thrombotic syndrome; PPV: positive predictive value; 
NPV: negative predictive value; CI: confidence interval
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COPD management guidelines assembling effective care elements to 
reduce the burden of COPD to patients and health systems. Because 
comprehensive care is complex shortcomings in health service 
delivery for COPD are common.
Objectives: To test whether a multifaceted intervention delivered to 
general practitioners (GPs) and their practice assistants increases 
adherence to recommended key elements and processes of COPD 
care.
Methods: Cluster-randomized pragmatic clinical trial, 1:1 
randomization on the GP-level. The intervention was designed to 
improve knowledge but also and particularly governing professional 
behavior by implementation of a primary care “COPD care bundle”, a 
tool to support evidence-based decision making and practice. Data 
was collected using questionnaires at GP and patient level at baseline 
and one year after the intervention. The primary outcome measure 
was the implementation of 15 individual (figure) processes of care. The 
primary outcome was the composite score of implemented processes 
measured at the patient level. 
Results: Thirty-five GPs and 216 patients median age 69 years, 59% 
female, 69% GOLD stadium A or B were enrolled, 161 patients 
completed follow-up (drop-out rate 25%). After one year the composite 
score of implemented care processes increased from 4.7 to 6.1 (+1.4) 
in the intervention group and decreased from 5.3 to 4.4 (–0.9) in the 
control group. Linear regression model adjusting for baseline 
characteristics revealed a between-group difference of +2.0 (95% CI 
+1.2 to +2.8) implemented processes in favour of the intervention 
group. The effect remained statistically significant in sensitivity 
analyses simulating missing data due to drop-out. Detailed analyses 
showed that the intervention significantly increased adherence in 
10 out of 15 processes of care (fig.).
Conclusion: A multifaceted intervention comprising GP education and 
a COPD care bundle resulted in increased implementation of 
recommended care processes.
<2 ng/L), and the 0h/1h algorithm recommended in the European 
Society of Cardiology guideline combining LOD and 1h-algorithm.
Results: Among 2828 enrolled patients, AMI was the final diagnosis in 
451 (16%) patients. The LOD approach ruled-out 453 patients (16%) 
with a sensitivity of 100% (95% CI, 99.2–100%), the single cut-off 1516 
patients (54%) with a sensitivity of 97.1% (95% CI, 95.1–98.3%), the 
1h-algorithm 1459 patients (52%) with a sensitivity of 98.4% (95% CI, 
96.8–99.2%), and the 0h/1h-algorithm 1463 patients (52%) with a 
sensitivity of 98.4% (95% CI, 96.8–99.2%). Predefined subgroup 
analysis in early presenters (≤2h) revealed significantly lower 
sensitivity (94.2%, interaction p = 0.03) of the single cut-off, but not the 
other strategies. Two-year survival was 100% with LOD and 98.1% 
with the other strategies (p <0.01). 
Conclusions: All four rule-out strategies balance effectiveness and 
safety equally well. The single cut-off should not be applied in early 
presenters, while the three other strategies seem to perform well also 
in this challenging subgroup. 
Figure 1
Figure 2
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Background: Chronic obstructive pulmonary disease (COPD) is 
progressive, disabling and associated with increased mortality. 
Research efforts and international collaborations led to comprehensive 
Figure: Intervention effects on processes of care.
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Introduction: The benefits and harms of adjunctive systemic 
corticosteroids for community-acquired pneumonia (CAP) are 
inconclusive. We aimed to evaluate the effects of adjunctive 
corticosteroids in adults hospitalised with CAP on patient-important 
outcomes using individual patients’ data of randomised placebo-
controlled trials and to explore subgroup differences.
Methods: We systematically searched MEDLINE, EMBASE, 
Cochrane Central Register of Controlled Trials, and trial registers plus 
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Objective: Standard operating procedures (SOP) for office blood 
pressure measurement (OBPM) vary highly between different 
guidelines. The NICE 2013 guidelines for arterial hypertension (AH) 
SOP recommends a first blood pressure measurement (BPM) after 5 
minutes rest and a second BPM if blood pressure (BP) is >139 mm Hg 
systolic (s139) or >89 mm Hg diastolic (d89). We aimed to study how 
many probably hypertensive patients may be missed by this approach 
due to short term masked hypertension (STMH). 
Design and method: In this cross-sectional, single-centre trial, 1000 
adult subjects were recruited. Seven sequential BPM were performed 
by an operator after five minutes rest in a quiet room and in sitting 
position. The BPM were taken using a standard device (Omron 
HBP-1300 professional BP monitor, appropriate cuff size), alternating 
with a tested smartphone app. Standard BPM were spaced 2 minutes 
apart. Overall, 4 standard and 3 smartphone BPM were taken, 
however, only standard BPM were used for this study. Additional 
information about cardiovascular risk factors, concomitant disease, 
and medication were collected. We compared the first BPM out of four 
to the three following BPM. STMH was defined as first BP <s140 and 
<d90 mm Hg and one of the consecutive BPM >s139 or >d89 mm Hg. 
Results: Complete measurements were available in 802 subjects. We 
identified 528 (65.8%) subjects with a BP<s140 and <d90 mm Hg in 
the first measurement. In 61/528(11.6%) subjects at least one 
consecutive BPM was >s139 or >d89 mm Hg and in 18/528 (3.4%) the 
mean of 2nd-4th measurement was >s139 or >d89 mm Hg. 412/802 
(51.4%) subjects had no history of AH and normal first BPM. In this 
group STMH was present in 45/412 (10.9%). Subjects with STMH 
showed no differences in clinical parameters in comparison to subjects 
with normal BPM over all measurements. 
Conclusion: By applying the SOP for OBPM suggested by NICE we 
found short term masked hypertension in more than 10% of all 
apparently normotensive subjects and especially in 11% of apparently 
normotensive subjects without known AH. Therefore by this SOP a 
significant proportion of patients may be missed for further evaluation. 
a hand search of conference proceedings (all through 9 June 2016)  
for eligible trials. Data from 1,506 individual patients in six trials were 
analysed using uniform outcome definitions. We investigated pre-
specified effect modifiers using multivariable hierarchical regression 
adjusting for pneumonia severity, age, and clustering effects. 
Results: Within 30 days of randomisation, 37 of 748 patients (5.0%) 
assigned to corticosteroids and 45 of 758 patients (5.9%) assigned to 
placebo died (adjusted odds ratio [OR], 0.75; 95% confidence interval 
[CI], 0.46–1.21, p = 0.24). Time to clinical stability and length of 
hospital stay were reduced by approximately one day with 
corticosteroids (adjusted difference, –1.03 days; 95% CI, –1.62-(–0.43), 
p = 0.001; and –1.15 days; 95% CI, –1.75-(–0.55), p <0.001, 
respectively). Patients who received corticosteroids had a higher 
incidence of hyperglycaemia requiring insulin treatment (160 [22.1%] 
vs 88 [12.0%]; adjusted OR, 2.15; 95% CI, 1.60-2.90, p <0.001; 
number needed to harm [NNH], 9; 95% CI 6–17) and CAP-related 
re-hospitalisation (33 [5·0%] vs 18 [2.7%]; adjusted OR, 1.85; 95% CI, 
1.03–3.32, p = 0.04; NNH, 45; 95% CI 18–1235). There were no 
significant differences for other CAP-related or corticosteroid-related 
adverse effects between groups. We did not find significant effect 
modification by CAP severity or degree of inflammation. 
Conclusions: Adjunct corticosteroids for patients hospitalised with 
CAP reduce time to clinical stability and length of hospital stay by 
approximately one day without a significant effect on overall mortality 
but with an increased risk for CAP-related rehospitalisation and 
hyperglycaemia. 
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measured according to the NICE 2013 guidelines –  
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Effects of exercise and vitamin D on quality of life  
after hip fracture
Klavs Renerts1,2,3, Karina Fischer1,2,3, Otto Meyer1,2,3, Robert 
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Introduction: Exercise and vitamin D supplementation are 
inexpensive and accessible means of aiding the recovery process after 
hip fracture. However, information on the benefit of these interventions 
on health-related quality of life (HRQL) after hip fracture is missing. We 
tested the effects of a simple home exercise program and vitamin D 
supplementation on HRQL in the first 12 months after hip fracture in  
an ancillary study of the Zurich Hip Fracture Trial that tested the 
interventions in a 2×2 factorial trial design. 
Methods: We enrolled 165 of 173 acute hip fracture patients from the 
original trial who had baseline information on HRQL (mean age 84 
years, 79% females, 77% community dwelling). We then tested the 
effects of the simple home exercise program (home exercise program 
+ standard physiotherapy vs. standard physiotherapy alone) and 
vitamin D supplementation (800 vs. 2000 IU/day) on HRQL over time. 
HRQL was measured as EQ-5D index score, calculated from the 
EQ-5D-3L questionnaire at baseline, 6 months and 12 months. At 
baseline, participants were asked to estimate their pre-fracture HRQL. 
Effects by treatment were analyzed using multivariable repeated-
measures analysis adjusted for age, gender, body mass index, 
comorbidities, mini-mental state examination (MMSE), living status, 
and baseline serum 25-hydroxyvitamin D concentration. 
Results: The adjusted EQ-5D index score significantly worsened from 
0.71 pre-fracture to 0.57 over time, but did not differ by treatment. 
However, while all other groups remained stable after the 6-month 
decline, the control group receiving only low dose vitamin D (800 IU/
day) and no home exercise program experienced a significant further 
decline in the EQ-5D index score between 6 and 12 months of 
follow-up (p = 0.028). Notably, independent of the interventions and 
other covariates, patients with a better baseline MMSE score and 
those living in the community prior to their fracture, had a significantly 
lower decline in HRQL after hip fracture. 
Conclusion: Based on our trial hip fractures have a long-lasting 
negative effect on HRQL up to 12 month after hip fracture. A simple 
home exercise program and high-dose vitamin D may help prevent a 
further decline in HRQL after the first 6 months of the index fracture.
Funding: This project was supported by the Baugarten Centre Grant 
for the Centre on Aging and Mobility, and by the University Research 
Priority Program “Dynamics of Healthy Aging”, University of Zurich. 
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Vitamin D status and body composition 
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Introduction: Vitamin D has been linked to muscle health and insulin 
sensitivity. However, there is limited data on whether 25-hydroxyvitamin 
D (25(OH)D) status is associated with body composition. We 
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Pain sites and severity, a national survey of health- 
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older adults with pain
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François Herrmann4, Christophe Luthy1 
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Sciences – Geneva, University of Applied Sciences and Arts of 
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Background: Regarding the epidemiology of pain in older adults, data 
are lacking about the association between pain severity and its impact 
on of health-related quality of life (HRQoL). The purpose of this study 
was to investigate pain prevalence and sites, its self-reported 
interferences with daily life activities, and the effect of pain severity on 
HRQoL in a Swiss community-dwelling population aged ≥65 years. 
Methods: This cross-sectional national survey included a sample of 
individuals selected randomly from population records, stratified by 
age and gender. Respondents answered a face-to-face interview 
addressing pain location, intensity and interference with activities, and 
quality of life variables. Logit regression models were applied for binary 
outcomes, linear regression for continuous outcomes, and Poisson 
regression for count outcome. For each analysis, Wald Chi-square and 
95% confidence intervals were used. 
Results: Among the 2’995 individuals considered, 36.4 % reported 
pain. The results indicate that pain increases with age; more precisely, 
this increase concerns pain intensity from age 85 onward. Pain 
severity was strongly associated with HRQoL and functional impact, 
i.e., all scales involving physical activities were affected in those 
individuals reporting severe pain; it was also associated with the 
individuals’ perception of their overall HRQoL. Pain severity had a 
significant effect on this perception.
Conclusions: Our results point to the importance of devoting attention 
to pain intensity rather than to the number of pain sites. Because of the 
demographic transition the management of pain problems should 
emphasize early referral and timely treatment in order to prevent the 
burden of disease and functional loss associated to pain severity. 
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Cognitive function in DO-HEALTH
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Introduction: Impaired cognition and impaired physical function are at 
the root of disability at older age and often occur together. In this study, 
we assess cognitive function among 2157 seniors from 5 European 
countries enrolled in the large DO-HEALTH study using two different 
screening tools (Montreal Cognitive Assessment and Mini Mental 
Examination). In addition, we correlated cognitive function with 
performance in physical function tests.
Methods: DO-HEALTH is the largest ongoing European Longevity 
Trial testing the role of vitamin D and/or omega 3-fats and/or a simple 
home exercise program among 2157 community-dwelling seniors 70 
years and older from 5 European countries. Participants were required 
to have a Mini-Mental State Examination (MMSE) score of at least  
26 to be eligible for the study. At baseline, cognitive function was 
additionally assessed using the Montreal Cognitive Assessment 
scores (MoCA). Physical function tests were conducted at the baseline 
clinical visit and included the short physical performance battery 
(SPPB) that comprises balance, gait speed and the repeated-sit-to-
stand test.
Results and conclusions: First findings on baseline data from all 
2157 DO-HEALTH seniors will be presented at the meeting. 
investigated if and to what extent 25(OH)D status is associated with 
body composition (muscle and fat mass), as well as insulin resistance 
among relatively healthy community-dwelling seniors.
Methods: We enrolled 271 seniors age 60 years and older (mean age 
70.4 years, 53% women, 31.4% vitamin D deficient (<20 ng/mL)) 
undergoing elective surgery for unilateral knee replacement due to 
severe knee osteoarthritis (Baseline Exam Zurich Knee OA Trial). 
Analyses compared baseline body composition (percentages of total 
lean mass (TLM%) and total fat mass (TFM%), appendicular lean 
mass index (ALMI), and fat mass index (FMI)) assessed by dual-
energy X-ray absorptiometry) and insulin resistance between quartiles 
of baseline serum 25(OH)D levels using multivariable linear regression 
models. Models were controlled for age, gender, smoking status and 
physical activity. 
Results: While we did not find a difference on muscle mass, 
participants in the lowest 25(OH)D quartile (4.7–17.5 ng/ml) had a 
higher FMI than participants in the third (26.1–34.8 ng/ml; 9.3 vs. 8.4 
kg/m2; P = 0.049) and highest (34.9–62.5 ng/ml; 9.3 vs. 8.4 kg/m2;  
P = 0.044) quartile. Moreover, participants of the second 25(OH)D 
quartile (17.6–26.0 ng/ml) had higher β-cell function (77.9% vs. 59.6%; 
P = 0.018) consistent with their lower insulin sensitivity (152.8% vs. 
215.3%; P = 0.005) compared with participants of the highest 25(OH)
D quartile. Insulin resistance was more prevalent among participants 
in the lowest 25(OH)D quartile compared with the highest quartile 
(23.8% vs. 6.3%; P = 0.006). 
Conclusions: Our findings suggest an inverse association between 
serum 25(OH)D level and FMI. Consistently, prevalence of insulin 
resistance was higher among seniors with low serum 25(OH)D status. 
Thus, based on these cross-sectional analyses a replete vitamin D 
status may support preserving a healthy body composition and help 
prevent insulin resistance among seniors. 
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Bioimpedance-derived phase angle and mortality  
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Background: Phase angle measured by bioelectrical impedance 
analysis (BIA) may be a marker of health state. 
Objective: This historical cohort study of prospectively collected BIA 
measurements aims to investigate the link between phase angle and 
mortality in older people and evaluate whether a phase angle cut-off 
can be defined.
Design: We included all adults aged 65 years and over who 
underwent a BIA measurement by the Nutriguard® device at the 
Geneva University Hospitals. We retrieved retrospectively the phase 
angle and co-morbidities at the last BIA measurement and the 
mortality until December 2012. We calculated phase angle 
standardized for sex, age, and body mass index, using reference 
values determined with the same brand of BIA device. Sex-specific 
and standardized phase angle were categorized into quartiles. The 
association of mortality with sex-specific or standardized phase angle 
was evaluated through univariate and multivariate Cox regression 
models, Kaplan-Meier curves, and ROC curves. 
Results: We included 1307 (38% women) participants, among whom 
628 (44% women) died. In a multivariate Cox regression model 
adjusted for co-morbidities and setting of measurement (ambulatory 
vs. hospitalized), the protective effect against mortality increased 
progressively as the standardized phase angle quartile increased 
(HR 0.71 (95% CI 0.58, 0.86), 0.53 (95% CI 0.42, 0.67), 0.32 (95%  
CI 0.23, 0.43)). The discriminative value of continuous standardized 
phase angle, assessed as the area under the ROC curve, was 0.72 
(95%CI 0.70, 0.75). We could not define an acceptable phase angle 
cut-off for individual prediction of mortality (LK), based on sensibility 
and specificity values.
Conclusions: This study shows the association of phase angle and 
mortality in older patients, independently of age, sex, comorbidities, 
BMI categories, and setting of measurement. 
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insufficient levels of 25(OH) vitamin D. In a follow up enquiry on further 
health status of participants, SENIORLAB allowed to deduce, that the 
cystatin C/creatinine ratio lets survey mortality and subjective overall 
morbidity at follow up when computed by logistic regression. In  
289 participants evaluated, serum uromodulin displayed inverse 
relationship with creatinine, cystatin C and urea and we now are 
convinced, in line with others, that serum uromodulin behaves in a 
manner opposite that of the different conventional renal retention 
markers: lower serum concentrations go along with reduced 
glomerular filtration rates. SENIORLAB thus not only establishes 
reference intervals in the elderly but also helps to elucidate 
physiopathological aspects of selected parameters as well as to 
grapple with a problem raised by WHO about the definition of health. 
Upon follow up evaluations of study participants years later, biomarker/
risk factor status for length/quality of remaining life years might show 
up for certain analyses. So far carried out lab assays with this 
sedentary study participant cohort in the Swiss midlands, a high-
income population (OECD classification) might serve as reference  
to study global health issues in low and middle income or poorer 
populations as well as in migrants; the global burden of 
noncommunicable diseases is at stake. 
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Introduction: Physical frailty is at the root of accelerated aging, and  
is an independent predictor of worse clinical outcomes among older 
adults in acute care. By 2030, the personal, societal, and health 
economic burden of frailty is expected to at least double, in parallel  
to the projected growth of the older segment of the population. In this 
study, we will assess the prevalence of frailty among 2157 seniors 
from 5 European countries enrolled in the large DO-HEALTH study 
using the Linda Fried Frailty Score. 
Methods: DO-HEALTH is the largest ongoing European Longevity 
Trial testing the role of vitamin D and/or omega 3-fats and/or a simple 
home exercise program among 2157 community-dwelling seniors 70 
years and older from 5 European countries. At baseline, we assessed 
the phenotypic model of physical frailty operationalized by five 
characteristic domains (fatigue, weight loss, slowness, low activity 
level and weakness). 
Results and conclusions: First findings on baseline frailty data from 
all 2157 DO-HEALTH seniors from 5 European countries (Switzerland, 
Germany, Austria, France and Portugal) will be presented at the 
SGAIM Spring Meeting in May 2017. 
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Introduction: By 2030, seniors age 70 years and older will double,  
as will the number of seniors with falls and resulting impairments in 
function and mobility. In this study, we will compare functional status 
among fallers and non-fallers among 2157 seniors from 5 European 
countries enrolled in the large DO-HEALTH study. 
Methods: DO-HEALTH is the largest ongoing European Longevity 
Trial testing the role of vitamin D and/or omega 3-fats and/or a simple 
home exercise program among 2157 community-dwelling seniors 70 
years and older from 5 European countries. At baseline, we asked 
participants about their fall status in the year prior to enrollment and 
had a target recruitment of 40% for participants with a prior fall. In this 
study we will present baseline functional measures of gait speed, 
chair-rise test, and grip strength by fall status. 
Results and conclusions: First findings on baseline functional data 
from all 2157 DO-HEALTH seniors from 5 European countries 
(Switzerland, Germany, Austria, France and Portugal) by fall status will 
be presented at the SGAIM Spring Meeting in May 2017. 
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SENIORLAB: a prospective observational lab assay  
survey in 1467 sedentary healthy elderly
Martin Risch1, Urs Nydegger2, Lorenz Risch3 
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Reference intervals for laboratory analyses by and large are provided 
by analytical platform providers – provenience and preanalytics of 
materials for calculation of intervals often remain arcane particularly 
relating to age group of donors. In an observational, prospective cohort 
study on 1467 healthy uniracial caucasian residents >60 yrs of age, 
105 frequently used lab tests were done on one blood sample/
participant and reference intervals were calculated according to the 
CLSI-C28-A3c guideline separately with partitioning factors, e.g. age, 
gender and adapted exlusion criteria such as smoldering inflammation 
or iron deficiency; outliers were eliminated according to Dixon&Reed. 
With a nonrestrictive definition of health several pathological laboratory 
results pointing to occult disease have been found and published from 
SENIORLAB so far. Thus, 64.5% of the cohort showed prediabetic 
fasting plasma glucose and/or glycated hemoglobin (HbA1c); total 
serum folate levels but not red blood cell folate decreased with 
progressing age and 66% of 1470 evaluable study participants had 
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Cellular immunotherapy with multiple infusions of ex vivo 
expanded haploidentical natural killer cells after autologous 
transplantation for patients with plasma cell myelom
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Plasma cell myeloma (PCM) is currently treated with chemotherapy 
and autologous stem cell transplantation (ASCT) but relapse rates 
remain high. Adoptive transfer of mature haploidentical natural killer 
(NK) cells is a promising approach to provide PCM patients with highly 
immunocompetent effector cells with anti-myeloma function early post 
transplantation. Here we report on the current clinical Phase I/II trial of 
multiple preemptive infusions of good manufacturing practice (GMP) 
expanded NK cells to PCM patients. Ten patients were recruited 
(median age: 59y). All patients received 4 cycles of VTD chemo therapy 
(reaching 4xCR, 5xVGPR and 1xPR) before high dose melphalan and 
ASCT. NK cells from haploidentical family donors were purified from 
leukapheresis by T cell depletion and NK cell selection. Highly pure NK 
cells (mean: 4.8×108 cells) were obtained with a minimal T cell 
contamination corresponding to a 6.1 log T cell depletion. After 
expansion ex vivo for 19 days in GMP-medium containing autologous 
irradiated feeder cells, interleukin-2 and -15, NK cell numbers 
increased 54-fold (range: 38- to 76-fold). In three NK cell products T 
cell contents were 10x above limit of clinical trial and were successfully 
reduced by 2° T cell-depletion from 11 to 0.3×105cells/kg body weight 
(BW). NK cells were cryopreserved in escalating doses (1.3×106, 
1.3×107 and multiple doses of maximal 1.0×108 cells/kg BW). The PCM 
patients received 65–460×108 expanded NK cells (median: 3.8×108 
cells/kg BW, range: 0.9–5.7×108 cells/kg BW) as 3–8 infusions 
(median. 6 DLIs). The NK-DLIs were administered between day 2 and 
21 after ASCT and were well tolerated without any acute adverse 
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adhesion capacity to stromal cells and (2) dislocating healthy 
hematopoietic stem/progenitor cells from the niche. Consistently, in 
vivo DKK-1 pre-treatment promoted leukemic cell homing to the BM. 
Conclusion: Our data suggest that CDX2 plays important roles in 
human AML cells during in vivo leukemogenesis by sustaining their 
endogenous canonical WNT activity and concomitantly inducing 
DKK-1 secretion to alter stromal cells and healthy hematopoiesis. 
185
Development of a peptide macrocycle factor XII inhibitor  
for safe anticoagulation therapy
Raja Prince1,2, Jonas Wilbs3, Simon J. Middendorp3,  
Christian Heinis3, Anne Angelillo-Scherrer1,2 
1Department of Hematology and Central Hematology Laboratory, 
Inselspital, Bern University Hospital, University of Bern; 2Department 
of Clinical Research, University of Bern, Bern; 3Institute of Chemical 
Sciences and Engineering, Ecole Polytechnique Fédérale de 
Lausanne (EPFL), Lausanne, Switzerland
Introduction: Factor XII (FXII) is a plasma serine protease that was 
identified as a coagulation factor. FXII has a highly conserved amino 
acid sequence across disparate species, suggesting that this molecule 
does have a physiologic function. Mechanistic research based on 
animal models indicates that FXII contributes to thrombotic disease  
by triggering excessive coagulation. Inhibiting FXII has been shown  
to reduce thrombosis without increasing the bleeding risk, a major 
side-effect of currently used anticoagulants. Until recently, several 
protein-based FXII inhibitors were developed, out of which at least one 
is in clinical trial, but no high affinity small molecule inhibitor has been 
reported. 
Methods: Bicyclic peptide synthesis, protease inhibition assays for  
the following serine proteases: tPA, uPA, factor XIa, plasma kallikrein, 
thrombin, plasmin, trypsin, factor VIIa, factor Xa, trypsin and factor 
XIIa, structural model and structure analysis, plasma stability assays, 
aPTT and PT coagulant activity measurements, pharmacokinetics in 
mouse and rabbit, FeCl3 injury thrombosis model in mesenteric 
arteries in mouse. 
Results: We have generated a potent and highly selective FXII 
inhibitor based on a macrocyclic peptide format (MW <2000 kDa). 
Recently, we had improved the potency and stability of the inhibitor 
using various approaches based on unnatural amino acid 
incorporation. The final peptide shows high inhibitory affinity and 
selectivity with a high stability in plasma (Ki = 380 ± 80 pM, >200,000-
fold selectivity, t1/2 plasma >96 h). The inhibitor prolonged intrinsic 
coagulation in human, mouse and rabbit plasma (EC2X human = 1 µM). 
Pharmacokinetic studies in mouse and rabbit showed that the peptide 
was active in vivo and no signs of toxicity or abnormal bleeding were 
observed. We then recorded thrombus formation in mesenteric 
arterioles by intravital microscopy in mouse, a thrombosis model 
sensitive to defects in the intrinsic pathway of coagulation. The peptide 
could substantially reduce thrombus formation (peptide: 3/9 (33%), 
control: 7/8 (87%), P <0.05), full occlusion (peptide: 0/9 (0%), control: 
5/8 (63%), P <0.05), time to thrombus formation (peptide: 20 ± 3.6 
min, control: 9.6 ± 5.7 min, P <0.05). 
Conclusion: Our results suggest that FXII inhibition by a peptide 
macrocycle can potentially offer a safe anticoagulation therapy. 
events. No signs of acute or chronic graft-versus-host disease were 
observed after a total of 57 NK-DLIs. Engraftment occurred between 
days 13-24 (median: 16 days). Infused donor NK cells were monitored 
by short-tandem repeats PCR. Donor NK cells were detected in blood 
one and 20 hours post infusion (% donor NK of enriched blood NK 
cells: mean: 30%, range: 9–90%, and mean: 17%, range: 0–33%, 
respectively) indicating significant NK cell survival in same recipients. 
Clinical responses at last follow-up compared to a retrospective cohort 
of matched control patients will be presented. These results 
demonstrate the feasibility of large-scale GMP expansion and safety 
and tolerability of multiple high-dose infusions of human NK cells as 
immunotherapy after stem cell transplantation for PCM. 
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Objectives: The caudal-type homeobox (CDX) gene family regulates 
embryonic hematopoiesis via downstream HOX genes and 
interactions with the WNT signaling pathway. CDX2 expression is not 
detected in healthy bone marrow (BM) cells but present in >80% of 
human acute myeloid (AML) and lymphoid leukemia (ALL). Ectopic 
activation in murine BM cells induces myeloid leukemia. Here, we 
explore the functional role and molecular targets of CDX2 in human 
leukemia.
Methods: CDX2 expression was modulated via lentiviral and siRNA 
treatment in human BM CD34+ and human leukemic cell lines. CDX2 
modified and control cells were subjected to growth, colony forming 
(CFU), cell cycle, flow cytometry, adhesion and qRT-PCR assays and 
analyzed in vivo upon xenotransplantation in NOD/SCID/IL2Rγnull 
(NSG) mice for bone marrow (BM) homing and leukemogenesis. 
DKK-1 protein levels were measured in the supernatant via ELISA and 
the effect of DKK-1 supplementation on leukemic versus healthy 
hematopoietic cells explored in in vitro and in vivo assays.
Results: CDX2 knockdown in AML cells strongly reduced 
clonogenicity while leaving proliferation, apoptosis and cell cycle 
unaltered. Importantly, CDX2 knockdown profoundly suppressed in 
vivo leukemogenic properties. Gene set enrichment analyses (GSEA) 
of microarray data collected on CDX2 overexpressing versus control 
leukemic cells revealed WNT signaling and cell adhesion genes as the 
pathways most prominently regulated by CDX2. Surprisingly, CDX2 
overexpressing leukemic cells showed both induction of activated 
beta-Catenin and of secreted DKK-1, a known WNT inhibitor. In 
functional assays, CDX2 was shown to positively regulate leukemic 
cell adhesion to stromal cells via DKK-1. Interestingly, DKK-1 showed 
opposite effects on healthy hematopoietic stem/progenitor cells, 
reducing their clonogenicity and stromal cell adhesion. These data 
suggest that leukemic cells might use DKK-1 secretion to confer them 
competitive advantage for BM niche occupation by (1) increasing their 
QUICK ORAL PRESENTATIONS  
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Thromboembolic events in patients with ITP
Céline Moret1, André Tichelli2, Anne Angelillo-Scherrer3, Alicia Rovó3 
1University of Bern, Bern; 2University Hospital of Basel, Basel; 
3Hematology, University Hospital of Bern, Bern, Switzerland
Introduction: Immune thrombocytopenia (ITP) is characterized by 
severe thrombocytopenia due to autoantibody- and cell-mediated 
peripheral platelet destruction and attenuated thrombopoiesis. Despite 
a higher risk for bleeding, thromboembolic events (TEE) have been 
observed. The objective was to investigate the prevalence and type of 
TEE and the potential risk factors. 
Method: Retrospective cohort which included all patients followed 
between 01/1990 and 05/2016 in our clinic. Information on gender, 
age, date of diagnosis, platelet count, type and clinical form, 
treatments, response to treatment, cardiovascular risk factors, number 
and type of TEE, date and cause of death, and follow up time were 
collected in 438 adult patients. We evaluated and compared risk 
factors of ITP patients with and without TEE in univariate and 
multivariate analysis. 
Results: Of all patients, 10% (44) presented ≥1 TEE after ITP 
diagnosis. In total 54 TEE occurred: 34 venous (61%), 19 arterial 
(34%) and 3 arterial and venous (5%). The most frequent venous TEE 
are pulmonary embolism, deep vein thrombosis, and superficial vein 
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(MFI: 3470 ± 508 C vs 3232 ± 591 IVF). Upon thrombin stimulation 
(0.1 U/ml), platelets from IVF mice exposed higher levels of P-selectin 
(fold increase versus resting state: 54.53 ± 37 C vs 95.64 ± 72 IVF 
mice, p = 0.1) and exhibited significantly more active integrin 
alpha2bbeta3 (fold increase 21.48 ± 15 C vs 172 ± 190 IVF mice, 
p <0.01).
Conclusions: Mice generated by IVF display a reduced platelet count, 
due to a diminished platelet production. On the other hand, their 
circulating platelets show an increased response to thrombin as 
agonist. Given the key role played by platelets in thrombotic events 
and the fact that IVF individuals are at higher risk of cardiovascular 
events, these preliminary data warrant further research on to the 
effects of ART on platelet production, count and function. 
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Effects of chronic viral infections on the functional and 
structural integrity of bone marrow stromal networks
Stephan Isringhausen1, Nike Kraeutler2, Ute Suessbier1, Patrick 
Helbling1, Álvaro Gomáriz1, Larisa Kovtonyuk1, Hui Chyn Wong1, 
Annette Oxenius2, Markus Manz1, Cesar Nombela Arrieta1 
1Hematology, University Hospital and University Zurich; 2Institute for 
Microbiology, ETH Zürich, Zurich, Switzerland
Introduction: Hematopoiesis is sustained by a rare population of 
self-renewing, multipotent hematopoietic stem and progenitor cells 
(HSPCs), which reside in specialized nurturing microenvironments 
within bone marrow (BM) tissues. The basic tissue infrastructure of the 
BM is provided by stromal cellular networks of mesenchymal, neural 
and vascular origin, which are critically involved in the fine regulation 
of different stages of hematopoiesis. Viral infections act as major 
stressors to the hematopoietic system, inducing a massive and 
adaptive response in cellular output. Albeit the effects of viral infections 
and ensuing inflammatory responses on hematopoietic cells have 
been studied in detail, how viral infections can alter BM stromal 
scaffolds and thus shape hematopoietic responses remains poorly 
defined. 
Methods: We here perform a detailed multidimensional analysis of  
the structural and functional effects of viral infections on the BM 
microenvironment. We combine flow cytometric analysis for detailed 
quantification of cellular subsets, with conventional in vitro and in vivo 
assays to assess cellular fitness. Finally, to analyze microarchitectural 
effects we employ advanced 3D confocal microscopy methods 
pioneered in our laboratory.
Results: Chronic LCMV infections result in a substantial loss of BM 
endothelial and mesenchymal stromal progenitor cell populations  
and a decrease in their capacity to produce HSPC-sustaining factors. 
Moreover, we observed that chronic LCMV infection triggers 
vasodilation of BM sinusoids, intense vascular remodeling and a 
substantial disruption of extracellular matrix networks throughout the 
BM cavity. Major damage to BM stromal integrity is accompanied by a 
profound and sustained reduction in the number of both hematopoietic 
multipotent progenitors as well as hematopoietic stem cells. 
Competitive repopulation assays reveal that remaining HSCs are also 
strongly impaired in their repopulation capacity for prolonged times 
after LCMV infection. Finally, our results indicate that the observed 
alterations in the composition and functionality of cells in the BM are, 
at least partially, mediated by activated virus-specific CD8 T cells. 
Conclusion: The BM microenvironment supporting hematopoiesis 
suffers long-lasting alterations as a consequence of infections, which 
are likely to impact the hematopoietic function of the BM and HSC 
regulation. 
thrombosis; arterial TEE were cerebrovascular insults, myocardial 
infarction and peripheral artery thrombosis. At time of TEE, 43% of 
patients were taking corticosteroids, 14% thrombopoietin receptor 
agonists (TPO-ra) and 18% were off-treatment. In the univariate 
analysis, older age at diagnosis (≥50 years, P = 0.015), longer interval 
since ITP (P = 0.001), persistent/chronic ITP (versus acute, P = 0.009), 
≥2 treatments (P = 0.0002), TPO-ra at time of thrombosis (P = 0.027), 
non-response to first treatment (P = 0.010), smoking (P = 0.011), 
arterial hypertension (P = 0.005), and obesity (P = 0.041) revealed to 
be significant. The multivariate analysis model showed that older age 
at diagnosis (P = 0.016), splenectomy (P = 0.021), ≥2 treatments  
(P = 0.006), persistent or chronic ITP (P = 0.033) were independent 
risk factors for TEE. The cumulative incidence of TEE at year 1, 5,  
10, 15 and 20, is respectively 6.2% (95% CI, 4.1–9.3), 11.9% (95% CI, 
8.3–17.0), 15.8% (95% CI, 11.1-22.4), 24.2 % (95% CI, 16.9–34.7) and 
32.8% (95% CI, 22.8–47.3). Death occurred in 7/44 (16%) of patients 
with, and in 12/394 (3%) without TEE (P = <0001). Most frequent 
cause of death was infection (32%) and bleeding (21%). 
Conclusion: ITP patients are at risk for TEE. Those patients who 
underwent splenectomy, had chronic disease, needed a higher 
number of treatments for ITP, and smoke were more likely to develop 
TEE. 
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Mice generated by in vitro fertilization show a reduced  
platelet count accompanied by a heightened response  
to thrombin
Simona Stivala1, Theo Meister2, Rodrigo Soria Maldonado2,  
Sara Gobbato1, Nicole Bonetti1, Giovanni Camici3, Thomas F. 
Lüscher4, Urs Scherrer2, Jürg H. Beer1,5 
1Laboratory for Platelet Research, Center for Molecular Cardiology, 
University of Zurich, Zurich; 2University Hospital Bern, Bern; 3Center 
for Molecular Cardiology, University of Zurich; 4Cardiology, University 
Hospital of Zurich, Zurich; 5Internal Medicine, Cantonal Hospital 
Baden, Baden, Switzerland
Background: Children conceived by assisted reproductive technology 
(ART) show vascular dysfunction, increased arterial pressure and 
early atherosclerosis, conditions associated with a higher risk of 
cardiovascular morbidity. The effect of ART on the synthesis, 
maturation and function of platelets is unknown. Therefore, we 
investigated platelet production and reactivity in a murine model of in 
vitro fertilization (IVF).
Methods: IVF mice were generated by in vitro insemination of oocytes 
from FVB female mice, followed by transfer to pseudopregnant NMRI 
females 48 h later. IVF and control (naturally born, C) male mice (n = 
12) were euthanized at the age of 12 weeks. Total blood cell count, 
mean platelet volume (MPV) and reticulated platelet analysis was 
performed on EDTA blood, while platelet receptor expression (GPVI 
and GpIb) and platelet activation were determined by flow cytometry 
on citrated platelets.
Results: IVF mice showed a significantly reduced platelet count 
compared to control mice (860.15 ± 172×103/ul IVF vs 1119.5 ± 243 
×103/μl C, p = 0.013), accompanied by a slightly reduced (albeit not 
significantly) mean platelet volume (MPV: 5.07 ± 0.35 μm3 IVF vs 5.25 
± 0.6 μm3 C, p = 0.41). Total blood leukocytes and erythrocytes counts 
were not different between the two groups. Newly synthesized platelets 
(reticulated platelets) stained by thiazole orange (TO) were 
significantly reduced in IVF mice (% TO positive platelets: 8.47 ± 3 C 
vs 4.9 ± 0.9 IVF, p = 0.003), indicating reduced production. Collagen 
receptor GPVI expression was unchanged (mean fluorescence 
intensity MFI: 2575 ± 329 C vs 2554 ± 442 IVF), and also vWF 
receptor GpIb levels were similar between the two groups of mice 
Figure 2: Reticulated plts.
Figure 1: Platelet count C and IVF mice.
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Results: Platelet mass (number and size) was increased in the oldC. 
Reticulated platelet counts were higher in the yoC, suggesting 
decreased clearance in the oldC. This was supported by hepatic and 
splenic cryosection histology: areas positively covered by staining for 
CD41 in the yoC were larger than those in the oldC. The GC index was 
similar in the yoC and oldC. GP IIb/IIIa and P-selectin were increased 
in the oldC after activation with thrombin.
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Hematopoietic stem cell transplant-associated  
thrombotic microangiopathy and acute graft- 
versus-host disease
Sarah Kraft1, Noémi Bollinger1, Benjamin Bodenmann1,  
Dominik Heim1, Jakob Passweg1, Christoph Bucher1,  
Claudia Lengerke1, Alexandar Tzankov2, Michael Medinger1 
1Hämatologie; 2Institut für Pathologie, Universitätsspital Basel, Basel, 
Switzerland
Introduction: Steroid refractory acute graft-versus-host disease 
(GvHD) remains a major complication of allogeneic hematopoietic 
stem cell transplantation (allo-HSCT). GvHD has been associated  
with transplant-associated thrombotic microangiopathy (TA-TAM). 
Complement is thought to be a major mediator of endothelial damage. 
We hypothesize that a TA-TMA, related to dysregulation of the 
alternative complement pathway correlates with organ damage.
Methods: A retrospective analysis of 660 consecutive patients with 
hematological malignancies receiving an allo-HSCT at the University 
Hospital Basel in the period from 2003 to 2013 was performed. Data 
on the occurrence, risk factors and outcome of patients with TA-TMA 
and the correlation with acute GvHD was collected. Available biopsies 
of organs suspected to be affected by TAM and/or GvHD will be 
performed. Routine bone marrow biopsies for histological, 
immunohistochemical signs of TA-TAM and complement activation will 
be analyzed. Serum samples will be used to characterize markers of 
complement activation using plasma levels of C5b-9 and C5b-9 
deposition in tissues biopsies.
Results: 660 patients (AML n = 260; ALL n = 152; MDS/MPN n = 93; 
lymphoid neoplasm n = 85; plasma cell disorder n = 53; bone marrow 
failure n = 17) underwent myeloablative (n = 432) and non-
myeloablative (n = 228) allo-HSCT at a median age of 47 years (range 
19-71 years). Forty-eight (7.3%) patients matched the established 
diagnostic criteria for TAM (increased LDH, platelet count <50 G/L  
or <50% of normal baseline, schistocytes >2 per high power field, 
creatinine increase). The median time to onset of TAM was 36 days 
post-transplant (range 22 to 67 days). Subjects with TA-TAM had 
significantly higher 3-year non-relapse mortality compared to those 
without (47.8% vs 18.2%, P <0.001). Grades 2 to 4 aGvHD and 
cytomegalovirus viremia were independent risk factors for TA-TAM, 
and serum LDH level >500 U/L as well as arterial hypertension were 
early signs of TA-TMA occurrence. Patients with clinically relevant 
aGvHD (≥ grade 2) had more TA-TAM than patients without aGvHD 
(45% versus 24%; p <0.001). TAM correlated with aGvHD severity; the 
higher the aGvHD grade, the more the patients who suffered from 
TAM. 
Conclusions: Allo-HSCT recipients with grades 2 to 4 aGvHD or 
cytomegalovirus viremia should be closely monitored for the presence 
of TA-TMA. At the meeting first results of histological, 
immunohistochemical and complement activation analyses will be 
presented. 
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A model of platelets in the aging organism reveals  
increased numbers and enhanced activatability,  
possibly mediating a larger stroke burden
Nicole Bonetti1, Simona Stivala1, Sara Gobbato1, Martin F. Reiner1,2, 
Thomas F. Lüscher3, Giovanni G. Camici1, Jürg H. Beer1,2 
1Center for Molecular Cardiology, Universität Zürich, Schlieren; 2Klinik 
für Innere Medizin, Kantonsspital Baden, Baden; 3Zurich Heart House, 
Universitätsspital Zürich, Zürich, Switzerland
Background: Age is a key risk-factor for cardiovascular disease 
(CVD). Platelets play a major role in CVD. Yet, little is known about 
age-dependent changes in their function. Thus, we used a mouse 
model of aging, in absence of any confounding factors, to analyze 
platelets in aging and their putative role in ischemia/reperfusion (I/R) 
brain injury. 
Methods: To discern specific aging effects from confounding factors, 
we used young (12 weeks, young Cohort; yoC) and very old 
(>20-months, old Cohort; oldC) C57BL/6 wildtype mice. Blood cell 
count and MPV were measured in EDTA-anticoagulated blood. 
Reticulated platelets were determined by thiazole-orange staining. 
Platelet clearance was assessed on CD41-stained hepatic and splenic 
cryosections. Plasma glycocalicin (GC) was assayed by ELISA. 
Platelets were activated with thrombin or collagen I and analyzed by 
flow-cytometry. I/R brain injury was induced by transient middle 
cerebral artery occlusion for 30 mins followed by 48 h of reperfusion. 
Stroke size was assessed by triphenyltetrazolium chloride (TTC) 
staining; neurological function by RotaRod and Bederson tests.
Stroke size was doubled in the oldC and related to significantly poorer 
neurological performance.  
Conclusions: Our model reveals 1) higher platelet numbers and 
larger platelet size irrespective of reticulated platelets, 2) reduced 
hepatic and splenic clearance and 3) increased procoagulant and 
pro-inflammatory response in the oldC. These platelet changes in the 
oldC may be related to 4) larger stroke size and poorer functional 
outcome. The model may delineate the role of platelets in age-related 
CVD, and provide insight into the therapeutic relevance of targeting 
platelet changes in aging. 
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Autophagy pathways active during APL therapy –  
identification of key autophagic networks
Magali Humbert, Jin Jing, Deborah Krauer-Shan, Mario P. Tschan 
Experimental Pathology, TP2, University of Bern, Institute of 
Pathology, Bern, Switzerland
Introduction: Autophagy is an intracellular degradation system that 
ensures a dynamic recycling of cytoplasmic contents. It is required for 
self-renewal and cell survival under stress. There is accumulating 
evidence for additional functions of autophagy during myeloid 
development and therapy responses in acute myeloid leukemia (AML). 
In this study we aimed at identifying the autophagy-related network 
involved in AML therapy responses.
Methods: In this study, we analyzed primary APL/AML samples and 
cell lines to characterize the autophagy mechanisms active during 
all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) therapy. 
Techniques used were qPCR, western blotting, FACS, 
immunofluorescence microscopy, autophagic flux analyses, 
immunoprecipitation, lentiviral knockdown and overexpression 
systems, ChIP as well as promoter reporter analyses.
Results: In general, expression of most autophagy-related (ATG) 
genes was attenuated in primary AML patient samples and reactivated 
upon neutrophil acute promyelocytic leukemia (APL) and CD34+ 
differentiation. Importantly, we identified several of these myeloid 
differentiation associated ATG genes as novel transcriptional targets of 
the hematopoietic transcription factor PU.1. Regarding the autophagic 
mechanisms, we found that ATRA-induced autophagy during APL 
differentiation is Beclin-1 independent. Moreover, knocking down 
ATG16L2 but not ATG16L1, both genes are involved in 
Figure 1
Figure 2
PRIMARY AND HOSPITAL CARE – ALLGEMEINE INNERE MEDIZIN 2017;17(SUPPLEMENTUM)
GASTGESELLSCHAFT SGH / SOCIÉTÉ CONVIÉE SSH 28 S
3 patients had grade III events. The mean blood counts were similar 
between start and end of therapy. In 20 patients bone marrow biopsy 
was available, showing an increase in the nestin+ MSCs cells from a 
median of 1.09 (IQR 0.38–3.27)/mm2 to 3.95 (IQR 1.98–8.79)/mm2  
(p <0.0001) and a slight decrease of myelofibrosis from a median 
grade of 1.00 (IQR 0.50–3.00) to 0.75 (IQR 0.50–2.00) (p = 0.02) 
between start and end of therapy.  
Conclusion: Therapy with mirabegron for 24 weeks failed to reach the 
primary endpoint of reducing the JAK2-V617F allele burden ≥50% in 
MPN patients. However, an increase in the nestin + MSCs in bone 
marrow and a slight decrease of myelofibrosis were found, suggesting 
that mirabegron can reverse the damage inflicted by the JAK2-V617F 
positive MPN clone on the nestin + stem cell niche. 
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Utility of thromboelastometry analysis in patients  
with mild bleedings disorders
Anna Wieland Greguare-Sander1,2, Walter A. Wuillemin1,3,  
Michael Nagler2 
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Luzerner Kantonsspital, Luzern; 2Department of Haematology and 
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and University of Bern; 3University of Bern, Bern, Switzerland
Background: Viscoelastic methods are regarded as promising 
concept to overcome the limitations of conventional laboratory assays 
in patients with haemostatic disorders, particularly in the perioperative 
setting. Their performance regarding frequently occurring mild bleeding 
disorders (MBD) such as von Willebrand disease, platelet function 
disorder, or mild haemophilia is however unknown.
Aim: We conducted a prospective cross-sectional study to investigate 
the value of thromboelastometry analysis for diagnosis and prognosis 
of MBD.
Methods: Thromboelastometry analysis (ROTEM®) was conducted in 
all consecutive patients referred between January 2011 and March 
2013 with a suspected bleeding disorder. Diagnostic work-up was 
done according to current guidelines. 
Results: MBD was diagnosed in 111 out of 217 patients (52.1%), 
median age was 40.1 years, IQR 28.9, 59.2; 67.6% were female. 
Possible or definite platelet function disorder was diagnosed in 50 
patients (42.7%), von Willebrand disease (vWD) in 24 patients (11.1%), 
mild haemophilia in 4 patients (1.8%), mild factor XI deficiency in 2 
patients (0.9%), low von Willebrand factor associated with blood group 
0 in 13 patients (6.0%), anticoagulation treatment in 3 patients (1.4%), 
and a systemic disorder in 15 patients (6.9%). Presence of MBD was 
not associated with a significant difference in thromboelastometry 
parameters (CT EXTEM, MCF EXTEM, CT INTEM, MCF INTEM, 
MCF FIBTEM). In addition, no significant differences were observed 
with regard to categories of the ISTH bleeding assessment tool. Minor 
differences – all within the established ROTEM reference ranges – 
were noted for some MBD: mild haemophilia (MCF EXTEM, MCF 
INTEM, MCF FIBTEM), definite vWD type 1 (MCF FIBTEM), 
anticoagulation treatment (CT EXTEM), and systemic disorders  
(CT EXTEM).
Conclusions: Our data do not support the utility of 
thromboelastometry analysis for diagnosis, prognosis or management 
in patients with mild bleeding disorders, particularly in the 
perioperative setting. 
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Establishment of a patient-derived myelofibrosis  
xenograft mouse model
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Introduction: A growing number of patient-derived xenograft (PDX) 
mouse models have been developed over the past few decades that 
allow engraftment of human hematopoietic stem cell (HSC) 
malignancies in order to study the evolution of HSC and leukemic 
stem cells, as well as disease heterogeneity. Myelofibrosis (MF) is a 
HSC disorder characterized by bone marrow fibrosis that has the 
potential to transform into acute myeloid leukemia. However, the 
engraftment of MF SCs in PDX models is poor (Wang et al., JCI 2012) 
presumably due to the lack of supportive factors in the bone marrow 
(BM) microenvironment. We hypothesized that the constitutive 
expression of human cytokines and growth factors in a PDX model 
autophagosome maturation, in APL cells significantly attenuated 
neutrophil differentiation clearly indicating that ATG16L2 but not L1 is 
needed for a successful ATRA response. Moreover, we identified a 
novel link from the neutrophil enhancer kinase DAPK2 to autophagy 
via its binding to the ATG gene ATG5 upon ATRA treatment. On the 
other hand, DAPK2 is dispensable for ATO-mediated induction of 
autophagy but not cell death. We further showed that DAPK2 stabilizes 
the transcription factor p73 and that DAPK2 expression is 
transcriptionally regulated by p73 thereby creating a positive feedback 
loop during ATO induced cell death. 
Conclusions: Our data provide strong evidence for a particular, 
non-canonical subtype of autophagy operative during neutrophil 
differentiation of APL cells as opposed to canonical autophagy in ATO 
therapy. Deciphering the particular autophagy pathway active during 
APL differentiation and cell death responses is a prerequisite to 
develop novel therapies that are based on autophagy modulation for 
this disease.
Figure: Autophagy in APL Therapy.
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Effects of the sympathicomimetic agonist mirabegron  
on disease course, allele burden, marrow fibrosis, and  
nestin positive stem cell niche in patients with JAK2-mutated 
myeloproliferative neoplasms: a prospective multicenter  
phase II trial SAKK 33/14
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Introduction: Nestin+ mesenchymal stem cells (MSCs) are reduced 
in bone marrow of JAK2-V617F positive myeloproliferative neoplasms 
(MPN) patients due to damage of the sympathetic nerve fibers 
triggered by cytokines from the mutant cells. In a mouse model therapy 
with a beta-3 sympathicomimetic agonist corrected the damage 
inflicted by the MPN clones on their niches and ameliorated the MPN 
phenotype. To test the effect on disease-control in patients with MPN 
we performed a phase II trial with the beta-3 sympathicomimetic 
agonist mirabegron. 
Methods: The trial consisted of mirabegron 25 mg daily during the first 
week, followed by 50 mg daily for at least 24 weeks. Patients with a 
cytohistologically confirmed diagnosis of MPN and a JAK2-V617F 
allele burden >20% in granulocytes at study entry were eligible, if not 
treated with JAK2 inhibitors or interferon. Reduction of the JAK2-
V617F allele burden ≥50% was the primary end point. Secondary end 
points included blood count changes or MPN related symptoms. As a 
side study, bone marrow biopsies were quantified for nestin+ MSCs, 
fibrosis and CD34+ hematopoietic stem and progenitor cells. 
Results: Thirty-nine patients have been accrued in 10 institutions in 
Switzerland: 8 (21%) had essential thrombocythemia, 22 (56%) 
polycythemia vera, 9 (23%) primary myelofibrosis, 27 (69%) were male 
and the median age was 62 (IQR 53–72). Twenty-eight (72%) patients 
had cytoreductive therapy, the remaining patients had antiaggregation, 
anticoagulation or phlebotomy. No patient reached the primary 
endpoint, one patient achieved a 25% reduction in allele burden by 24 
weeks. Adverse events were mostly grade I or II on the CTCAE scale, 
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Different anticoagulant effects despite similar  
Rivaroxaban plasma concentrations in individual  
obese patients
Debora Bertaggia Calderara1, Dino Kröll 2, Christiane Gerschheimer1, 
Nicole Nicolas1, Philipp Nett2, Guido Stirnimann2, Lorenzo Alberio1 
1Department of Hematology and Central Hematology Laboratory, 
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Introduction: Rivaroxaban (RVX), a direct inhibitor of factor Xa, has 
been developed to bypass the limitations of traditional anticoagulants, 
such as intensive coagulation monitoring, drug-drug and drug-food 
interactions, or large inter-individual variations in dose-response. RVX 
has predictable pharmacokinetics and pharmakodynamics. Thus, there 
is no need for laboratory monitoring or guided dose adjustment in 
patients. However the “one dose fits all” concept based on randomized 
clinical trials might not be always adequate for individual patients in 
everyday clinical practice. 
Objectives: The aim of this study was to assess the anticoagulant 
effect of similar plasma concentrations of RVX on thrombin generation 
(TG) in obese patients undergoing bariatric surgery and to compare 
individual anticoagulation profiles before and after surgery. 
Methods: A total of 12 patients receiving a single dose of RVX (10 
mg) before bariatric surgery and on the third postoperative day had 9 
citrate whole blood samples taken during the 24 hours following drug 
ingestion. RVX plasma concentration was quantified at baseline and at 
different time points from ingestion with a calibrated automated anti-Xa 
chromogenic assay. RVX anticoagulant effect was assessed ex-vivo by 
monitoring tissue factor induced TG in platelet-poor-plasma (PPP) with 
calibrated automated thrombogram (CAT). 
Results: TG measurements showed that despite similar RVX-
concentrations, patient thrombograms significantly differed (fig. 1).
 
may promote the development of the human MF clone in vivo. 
Therefore, we used next-generation mice that express human M-CSF, 
IL-3, GM-CSF, TPO, and SIRPαTg (MISTRG) in order to develop a pre-
clinical MF PDX model. 
Methods: Purified peripheral blood stem and progenitor (CD34+) cells 
were collected from MF patients and intrahepatically transplanted into 
sublethally irradiated newborn MISTRG mice. 5–9 weeks after 
transplantation mice were sacrificed and analyzed for human 
engraftment using flow cytometry and immunohistochemistry. 
Results: Engraftment was seen from four out of seven patient samples 
transplanted in MISTRG mice with an overall total median  
of 16.1% in the BM and 7.1% in the peripheral blood (PB) of human 
CD45+ cells. Over 60% of engrafted cells were of myeloid origin in the 
BM and PB, 18.55% and 50.85% were monocytes in the BM and PB 
respectively. In addition, a significant frequency of human CD34+ 
hematopoietic stem and progenitor cells (HSPCs) was observed in 
engrafted mice. Overall, the results suggest that the next-generation 
MISTRG mice support human MF engraftment. 
Conclusions: MISTRG mice support unprecedented myelo-monocytic 
differentiation of human MF SCs in 57% of patient samples 
investigated so far. Immunohistochemistry will also be performed on 
the BM and spleen of these mice in order to check for fibrosis and 
megakaryocytes. In order to determine whether specific somatic 
mutations promote human MF engraftment in PDX models next-
generation sequencing will be performed on transplanted patient 
samples. 
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Introduction: The tumor suppressor protein p53 is inactivated in a 
large variety of cancer cells including acute myeloid leukemia (AML). 
While TP53 gene mutations are rarely observed in AML cells at 
diagnosis, p53 protein function is commonly suppressed by 
overexpression of the cellular p53 inhibitor MDM2. In addition, other 
growth factor signaling pathways such as the MAPK cascade 
(RAS-RAF-MEK-ERK) are often active in AML cells. Consequently, 
combined administration of MDM2 antagonists and MEK inhibitors 
may present a promising anti-leukemia treatment strategy. 
Methods: The aim of this study was to identify AML subgroups with 
particular sensitivity against the combined treatment with MDM2 
antagonists and MEK inhibitors. In particular, molecular subgroups 
defined by the mutational status of TP53, FLT3 and NPM1 were 
screened. The MDM2 antagonist Idasanutlin and the MEK inhibitor 
Cobimetinib were assessed as single agents and in combination in a 
variety of AML cell lines and AML blast cells for their ability to induce 
apoptosis and cell death. AML cell lines and blast cells comprised all 
major morphologic and molecular AML subtypes. 
Results: We found a considerably differing anti-leukemia efficacy 
across various AML cell types depending on the molecular 
background. AML cells with maximum sensitivity to single compound 
treatment as well as to the combined treatment with both Idasanutlin 
and Cobimetinib were characterized by wildtype status of the TP53, 
FLT3 and NPM1 genes. Remarkably, combined treatment with 
Idasanutlin and Cobimetinib together was more effective than single 
compound treatment. In contrast, AML cells with FLT3-ITD or with 
mutated NPM1 were less sensitive. Finally, TP53mut cells were largely 
resistant to both compounds as well as to the combined treatment. 
Conclusion: Our data indicate that AML cells defined by the wildtype 
status of the TP53, FLT3 and NPM1 genes accounting for up to 25% 
of AML patients emerge to be most sensitive to the combined 
treatment with Idasanutlin and Cobimetinib. In contrast, AML cells with 
mutations in FLT3 or NPM1 are less sensitive, whereas AML cells with 
mutated TP53 are largely resistant. These results propose that the 
combination of an MDM2 and a MEK inhibitor may be an effective and 
specific treatment to target AML subtypes with wildtype status of the 
TP53, FLT3 and NPM1 genes. 
First, we observed large inter-individual variations among patients. 
Second, we also observed different TG patterns for the same 
individual before and after surgery. Specifically, at similar RVX 
concentrations, patients had higher thrombotic profiles in the post-
operative phase. 
Conclusions: CAT analysis shows that in obese patients, inter-
individual differences exist in TG inhibition in response to a similar 
plasma concentration of RVX. Those differences appear to reflect the 
peculiar prothrombotic potential of each individual patient and suggest 
that the same RVX doses might not exert the same anticoagulant 
effect in different patients and/or in the same patient at a different point 
in time. This might be of particular relevance in the postoperative 
phase, in which the lower TG inhibition observed could indicate that 
the preoperative RVX dose is less efficient in providing a good 
prophylactic anticoagulation. 
Figure 1
PRIMARY AND HOSPITAL CARE – ALLGEMEINE INNERE MEDIZIN 2017;17(SUPPLEMENTUM)
GASTGESELLSCHAFT SGH / SOCIÉTÉ CONVIÉE SSH 30 S
Hematology and Transplantation, St. Petersburg Pavlov State Medical 
University, St. Petersurg, Russian Federation; 17Department of 
Hematology, Hemostasis, Oncology and Stem Cell Transplantation, 
Hannover Medical School, Hannover, Germany; 18Department of 
Hematology, Radboud University Medical Center, Nijmegen; 
19Department of Hematology, University Medical Center Groningen, 
Groningen, The Netherlands; 20Deutsche Klinik für Diagnostik HELIOS 
Klinik, Wiesbaden, Germany; 21Centre for Haematology, Imperial 
College London at Hammersmith Hospital, London, United Kingdom; 
22Department of Stem Cell Transplantation, University Medical Center 
Hamburg-Eppendorf, Hamburg, Germany
Introduction: Patients (pts) relapsing with CML after allogeneic 
hematopoietic stem cell transplantation (alloHSCT) may be treated 
with TKI and/or DLI. As nowadays the majority of CML pts would have 
received at least imatinib prior to transplantation, we were interested in 
analizing a) the type of TKI used after alloHSCT, b) the indication for 
TKI treatment, c) the outcome of this treatment and d) the temporal 
relationship with DLI if given. 
Patients and methods: 435 pts received TKI after first allogeneic 
HSCT for CML. The indications for TKI were the same as for 
transplantation (n = 25), for relapse/progression/persistent disease (n 
= 246), for prophylaxis/pre-emptive (n = 147), planned (n = 5), others 
(n = 8) and missing (n = 4). 
Results: Median follow-up from start of TKI was 55 (1–171) months. 
The median time interval from transplant to TKI was 6 (0.2–165) 
months. It was longer for TKI given for relapse/progression with 15 
(1–89) months and shorter for TKI given for prophylaxis/pre-emptive 
with 1.6 (0.2–43) months. It was longer for imatinib with 11 (0.2–121) 
months vs 3.8 (0.2–165) months for other TKI. Best response after TKI 
was complete molecular remission in 17.7%, cytogenetic remission in 
4.4%, hematological remission in 20.2% and no response/progression/
relapse in 57.7% of pts. 50% of pts treated with imatinib had a 
response (molecular/cytogenetic/hematological) vs 34% with nilotinib, 
33% with dasatinib and 33% with bosutinib/ponatinib, p = 0.014. In 
univariate analysis, OS, RFS and RI were better for imatinib vs other 
TKI (table).
  All patients Imatinib Other TKIs p value
5-yr OS 60% (55–65%) 66% (60–73%) 51% (42–60%) 0.0024
5-yr RFS 47% (42–53%) 53% (46–60%) 40% (32–48%) 0.0102
5-yr RI 25% (21–30%) 21% (16–27%) 31% (24–38%) 0.0454
5-yr NRM 27% (23–32%) 26% (20-31%) 29% (22-36%) 0.365
In multivariate analysis for OS, imatinib vs other TKI post-transplant 
did not show anymore an effect, HR 1.19 (0.85–1.67), p = 0.317. 
Factors influencing OS were time from diagnosis to transplant, HR 1.01 
(1.00-1.01), p = 0.009, AP vs CP1, HR 1.80 (1.11–2.91), p = 0.017 and 
BC/>CP1 vs CP1, HR 2.3 (1.58–3.33), p <0.0001. In multivariate 
analysis for RFS imatinib vs other TKI did not have an effect. Other 
factors having a tendency or influencing RFS were time from diagnosis 
to transplant, HR 1.00 (1.00–1.01), p = 0.054, AP vs CP1, HR 1.52 
(1.00-2.31), p = 0.050, BC/>CP1 vs CP1, HR 2.11 (1.55–2.88),  
p <0.001. 
Conclusion: These data suggest that TKI after alloHSCT induce a 
response in about 42% of pts regardless of the type of TKI used and 
that time from diagnosis to transplantation as well as the phase of 
disease at transplant remain the main factors influencing the outcome 
of CML patients relapsing after alloHSCT. 
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Introduction: During adulthood, bone marrow (BM) cavities are  
the primary sites of production of vast amounts of blood cellular 
components from a rare population of hematopoietic stem cells 
(HSCs). Beyond their hematopoietic function, BM tissues host immune 
responses and maintain immunological memory. In addition to 
hematopoietic cells, the BM is populated by a heterogeneous mixture 
of endothelial, mesenchymal and neural stromal cells, which provide 
the necessary infrastructure for hematopoiesis to unfold and play 
essential regulatory roles. A thorough understanding of the spatial 
distributions, structural dynamics and interactions established by 
diverse cellular components within the complex landscape of the BM, 
is key for the generation of comprehensive models of healthy and 
pathological hematopoiesis.
Methods: In our laboratory we have recently developed advanced 
microscopy protocols that enable the 3D visualization of large volumes 
of BM tissues at an organ-wide level and with cellular and subcellular 
resolution. Here we report the generation of customized computational 
tools, which allow to generate quantitative spatial information in an 
automatic and unbiased fashion, and enable the extraction of spatial 
statistics for rigorous analysis of cellular interactions. 
Results: We have employed this newly developed software suite to 
describe for the first time the spatial distribution of key components of 
the HSC niche, namely sinusoidal vessels and mesenchymal stromal 
cells. Our data demonstrate that in general the quantitative 
contribution of BM stromal cells to the total BM cellular asset is 
substantially underestimated by widely employed flow cytometric 
techniques. Detailed topological analysis reveals that the highly 
branched sinusoidal vessel network occupies on average 18% of the 
BM volume, subsequently constraining the space available for cells to 
distribute. Using rigorous spatial statistics we estimate that 95% of the 
BM space is contained within a distance of 22 µm from the nearest 
sinusoid. Nonetheless, mesenchymal stromal cells are significantly 
enriched in perivascular locations, pointing to a preferential interaction 
between these two key stromal components. Collectively our analyses 
provide quantitative measurements defining microarchitectural 
organization of BM stroma in homeostatic conditions. We anticipate 
that the tools developed will be instrumental to investigate the 
microarchitectural alterations underlying pathological hematopoiesis. 
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emerge to be most sensitive to the combined treatment with 
Midostaurin and HDM201 whereas AML cells with wildtype FLT3 or 
mutated NPM1 are less sensitive, and TP53 mutated cells are not 
sensitive at all. These results indicate that the combined use of an 
MDM2 and a FLT3 inhibitor may be both a promising and specific 
treatment option to target FLT3-ITD AML. 
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Introduction: Thrombotic events such as microvascular occlusions – 
a hallmark of immune-mediated thrombotic thrombocytopenic purpura 
(iTTP), are the main causes of morbidity and mortality among 
systemic Lupus erythematosus (SLE) patients with a prevalence of 
10%. Renal thrombotic microangiopathic symptoms (TMA) are 
observed frequently together with an overactivated classical 
complement system where anti-C1q antibodies (Abs) were shown to 
be strongly linked to the severity of active lupus nephritis. Given the 
considerable overlap of clinical symptoms between SLE and iTTP,  
we evaluated if ADAMTS13 activity, anti-ADAMTS13 and/or anti-C1q 
antibodies (Abs) titers might serve as diagnostic markers to distinguish 
primary iTTP from conjoint (secondary) iTTP/SLE.
Method: ADAMTS13 activity (FRETS-VWF73 assay) and presence  
of circulating anti-ADAMTS13 and/or anti-C1q titers (commercial 
ADAMTS13 INH ELISA or C1q ELISA, respectively) were assessed in 
blood samples of a SLE cohort (n = 93; 40/93 with active lupus, 13/93 
in remission and 40/93 with complement-mediated complications only) 
and compared to a cohort of acute iTTP (n = 92; 67 first episode,  
25 with a relapse) and 41 healthy controls. 
Results: ADAMTS13 activity was severely deficient (<5%) in 96% 
(88/92) iTTP patients and the 5 iTTP/SLE patients. Anti-ADAMTS13 
Abs were found in 43% (40/93) of SLE patients (titer >15 AU/ml, range: 
16–85 U/ml) compared to 95% (87/92) in iTTP patients with a median 
of 62.8 AU/ml (range 5 to >104 AU/ml) and only 5% (2/41; 16 and 26 
AU/ml) in healthy controls. Anti-C1q Ab titers (positive 15 U/ml) were 
significantly increased in SLE patients (65/93, 70% with median 140 
U/ml) when compared to iTTP (21% positive, median 33 U/ml) and 
healthy controls (19% positive, median 49 U/ml). Patients suffering 
from more than 1 autoimmune disease (n = 16) in both the SLE and 
iTTP cohort, lupus nephritis (SLE cohort, 22/40), TMA-associated 
nephritis (5/40) or concurrent SLE/iTTP (5) were marked by high dual 
positive Ab titers with median anti-C1q and anti-ADAMTS13 titers of 
130 U/ml, respectively 40 AU/ml. 
Conclusions: Our findings show that SLE patients presenting with a 
TMA-like picture (lupus nephritis) or iTTP patients with renal TMA 
constitute a specific subgroup marked by high anti-ADAMTS13 and 
anti-C1q Ab titers. Evaluation of larger patient cohorts with well 
documented clinical courses will allow to confirm dual Ab positivity as 
a marker for secondary complications in SLE and iTTP. 
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Introduction: Acute Myeloid Leukemia (AML) is a rare disease with 
an increasing incidence in the elderly and an emerging impact on 
health system resources. The trends in incidence and mortality of AML 
have not been studied in detail in Switzerland for comparison with 
other countries.
Methods: This is a population-based, retrospective observational 
analysis of AML cases reported to the Cantonal Cancer Registries 
(CCRs) in Switzerland between 1989 and 2012 and aggregated by the 
National Institute for Epidemiology and Cancer Registration (NICER). 
The Swiss Federal Statistics Office (SFSO) provided canton-specific 
mid-year estimates of the general population and mortality statistics.
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Background: The application of individualized medicine based on 
genetic factors to patients requiring anticoagulant treatment is 
hampered by a lack of knowledge on their long-term effects on 
relevant clinical outcomes. 
Aim: To fill this gap, we examined the association between 
polymorphisms of the vitamin K-epoxide reductase (VKORC1) as well 
as the cytochrome P450 enzyme gene (CYP2C9) and long-term 
clinical outcomes in a prospective, multicenter cohort study of elderly 
patients treated with vitamin K antagonists for venous 
thromboembolism (VTE).
Methods: Consecutive patients aged 65 years or older with an acute, 
objectively confirmed VTE were identified between 2009 and 2013 in 
all five university hospitals and four high-volume non-university 
hospitals in Switzerland. The primary outcome was the time to any 
clinical event, i.e. overall mortality, major- and non-major clinically 
relevant bleeding, or recurrent VTE.
Results: Overall, 774 patients were followed for a median duration of 
30.1 months. The primary outcome occurred in 334 patients (43.2%) 
and 119 patients died (15.4%). Major bleeding occurred in 100 patients 
(12.9%), clinically relevant non-major bleeding in 167 patients (21.6%), 
and recurrent VTE in 100 patients (12.9%). After adjustment, the 
presence of CYP2C9 variants was significantly associated with any 
clinical event (hazard ratio [HR] 1.34; 95% CI 1.08, 1.66), death (HR 
1.74; 95% CI 1.19, 2.52), and clinically relevant non-major bleeding 
(sub-hazard ratio [SHR] 1.38; 95% CI 1.01, 1.55), but not with major 
bleeding (SHR 1.03; 95% CI: 0.69, 1.55) and recurrent VTE (SHR 0.95; 
95% CI 0.62, 1.44). The presence of VKORC1 variant was not 
associated with any clinical event. No relevant differences in the 
percentage of time spent within the therapeutic range were observed 
in patients with and without CYP2C9 variants [DA1]. 
Conclusions: In conclusion, our results demonstrate a significant 
association between CYP2C9 polymorphisms and deaths, probably 
because of effects independent from quality of anticoagulation and 
major bleeding. 
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Introduction: Prognosis of acute myeloid leukemia (AML) patients 
with FLT3-ITD is poor, particularly in FLT3-ITD AML patients in relapse 
or refractory to conventional induction treatment or in FLT3-ITD AML 
patients unfit for intensive treatment, thus highlighting an unmet need 
for novel therapeutic approaches. The combined use of compounds 
targeted against the mutated FLT3 receptor and against cellular 
inhibitors of the master tumor suppressor p53 might propose an 
effective treatment option for this poor risk group of AML patients. 
Methods: In this study, we assessed the protein kinase inhibitor 
Midostaurin (PKC412) and the MDM2 inhibitor HDM201 as well as 
cytotoxic compounds used for conventional induction treatment as 
single agents and in combination in AML cell lines and in AML blast 
cells for their ability to induce apoptosis and cell death in leukemic 
cells. AML cell lines and blast cells represented all major morphologic 
and molecular subtypes, including FLT3-ITD and FLT3 wildtype, 
NPM1 mutant and wildtype, as well as TP53 mutant and wildtype cell 
lines. 
Results: We found that Midostaurin and HDM201 appear to 
specifically target FLT3-ITD AML cells that are wildtype for TP53  
and NPM1. FLT3-ITD cells were significantly more sensitive to both 
compounds than FLT3 wildtype cells whereas TP53 mutant cells  
were not sensitive at all. The presence of a mutated NPM1 allele 
significantly reduced the susceptibility to both compounds. Moreover, 
the combination of Midostaurin and HDM201 was superior to single 
agent therapy and more specific and effective against FLT3-ITD cells 
than the combination of Midostaurin together with conventional 
cytotoxic induction treatment. 
Conclusion: Our data indicate that AML cells with FLT3-ITD, NPM1 
wildtype and TP53 wildtype accounting for up to 30% of AML patients 
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females. Age-standardized mortality rates ranged from 1.1–2.4 in 
males, and 0.8–1.7 in females. Mortality rates were lowest in the 
earliest time periods, indicating a reporting bias for 1989-2000. The 
fraction of unclassifed AML decreased from 78% to 39% during the 
observation time. However, the proportion remained high (50% and 
1.4%) in the older compared to younger patients in 2008–2012 (age 
cut-off: median age).
Discussion: AML incidence remained stable during the observation 
period, indicating that the 27% rise in case-frequency is related to 
population growth and ageing and not to an increase of age-specific 
risk. Elderly AML patients are more frequently not further subclassifed, 
suggesting that diagnostics and reporting is less accurate in elderly 
patients. As previously reported for MDS patients, the currently 
available data is also insufficient for detailed health services research 
in AML patients. Further collection of longitudinal data on treatment, 
side effects and outcomes is warranted. 
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Objectives: Although considered a curable disease, acute myeloid 
leukemia (AML) leads to death in a considerable percentage of 
patients. The main obstacle to cure is relapse after apparent remission, 
which, from a cellular perspective, is thought to occur from so-called 
leukemic stem cells (LSCs). Several reports have documented that 
surface expression of the HSC marker CD34 can identify 
subpopulations of leukemic blasts with LSC properties and stem 
molecular signature within AML. However, ~30% of AML do not 
express CD34 on the cell surface, mainly in NPM-mutated AML that 
show low CD34 expression, and no other reliable marker for LSC 
isolation has been reported in this disease subtype. Recently, the 
G-coupled protein receptor 56 (GPR56), a molecule regulating cell 
adhesion, has been implicated as LSC marker in CD34 positive AML. 
Here, we aim to analyze whether surface expression of GPR56 can  
be used as LSC marker in CD34 negative (NPM-mutated) AML,  
where the LSC compartment has not yet been characterised. 
Methods: CD34 negative AML patient samples were screened for 
GPR56 surface expression by flow cytometry using an anti-human 
GPR56 PE antibody, followed by subsequent FACS to separate 
GPR56-negative and positive leukemic blasts that were either used for 
in vitro colony forming unit (CFU) or in vivo xenotransplantation assays 
in immunosuppressed NSG mice. 
Results: Flow cytometric assessment of GPR56 surface expression 
revealed heterogeneous but distinct GPR56 expression in each of the 
analysed samples (n = 6 CD34-negative AML patient blasts). Pilot data 
indicate that only GPR56+ (and not GPR56-) cells indeed induce CFU 
and in vivo leukemogenicity, indicating that clonogenicity and in vivo 
leukemogenesis are confined to GPR56+ cells in CD34- AML. We are 
currently awaiting further results from additional patient samples. 
Conclusion and outlook: Our preliminary data suggests that GPR56 
might indeed be used as a novel stem cell marker in CD34 negative 
AML. In order to solidify these results, we will perform RNA 
sequencing experiments to retrieve the LSC signature in GPR56+ vs. 
GPR56- sorted AML blasts. Since it has been recently shown that 
GPR56 expression promotes migration and adhesion of healthy HSCs 
to the BM niches, we furthermore plan to functionally characterize the 
role of GPR56 in CD34 negative AML by analysing the adhesion 
capacity of GPR56+/- cells in in vitro co-culture experiments with MS5 
stromal cells and in in vivo homing assays. 
Results: The coverage of the Swiss population by the CCRs 
increased from 55.3% to 65.1% during the observation time. 3684 new 
AML cases were registred, corresponding to an extrapolated number 
of 6226 new AML cases in the Swiss population during the 
observation time. The extrapolated mean annual case frequency 
increased from 235 to 299 AML cases (+27%). Age-standardized 
incidence rates ranged from 3.3–3.6 in males, and 2.5-2.8 in females 
per 100’000 patient-years, respectively, and remained stable 
throughout the observation time. Median age at diagnosis was 66 
years for males in all time periods and ranged from 67-70 years in 
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Introduction: Hematopoietically active bone marrow (BM) tissues are 
highly sensitive to cytoreductive treatments such as ionizing irradiation 
and chemotherapeutic agents, which are the treatment of choice for 
multiple malignancies and employed as conditioning regiments in BM 
transplantations. The cytotoxic damage and killing of rapidly cycling 
hematopoietic progenitors induced by myeloablative therapies have 
been extensively characterized. However, it is still largely unknown 
whether and to what extent these treatments target BM stromal cells  
of endothelial and mesenchymal origin, which critically regulate 
hematopoiesis. Here we have analyzed the dynamics of BM stroma 
upon myeloablation, the resulting microarchitectural effects on BM and 
the kinetics of regeneration of BM tissues post-injury. 
Methods: In this study we employ advanced flow cytometric protocols 
to analyze quantitative changes in cellular populations. Structural 
effects on the murine BM microenvironment are in turn visualized and 
quantified by using advanced 3D-confocal microscopy in combination 
with newly developed computational tools for image-based analysis. 
Results: As previously reported, ionizing irradiation and 5-FU 
treatment led to a severe loss of hematopoietic stem and progenitor 
cells (HSPCs). Notably, a similar profound decrease in endothelial and 
mesenchymal stroma was observed. Decline in stromal cell numbers 
was apparent 7 days after treatment and encompassed a major loss of 
structural integrity of the BM microenvironment. 3D imaging revealed 
massive sinusoidal dilation followed by appearance of ruptures in 
vessel walls. Structural effects and cellular effects were partially 
reversed 14 days post treatment in a regenerative process that 
culminated 4 weeks after treatment. In addition, massive de novo 
differentiation of mesenchymal progenitors into adipocytes lead to 
adipogenic infiltration of large regions of the BM. Of note, this process 
was fully reversible as virtually almost all adipocytes were cleared from 
BM tissues 56 days after treatment. To compensate for impaired BM 
function, reversible extramedullary hematopoiesis was prominent at 
time points of maximal BM damage.
Conclusion: Our observations demonstrate that the stromal BM 
microenvironment is highly sensitive to myeloablative therapies. Of 
note, BM tissues are endowed with an intrinsic regenerative and 
self-organizing capacity that enables rebuilding of a fully functional 
tissue microenvironment after severe damage. 
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Life-long self-renewing hematopoietic stem cells (HSCs) repetitively 
contribute to replenishment of mature blood cells. Aged HSCs show 
reduced self-renewal, less efficient bone marrow (BM)-homing 
capacity, and myeloid-skewed differentiation. We demonstrated a 
cell-intrinsic drive towards dormancy in HSCs imprinted by increased 
divisional history (JExpMed 2011). Here, we tackle the questions what 
extrinsic and intrinsic factors determine HSC behaviour at the cellular 
and molecular level. We have established in vivo single HSC divisional 
tracking with CFSE (5(6)-carboxyfluorescein diacetate N-succinimidyl 
ester), and subsequent isolation of different divisional classes of 
HSC-containing cell fractions (LKS) based on CFSE dilution for in vivo 
HSC functional readout. CFSE-labeled young (8–12 week old) and 
aged (>2 year old) LKS were transferred into non-irradiated young or 
aged recipients, respectively. To test biological function of HSC with 
distinct divisional histories, quiescent or cycling LKS were isolated and 
transplanted into lethally irradiated mice. The transplanted mice were 
monthly bled to follow long-term donor engraftment and lineage 
repopulation. To dissect aging-associated extrinsic factors, we 
performed antibody based protein arrays and transcriptome analysis 
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Allogeneic hematopoietic cell transplantation (HCT) is the only curative 
treatment for many malignancies of the blood. Graft T cells (Tc) are 
critical to control malignant cells but can also induce graft-vs-host-
disease (GVHD), in which donor Tc target and destroy host tissues. 
Little attention has been paid to effects of alloreactive Tc on the bone 
marrow (BM) and how structural damage of its microenvironment 
affects hematopoietic recovery and function. Here, we studied in an 
MHC-matched, minor antigen mismatched mouse model the effects of 
lethal irradiation and HCT of purified hematopoietic stem cells (HSC; 
cKIT+Sca1+Lin-) +/- Tc on the hematopoietic and non-hematopoietic 
BM compartments. At 1, 2, 3, and 4w post-HCT bones and marrow 
were analyzed by FACS and 3D-confocal microscopy. Post allo-HCT 
there was a transient weight loss in both groups (HSC and HSC+Tc), 
but no overt GVHD. Total BM cell counts dropped, but at 2w mice 
given HSC had significantly higher absolute BM counts compared with 
HSC+Tc recipients. Strikingly, B-cell recovery occurred promptly in 
HSC recipients but was severely impaired in the HSC+Tc group. 
Likewise, granulocyte recovery at 2, 3, and 4w was significantly better 
in HSC vs. HSC+Tc recipients. Regarding the non-hematopoietic 
compartment CD45-Ter119-CD31+ endothelial cells (EC) were 
significantly reduced in both groups compared with wildtype controls 
(WT) at 1, 2, and 3w post-HCT but recovery was superior in the HSC 
vs the HSC+Tc group with significantly higher EC counts at 2+3w.  
The most pronounced effects were observed for CXCL12-abundant 
reticular (CAR) cells (CD45-Ter119-CD31-CD140B+), which were 
initially reduced in HSC recipients but normalized at 4w post-HCT. In 
HSC+Tc recipients CAR cells were significantly lower and remained 
reduced at w4. 3D-confocal microscopy confirmed these observations 
and revealed rapid recovery of extracellular matrix and vascular 
structures, with simultaneous disappearance of adipocytes at 2w 
post-HCT in the HSC group. In contrast, in recipients of HSC+Tc 
severe disruption of the structural integrity (Figure1) but rather 
occupation of space by adipocytes. In clinical HCT delayed 
hematopoietic reconstitution presents a major problem contributing to 
increased morbidity and mortality. Our data show that alloreactivity 
has a major impact on the non-hematopoietic compartment of the BM 
in terms of both damage and reconstitution of the microarchitecture 
and ultimately hematopoietic recovery. 
Figure 1
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conditions were severely hypoglycemic and showed almost no 
increased glucose tolerance despite normal insulin levels. These 
metabolic changes were also present in recipients transplanted with 
bone marrow from VF or Ex12 donors, indicating that the changes are 
caused by the mass of mutant hematopoietic cells. Intriguingly, HFD 
treatment significantly ameliorated early mortality of MPN mice. This 
effect was not due to reduction in elevated platelet and erythrocyte 
numbers, implying that altered energy homeostasis likely attributable 
for early mortality of MPN mice. Integrated transcriptomics, and 
metabolomics analysis together with metabolic functional assays 
identified increased reliance of mutant HSPCs on fatty acid oxidation, 
glycolysis, and amino acid metabolism causing clonal expansion of 
MPN initiating HSPCs. Pharmacological targeting of JAK2 activation 
with classical JAK2 inhibitor, Ruxolitinib, reduced MPN associated 
hypoglycemia, MPN clonal expansion, and disease burden. 
Conclusion: Hypoglycemia and energy crisis are likely to contribute to 
lethality of MPN mice. Maintaining energy homeostasis and adipose 
tissue depots by high fat diet improved survival of MPN mice. Targeting 
the metabolic dependencies of the mutant MPN clone is a novel 
potential strategy for MPN treatment. 
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Introduction: In classical Hodgkin lymphoma (cHL) the low 
representation (1–5%) of Reed-Sternberg cells (RS) challenged tumor 
genotyping on the diagnostic tissue biopsy. Cell free DNA (cfDNA) is 
shed into the blood by tumor cells undergoing apoptosis and can be 
used as source of tumor DNA for the identification of somatic 
mutations. This study aims at providing the evidence that the genetic 
profile of the cHL can be accurately tracked by using plasma cfDNA. 
Methods: The study incudes a panel of 24 newly diagnosed cases  
of cHL provided with cfDNA from plasma and paired DNA from 
granulocytes as source of germline DNA to filter out polymorphisms 
and sequencing noise. Paired genomic DNA from formalin fixed 
paraffin embedded (FFPE) tumor tissue biopsies was available for  
22 cases. A targeted resequencing panel including the coding exons 
and splice sites of 77 genes that are recurrently mutated in aggressive 
B-cell lymphomas was used for genotyping. DNA samples were 
analyzed by ultra-deep-next generation sequencing (NGS) on the 
MiSeq platform (Illumina) using the CAPP-seq strategy. 
Results: Genotyping of plasma cfDNA identified 145 non-synonymous 
somatic mutations in 37 genes, including STAT6 (45%) TNFAIP3 
(45%), ITPKB (30%) B2M (20%), GNA13 (15%) CIITA (10%) XPO1 
(10%) and CD58 (5%) among the most recurrently affected. The 
mutational profiles pointed to the involvement of PI3K/AKT signaling, 
cytokines signaling, NF-kB signaling and the immune escape in cHL. 
ITPKB (a negative regulator of the PI3K/AKT signaling pathway) was 
specifically mutated in the cHL across aggressive B cell lymphomas. 
By using highly sensitivity techniques, most of the mutations 
discovered in cfDNA were also identified in pair tumor DNA from the 
tissue biopsy, thus confirming their tumor origin. 
Conclusions: This study provides the evidence that cHL can be 
genotyped using plasma cfDNA as source of tumor DNA, and 
identified ITPKB as a new gene involved in this lymphoma type. 
with total BM of young versus aged animals. The effect of identified 
candidates on HSC behavior was further tested in vivo by employing 
CFSE assay. BM analysis at 8 weeks after divisional tracking showed 
that young LKS proliferated faster than old LKS independent of the BM 
environment, while both young and aged LKS were more dormant in 
an old environment. In secondary recipients, dormant aged HSCs, 
independent of environmental age, favor myelopoiesis. In contrast, 
cycling aged HSCs that were exposed to a young environment showed 
balanced lineage repopulation similar as do young HSCs. Expression 
levels of some inflammatory cytokines and myeloid differentiation 
factors were altered in aged BM. These factors drive young HSC 
towards proliferation and differentiation, while this effect is limited on 
aged HSCs, in part likely due to their increased quiescent state. These 
findings demonstrate that HSC proliferation and differentiation are 
controlled by cell-intrinsic and -extrinsic factors: extensive proliferative 
history imprints a quiescence program on HSCs that is associated with 
myeloid-biased differentiation; lineage skewing of HSC during aging 
can be modulated via environmental cues. 
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Background: Myeloproliferative neoplasms (MPN) are clonal 
disorders of hematopoietic stem cells (HSC) driven by activation of 
oncogenic mutations such as JAK2-V617F. MPNs are characterized  
by elevated platelet and/or erythrocyte production or development of 
myelofibrosis. We studied several mouse models of MPN that are 
driven by mutant JAK2-V617F (VF) or by an activating mutation in 
exon 12 (Ex12). These mice exhibit all features of MPN and result in 
early mortality. The causes of death in these mice are largely 
unknown, since hemorrhagic and thrombotic complications are 
relatively rare and leukemic transformation is not observed. We noticed 
that VF and Ex12 mice display markedly decreased body fat and 
therefore we performed a detailed analysis of metabolism in these 
mice.
Results: Hematopoietic specific activation of VF or Ex12 mutations in 
mice caused global metabolic changes including adipose tissue 
atrophy due to increased adipocyte lysis in white and brown fat tissues, 
systemic metabolic changes, and resistance to high-fat diet (HFD) 
induced obesity in mice. In addition, these mice under normal dietary 
Figure 1
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duration was tailored based on residual vein thrombosis. Recurrence 
rates were determined. A cox proportional hazards model employing 
anticoagulation treatment as time-varying covariate was used to define 
risk factors for recurrence.
Results: Out of 479 patients diagnosed with proximal DVT, 474 
completed the two-year CCP (99%), and 457 (94.7%) the extended 
follow-up (2231.2 patient-years; median follow-up 4.6 years; median 
age 58.0 years; 50.4% females). Overall VTE recurrence was 2.9 per 
100 patient-years, 1.3 if provoked by surgery, 2.1 if a non-surgical 
transient risk factor was present, and 4.0 if unprovoked. Residual 
thrombosis was present in 141 patients (29.8%). Duration of 
anticoagulation was 3 months in 75 patients (15.7%), 6 months in 230 
(48.0%), 12 months in 95 (19.8%) and indefinite in 79 (16.5%). DVT 
was provoked by surgery in 95 patients (19.9%), by a transient 
non-surgical risk factor in 107 patients (22.3%) and unprovoked in 265 
(55.3%). Significant predictors of recurrent events were unprovoked 
VTE (adjusted hazard ratio [HR] 4.6; 95% CI 1.7, 11.9), elevated 
d-dimers one month after stop treatment (HR 3.3; 1.8, 6.1), male sex 
(HR 2.8; 1.5, 5.1), high factor VIII (HR 2.2; 1.2, 4.0) and use of 
contraceptives (HR 0.1; 0.0, 0.9). 
Conclusions: Patients with DVT managed within an established 
clinical care pathway according to the presence of residual vein 
thrombosis had low incidences of VTE recurrence. In accordance with 
other clinical settings, unprovoked VTE, male sex, elevated D-dimers 
one month after stop treatment, inflammation, and high FVIII were 
identified as major predictors for recurrent VTE. 
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Introduction: Laboratory tests currently used to investigate a bleeding 
diathesis may fail to reveal the underlying hemostatic disorder. Flow 
cytometry (FC) improved our tools for exploring platelet (PLT) function 
and profiling defects associated with a bleeding diathesis. Our aim  
is to hone standard FC analysis by extending investigations to 
intracellular signaling. In this work, we assessed free intracellular Ca2+ 
upon PLT activation.
Method: Platelet-rich plasma was obtained from citrate-anticoagulated 
whole blood. PLTs were activated with increasing concentrations of 
thromboxane analogue U-46619, ADP, thrombin, the two selective 
thrombin receptor agonists TRAP6 (PAR-1 agonist) and AYPGKF 
(PAR-4 agonist), convulxin (agonist of the GPVI collagen receptor), 
and ionophore. Activation end-points were secretion of alpha-granules 
(detected by P-selectin expression) and activation of the fibrinogen 
receptor (visualized by PAC-1 binding). Intracellular free Ca2+ was 
detected by its indicator Fluo-3 AM. After measurement of a stable 
baseline, PLTs were activated with various agonists, and Fluo-3 
fluorescence was continuously acquired over time, up to 10 minutes, 
on a BD Accuri C6 flow cytometer.
Results: Optimal dose-response concentrations were determined  
for each agonist and Ca2+ monitoring following PLT activation was 
performed. Maximal and sustained cytosolic Ca2+ increase was 
observed after PLT activation with ionophore. Very strong and 
sustained increase was also observed by activation with convulxin  
and thrombin. While convulxin was able to induce a strong Ca2+ spike 
followed by a plateau, thrombin induced an initially strong Ca2+ 
response, which subsequently declined. Both selective PAR agonists, 
TRAP6 and AYPGKF, demonstrated a strong increase with rapidly 
declining intracellular Ca2+, but their combined action was not able to 
fully replicate thrombin effect. Finally, although a similar weak Ca2+ 
mobilization was observed with U-46619 and ADP, these agonists 
differently affected convulxin and thrombin responses when employed 
in combination.
Conclusion: The present work highlights the use of continuous 
calcium monitoring to complement FC analysis of PLT function. We 
demonstrate characteristic Ca2+ mobilization patterns following PLT 
activation with various agonists. This technique will sharpen the ability 
to detect PLT signaling defects in bleeding patients investigated for 
platelet function disorders. 
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Introduction: The laboratory gold standard for diagnosing HIT is a 
functional assay, e.g. the Heparin Induced Platelet Aggregation (HIPA) 
test. We assessed 3 quantitative immunoassays (IAs) detecting 
anti-PF4/heparin antibodies for their ability to predict the HIPA result. 
Our aim was to prospectively evaluate a rapid algorithm able to 
confirm or exclude HIT with a laboratory turn-around-time of 30 
minutes.
Methods: We conducted a retrospective (05.2014–08.2015; n = 220) 
and a prospective (09.2015–08.2016; n = 234) study in patients with 
HIT suspicion. 46 plasma samples of the retrospective study and all 
samples of the prospective one were analyzed by 3 IAs (ELISA 
Zymutest HIA monostrip IgG; AcuStar HIT IgG; ID-H/PF4-PaGIA). 
ROC analysis let us compare the areas under the curve (AUC) and 
determine cut-offs with 100% negative (NPV) and positive (PPV) 
predictive values for a positive HIPA.
Results: HIT diagnosis was confirmed by a positive HIPA in 10% of 
patients (22/220) in the retrospective and in 9.4% (22/234) in the 
prospective study. AcuStar showed an AUC of 0.98 both in the 
retrospective (p = 0.02 compared to Zymutest and p = 0.59 to PaGIA) 
and in the prospective study (p = 0.06 compared to Zymutest and p = 
0.52 to PaGIA). A 100% PPV was observed with a result >1.37 U/ml 
(identifying 18/22 HIPA-positive samples) and with a result >0.77 U/ml 
(identifying 20/22 HIPA-pos samples) in the retrospective and 
prospective studies, respectively. A 100% NPV was observed with  
a result of ≤0.12 U/ml and ≤0.18 U/ml (overall identifying 218/236 
HIPA-negative samples). PaGIA showed an AUC of 0.99 and 0.97 in 
the two studies. A titer ≥16 had a 100% PPV and a titer < 2 had a 
100% NPV (identifying 210/236 HIPA-negative cases). Applying 
conservative cut-off values of ≤0.12 (= negative) and ≥1.50 (= 
positive) for AcuStar results, only 13% of samples (36/280) were 
between these values (“grey zone”). Among them, 17 (47%) were 
correctly solved by PaGIA. Eventually, 7% of all samples (19/280) 
remained unclear until HIPA result. The in house cut-off produced no 
false positive or negative results.
Conclusion: The sequential application of two rapid immunoassays 
(AcuStar HIT IgG and ID-H/PF4-PaGIA) with in-house determined 
cut-off values with 100% NPV and PPV enables a reliable and 
conclusive diagnostic work-up for ~95% of patients with clinical 
suspicion of HIT, in a laboratory turn-around-time of 30 minutes. We 
are now conducting a prospective validation of this rapid diagnostic 
algorithm. 
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Background: Finding the optimal duration of anticoagulant treatment 
following an acute event of deep venous thrombosis (DVT) is 
challenging. Residual thrombosis has been identified as risk factor for 
recurrence, but data on management strategies based on residual 
thrombosis and associated recurrence rates in defined clinical care 
pathways (CCP) are lacking. 
Objective: To investigate the long-term clinical outcomes and 
predictors for VTE recurrence in a contemporary cohort of patients 
with proximal deep vein thrombosis (DVT) managed according to the 
presence of residual vein thrombosis.
Methods: All patients treated at Maastricht University Medical Center 
within an established clinical care pathway from June 2003 through 
June 2013 were prospectively followed for up to 11 years. Treatment 
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Methods: VEGF serum levels and miR-21 in PBMCs was measured 
in 93 patients with PCM directly before melphalan 200 mg/m2 followed 
by autologous hematopoietic stem cell transplantation (auto-HSCT) 
and 2 months after HSCT; and 35 healthy controls. The study 
population was divided into two groups after therapy: responders 
(stringent complete response, complete response, very good partial 
response, partial response) and non-responders (stable disease, 
progressive disease). Gene expression of miR-21 was quantified by 
SYBR green real-time fluorescent quantitative PCR. Further tube 
formation of HUVECs and VEGF secretion was measured in miR-21 
mimic or inhibitor transfected human plasma cell myeloma cell lines 
H929 and RPMI-8226.
Results: The expression level of miR-21 was significantly increased 
(2.7 ± 0.55 versus 0.78 ± 0.22; p <0.01) in PBMCs of PCM patients 
compared with healthy controls. Further, serum VEGF levels were 
increased in PCM patients (477 ± 145 pg/ml versus 178 ± 78 pg/ml in 
normal controls; p <0.01). After auto-HSCT, the expression level of 
miR-21 was significantly different in responders compared to non-
responders. Responders had a lower expression of miR-21 compared 
to non-responders. Further, serum VEGF levels decreased in 
responders to auto-HSCT compared to non-responders. VEGF 
expression was increased in the supernatant from miR-21 mimic 
transfected human PCM cell lines H929 and RPMI-8226 compared 
with the negative control, while VEGF was decreased in the miR-21 
inhibitor transfected cell lines. The angiogenic ability of HUVECs was 
increased under pretreatment with the supernatant from H929 and 
RPMI-8226 cells transfected with miR-21 mimic compared with 
negative controls and decreased when pretreated with miR-21 inhibitor 
transfected cells 
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Introduction: Complete protein S (PS) deficiency is a rare fatal 
thrombophilia associating purpura fulminans (PF) and disseminated 
intravascular coagulation (DIC). We obtained a full rescue of Pros1-/- 
lethality by targeting FVIII, F8-/-Pros1-/- mice showing neither PF or 
DIC. Pregnancy loss was not observed in Pros1+/- mice. Because 
thrombophilias are associated with pregnancy loss, we investigated 
the effect of complete lack of PS on pregnancy outcome in mice.
Methods: Pregnancy monitoring in F8-/-Pros1-/-, F8-/-Pros1+/+ and 
F8+/+Pros1+/+ mice by blood cell count, coagulation tests and histology 
of pregnant mice and embryos. 
Results: Vaginal plugs were observed in all F8-/-Pros1-/- females  
(n = 19) but, independently of the male breeder genotype, no litters 
were produced. Embryos collection revealed embryonic mortality at 
E11.5-12.5 (58% dead embryos; n = 41/71), E13.5-16.5 (69%; n = 
44/64). Most of dead embryos were macerated but some of them 
showed hemorrhages and thrombosis but no PF. Among embryos 
collected before E9.5–10.5, there was a lower number of embryos 
carrying the F8-/-Pros1-/- genotype than expected (33% vs 50%) and  
no live embryos collected after E12.5 were F8-/-Pros1-/-. All embryos 
collected from F8-/-Pros1+/+ and F8+/+Pros1+/+ pregnant mice were alive. 
Recurrent pregnancy loss never affected F8-/-Pros1-/- mice survival. 
Between E12-16 and in comparison to F8-/-Pros1+/+ gravid mice, 
F8-/-Pros1-/- pregnant mice displayed reduced platelet count (559 ± 79 
vs 829 ± 92G/L;P <0.05) and fibrinogen (1.0 ± 0.1 vs 2.4 ± 0.3g/L; P 
<0.001), and increased TAT complexes (25.4 ± 2.8 vs 12.6 ± 4.3 
ng/L;P <0.05) whereas PT was normal in both genotypes. Moreover, 
placenta but not lung and liver sections showed fibrin clots. 
Importantly, all blood and histological analyses were comparable in 
F8-/-Pros1+/+ and F8+/+Pros1+/+ pregnant mice. 
Treatment of F8-/-Pros1-/- pregnant mice with enoxaparin prevented 
pregnancy loss; newborns were normal. Pregnancy outcome was also 
positive with low-dose aspirin. However, the litter size was slightly 
reduced (n = 2–4) in the aspirin group as compared to the enoxaparin 
group (n = 5–6).
Conclusion: Targeting FVIII did not prevent pregnancy loss due to 
placental thrombosis in gravid Pros1-/- mice. Although F8-/-Pros1-/- 
pregnant mice displayed coagulation activation, there was no overt 
DIC. Aspirin or better enoxaparin treatment prevented pregnancy loss, 
indicating that thromboprophylaxis might apply to pregnancy in very 
severe inherited thrombophilias. 
FM310
Overexpression of miR-21 involved in plasma cell  
myeloma-associated angiogenesis
Michael Medinger, Dominik Heim, Claudia Lengerke,  
Martina Kleber, Jakob Passweg 
Hämatologie, Universitätsspital Basel, Basel, Switzerland
Introduction: Angiogenesis plays an important role in the 
pathophysiology of hematological malignancies including plasma cell 
myeloma (PCM). MicroRNA-21 (miR-21) is overexpressed and 
displays oncogenic activity in cancers. The aim of the present study is 
to examine the expression level of peripheral miR-21 in PCM patients 
and to determine its role in angiogenesis.
Conclusions: This study demonstrated that miR-21 was upregulated 
in PCM patients. Responders to auto-HSCT had a decrease of miR-21 
expression and VEGF levels. Further, miR-21 regulated angiogenesis. 
Therefore inactivation of miR-21 or activation of its target gene may be 
a potential therapeutic approach in PCM. 
Figure 1
PRIMARY AND HOSPITAL CARE – ALLGEMEINE INNERE MEDIZIN 2017;17(SUPPLEMENTUM)
GASTGESELLSCHAFT SGH / SOCIÉTÉ CONVIÉE SSH 37 S
Conclusion: We report here an early and long lasting increase of 
PD-1 expression on CD4 and CD8 T cells after allo-HSCT. Several 
factors, including TCD and transplantation from haploidentical donors, 
are associated with a further increase in PD-1 expression on T cells. 
These results will help harnessing the potential of PD-1 blockade after 
allo-HSCT. 
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Introduction: Sinusoidal obstruction syndrome (SOS) is frequent after 
HSCT and may have a mortality rate of up to 85%. Defibrotide has 
shown efficacy not only in the treatment of established SOS but also in 
SOS prevention in a prospective study in children as well as in adults 
(several retrospective studies). 
Patients and methods: Between 1999 and 2009, we gave defibrotide 
intravenously to 237 successive patients transplanted (248 
transplantations) for hematological diseases starting at day –7 up  
to day +20 post-transplantation (dose range 800–2400 mg/d) in 
combination with heparin. The control group did not receive defibrotide 
as prophylaxis anymore (2011–2015, total 241 patients with 248 
transplantations). 
Results: Median follow-up for the study group was 10 (range 2–16) 
years and for the control group 2.7 (range 1–18) years. None of the 
237 patients in the defibrotide group developed SOS (Baltimore 
criteria). The 100 day cumulative incidence (CI) of SOS was 0% in the 
defibrotide group as compared to 4.8% (95%CI 2.6–8%) in the control 
group, p = 0.00046. The day 100 event free survival (EFS) was not 
significantly different with 60% (95%CI 54%-66%) in the defibrotide 
group vs 53% (95%CI 47–59%) in the controls, p = 0.165, but the one 
year EFS was statistically different with 38% (95%CI 32%–44%) vs 
28% (95%CI 22–34%), p = 0.00969. The 100 day CI of acute GVHD 
was not significantly different between the two groups [27% (95%CI 
22–33%) in the defibrotide group vs 29% (95%CI 24–35%) in the 
control group, p = 0.707] while the 1 year acute GvHD CI was 
significantly reduced in the defibrotide group [31% (95%CI 25–37%)] 
compared with the control group [42% (95%CI 36–48%), p = 0.026]. 
The one year overall survival (OS), relapse incidence (RI) and 
non-relapse mortality (NRM) were not statistically different. Multivariate 
analysis, performed taking into account clinical factors known to 
influence the risk of SOS, confirmed the favorable impact of defibrotide 
on 100 day SOS CI [HR 7.5×10–7 (95%CI 1.8×10–7 –3.2×10–6), 
p <0.00001] (table).
SOS incidence at 1 year Hazard ratio Lower 
95%CI
Upper 
95%CI
p value
Age (>50 vs <50 years) 0.147 0.032 0.685 0.01500
AST/ALT (high vs normal) 34.410 5.813 203.700 0.00010
Bilirubin (high vs normal) 31.660 1.886 531.500 0.01600
HSCT Year (>2007 vs 
<2007)
0.009 0.000 0.180 0.00210
Conditioning (RIC vs 
MAC)
0.077 0.008 0.703 0.02300
Busulfan use (Yes vs No) 22.810 6.079 85.580 <0.00001
TBI (Yes vs No) 2.758 0.564 13.490 0.21000
HSCT Number (2nd vs 
1st)
2.501 0.468 13.370 0.28000
Defibrotide use (Yes vs 
No)
0.000 0.000 0.000 <0.00001
Conversely, multivariate analysis failed to confirm the impact of 
defibrotide on 1 year EFS or acute GvHD CI. 
Conclusion: To the best of our knowledge, this is the largest study on 
SOS-prophylaxis with defibrotide and it suggests that this drug may 
benefit the prevention of this liver complication. Our retrospective study 
needs to be confirmed in a prospective randomized trial. 
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Introduction: Blockade of the programmed-death 1 (PD-1) immune 
checkpoint represents a promising strategy to enhance anti-tumoral 
immune responses after allogeneic hematopoietic stem cell 
transplantation (allo-HSCT). However, observational studies suggest 
that PD-1 blockade can be complicated by the development of severe 
graft-versus-host disease (GvHD). A better knowledge of the dynamics 
of PD-1 expression by T cells after allo-HSCT is necessary in order to 
optimize PD-1 targeting therapies and limit toxicities. 
Methods: We analyzed by flow cytometry 124 freshly drawn blood 
samples isolated from 98 allo-HSCT recipients. 23 healthy blood 
donors served as controls (HC). 
Results: We observed a strong increase in PD-1 expression at the 
surface of CD4 and CD8 T cells isolated from allo-HSCT recipients 
compared with HC (Fig 1A). Importantly, we observed the significant 
increase of PD-1 expressing cells in all CD4 and CD8 T cell 
subpopulations studied (fig. 1B). We observed an inverse correlation 
between the time since allo-HSCT and PD-1 expression at T cell 
surface (fig. 1C). PD-1 expressing cells were higher than normal 
already at one month after allo-HSCT (fig. 1D). Thereafter, proportions 
of CD4 PD-1+ T cells remained higher than in HC up to more than  
5 years after HSCT, while PD-1 expression on CD8 T cells started to 
normalize at 1 year after transplantation (fig. 1D). The stem cell source 
(BM vs PBSC), conditioning regimen (RIC vs MAC), use of total body 
irradiation and disease status at HSCT did not impact PD-1 
expression. We observed higher proportions of PD-1+CD4+ but not of 
PD-1+CD8 T cells in patients having received in vivo and/or ex vivo 
T-cell depletion (TCD) compared with patient receiving T cell replete 
grafts (p = 0.0269). CD8 T cells from patients receiving grafts from 
haploidentical donors displayed higher proportions of PD-1+ cells than 
patients receiving grafts from matched related (p = 0.0492) or 
unrelated donors (p = 0.0049). No association was found between 
PD-1 expression on T cells and post-transplant complications, 
including acute or chronic GvHD, disease relapse and CMV 
reactivation. 
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matched (n = 10) or mismatched (n = 6) unrelated donors, 
haploidentical donors (n = 2) or cord blood (n = 2). Median time from 
HSCT to HS diagnosis was 66 days (range 6–326). Fever was present 
in almost all patients (93%) while we observed splenomegaly in 13 
(48%), hepatomegaly in 11 (41%), and lymphadenopathy in 8 (30%) 
patients. We found pancytopenia in 14 patients (52%). All patients 
displayed elevated ferritin levels. 11 patients (41%) had triglyceride 
levels at >4 mmol/l, while only 7 patients (26%) had fibrinogen <2.5 
g/L. Aminotransferases were elevated in half of the patients (n = 14). 
Bone marrow hemophagocytosis was found in 15 patients (56%) 
(fig. 1A). 20 patients (74%) had pharmacological immune suppression 
at time of HS diagnosis. Infections were the most frequent triggering 
events (48%) followed by cancer (30%) and GvHD (15%) (fig. 1B). 
Median survival after HS diagnosis was 58 days and the 1-year overall 
survival (OS) was 22% (fig. 1C). Treatments most frequently employed, 
either alone or in combination, were steroids (n = 16), IVIG (n = 7) and 
Etoposide (n = 7). Etiological anti-infectious or anti-cancer agents were 
employed alone in 7 patients. Three patients underwent a second 
allogeneic HSCT that provided long-term rescue in one patient. 
Conclusion: Our study, which is to the best of our knowledge the 
largest series of HS following HSCT reported so far, provides a 
description of HS as a rare but devastating complication of HSCT 
associated with an extremely high mortality. 
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Background and aims: Myeloproliferative neoplasms (MPN) are 
characterized by cellular proliferation due to a dominant clone defined 
by a driver mutation, with or without subclones with additional 
mutations and/or polyclonal hematopoiesis. Due to the loss of telomere 
sequences with each cell division, in neoplastic cells with a high 
mitotic rate telomeres are typically short. In the study with the 
telomerase inhibitor imetelstat (IM) we demonstrated rapid and durable 
hematologic and molecular responses (Baerlocher et al. N Engl J Med 
2015) and suppression of clones with non-driver mutations in patients 
(pts) with ET. Our aims were to evaluate telomere length values (TLV) 
in MPN pts and in ET pts treated with IM (IM-ET) as well as correlation 
with hematologic and molecular responses.
Patients and methods: 17 IM-ET pts who were resistant or intolerant 
to prior therapies and 63 MPN pts (16 ET, 34 PV, 13 MF) untreated  
or treated with standard of care (SOC-MPN) were analyzed. TLV  
were measured by automated multicolor flow-FISH.
Results: All IM-ET pts showed low TLV at baseline, with 12 pts below 
the 1st percentile, and TLV of SOC-MPN pts were around the 10th 
percentile. The median difference in TLV to the age-related 50th 
percentile (dTLV) in IM-ET pts was significantly lower than in SOC-ET 
pts and similar to dTLV of pts with MF. In IM-ET pts with shorter 
baseline TL, driver mutation burden at baseline was significantly 
higher (p = 0.03) and best reduction in driver mutation burden was 
significantly less (p = 0.03). In 10/13 IM-ET pts, dTLV were higher at 
best response, reflecting the reduction of neoplastic clones in relation 
to normal hematopoietic cells. This change of dTLV correlated 
significantly with the maximum reduction of the JAK2V617F burden  
(p = 0.0003). Of interest, the 3 IM-ET pts with lower or steady TLV after 
9 months of treatment had the highest number of additional mutations 
at baseline. 
Conclusions: The lower TLV found in pts with MPN and especially 
with MF compared to healthy individuals reflect the higher mitotic 
history of malignant clones. In the IM-ET cohort, driver mutation 
burden at baseline and best response during treatment correlate 
significantly with baseline TL. The higher TLV observed after 9 months 
of treatment and the correlation with the reduction in the driver 
mutation burden suggests that in ET pts, IM may suppress neoplastic 
clones and, in the absence of a high number of additional mutations, 
favor recovery of normal hematopoiesis. 
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Introduction: Reactive hemophagocytic syndrome (HS) is a rare 
complication that may occur after both autologous and allogeneic 
hematopoietic stem cells transplantation (HSCT). Only about sixty 
cases of post-HSCT HS have been reported in the literature so far. 
Methods: We performed a multicenter retrospective study on behalf of 
the SFGM-TC, including adult HSCT recipients diagnosed with HS 
after HSCT. The recently reported HScore was applied for confirmation 
of HS diagnosis. 
Results: Among the 33 patients reported, 2 patients were excluded 
because of insufficient data and 4 patients for an HScore less than 
169. We included in the final analysis 27 patients in which the HS 
diagnosis was confirmed (median HScore 218 and HS probability of 
97%). Median age was 45 years. 3 patients underwent autologous 
HSCT for non-Hodgkin lymphoma (NHL). 24 patients received 
allogeneic HSCT for hematological malignancies (n = 23) or severe 
aplastic anemia (n = 1) from HLA-identical siblings (n = 4), HLA-
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University of Eastern Piedmont (UPO). The validation cohorts included 
90 patients retrospectively observed at Oncology Institute of Southern 
Switzerland (IOSI) and 318 individual patient’s data from the 
multicenter observational study O-CLL1. 
Results: In the UPO training cohort, three independent prognostic 
variables predicting disease progression (PFS) were identified by the 
multivariate analysis: IGHV mutational status (HR = 3.6), palpable 
lymph nodes (H = 2.4) and lymphocyte count (H = 2.1). By recursive 
partitioning, patients concomitantly harboring unmutated IGHV genes 
and palpable lymph nodes had the highest risk of progression (median 
PFS, 2.5 years; 5-year PFS, 7%). The model correctly discriminated 
PFS in 73% of cases (c-index: 0.732) and showed a positive (PPV) 
and negative predictive (NPP) values for the identification of patients 
progressing within 5 years of 81% and 80%, respectively. The 
accuracy of the model was higher than that of the MDAAC-score 
(c-index = 0.593) and of the CLL-IPI score (c-index = 0.687). The 
model was validated in the IOSI (c-index = 0.712) and in the O-CLL1 
(c-index = 0.660) series. 
Conclusion: The presence of unmutated IGHV genes and palpable 
lymphadenopathy identifies Binet A CLL patients showing a high risk 
of progression and treatment requirement within 5-years from 
diagnosis. For this subset of CLL patients, enrollment into early 
interventional studies may be beneficial. 
Disclosures: None. 
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Introduction: The natural history of Binet A chronic lymphocytic 
leukemia (CLL) is highly variable, including patients showing 
progressive disease requiring treatment and cases with an indolent 
disease for whom a watch and wait approach is recommended. 
Recently, two prognostic scores (MDAAC-score and CLL-IPI) have 
been developed to predict prognosis of CLL, though they do not inform 
the outcome of patients with Binet A CLL. The aim of our study was to 
perform and validate a model retaining its prognostic value in the 
subgroup of Binet A patients. 
Methods: 637 patients affected by Binet A CLL were included into the 
study. The dataset was divided into training and validation series. The 
training cohort included 229 patients prospectively enrolled at the 
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Background or introduction: Tizanidine (TIZA) is indicated for the 
treatment of spasticity. The substance has antihypertensive effects  
0and is extensively metabolized via cytochrome P450 (CYP) 1A2. 
Co-administration with potent CYP1A2 inhibitors such as ciprofloxacin 
(CIPRO) resulted in significant increase of TIZA plasma concentrations 
in healthy volunteers. The combination is contraindicated and clinical 
effects in patients are unknown. 
Material and methods: Several adverse drug interactions with clinical 
reactions after concomitant use of TIZA and CIPRO were reported to 
the Regional Pharmacovigilance Centre of Zurich. We conducted a 
retrospective study of Individual Case Safety Reports (ICSRs) 
obtained from the World Health Organization (WHO) Global Database 
to analyse this drug safety issue. All ICSRs of TIZA registered in the 
WHO Database until August 2015 were included. Demographic data, 
drug administration information, the course of the adverse drug 
reaction (ADR), its severity and outcomes were analysed in patients 
with co-administration of TIZA and CIPRO. Other centrally-acting 
drugs (e.g. baclofen, benzodiazepines, opioids, antidepressants) or 
substances with hypotensive effects (e.g. calcium channel blockers, 
ACE-inhibitors, beta-blockers) were frequently co-administered. 
Results: Concomitant use of CIPRO was reported in 64 (2.0%) of 
3253 TIZA-related ICSRs. The majority of patients was female (n = 36, 
56%), the median age was 53 years (range 13–83 years). Most reports 
were derived from the US (n = 34; 53%) followed by Switzerland (n = 
11; 17%). Most of the reported ADRs were related to increased TIZA 
effects with hypotension and sedation. Most frequently reported terms 
included hypotension, asthenia, hypoventilation, somnolence, or 
unconsciousness. Patients who experienced ADRs had 3 other drugs 
when receiving TIZA daily doses ≥12 mg – or 6 other drugs when 
receiving TIZA daily <12 mg. One patient in each dosage group died. 
Conclusions: Concomitant use of CIPRO increases the risk of 
dose-dependent TIZA effects, such as hypotension and sedation. This 
combination should be absolutely avoided. Especially combinations 
with high doses of TIZA ≥12 mg/day but also lower doses <12 mg/day 
combined with CNS- and blood pressure lowering drugs may result in 
serious ADRs and even fatal outcomes. 
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Background and objective: Lysergic acid diethylamide (LSD) is used 
recreationally and in clinical research. The aim of the present study 
was to characterize the pharmacokinetics and exposure-response 
relationship of oral LSD.
Methods: We analyzed pharmacokinetic data from two published 
placebo-controlled, double-blind, cross-over studies using oral 
administration of 100 and 200 µg LSD in 24 and 16 subjects, 
respectively. Plasma concentrations of LSD, subjective effects, and 
vital signs were repeatedly assessed. Pharmacokinetic parameters 
were determined using compartmental modeling. Concentration-effect 
relationships were described using pharmacokinetic-
pharmacodynamic modeling. 
Results: Geometric mean (95% confidence interval) Cmax values  
of 1.3 (1.2-1.9) and 3.1 (2.6-4.0) ng/ml were reached 1.4 and 1.5 h  
after administration of 100 and 200 µg LSD, respectively. The plasma 
half-life was 2.6 h (2.2–3.4). The subjective effects lasted (mean ± SD) 
8.2 ± 2.1 and 11.6 ± 1.7 h following a dose of 100 and 200 µg LSD, 
respectively. Subjective peak effects were reached 2.8 and 2.5 h after 
administration of 100 and 200 µg LSD, respectively. A close 
relationship was observed between the LSD Plasma concentration 
and subjective response within-subjects, with moderate 
counterclockwise hysteresis. EC50 values were in the range of 1 ng/ml. 
No correlations were found between plasma LSD levels and its effects 
across subjects at or near Cmax and within dose groups.
Conclusions: The present pharmacokinetic data are important for the 
evaluation of clinical study findings (e.g., functional magnetic 
resonance imaging studies) and the interpretation of LSD intoxication. 
Oral LSD presented dose-proportional pharmacokinetics and 
first-order elimination up to 12 h. The effects of LSD were related to 
changes in plasma concentrations over time, with no evidence of 
acute tolerance.
The studies were registered at ClinicalTrials.gov (NCT02308969, 
NCT01878942). 
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DBS and extracted with 100 µl of methanol + 1% formic acid 
containing the stable isotopically-labeled Internal Standards for all 
antimalarials. Concentrations of all antimalarials were simultaneously 
determined by chromatography coupled to tandem mass spectrometry 
(LC-MS/MS) in DBS, venous blood spotted onto DBS, whole venous 
blood and plasma collected in 16 healthy volunteers who took a single 
dose of artemether-lumefantrine and were followed up to 336 hours.
Results: Lower limits of quantification were 2 ng/ml for pyrimethamine, 
6 ng/ml for desethyl-amodiaquine, and 20 ng/ml for the other 
antimalarials. The analytical inter-day variation coefficient was 
2.1–15.2%. Lumefantrine concentrations measured in plasma were 
twice as high as those measured in DBS and were highly correlated  
(r = 0.99). There were no differences in drug concentration between 
venous blood spotted on DBS cards and capillary blood directly 
spotted from volunteers’ finger. Lumefantrine could be quantified in 
volunteers up to 336 hours after drug intake.
Conclusion: With a low volume of 10-µl of blood, our technique 
enables precise and sensitive measurement of antimalarials in DBS. 
The concentration measured in capillary blood DBS reflects the drug 
levels measured in venous whole blood. These relationships could 
contribute to define the therapeutic ranges of lumefantrine 
concentrations measured in DBS. DBS sampling is a confident 
surrogate marker of drug level in plasma and is suitable for 
epidemiological studies. 
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Introduction: Dolutegravir (DTG), the latest integrase inhibitor (INIs) 
approved for HIV treatment is coformulated in a single tablet regimen 
with abacavir and lamivudine. DTG has demonstrated potent antiviral 
activity and a very good tolerability and is widely prescribed in 
HIV-infected patients (1). DTG is primarily metabolized via UDP-
glucuronosyltransferase (UGT 1A1) with a minor component of 
CYP3A4 (2). The aim of this observational study was to characterize 
DTG pharmacokinetic profile, to quantify interpatient variability and to 
identify potential factors that could influence drug exposure. 
Methods: All dolutegravir concentrations data were collected as part 
of routine therapeutic drug monitoring performed in our hospital, 
between June 2014 and December 2015 from HIV treatment-naive and 
experimented patients. A population PK analysis was performed by 
comparing various structural models using NONMEM®. The effect of 
relevant demographic factors and co-medications were on dolutegravir 
disposition was explored. 
Results: A total of 594 plasma levels were measured in 514 HIV-
positive patients under steady state regimen conditions. Plasma 
concentrations ranged between 31 and 7971 ng/mL. A one-
compartment model with first order absorption and elimination best 
characterized dolutegravir pharmacokinetics. Average DTG clearance 
was 0.93 (L/h), volume of distribution 18.9 (L), and mean absorption 
time 1.27 (h–1). The inter-subject variability on CL was estimated at 
27%. Among the demographic covariates tested, body weight and age 
influenced positively and moderately DTG CL (29% and 24% 
respectively) as well as smoking status (17%). Coadminisation of 
atazanavir decreased DTG clearance by 38% and the association of 
darunavir increased the clearance of DTG (14%). 
Conclusion: The variability in DTG pharmacokinetics appears lower 
than for other INIs. Several covariates were identified impacting DTG 
exposure however their effect appears to be relatively modest and 
seems not to be clinically significant except for atazanavir 
coadministration. 
1  FDA. 2013. TIVICAY (dolutegravir) FULL PRESCRIBING INFORMATION. 
administration FaD, http://www.accessdata.fda.gov/drugsatfda_docs/
label/2013/204790lbl.pdf. 
2  Castellino S, et al. Antimicrob Agents Chemother. 2013;57:3536–46. 
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Introduction: Neuropathic pain (NP) affects about 7% of the general 
population in European countries. Meta-analyses indicate that only a 
minority of NP patients has adequate response to drug therapy and 
management of NP is still an unmet medical need. New insights into 
the contribution of defined subtypes of GABAA receptors (GABAA Rs) 
to the different clinical effects of benzodiazepine (BDZ)s, including 
analgesia, have suggested that α1-sparing selective BDZs, such as 
N-desmethylclobazam (NDMC), may be a new realistic alternative for 
the treatment of NP. 
Method: Healthy volunteers, proof-of-concept RCT assessing 
antihyperalgesic and sedative effects of BDZs on a UVB-induced  
pain model of central sensitization [1]. Human cell electrophysiology 
(recombinant GABAA Rs) and mice behavioral experiments based  
on a chronic constriction injury model comparing diazepam (DZP), 
clobazam (CBZ) and NDMC activity profiles [2]. 
Results: In healthy volunteers, at the time of maximum effect, CBZ 
and clonazepam (CLN) antihyperalgesic effect was greater (vs. 
placebo) by respectively 15.7% (95% CI 0.8–30.5) and 28.6% (95%  
CI 4.5–52.6), p <0.05. Difference (vs. placebo) in sedation (VAS) was 
only significant for CLN 26.3 mm (95%CI 15.0–37.7), p <0.001 [1]. In 
recombinant receptors, NDMC had better α2- over α1GABAARs activity 
ratio than CBZ and DZP. Unlike DZP, NDMC caused no or modest 
sedation at antihyperalgesic doses in two strains of wild-type mice [2]. 
Conclusion: NDMC α2/α1 in vitro activity profile and long term clinical 
experience from its marketed parent compound (CBZ) make it an 
advisable clinical candidate for further proof-of-concept assessments 
in human. Therefore the HUG has manufactured a new chemical entity 
and initiated a drug development program for NDMC starting with a 
phase-I trial comparing analgesic and sedative effects of NDMC 20 
mg and 60 mg with clonazepam 1.5 mg in healthy volunteers and two 
phase-I single and repeated dose pharmacokinetic studies. 
1. Besson M. et al, Pain, 2015.
2. Ralvenius W. T. et al, Neuropharmacol, 2016. 
This research was sponsored by the National Swiss Fondation, SPUM 
33CM30_124117/1 
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Introduction: Measurement of the concentration of antimalarials in 
blood of the general population constitutes a suitable approach for 
estimating population drug exposure and is used in efficacy studies. 
Storage and transportation conditions of blood samples are common 
problems for studies in areas with a high prevalence of malaria. The 
dried blood spot (DBS) sampling technique allows facilitating storage 
and transportation procedures. We present a method for the analysis 
of 9 antimalarial drugs in DBS and show the relationship between the 
concentrations of lumefantrine in DBS, plasma and whole blood. 
Methods: Known concentrations of amodiaquine, desethyl-
amodiaquine, quinine, chloroquine, mefloquine, sulfadoxine, 
pyrimethamine, lumefantrine and desbutyl-lumefantrine were added in 
whole human blood. A 10µl-aliquot of spiked blood was applied onto a 
filter paper card (Whatman FTA DMPK-B) and allowed to dry for 3 
hours at room temperature. A 3 mm-punch was taken out from the 
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(rs7187684) for CES1. In addition, the association of two common 
linked CDA promoter variants (c.1-451C>T: ORdominant = 4.3, 95% CI: 
1.3-14.2, Padjusted = 0.017; and c.1-92A>G: ORdominant = 4.4; 95% CI 
1.3-14.5, Padjusted = 0.015) with increased risk of Cp-induced diarrhea 
was replicated. 
Conclusions: This is the first study to identify an association of 
genetic variation in CES1 with Cp-related toxicity. Given that a variant 
(rs2244613) of the same CES1 haplotype was previously associated 
with trough concentrations and bleeding from the CES1-metabolized 
anticoagulant dabigatran, this finding provides evidence for the 
existence of a common regulatory CES1 variant with possible clinical 
relevance for carboxylesterase-metabolized drugs. 
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Introduction: In vivo and in vitro studies respectively showed that 
cytochrome P450 (CYP) 2D6, CYP2C19, CYP2B6, and CYP1A2 
contribute to the metabolism of 3,4-methylenedioxymethamphetamine 
(MDMA, “ecstasy”). However, the role of genetic polymorphisms in 
CYP2D6, CYP2C19, CYP2B6, and CYP1A2 in the metabolism of 
MDMA in humans is widely unknown. Therefore, we characterized the 
effects of genetic variants in the involved CYP enzymes on the 
pharmacokinetics and pharmacodynamic effects of MDMA. 
Methods: The genetic variants in these CYP enzymes were 
characterized in 139 healthy subjects (69 male, 70 female, aged 
between 18–45 years) in a prospectively designed pooled analysis of 
eight double-blind, placebo-controlled, crossover studies. MDMA was 
administered orally in a single dose of 75 or 125 mg (dose range of 
0.8–2.7 mg/kg; mean = 1.7 mg/kg). Blood samples and 
pharmacodynamic measures were taken repeatedly up to 6 h after 
drug administration. Subjective effects were assessed using Visual 
Analogue Scales (VAS) including: “any drug effect” and “drug liking”. 
Genomic DNA was extracted from whole blood. Genotyping was 
performed using TaqMan SNP genotyping assays. 
Results: CYP2D6 poor metabolizers (PMs) exhibited increased 
maximum plasma levels of MDMA (+15%) and of its active metabolite 
3,4-methylenedioxyamphetamine (MDA, +50%) compared with 
extensive metabolizers (EMs), and decreased levels of the inactive 
metabolite 4-hydroxy-3-methoxymethamphetamine (HMMA, –50%). 
Blood pressure and subjective drug effects increased more rapidly 
after MDMA administration in CYP2D6 PMs than in EMs. MDMA-MDA 
conversion was positively associated with genotypes known to convey 
higher CYP2C19 or CYP2B6 activities. Additionally, CYP2C19 PMs 
showed greater cardiovascular responses to MDMA compared with 
other CYP2C19 genotypes. Furthermore, the maximum concentration 
of MDA was higher in tobacco smokers that harbored the inducible 
CYP1A2 rs762551 A/A genotype compared with the non-inducible 
C-allele carriers. 
Conclusion: The findings indicate that genetic polymorphisms in 
CYP2C19, CYP2B6, CYP1A2, but mainly CYP2D6 contribute to the 
metabolism of MDMA in humans. Additionally, genetic polymorphisms 
in CYP2D6 and CYP2C19 may moderate the pharmacodynamics 
effects of MDMA. 
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Introduction: Serotonin (5-hydroxytryptamine; 5-HT) is a monoamine 
derived from tryptophan, best known as an autacoid and 
neurotransmitter that modulates a wide range of physiological 
processes. Its multi-step metabolism, including its interconversion into 
melatonin (involving the pineal gland), has been poorly studied. In this 
work we developed an analytical method to determine plasma 
concentrations of 5-HT and 8 of its metabolites: melatonin (Mel), 
N-acetylserotonin (NAS), 6-hydroxymelatonin (6-OH Mel), 
5-Methoxytryptamine (5-MT), 5-Hydroxyindole acetic acid (5-HIAA), 
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Introduction: HCV prevalence amongst prisoners is typically high due 
to the large proportion of high-risk groups. We explored the cost-
effectiveness of expanding hepatitis C virus (HCV) screening and 
subsequent treatment in Swiss custodial settings, given the availability 
of rapid antibody saliva tests (Oraquick®) and dried blood spot tests 
(semi-quantitative viremia and viral genotype), and recent therapeutic 
advances which have higher cure rates and shorter treatment courses 
[1]. 
Methods: A comprehensive strategy offering screening to all 
detainees was compared to the current setup of screening high-risk 
individuals (e.g. from endemic countries, active or former injecting 
drug users [IDUs]). A decision tree simulated the diagnosis pathway, 
and results from a Markov model were included to predict treatment 
effects based on ledipasvir and sofosbuvir regimen, and natural 
progression over a lifetime time-horizon [2]. Deterministic and 
probabilistic sensitivity analyses were performed to explore parameter 
uncertainty and whether key input variations changed the cost-
effectiveness of comprehensive screening. 
Results: At a willingness-to-pay threshold of CHF 100,000 per 
quality-adjusted life-year (QALY), comprehensive screening had an 
84% probability of being cost-effective, with a corresponding NMB of 
CHF 33,451,972 and ICER of CHF 7,168/QALY. Results were most 
sensitive to the respective HCV prevalence in the current and 
comprehensive screening populations, treatment initiation rates, and 
screening offer acceptance rates. Compared to the current practice of 
screening high-risk individuals, comprehensive screening is likely to be 
cost-effective due to the increase in testing rates, which were 
conservatively estimated in this study. Furthermore, comprehensive 
HCV screening of prisoners may prove more cost-effective in countries 
where prisoners are not routinely screened. 
Conclusions: Comprehensive screening programmes could be 
considered in prison units with a large proportion of high-risk 
individuals and where detainees are incarcerated for enough time to 
complete a treatment course during their sentence. 
References
1  McLeod A, et al. Rise in testing and dianosis associated with Scotland’s Action 
Plan on Hepatitis C and introduction of dried blood spot testing. J Epidemiol 
Community Health. 2014;68(12):1182–8.
2  Dolan K, et al. Global burden of HIV, viral hepatitis, and tuberculosis in 
prisoners and detainees. Lancet. 2016;388(10049):1089–102. 
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Background: Capecitabine (Cp), an oral prodrug of 5-fluorouracil,  
is commonly prescribed to treat gastrointestinal and breast tumors. 
However, dose-limiting adverse effects occur in 20–35% of patients at 
standard doses, in particular hand-foot syndrome and diarrhea. The 
aim of this study was to evaluate, for the first time, the association of 
genetic variability in all enzymes of the Cp activation pathway with 
early-onset toxicity from Cp-based chemotherapy.
Patients and methods: The coding and exon-flanking regions of the 
cytidine deaminase gene (CDA) were sequenced in 144 Cp-treated 
patients, in whom Cp-related toxicities in the first two chemotherapy 
cycles were recorded. For the other investigated genes (CES1, CES2, 
TYMP, UPP1, and UPP2), sequencing of coding and exon-flanking 
regions was performed in a discovery subset of 48 patients (24 with 
severe Cp-related toxicity, 24 with no or mild toxicity), and associated 
candidate variants were subsequently genotyped in the full cohort.
Results: We identified a haplotype in the carboxylesterase 1 gene 
(CES1) associated with Cp-related toxicity ( ORadditive=2.2, 95%CI 
1.2-4.0, Padjusted=0.012; ORrecessive=10.3, 95%CI 2.1-49.4, Padjusted = 
0.0038 ). This common haplotype (frequency = 14%) encompassed 
five noncoding variants, including an expression quantitative trait locus 
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quantitation of PBTZ169 together with 6 currently known metabolites 
(5 active and 1 inactive) in biological fluids (e.g., plasma) from several 
species (e.g., rodent, dog, human, etc.). Secondly, an untargeted 
analysis approach using liquid chromatography hyphenated to 
high-resolution mass spectrometry (LC-HRMS) was applied to in vivo 
samples for the comprehensive analysis of the metabolites profile of 
PBTZ169. 
Results: Quantitative assays highlighted distinct cross-species 
differences in the pattern of metabolites profiles of PBTZ169. 
Moreover, targeted analysis using UHPLC-MS/MS reveals additional 
chromatographic peaks with consistent kinetics over the dosing 
interval in the monitored selected reaction monitoring traces. These 
newly identified PBTZ169 metabolites are additional oxidized species 
which, together with phase II biotransformation products, are currently 
being characterized in detail by LC-HRMS.
Conclusion: Overall knowledge about the behavior of PBTZ169 is 
currently being expanded through this comprehensive characterization 
and quantification of the in vivo phase I and II metabolite profiles of 
PBTZ169, in several relevant species, by using a combination of 
targeted and untargeted LC-MS-based approaches.
 
References: 
1 Makarov V, et al. Science. 2008;324:801–4.
2 Makarov V, et al. EMBO Mol Med. 2014;6:372–83. 
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Introduction: Epilepsy affects nearly one in a hundred persons. Its 
treatment is effective but not without side effects. Epileptic mothers are 
faced with the question of the possibility of breastfeeding under 
treatment. Knowledge about the passage of various antiepileptic drugs 
into breast milk and its consequences for the infant is limited. Faced 
with this uncertainty, breastfeeding is often discouraged for these 
patients. The aim of this work is to comprehensively review the 
available data regarding antiepileptic drugs during breastfeeding, to 
compare these data with the information provided by the summary of 
product characteristics (SmPCs), and to provide recommendations for 
the use of these drugs in breastfeeding women.
Methods: The 23 antiepileptic agents available in Switzerland were 
included in this study. We performed a systematic review of the 
literature using Medline and Lactmed. In Medline, the generic name of 
each antiepileptic drug was associated with the terms “Breastfeeding” 
or “Lactation” or “Milk, Human”. A breastfeeding compatibility score was 
developed and validated (1 = compatibility established; 2 = likely; 3 = 
uncertain, requiring surveillance; 4 = rather discouraged; 5 = clearly 
contra-indicated). The estimated score based on the literature review 
was compared with the estimated score based on the 
recommendations provided by the SmPCs.
5-Methoxyindole acetic acid (5-MIAA), 5-Hydroxytryptophol (5-HTP), 
5-Methoxytryptophol (5-MTP). Additionally, these molecules can be 
sulfo- or/and glucuro-conjugated. Our first aim was to determine the 
physiological range and circadian variability of plasma levels of theses 
metabolites. 
Methods: An LC-MS/MS assay for the measurement of free 5-HT and 
its 8 metabolites in plasma was developed and fully validated. The 
determination of conjugate forms is underway. In a preliminary study, 
free 5-HT and its metabolites were measured in 21 healthy volunteers 
(aged 20 to 54 years, 12 males), over 24 hours. Blood samples were 
collected every hour between 10 PM and 6 AM in complete darkness, 
and every 2 hours the rest of the day. 
Results: A calibration curve ranging from 0.25 to 400’000 pg/ml was 
established for each analyte. The assay was found linear within this 
concentration interval. The sensitivity of the LC-MS/MS assay was 
dependent on the analyte investigated (0.25 to 390 pg/ml). No 
carryover was found. Intra- and inter-run coefficients of variation were 
acceptable (0.5% to 22.7%). Free 5-MT, 5-HTP and 5-MTP remained 
below the quantification limit. Mean values and SDs were determined 
for the remaining metabolites at each time point. All metabolites 
exhibited significant circadian variations over 24 hours, as already 
known for melatonin, but of less amplitude. 
Conclusion: We developed and validated a robust method for 
measuring serotonin and 8 metabolites in human plasma. The 
determination of these concentrations will afford a valuable tool for  
our understanding of pineal and digestive physiology, effects of drugs 
modulating serotoninergic transmission and paraneoplasic 
manifestations of neuroendocrine tumors. Circadian variations 
preclude the definition of single normal ranges. 
Figure 1: Mean plasma concentrations over 24 hours.
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Introduction: PBTZ169 is a drug candidate for treating tuberculosis 
(TB) with a new and unique mode of action, i.e., it covalently inhibits 
DprE1, a flavo-enzyme essential for the biosynthesis of key cell wall 
components of M. tuberculosis [1]. A remarkable in vitro effectiveness 
has been demonstrated with minimum inhibitory concentration (MIC) 
values below 0.0005 µg/mL, together with no general anti-bacterial 
activity [2]. In vitro metabolism studies demonstrated that PBTZ169 
undergoes primarily hepatic phase I biotransformation into several 
metabolites. Moreover, hydroxyl- and oxo-metabolites of PBTZ169 
have been shown to also possess anti-TB activity in vitro, with 
appreciable MIC values. For a comprehensive pharmacokinetic-
pharmacodynamic analysis, it is therefore necessary to fully 
characterize the in vivo profiles of active (and inactive) metabolites  
of PBTZ169, in various human and non-human species.
Methods: A bioanalytical method employing ultra-high pressure  
liquid chromatography coupled with tandem mass spectrometry 
(UHPLC-MS/MS) was developed for the accurate and sensitive Figure 1: Comparison between the compatibility scores.
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1993. The patents aim at protecting intellectual property from the 
strong market competition and therefore encourage innovation as well 
as reward the pharmaceutical industry from their investment in the 
R&D of drugs. However, heatstable formulations, combinations with 
other chemicals, new indications might be patented and marketed at 
higher price and also when the original patent is about to expire, a so 
called evergreening strategy. We aimed to determine the financial 
incentive of marketing heatstable formulation using the proprietary 
melt-extrusion (Meltrex®) technology allowing in addition to reduce the 
pill count from 6 to 4 per day. The Meltrex® technology was applied to 
ritonavir stand alone formulation in Oktober 2010 almost 4 years after 
the lopinavir/ritonavir (December 2006). 
Methods: Frequency of administration, dosage (in mg) and galenic 
form for all patients under ritonavir and lopinavir/ritonavir were 
collected from the Geneva Swiss HIV Cohort Study from January 2003 
to June 2016. Extracosts were calculated for three different scenarios 
assuming the replacement with the corresponding Swiss market price 
de-escalation of (1) lamivudine, (2) lamivudine/zidovudine and  
(3) efavirenz over time. Prices were adjusted by the inflation rate. 
Results: Over the study period the total cost was USD 2’805’135  
for the ritonavir and USD 13’351’886 for the lopinavir/ritonavir. The 
increase in cost for the Meltrex® technology per patient was 17% for 
ritonavir 4% for lopinavir/ritonavir, leading to an extracost of USD 
166’358 and USD 368’255 respectively. Theoretical savings if generic 
ritonavir would enter the market after original ritonavir patent 
termination would be USD 994’080 for lamivudine price de-escalation, 
USD 750’917 for lamivudine/zidovudine and USD 600’741 for 
efavirenz.
Conclusions: The financial incentive encourage the pharmaceutical 
firm to be innovative leading to negotiate higher prices and at the 
same time to extent of the originator patent. The consequence is a 
financial impact for the society by preventing competition from generic 
equivalent and the delay in the accessibility of innovation for the 
patient. 
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Introduction: The hospital-to-home transition is a vulnerable stage  
in patient care. Patients might experience problems with medication 
supply, which possibly lead to therapy interruptions. The objectives  
of this study were to investigate medication supply after hospital 
discharge, and patients’ and physicians’ opinions about optimisations. 
Methods: A telephone interview was conducted with 100 discharged 
patients from the surgical and internal medicine’s wards from the 
cantonal hospital in Baden. Inclusion criteria were: ≥50 years old, 
discharged home with a discharge prescription. Patients were recruited 
by telephone between the 2nd and 6th day after discharge, and a 
piloted, structured interview on experiences and optimisations of the 
medication supply process took place. Semi-structured interviews 
were conducted with five physicians. Results from patient interviews 
and the general discharge process were discussed. 
Results: Patients were 65.6 ± 17.4 years old, 39% female, and 53% 
from the internal medicine’s ward, and 97% regularly visit the same 
pharmacy. At the time of the interview, 77 had their prescription filled. 
Of these, 78% visited the pharmacy on the day of discharge, but it 
took up to six days until they received all medication. Supply problems 
were encountered by 14 of 77 patients (18%), mainly because of 
medication not being on stock at the community pharmacy. Four 
patients experienced therapy interruptions for a maximum of three 
days. Patients discharged from internal medicine’s wards had more 
supply problems compared to surgical wards (relative risk = 5.56,  
p = 0.007). Patients experiencing supply problems had statistically 
significant more daily medication intakes (8.0 ± 4.32 vs. 4.9 ± 3.04,  
p = 0.010). Physicians were surprised about the late prescription filling 
and worried about disease outcomes. However, interruptions were 
interpreted as rare. The strategy to transfer prescriptions from hospital 
to community pharmacy prior to discharge was refused by 71% of 
patients and not favourable for the physicians, mainly because of a 
questionable benefit. But both groups indicated that bridging supply 
would be welcome. 
Conclusion: This study showed that patients discharged from a Swiss 
hospital encounter supply problems, but therapy interruptions are rare. 
Bridging supply was preferred compared to an early prescription 
transfer. Interventions should consider these opinions and focus on 
internal medicine patients with a high number of medication. 
Results: 75 articles were identified as containing exposure and safety 
data for 15 antiepileptic agents during breastfeeding. The comparison 
between the score values based on the literature review and on the 
SmPCs revealed a very low degree of concordance (weigthed kappa: 
0.08).
Conclusion: Phenobarbital, primidone, carbamazepine, valproate, 
and levetiracetam are probably compatible with breastfeeding. 
Treatment with phenytoin, ethosuximide, clonazepam, oxcarbazepine, 
vigabatrin, topiramate, gabapentin, pregabalin, lamotrigine, 
zonisamide may be authorized during breastfeeding. However, 
breastfed infants should be carefully monitored for side effects. Data 
on use of mesuximide, clobazam, rufinamide, felbamate, lacosamide, 
sultiame, perampanel and retigabine are insufficient to adequately 
assess the risk for the breastfed infant. The reliability with which the 
current state of knowledge is reflected in the SmPCs should be 
improved.
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Introduction: A population pharmacokinetic model allows 
reconstructing the predictive distribution of drug concentrations in a 
population of patients, as a function of time and the dosing regimen. 
We propose to calculate a posteriori percentiles (i.e. percentiles from 
the posterior predictive distribution of concentrations) for the rendering 
of TDM results in a patient for whom past measurements are available. 
We illustrate the clinical usefulness of such a posteriori percentiles to: 
–  determine the probability that future concentrations lie within a 
pre-specified therapeutic range, under either the current or a 
modified dosing regimen 
–  detect significant changes in drug disposition, e.g. following 
drug-drug interactions or malfunction of elimination organs 
– identify patient adherence issues 
Methods: Considering a population pharmacokinetic model of 
Voriconazole (Pascual & al. Clin Infect Dis, 2012;55:381-90), a set of  
1 to 10 simulated trough concentrations was generated for a fictive 
patient under different dosing regimens. The distribution of predicted 
concentrations over the next dosing interval was reconstructed using 
the model while taking into account past values. This enabled us to 
assess the expectedness of future measurements in the patient, and 
the probability of the next trough concentration to lie within the 
therapeutic range, under different dosing regimens. 
Results: Based on 10’000 fictive patients, simulated TDM improved 
from 50% to 71% the chance of reaching the target therapeutic range 
of 1.5–4.5 mg/L. Using simulations, we show how the incremental 
consideration of historical information can reduce the width of the 
prediction interval for future concentrations in the patient being 
monitored. We also illustrate how a posteriori percentile curves may 
detect a future abnormal concentration measurement as the patient 
gradually becomes his own reference. 
Conclusion: When past concentration measurements are available for 
a patient, the rendering of a posteriori percentile curves depicts the 
likelihood of future concentrations in this patient, under the current or 
an adapted dosing regimen. Such percentiles constitute an important 
piece of information that can be graphically communicated to the 
physician, who can then judge whether a measured concentration is 
both expected and appropriate for the patient. This will contribute to 
better informed treatment decisions, representing a further step 
towards individualized drug dosage adaptation. 
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Background: The World Intellectual Property Organization reported 
more than 9’750 patents of ritonavir from the discovery in December 
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majority of GI hemorrhages (n = 32, 74%) was associated with a 
relevant drug. Female (15, 47%) and male (17, 53%) patients were 
equally affected. The median age between the groups was similar (59 
vs. 66 years in the ADE group). Most frequently implicated drugs were 
NSAIDs (59%) and oral anticoagulants (22%). Patients with vitamin-K 
antagonists and non-vitamin K oral anticoagulants (NOACs) were 
comparable (57% vs. 43%). In the ADE group the mean length of stay 
was longer (10.8 days, 95%CI 5.9–15.6 vs. 6.6 days, 95%CI 3.0–10.2) 
and total costs per patients’ hospitalization were higher (23.160 CHF, 
95%CI 10.363–35.958 CHF vs. 15.633 CHF, 95%CI 3.923–27.343 
CHF), compared to patients in whom the bleeding episode was not 
drug-related. Overall, nearly half of the patients was already taking a 
proton-pump inhibitor (19, 44%), 16 patients (50%) had a proton pump 
inhibitor in the ADE group vs. only 3 (27%) in patients who 
experienced GI bleeding without a drug being implicated. In both 
groups 2 patients had fatal outcomes (6% and 18%). 
Conclusions: Preliminary data suggest prolonged duration of 
hospitalization and increased costs incurred by patients with drug-
associated gastrointestinal bleeding compared to GI bleeding not 
induced by a drug. Further studies are needed to confirm these 
differences between drug-induced and non-drug-induced GI bleeding. 
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Enzymatic pathways metamizole metabolism in humans
Fabio Bachmann, Urs Duthaler, Deborah Rudin, Benjamin Berger, 
Manuel Haschke, Stephan Krähenbühl 
Division of Clinical Pharmacology & Toxicology, University Hospital 
Basel, Basel, Switzerland
Introduction: Metamizole (dipyrone, Novalgin®) is an analgesic  
drug used increasingly due to its favorable gastrointestinal and  
renal tolerability. The major metabolites of metamizole are the 
non-enzymatically generated methylaminoantipyrine (MAA), 
aminoantipyrine (AA), formylaminoantipyrine (FAA) and 
acetylaminoantipyrine (AAA). It is assumed that the metabolism  
of metamizole takes place in the liver but the CYPs involved are not 
known. The only identified enzyme in this pathway is N-acetyl 
transferase 2, which acetylates AA to AAA. The aim of the present 
study was to identify the enzyme responsible for the demethylation of 
MAA to AA.
Methods: MAA was incubated with human liver microsomes (HLM) 
over 6 hours. Inhibition assays were conducted by adding selective 
CYP450 inhibitors. CYP substrates were used to proof specific CYP 
inhibition. Induction assays were performed using HepaRG cells in  
the basal state and after induction with rifampicin (20 µM for 2 days). 
Moreover, the metabolism of MAA was investigated in human liver 
homogenate (HLH). Additionally, MAA was incubated in buffer 
containing oxidizing enzymes (horseradish peroxidase (HPO), 
soybean lipoxidase (SLO), human myeloperoxidase (MPO)). Drug 
concentrations were quantified by LC-MS/MS.
Results: HLM displayed a minor formation of AA (<1%) over 2 hours. 
Inhibition assays did not reveal a specific CYP for the demethylation. 
However, the inhibition cocktail reduced the metabolic microsomal 
activity by half. HepaRG cells treated with rifampicin (inducing 
CYP2B6, CYP2C9, CYP2C19 and CYP3A4) did not show an increase 
in MAA metabolism compared to basal conditions. Demethylation 
could also be shown in HLH, whereby the calculated reaction velocity 
was comparable to the reaction velocity in HLM. Extrapolation of MAA 
metabolism in HLM or HLH to the entire liver revealed that hepatic 
metabolism could explain only a minor portion of metamizole 
metabolism in humans. Interestingly, in the presence of HPO, SLO or 
MPO, MAA was rapidly metabolized, depending on the peroxidase 
used and the hydrogen peroxide concentration. Under these 
conditions, approximately 20% of MAA was demethylated to AA.
Conclusions: Comparison of the in vitro metabolism of MAA with the 
in vivo pharmacokinetics of metamizole suggests that the liver is not 
the main location of metamizole metabolism in humans. Our data 
imply that extrahepatic peroxidases might play an important role in 
MAA metabolism. 
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Role of cytochrome P450 3A4 and 1A2 phenotyping  
in patients with advanced non small-cell lung cancer  
receiving erlotinib treatment
Peter Benjamin Berger1, Zinnia Parra-Guillen2, Manuel Haschke1, 
Massimiliano Donzelli 3, Daria Winogradova1, Charlotte Kloft2, 
Bogumila Pfister4, Martin Früh4, Stephan Krähenbühl1, Silke 
Gillessen4, Markus Joerger4 
1Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, 
Switzerland; 2Institute of Pharmacy, Freie Universität Berlin, Berlin, 
Germany; 3Roche Innovation Center, Basel; 4Department of Medical 
Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, 
Switzerland
Introduction: The oral EGFR tyrosine kinase inhibitor erlotinib is 
metabolized by cytochrome p450 (CYP) 3A and CYP1A. In this study 
patients with advanced non small- cell lung cancer (NSCLC) were 
phenotyped for CYP3A4 (midazolam) and CYP1A2 (caffeine) using 
plasma and dried blood spot (DBS) samples to assess the correlation 
between phenotype and pharmacokinetics and pharmacodynamics of 
erlotinib.
Methods: We prospectively included 36 patients with advanced 
NSCLC receiving oral erlotinib 150 mg once daily. On day 1 and after 
an overnight fast, 2 mg oral midazolam and 100 mg oral caffeine were 
administered. Plasma and DBS were collected to determine 
concentrations of erlotinib, midazolam, caffeine and their metabolites 
(OSI-420, 1-hydroxymidazolam, paraxanthine) up to 6 hours. Plasma 
and DBS samples were analyzed using UPLC-MS-MS, and PK data 
were processed using population modeling.
Results: A high correlation was found between plasma and DBS 
concentrations for erlotinib (R2 = 0.960, P <0.0001), OSI-420 (R2 = 
0.971, P <0.0001), midazolam (R2 = 0.995, P <0.0001) and caffeine 
(R2 = 0.968, P <0.0001). Individual caffeine clearance was significantly 
correlated with erlotinib clearance (R2 = 0.33, P = 0.048), but 
midazolam clearance was not (R2 = -0.09, P = 0.596). There was a 
trend for lower erlotinib clearance in patients experiencing grade 2 or  
3 skin rash as compared to patients experiencing grade 0 or 1 rash 
(3.15 vs. 3.93 L/hr, P = 0.086). 
Conclusions: Probe drug phenotyping is unlikely to substitute 
therapeutic drug monitoring of erlotinib in patients with advanced 
NSCLC, but capillary blood sampling may replace more invasive 
venous blood sampling to monitor erlotinib concentrations. 
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Cost analysis of gastrointestinal (GI) bleedings  
associated with adverse drug events
Silvina Bravo Reiter1, Hendrike Dahmke2, Luc Biedermann3,  
Jörk Volbracht1, Jürg Hodler1, Gerd A. Kullak-Ublick2, Stefan Weiler2 
1Medical Controlling, Medical Directorate; 2Regional 
Pharmacovigilance Centre Zurich, Department of Clinical 
Pharmacology and Toxicology; 3Division of Gastroenterology and 
Hepatology, Universitätsspital Zürich, Zürich, Switzerland
Introduction: Adverse drug events (ADE) are a problem in health care 
systems all over the world. About 10% of the admissions to hospitals 
are related to ADE and are associated to considerable increases in 
costs. For the present study gastrointestinal (GI) bleeding was selected 
as it is one of the most often observed ADE. The aim of the study is to 
estimate the incidence of GI bleeding associated with drugs in patients 
admitted to a tertiary hospital and to calculate costs associated with 
the ADE. 
Methods: In a retrospective study all hospital admissions in 2015 were 
screened for GI bleeding by selecting cases with relevant ICD codes in 
the primary diagnosis. Cases were categorized as “ADE cases” when 
one or more drugs from the entry medications were considered 
relevant for the GI bleeding. The costs due to the ADE was defined as 
the total cost allocated to the case and compared to patients without 
such drugs. 
Results: Within 1 year, 86 out of 39.724 admissions (0.22%) were  
due to GI bleeding. Half of the patients (n = 43, 50%) agreed to 
retrospective data research and were included in the analysis. The 
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frequent hospitalizations because of relatives’ wish (OR = 2.39, 95% 
CI = 1.90, 3.05), difficult symptom control (OR =2.26, 95% CI = 1.84, 
2.81), missing resources of GPs (OR = 2.16, 95%CI = 1.68, 2.80) or 
small or missing caring network 
(OR = 2.11, 95% CI = 1.71, 2.63). Intriguingly, GPs were more likely  
to transfer their patients often to the hospital if GPs used palliative 
councils often (OR = 1.93, 95% CI = 1.22 3.10). 
Conclusions: GPs reporting frequent hospital admissions of palliative 
care patients at the end-of life were shown to be less confident in 
non-somatic palliative care skills, irrespective of age, gender and 
regional characteristics. Thus, favoring the acquisition of these skills 
through continuous medical education and providing alternative 
options to hospitalisation might reduce hospital admissions shortly 
before death. 
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Elegibility for PCSK9 inhibitors in the general population
David Nanchen1, Pedro Marques-Vidal2, Arnold von Eckardstein3, 
Jacques Cornuz1, Gerard Waeber2, Vincent Mooser2,  
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Introduction: PCSK9 inhibitors are new lipid-lowering drugs 
recommended for very high-risk patients such as those with familial 
hypercholesterolemia or cardiovascular disease (CVD) not reaching 
optimal LDL-cholesterol levels despite maximum dose of statins. 
Because these news drugs are 40 times more expensive than statins, 
the societal impact of using these drugs in the general population is 
unknown. 
Aims: We aim to assess the proportion of patients potentially eligible 
for PCSK9 inhibitors in the Swiss general population according to the 
latest 2016 European and American guidelines. 
Methods: We studied 4,905 adults aged 35–75 years from the 
CoLaus study, a prospective population-based cohort in Switzerland, 
with available lipid measurements both at baseline and at the 5-year 
follow-up visit. At baseline, the prevalence of patients at very-high risk 
of CVD was assessed. After 5-years, according to 2016 European 
Society of Cardiology (ESC) and 2016 American College of Cardiology 
(ACC) guidelines, we assessed eligibility for PCSK9 inhibitors, defined 
as unmet LDL-cholesterol goals despite use of rosuvastatin 20 mg, 
atorvastatin 40 mg or simvastatin 40 mg, assuming a 20% additional 
reduction of LDL-cholesterol with addition of ezetimibe. 
Results: The prevalence of very high-risk patients at baseline was 
16.3% (n = 715) respectively 12.3% (n = 604), and after 5 years only 
1.2% (n = 58), respectively 1.8% (n = 87) reached optimal lipid target 
according to ESC, respectively ACC guidelines. Most of very high-risk 
patients would first need initiation or intensification of statins or 
ezetimibe, before prescription of PCSK9 inhibitors (see figure). 
P316
Smarter Medicine Hospital: quantified self
Marc Oertle, Armin Stucki 
Innere Medizin, Spital Thun, Thun, Switzerland
Introduction: Based on the choosing wisely initiative, corresponding 
top-five Smarter Medicine Recommendations SMR for Swiss hospitals 
were published. Nearly no data exist with regard to adherence to these 
key values, however. Tools like big data analytics / data mining based 
on clinical information systems help to quantify, understand and 
influence our institutions’ processes and thus achieving continuous 
improvement. 
Methods: Retrospective, anonymized, quantitative analysis of all 
inpatients (Internal medicine) in 2016 concerning key values linked  
to the top-5 list. 
Results: 3’930 inpatients (41% female, average length of stay  
6.6 days, mean age 71.3 years) were analyzed. Blood tests: in a 
cumulative amount of 20’024 inpatient days, 19’116 phlebotomies were 
performed. This results in 5 blood tests per patient stay (including 
phlebotomy on admission/ED) or an average of 0.8 blood samples per 
patient and day. Urinary catheter (UC): 607 (15.4%) received a UC, 41 
(1%) already had it on admission. Mean duration of maintenance was 
4.8 ± 3.8 days. In 1% of UC patients, nosocomial urinary tract infection 
was documented. Blood transfusions BT: 408 BT where performed. On 
average, hemoglobin level prior to transfusion was 74.0 ± 10.3 g/l and 
1.6 ± 0.6 red blood cells RBC units were administered. Bed rest: in 
3’505 inpatients formal assessments were performed; 159 (4.5%) were 
initially under bed rest, additional 128 (0.4%) during hospitalization.  
On average, bed rest lasted for 2.9 days regardless of causes. 
Benzodiazepines: 3’427 patients had at least one drug prescription, 
both on admission and discharge. 365 (10.7%) had benzodiazepine 
prescriptions on admission, 373 (10.9%) on discharge. During 
hospitalization, 1473 (5.3%) out 27’886 on demand prescriptions were 
benzodiazepines. 628 (43%) where second line prescriptions (given a 
first line non-benzodiazepine prescription) for sleep disorders. Only 28 
(1.9%) had benzodiazepines as first-choice on demand prescription for 
sleeping disorders. 
Conclusion: For a first time, this quantitative assessment with regard 
to SMR offers both, deep insight into (selectively excellent) adherence 
to key values as well as a launching point for benchmarking with other 
institutions and further quality improvements. Information management 
will play a key role (including correlated data, e.g. diagnoses, 
co-morbidities, indications) in order to achieve precise decision 
support, process improvements and increased quality of care at lower 
costs. 
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Background: Hospital admissions of palliative care patients at the 
end-of life are considered inappropriate and should be avoided. This 
study aimed to evaluate the frequency and type of GPs self-reported 
end-of-life hospital referrals. Further, the association between frequent 
hospital referrals and referral reasons, confidence in end-of-life care 
and regional palliative care network were assessed.
Design and setting: Cross-sectional postal survey involving a 
stratified random sample of 2000 GPs in Switzerland in 2014. 
Methods: Main outcome measure was GPs assessment of the type 
and frequency of end-of-life referrals 1–3 weeks before death. The 
association between hospital admissions frequency and GP 
characteristics was tested using logistic regression models, controlling 
for age, gender and regional characteristics.
Results: The questionnaire was completed by 579 Swiss GPs 
(Response Rate 31%). Thirty-seven percent of GPs reported frequent 
hospital admissions shortly before death. Logistic regression analysis 
indicated GPs were less likely to report frequent hospitalizations 
shortly before death when they felt confident in crisis anticipation (OR 
= 0.76, 95% CI = 0.60, 0.96), in coping with patient’s wish to die (OR = 
0.74, 95% CI = 0.60, 0.91) and in handling spiritual needs (OR = 0.80, 
95% CI = 0.68, 0.94). Furthermore, GPs were twice as likely to report Figure 1
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How well are Swiss French-speaking physicians  
prepared for independent practice in ambulatory  
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Dagmar M Haller1,3, Marie-Claude Audétat2,3, Johanna Sommer3 
1Hôpitaux Universitaires de Genève; 2Unité de Développement et de 
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Internistes Généralistes et Pédiatres, Faculté de Médecine, Université 
de Genève, Genève, Switzerland
Introduction: Moving from training to independent practice represents 
a major transition in professional life. The aim of this study was to 
explore the extent to which Swiss general internists who recently set 
up private practice felt prepared to work as independent physicians. 
Methods: We conducted focus groups among a sample of physicians 
practicing as general internists (FMH) for <5 years in different working 
contexts of the French-speaking part of Switzerland. Questions 
focused on positive and negative aspects of setting up a practice, 
degree of preparedness, strengths and weaknesses of postgraduate 
training. Transcripts were analysed according to dimensions described 
in organisational socialisation and work role transition frameworks.
Results: 28 physicians from 5 cantons participated in 7 focus groups: 
1/3 trained exclusively in academic settings, most worked in an urban 
or suburban area and predominantly in small group practices. Most 
positive reported elements of setting up practice referred to notions of 
freedom, autonomy and mastery, and physician patient relationships 
while negative reported elements referred to feelings of stress and 
loneliness related to non-clinical tasks such as administrative, financial 
and time management as well as medico-legal issues for which all 
participants felt both incompetent and unprepared. Although 
physicians felt adequately prepared to perform most medical tasks, 
they reported discomfort in dealing with common problems in 
rheumatologic, minor traumatology, ENR, skin and psychiatric 
problems in all contexts and in paediatrics, gynaecology, as well as 
surgical skills if working in rural areas. Several participants reported 
not having anticipated the importance of having a network of 
specialists once in independent practice. They also described several 
practice-based ethical dilemmas opposing professional values to 
reality of practice (freedom, autonomy, altruism versus work-life 
balance, practice business management and patient accountability) 
which forced them to clarify their professional roles and expectations. 
Adjustments to these new tasks were mainly made informally.
Conclusion: Postgraduate training in ambulatory general internal 
medicine could be further improved to better support the reality of 
transition. More emphasis should be put on learning and teaching in 
the environment for which physicians are being prepared, especially 
during the last years of training. 
According to ESC respectively ACC guidelines, 0.2% (n = 9) 
respectively 4.9% (n = 243) of the general population would be eligible 
for PCSK9 inhibitors. If initiation or intensification of statins at 5-year 
would not be possible because of statin intolerance, 1.4% (n = 70) 
respectively 9.6% (n = 471) would be eligible for PCSK9 inhibitors 
according to ESC respectively ACC guidelines. 
Conclusion: A large number of patients at very high-risk for CVD had 
sub-optimal statin therapy and did not reach optimal lipid targets after 
5 years. Although there are large differences of eligibility between 
European and American guidelines, the amount of prescription of 
PCSK9 inhibitors in the general population will also depend on the 
ability to intensify statin use and dosage. 
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Background: Several factors, such as cultural habits, type of hospital 
(university vs. non-university), local organization and practice (number 
of patients per resident) and resident characteristics may influence 
residents’ time allocation. We thus aimed to evaluate the composition 
of internal medicine residents’ working day in two different teaching 
hospitals and to assess the proportion of time spent with direct patient 
care. 
Methods: Two different time motion studies were performed in the 
departments of internal medicine of CHUV and KSB. Trained 
observers recorded residents’ activities during day shifts. To ensure 
comparability, the same study protocol, tablet-based software and 
instruction manual were used. Out of 22 recorded activities, we 
selected for comparison: activities directly related to patients, 
documentation, supervision, personal time and direct patient contact. 
The time spent per patient per day was calculated based on patient-
equivalents. One patient-equivalent was defined as the presence of a 
patient during the whole observed shift of an individual resident. We 
compared mean values using the two-sided, untailed t-test. 
Results: Demographic baseline characteristics of residents are shown 
in table 1.
KSB residents had a shorter post-graduate training (21 vs 31 months, 
p <0.001). Residents were observed during 486.4 hours (43 shifts) in 
KSB vs 568.2 h (49 shifts) in CHUV.Mean shift duration were similar 
(11.3 ± 1.1h in KSB vs 11.6 ± 1.3h in CHUV, p = 0.19). Mean patient-
equivalent was 7.4 ± 1.0 in KSB vs 7.8 ± 2.3 at CHUV (p = 0.27). 
Mean durations of activities are presented in table 2. In CHUV, 
residents dedicated more time to patients (114.7 ± 44.9 vs. 94.9 ± 31.4, 
p = 0.015; i.e. 14.6 vs 12.6 minutes/patient/day) and for EMR 
documentation, whereas in KSB, residents spent more time writing the 
discharge letter, performing transmission with the team and for 
communication with patients and families.
Conclusions: 1) Despite shorter post-graduate training for KSB 
residents,allocation of time was similar regarding total working hours, 
patient-equivalents and supervision. 2) Differences in allocation of time 
for documentation may be due to different computer systems favouring 
either discharge letter or documentation in EMR. 3) These data provide 
the basis for the implementation of measures to reduce resp. optimize 
Table 1: Baseline characteristics of residents.
Table 2: Comparison of time spent in different activities.
the administrative load and to increase the time spent with patients. 
No major differences document an excellent Rösti-collaboration rather 
than a “-Graben”. 
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anaemia. In the longitudinal analysis, we used multivariable Cox 
regression to compare the incidence of anaemia among participants 
with SHypo/SHyper and euthyroidism. 
Results: In the cross-sectional population (n = 12,337), the mean  
age was 59 years and 53.1% were women. 11,174 (90.6%) 
participants were euthyroid and had a mean Hb of 13.9 g/dl. No 
relevant differences in Hb were observed among TSH categories. In 
multivariable analyses, Hb was 0.23 g/dl (95%CI-0.40 to-0.06) lower  
in OHypo, and 0.40g/dl (95%CI-0.78 to-0.01) lower in OHyper than in 
euthyroidism. In the logistic regression, OHypo was associated with 
anaemia (adjusted OR 1.89, 95%CI 1.23–2.88), OHyper showed a 
borderline association (adjusted OR 2.16, 95%CI 0.94–4.95) whereas 
no association was found in SHypo/SHyper. In the longitudinal 
analysis, 460 of 7,031 participants (6.5%) developed anaemia during  
a follow-up of 55,733 person years (median 4.7 years). When we 
compared SHypo/SHyper to euthyroidism, the adjusted hazard ratio  
of anaemia was 1.01 for SHypo (95%CI 0.68–1.51) and 0.52 for 
SHyper (95%CI 0.23–1.18). Results were similar in all sensitivity 
analyses.
Conclusion: Considering the minimal changes in Hb among the TSH 
categories and the lack of prospective association between thyroid 
dysfunction and anaemia, in our study subclinical thyroid dysfunction 
does not seem to be an independent risk factor for the development of 
anaemia. 
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Undernutrition is associated with increased financial  
losses in hospitals
Saman Khalatbari-Soltani, Gérard Waeber, Pedro Marques-Vidal 
Department of Internal Medicine, Lausanne University Hospital 
(CHUV), Lausanne, Switzerland
Background and aims: Undernutrition is associated with increased 
hospital costs. Whether these increased costs are totally compensated 
by third payer systems has not been assessed. We aimed to assess 
the differences between actual and reimbursed hospital costs 
according to presence/absence of nutritional risk, defined by a 
Nutritional risk screening-2002 (NRS-2002) score ≥3.
Methods: Retrospective study using administrative data for years 2013 
and 2014 from the department of internal medicine of the Lausanne 
university hospital. Total and specific costs (i.e. related to treatments, 
medical interventions, imaging, laboratory analyses, food, intensive 
care units…) were obtained. Reimbursed costs were based on the 
Swiss Diagnosis Related Group (DRG) system and we considered 1 
DRG point = 10’500 CHF (average value for 2014). Coverage of the 
costs was computed as the ratio costs/reimbursements and expressed 
as percentage, and further categorized as complete (≥100%) or less 
than complete (<100%).
Results: 2200 admissions with NRS-2002 data were included (mean 
age 76 years, 53.9% women), 1398 (63.6%) of which were considered 
nutritionally ‘at-risk’. After multivariate adjustment, patients nutritionally 
‘at-risk’ had higher costs (multivariate-adjusted difference ± standard 
error: 34’206 ± 1246 vs. 22’214 ± 1666 CHF, p <0.001) and higher 
reimbursements (26’376 ± 1105 vs. 17’783 ± 1477 CHF, p <0.001)  
than patients ‘not at risk’. Still, reimbursements failed to cover the 
costs, leading to an average deficit of 7831 ± 660 CHF in patients 
‘at-risk’ vs. 4431 ± 881 in patients ‘not at-risk’ (p <0.003). Being 
nutritionally ‘at-risk’ also led to a lower likelihood of complete coverage 
of costs: multivariate-adjusted odds ratio and 95% confidence interval 
0.77 (0.62–0.97), p <0.05. Patients ‘at-risk’ had lower percentage of 
total costs in medical interventions, food, imaging and “other”, but the 
absolute differences were less than 2%.
Conclusion: Hospital costs of patients nutritionally ‘at-risk’ are less 
well reimbursed than of patients ‘not at-risk’. Better reporting of 
undernutrition in medical records and better reimbursement of 
undernourished patients is needed. 
P322
Should thyroid tests be performed to investigate  
the causes of anaemia? A large population-based study
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Introduction: A relationship between overt thyroid dysfunction and 
anaemia is commonly mentioned, but limited data are available on the 
association with subclinical thyroid dysfunction. In a large population-
based cohort, we aimed to quantify the effect of thyroid function on 
haemoglobin concentration (Hb) and to study the association with 
anaemia. 
Methods: We analysed participants from the EPIC-Norfolk cohort  
with thyroid stimulating hormone (TSH), free thyroxine (fT4) and Hb 
measured at baseline and follow-up. Hypothyroidism was defined as 
TSH >4.49 mIU/l, either subclinical (SHypo) with normal fT4 or overt 
(OHypo) with low fT4. Hyperthyroidism was defined as TSH <0.45 
mIU/l, either subclinical (SHyper) with normal fT4 or overt (OHyper) 
with elevated fT4. Euthyroidism was the reference category (normal 
TSH/fT4). Anaemia was defined as Hb <12 g/dl for women and <13 g/
dl for men. In the cross-sectional analysis, we used multiple linear 
regression to compare Hb across the TSH categories and logistic 
regression to analyse the association between thyroid dysfunction and 
Figure 1: Haemoglobin concentrations in thyroid dysfunction.
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Introduction: Generalisation of mammography screening contributed, 
at least in part, to the decrease in breast cancer mortality in developed 
countries. The implementation of an organised programme has been 
suggested to increase screening participation and reduce social 
disparities in screening access. We aimed to describe the evolution  
of socioeconomic inequalities in mammography screening before  
and after the introduction of an organised programme in Geneva, 
Switzerland.
Methods: We included 5345 women with no past history of breast 
cancer, aged 50–74 years and who participated in the cross-sectional 
Bus Santé study, between 1992–2014. Outcome measures were:  
a) never had a mammography (1992–2014) and b) never had a 
mammography or not in the two years before survey (for subgroup 
analysis, 2007–2014). We divided educational attainment in 3 groups 
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Conclusion: Guidelines calling for immediate invasive procedures in 
patients with LBBB should be reevaluated. Specific ECG criteria and 
suggested (h)s-cTn thresholds allow an accurate and immediate triage 
to coronary angiography in patients with LBBB and symptoms 
suggestive of AMI (fig. 2). 
 
(primary, secondary and tertiary) and considered two periods - before 
the introduction of screening programme in 1999 and after. We 
calculated the relative (RII) and slope (SII) indexes of social inequality, 
which measure the relative and absolute inequalities between the 
different educational levels, respectively. We used Poisson models to 
compare screening prevalence before and after screening programme 
implementation.
Results: We observed a decrease in the proportion of unscreened 
women during the study period from 30.5% to 3.6%. Lower educated 
women more probably never had a mammography (RII = 2.39,  
p <0.001; SII = 0.10, p <0.001). Implementation of an organised 
screening programme coincided with a decrease in the proportion  
of unscreened women independently of educational attainment 
(prevalence ratiobefore vs. after = 4.41, p <0.001). However, both absolute 
and relative inequalities persisted (RII = 2.11, p = 0.01; SII = 0.04,  
p = 0.01).
Conclusion: Introduction of an organised programme increased 
participation but was not sufficient to eliminate socioeconomic 
disparities in breast cancer screening. 
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Diagnosis of acute myocardial infarction in patients  
presenting with left bundle branch block
Thomas Nestelberger1,2, Louise Cullen3, Cedric Jaeger2,4,  
Zaid Sabti 2,5, Jasper Boeddinghaus1,2, Christian Mueller2,5 
1Division of Internal Medicine, University Hospital Basel; 
2Cardiovascular Research Institute Basel (CRIB), University Hospital 
Basel, Basel, Switzerland; 3Royal Brisbane & Women’s Hospital, 
Herston, Brisbane, ACT, Australia; 4Department of Nephrology, 
University Hospital Basel; 5Department of Cardiology, University 
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Introduction: Patients with suspected acute myocardial infarction 
(AMI) in the setting of left bundle branch block (LBBB) present an 
important diagnostic and therapeutic challenge to the clinician, 
highlighted by divergent recommendations given by the respective 
guidelines in the United States and Europe. It is currently unknown, 
whether patients presenting with acute chest pain and new/
presumably new LBBB should also receive immediate coronary 
angiography and/or thrombolysis such as those with clear ST-segment 
elevations.
Methods: We aimed to prospectively evaluate the incidence of AMI, 
and the diagnostic performance of selected ECG criteria and 
high-sensitivity cardiac troponin (hs-cTn) T and I among 8830 patients 
presenting with symptoms suggestive of AMI to the emergency 
department. Presence of LBBB, ECG criteria (Sgarbossa, Smith, 
Selvester), and final diagnoses were adjudicated by independent 
cardiologists. Findings of the derivation cohort (n = 4015) were 
validated in two external cohorts.
Results: In the derivation cohort, LBBB was present in 140 patients 
(3.5%). AMI was the adjudicated final diagnosis in 32% of patients with 
LBBB, with similar incidence in those with known LBBB versus those 
with presumably new LBBB (29% vs 35%, p = 0.42). ECG criteria had 
modest accuracy (64–71%), low sensitivity (2–18%), and high 
specificity (94–100%) for AMI. Diagnostic accuracy of hs-cTnT and 
hs-cTnI at presentation as quantified by the area under the receiver-
operating characteristics curve was very high (0.91; 95%CI 0.85-0.96 
and 0.89, 95% CI 0.83–0.95; fig. 1). Hs-cTnT levels ≥42 ng/l (hs-cTnI 
≥45 ng/l) provided a positive predictive value of 80% for AMI and 
together with known coronary artery disease (odds ratio 4.6, 95%CI 
2.0–10.4) predicted AMI in multivariate analysis (odds ratio 30.5, 
95%CI 11.7–80.1). These findings were confirmed in both validation 
cohorts.
 
Figure 1
Figure 2
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Interventions recommended to prevent, manage and treat 
compassion fatigue: a systematic review of the literature
Francis Vu, Patrick Bodenmann 
Centre des Populations Vulnérables, Policlinique Médicale 
Universitaire, Lausanne, Switzerland
Background: In healthcare and social professions, compassion 
fatigue (CF) is a term used to refer to a state of advanced and 
profound exhaustion and distress resulting from the repeated empathic 
and compassionate engagement with traumatised and suffering 
populations. This study provides a critical appraisal and review of the 
existing recommendations to prevent, manage and treat CF. 
Methods: Five electronic databases (Medline/Pubmed, Embase, Web 
of Science, CINAHL plus and PsycINFO) were consulted. Because of 
the conceptual ambiguity of CF, the first search strategy was to identify 
articles published between January 1980 to March 2016, in English or 
in French, using the term “CF” and the terms that were used 
interchangeably with it in the literature (namely “secondary traumatic 
stress and “vicarious traumatisation”). The second search strategy was 
to identify and review published articles containing suggested 
strategies and interventions for combating CF. The literature search 
was completed by hand searching reference lists. Each of the articles 
was analyzed in detail using an evaluation form. Duplicate papers, 
papers which did not provide an abstract, and papers that were not 
related to the topic of this study were removed (see fig. 1). 
 
Figure 1
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No association between grip strength and  
cardiovascular risk; the CoLaus population-based study
Cédric Gubelmann, Peter Vollenweider, Pedro Marques-Vidal 
Department of Medicine, Internal Medicine, Lausanne University 
Hospital, Lausanne, Switzerland
Background: Low grip strength (GS) is predictive of cardiovascular 
(CV) disease but whether it improves CV risk prediction over existing 
CV risk scores has not been evaluated. We assessed the predictive 
value of low GS on incident CV events taking into account several CV 
risk equations in a Swiss population-based study.
Methods: 2707 adults (54.8% women, age range 50–75 years) were 
followed for a median time of 5.4 years. GS was assessed using a 
hydraulic hand dynamometer. Low GS was defined according to Fried 
criterion. CV absolute risk at baseline was assessed using recalibrated 
SCORE, Framingham and PROCAM risk equations. 
Results: 188 incident CV events occurred during follow-up. The 
unadjusted positive association between low GS and incident CV 
events disappeared after adjusting for CV absolute risk (table).
Conclusion: Low GS is not predictive of incident CV events when 
taking into account CV absolute risk. 
Table: Association grip strength and CV events.
  Hazard Ratio [95%CI] P value
Unadjusted 1.76 1.13–2.76 0.01
Adj. for SCORE 1.23 0.79–1.94 0.36
Adj. for Framingham 2001 1.34 0.86–2.10 0.20
Adj. for PROCAM 2007 1.47 0.94–2.31 0.09
Results: Fifty published original articles met the inclusion criteria: 
three articles were systematic literature reviews, seven were 
experimental studies, six were descriptive studies, seven were 
qualitative studies, two were mixed method studies, and twenty-five 
were evidence based on the authors’ opinion. The analysis of the 
articles suggested that CF can be combated among helping 
organisations and professionals, which requires increasing their (self-) 
awareness of occupational hazards through education, debriefings 
and supervisions, and equipping them with adequate knowledge and 
skills that will enhance their coping and resiliency resources. It also 
requires developing and nurturing self-care and self-management 
strategies, and promoting organisational and structural changes that 
will mitigate work environment constraints (see fig. 2).
Conclusions: CF can be combated among helping organisations and 
professionals. Additionally, combating successfully CF may also 
require redefining our own perceived role and missions as a helping 
professional, including changes in our ways and levels of expectation 
to fulfil them. 
Figure 2
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Trying hard to reconciliate the medication upon  
admission in a tertiary internal medicine department
Antoine Garnier1, Carole Nachar2, Joelle Servet1, Sylvie Robert1, 
Gérard Waeber1, Jean-Blaise Wasserfallen3, Monica Cosma-Rochat3 
1Internal Medicine Department, University Hospital of Lausanne; 
2Pharmacy Department; 3Medical Directorate, University Hospital  
of Lausanne (CHUV), Lausanne, Switzerland
Background: Medication discrepancies largely arise due to 
communication issues at transition steps. Up to 70% of patients have 
at least one discrepancy between regularly taken drugs and hospital-
prescribed drugs. A lack of accuracy in medication history is 
responsible for 50% of medication errors and for 20% of adverse drug 
effects occurring in hospitals. We aimed to assess the feasibility of a 
medication reconciliation process upon admission.
Methods: Within “Progress!”, the national initiative of Patient Safety 
Switzerland, we developed our process from own expertise and 
literature. Interns were trained to collect two different sources of 
information (medical and practical) and confront them within a 
structured interview with the patient, which included questions about 
allergies and over-the-counter drugs. We developed a electronic 
medical record (EMR) form to support the process. The nurses 
provided the practical source (i.e pillbox). We included all consecutive 
patients admitted in two unit of the internal medicine during one year. 
Exclusion criteria were age <65 years and not being directly admitted 
from home. Interns were asked if the reconciliation would have clinical 
significance (yes or no) and to assess the time spent on a 5-step 
scale.
Results: Starting November 2015, 1’155 admitted patients were 
screened. 621 were excluded because of age (n = 369), not directly 
admitted from home (n = 243), or lost follow-up (n = 9). Of the 534 
included patients, 62% were females. Average age was 80.4 (SD ± 
8.0) years. Interns performed 302 reconciliations (56.9%). Average 
delay until completion was 37.7 (SD ± 59.2) hours after admission. 
Interns assessed 54% of reconciliations as useful (116 / 213 answers). 
Time spent for reconciliation was estimated between 15 and 30 
minutes in 44% (101 / 229 answers) and over 30 and 45 minutes in 
31%. Lessons learned include: 1) the difficulty to get information from 
partners delays the reconciliation; 2) a high rate of reconciliation needs 
training and support of interns; 3) a good EMR is the key tool for an 
efficient reconciliation.
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collaboration. Medical students who participated in OSTEs were 
invited to take part into focus groups. They were asked about what 
they learnt and how this experience influenced their vision of being a 
student, resident, and supervisor. Discussions were analysed using a 
framework based on personality and social structure perspectives 
(PSSP model).
Results: Focus groups took place with 25 medical students from 4th to 
6th years. PID emerged at three levels. On the institutional level, having 
the opportunity to take part into clinical supervisors’ training helped 
students develop a feeling of being a professional inside the institution 
and allowed them to enter further into the community of practice On 
the interactional level, students realised they could become actors of 
change by actively seeking or giving feedback. On the personal level, 
they discovered that mistakes could become sources of learning rather 
than blaming and felt better prepared to cope with faculty feedback. 
Finally, they realised that being a medical supervisor was about 
mastering medical and teaching competencies.
Discussion: Taking part in OSTEs has a positive impact on students’ 
perceptions regarding the institution as a learning environment, their 
role as actors of change and their own position towards mistakes. 
Including students’ participation in OSTEs seems to be a way to 
support their PID while sustaining faculty development. 
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Frequency of use and acceptability of clinical prediction  
rules for pulmonary embolism among Swiss general  
internal medicine residents
Nicolas Faller1, Odile Stalder2, Andreas Limacher2, Stefano Bassetti3, 
Jürg-Hans Beer4, Daniel Genné5, Edouard Battegay6, Christlieb 
Haller6, Daniel Hayoz7, Jörg Leuppi8, Beat Müller9, Arnaud Perrier10, 
Gérard Waeber11, Nicolas Rodondi1,12, Drahomir Aujesky1 
1Division of General Internal Medicine, Bern University Hospital;  
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University of Bern, Bern; 3Department of Internal Medicine, Basel 
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Hospital, Zürich; 7Department of Internal Medicine, Cantonal Hospital 
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Background: Whether the Revised Geneva Score (RGS) and the 
Pulmonary Embolism Severity Index (PESI), two well validated and 
recommended clinical prediction rules (CPRs) for pulmonary 
embolism, are used in daily clinical practice remains unexplored.  
We evaluated the frequency of use, the acceptability among clinicians, 
and which factors drive the use of the RGS and the PESI. 
Methods: We conducted an online survey among Swiss general 
internal medicine residents from five university and five non-university 
hospitals in July 2016 to examine the frequency of use of the RGS  
and PESI. We assessed rule acceptability using the 12-item Ottawa 
Acceptability of Decision Rules Instrument (OADRI). Each item is 
rated on a 6-point scale, 0 points indicating a low and 6 points a high 
acceptability. We further explored the association between physician 
and educational factors and rule use using a mixed logistic regression 
model. 
Results: The response rate was 433/859 (50.4%). Overall, 61% and 
35% of the residents indicated that they always or regularly use the 
RGS and the PESI, respectively. The mean overall OADRI score was 
4.3 points for the RGS and 4.1 points for the PESI, indicating good 
overall rule acceptability. Participants judged both the RGS and the 
PESI to be easy to use (mean score for the RGS 5.4 points; mean 
score for the PESI 4.7 points) and to have a clear wording (RGS 5.1; 
PESI 4.7), but not to be easy to remember (RGS 3.8; PESI 3.0). Rule 
acceptability (odds ratio [OR] 5.71 per score point, 95% confidence 
interval [CI] 3.34–9.76), prior training in the emergency department 
(OR 4.96, CI 2.09–11.76), number of years since graduation  
(OR 1.37 per year, CI 1.04–1.80), availability of internal guidelines 
recommending RGS use (OR 4.15, CI 2.05–8.38), and younger age 
(OR 0.83 per one-year increase, CI 0.72–0.96) increased the odds  
of using the RGS. Rule acceptability (OR 6.27 per score point, CI 
4.04–9.73), learning of the rule during medical school (OR 2.06,  
CI 1.22–3.48), and younger age (OR 0.83 per one-year increase,  
CI 0.72–0.96) increased the odds of using the PESI.
Conclusions: Despite subjective benefit, medication reconciliation 
performed by the physicians alone is time-consuming and barely 
feasible without added resources. Wide implementation is desirable 
but needs to be supported by good IT tools, active participation of 
other caregivers, and might have to be restricted to high-risk patients. 
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Integrative hospital treatment in older patients to  
benchmark and improve outcome and length of stay –  
the In-HospiTOOL study – a quasi-experimental, multicenter 
comparative effectiveness health care research trial
Alexander Kutz1, Philipp Schuetz1, Daniel Koch2, Antoinette Conca2, 
Katharina Regez2, Mehrnaz Prins3, Beat Mueller1, In-HospiTOOL 
study group 
1Allgemeine Innere Medizin; 2Pflegewissenschaften; 3Sozialdienst, 
Medizinische Universitätsklinik, Kantonsspital Aarau, Aarau, 
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Introduction: Health care costs are high and rising also due to an 
aging, polymorbid population, why resource allocation becomes a 
priority. There is lack of evidence-based tools namely for polymorbid 
patients to improve integrative in-hospital care and transition process 
in an acute care hospital setting. Also, there is no reference standard 
for quality benchmarking in Switzerland which is mandatory to 
compare quality of different institutions. To address these issues, we 
propose a multicenter “before-and-after” trial to study the effect of an 
inter-professional inpatient management tool on length of stay and 
other patient-centered outcomes.
Methods: In-HospiTOOL combines several patient discharge 
measures and was developed involving multiple professions. An 
electronical monitoring and reporting system enables clinical user 
oriented benchmarking to assess hospital processes, quality, delays in 
hospital transition and barriers for discharge stratified by profession. 
For external multicenter validation, In-HospiTOOL will be implemented 
in five Swiss secondary and tertiary care hospitals. We will use a 
quasi-experimental approach and compare length of stay before and 
after hospital-wide implementation of the management tool in relation 
to changes in length of stay in hospitals not using the tool (time-trend 
analysis with data from other Swiss hospitals provided by the Swiss 
Federal Office of Health serving as controls). 
Expected results: We expect a total inclusion rate of 45’000 patients 
across all three 6-month study periods (observation, implementation, 
intervention). Based on our monocentric experience we expect the 
In-HospiTOOL to have a strong effect on inter-professional team work 
in this polymorbid setting which results in reduction in length of stay of 
at least 1 day. We also expect that patient outcomes are not negatively 
affected by the intervention (e.g. intensive care unit admission, 
mortality, unplanned readmission, patient satisfaction). A safe 
reduction of length of stay will have positive implication on overall 
hospital costs.
Conclusion: The trial will yield concise information on whether and 
how the “In-HospiTOOL” improves inter-professional team work and 
thereby reduces length of stay without negatively impacting subjective 
and objective markers of patient outcomes. The large amount of 
collected patient data will enable comparison of transition processes 
within different hospitals and establish a benchmarking for patient care 
quality. 
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Students’ implication in faculty development programs 
contributes to their development of professional identity
Jehanne de Grasset1, Marie-Claude Audétat2,3, Nadia Bajwa1,3,  
Hélène Richard1, Nicole Jastrow-Meyer1, Mathieu Nendaz1,3,  
Noelle Junod Perron1,3 
1Hôpitaux Universitaires de Genève; 2Unité des Internistes 
Généralistes et Pédiatres, Faculté de Médecine, Université de 
Genève; 3Unité de Développement et de Recherche en Éducation 
Médicale, Faculté de Médecine, Genève, Switzerland
Background: Medical students develop their professional identities 
through various activities and relationships within different settings.  
As students are being increasingly involved as simulated learners in 
objective structured teaching encounters (OSTEs) for Faculty 
development purposes, we explored if taking part in OSTEs influenced 
their actual and projected professional identity development (PID). 
Methods: A Faculty development program was developed at the 
Geneva University Hospitals (Switzerland) to train faculty members 
from five departments (including hospital and ambulatory general 
internal medicine) in clinical teaching skills on domains such as clinical 
reasoning, communication, professionalism, and inter-professional 
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We analyzed the treatment duration and the median MED daily dose 
in non-cancer related opioid use. Treatment duration was categorized 
<90 days, 90 to <120 days, and chronic opioid use of ≥120 days. 
Based on the total dose and duration we calculated the median MED 
dose per episode categorized into less than 20, 20 to <50, 50 to <100, 
and ≥100 mg/day. 
Results: Overall, we analyzed 597’536 episodes (94% non-cancer 
diagnoses, 6% cancer diagnoses) of opioid use in 376’664 patients.  
In 207’334 episodes (152’493 patients) more than one opioid claim 
was reimbursed: 90.8% of these opioids were used for non-cancer 
diagnosis, in 9.2% for cancer diagnoses. More than one opioid claim 
for strong opioids was found in 78431 episodes (66’440 patients); in 
17.2 % for cancer diagnoses, 82.8% for non-cancer diagnoses. In 
non-cancer episodes, treatment duration was mainly less than 90 days 
(82%) and mostly at a dose of less than <20 mg MED. In 15% of the 
episodes a chronic opioid use was found. Of the patients taking 
opioids at a maximum dose of 100 mg and more, 56% were chronic 
opioid users (fig. 1).
Conclusion: The analysis of opioid use in a Swiss population showed 
that opioids were mainly used for non-cancer diagnoses. Further, a 
small population potentially at risk for opioid related serious adverse 
events was identified. 
Conclusion: Among Swiss general internal medicine residents, the 
RGS was more frequently used than the PESI. Both CPRs had a good 
acceptability. Several factors, including rule acceptability, prior training 
in the emergency department, availability of internal guidelines 
recommending rule use, learning of the rule in medical school, and 
younger physician age were associated with rule use. 
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Effect of a quality improvement intervention with  
the implementation of an endoscopy safety checklist
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Introduction: Safety checklists might have a place in interventional 
procedures such as gastrointestinal (GI) endoscopy. The aim of this 
study was to reinforce commitment in safety culture and better 
communication among team members in endoscopy and to prove 
feasibility of successful checklist adoption before selected GI 
procedures. 
Methods: before-after quality improvement (QI) study involving all 
consecutive patients admitted for a colonoscopy at McGill University 
Health Center from November 2016 to January 2017 (ongoing study). 
Psychometric properties of the checklist have been assessed through 
a validation process. A questionnaire-based survey was administered 
to all staff members and to a random sample of 250 patients before 
and after the QI intervention. Patient and team satisfaction using 
5-point scale questionnaires were the primary outcome. Secondary 
outcomes included different per-procedure outcome and complications.
Results: During the 3-month baseline period and comparative 
intervention period, 1318 and 990 (still enrolling) colonoscopies were 
performed respectively. Out of these initial 990, 707 have completed 
checklists (72%). 147 of the random sample of 250 patients returned 
the satisfaction questionnaire (59%) before the QI intervention and 76 
after (ongoing study). Mean overall scores for patient satisfaction were 
high at baseline and do not differ (4.66 vs 4.69, p = 0.5). However, 
perception of team communication and teamwork from the patient 
perspective (blinded to the study aim) was improved after checklist 
implementation (4.6 vs 4.88, p = 0.03). 57 of 76 patients noticed the 
use of the checklist and only 3 (4%) felt anxiety regarding its use 
during the procedure. Comparative analyses of team satisfaction and 
per-procedural outcome are pending completion of enrollment.
Conclusion: This QI study demonstrates that adoption of an 
endoscopic checklist before GI procedures (in this case, colonoscopy) 
is feasible and increases patient favourable perception of team 
communication and teamwork without causing anxiety. This may be 
one mechanism through which safety outcomes can subsequently be 
improved. Future research should aim to further elucidate the 
relationship between checklists use and safety outcomes through 
better communication in this specific setting using more consistent 
methodological approaches such that best practice guidelines can be 
more fully practiced. 
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in a Swiss population
Maria Monika Wertli1,2, Ulrike Held2, Andri Signorell 3,  
Oliver Reich3, Johann Steurer2, Jakob M. Burgstaller2 
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Introduction: Globally, opioids are increasingly used for non-cancer 
pain. In Switzerland, the use in strong opioids more than doubled 
between 2006 and 2013. Studies suggest that the use of opioids in  
a daily morphine equivalent dose (MED) of 100 mg and more are 
associated with an increased risk of potential serious side effects. The 
objectives of this study were twofold: 1) to assess the use of opioids 
for cancer and non-cancer pain in a Swiss population; 2) to assess in 
non-cancer pain patients the proportion of opioid use at a daily MED 
dose of 100 mg and more. 
Methods: Analysis of insurance claims for opioids between 2006 and 
2014 from one of the major health insurers in Switzerland covering 1.2 
million individuals (approximately one-sixth of the Swiss population). 
Included were persons with at least one opioid prescription claim. 
Strong opioids used in drug substitution programs were excluded.  
All opioids were converted into mg MED. Opioid use was divided into 
cancer and non-cancer diagnosis using the Anatomical Therapeutic 
Chemical (ATC) drug classification and predefined Tarmed positions. 
Figure 1: Treatment 
Duration and median 
Daily Dose.
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Comparisons of intra- and interprofessional conflicts  
in healthcare teams
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Georges L. Savoldelli1,11, Patricia Hudelson12, Mathieu R. Nendaz1,7 
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Geneva University Hospitals; 4Faculty of Medicine, University of 
Geneva, Unit of Primary Care; 5Geneva University Hospitals, Medical 
Directorate; 6Geneva University Hospitals, Institute of Primary Care,; 
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Introduction: Interactions between healthcare professionals range 
from good communication to conflict and may affect patient care.  
While much research has focused on interprofessional collaboration, 
conflict is still poorly understood. Our goal was to develop a deeper 
understanding of conflicts in healthcare teams by comparing intra- and 
interprofessional conflicts so as to inform interprofessional training 
programs, which are increasingly introduced in clinical settings.
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Caring for chronic wounds: a pilot survey of knowledge,  
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Raphael Masson1, Martine Louis-Simonet2, Michel Kossovsky3, 
Gabriel Gold1, Jean Luc Reny1, Virginie Prendki1, and the house staff 
in general internal medicine post-graduate training from the Internal 
Medicine, Rehabilitation and Geriatrics Department of Geneva 
University Hospitals and the University of Geneva 
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de Genève, Thonex; 2Médecine Interne Générale; 3Médecine Interne 
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Genève, Switzerland
Objective: Assess house staff (HS) knowledge, attitude and 
perceptions regarding chronic wounds and their treatment.
Methods: Pilot study among 171 HS in general internal medicine post-
graduate training who were invited by email to complete an  
online web-based questionnaire in January 2017.
Results: We received 50 responses (29% participation rate). Nearly all 
responders (92%) had managed chronic wounds during the prior 
month. 64% had dealt with issues related to wounds at least 10 times 
since graduation and all felt this would recur in their future careers. For 
56% of them, this represented a major real public health issue. 52% of 
responders did not feel confident managing chronic wound, specifically 
with regards to choice of dressing, pressure relief, debridement, probe 
to bone test, arterial assessment or restraint use. They were more 
comfortable recognizing etiology, infection and factors that may delay 
healing. 59% reported lack of practical training and 4% lack of interest. 
92% received less than 10 hours of undergraduate teaching about 
chronic wounds and 89% wished for further training. 61% of HS felt 
that the choice of dressing was “very important” and 35% considered it 
to be “vital”. Nearly all (98%) trusted nurses to select local treatment. 
77% of HS were in favor of using a smartphone application to support 
wound management and 90% felt telemedicine could also be helpful. 
Potential wound management barriers were, by decreasing frequency: 
lack of training, the diversity of wounds, lack of consensus, 
multidisciplinary approach, the workload, the off-putting appearance of 
wounds and discouraging prognosis.
 
Methods: We conducted 82 semi-structured interviews with randomly 
selected residents, fellows, nurses, nurse managers, and nursing 
assistants across four departments of the Geneva University 
Hospitals: internal medicine, family medicine, pediatrics, and surgical 
units. Interviews focused on sources, consequences, and responses  
to conflicts. Content analysis enabled us to identify features 
characterizing conflicts. Descriptive and inferential statistics were used 
to compare the features between intra- and interprofessional 
situations.
Results: Of the 130 situations of conflicts shared by participants, 57% 
were intra-professional and 43% were interprofessional. Regarding 
sources of conflicts, relationship difficulties caused more intra- than 
interprofessional conflicts (62% vs 41%, P = .02), whereas 
disagreements on patient-related tasks (27% vs 48%, P = .02) and 
general perceptions of a group vis-à-vis another group (3% vs 27%,  
P <.001) generated more interprofessional conflicts. There were no 
significant differences between intra- and interprofessional conflicts  
for most consequences, except for professional mobility, which tended  
to be affected by intra-professional conflicts (20% vs 9%, P = .09). 
Individuals involved in intra-professional conflicts tended towards 
denial and avoided actively managing conflicts (47% vs 30%, P = .07). 
For other responses, differences between intra- and interprofessional 
conflicts were not significant.
Conclusion: There are differences between intra- and 
interprofessional conflicts, particularly for conflict sources. These 
differences suggest that interprofessional education would benefit from 
integrating situations that focus on collaborative patient care. The 
similarities we observed between intra- and interprofessional conflicts 
in terms of consequences and responses to conflicts evidence the 
need to focus on a variety of situations, relationships, and professional 
roles that reflect clinical settings when designing educational 
interventions. 
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Cardiovascular disease risk factors among male youths  
in Southern Switzerland: a transversal study
Franco Muggli 1, A Rabufetti 2,3, Giacomo Simonetti 2,3,  
Mario Bianchetti 2,3, Augusto Gallino4 
1Esercito Svizzero, Centro di Reclutamento della Svizzera Italiana, 
Monte Ceneri; 2Dipartimento di Pediatria della Svizzera Italiana, 
Ospedale Regionale Bellinzona e Valli, Bellinzona; 3Universität Bern, 
Bern; 4Unità di Cardiologia, Ospedale Regionale Bellinzona e Valli, 
Bellinzona, Switzerland
Introduction: Cardiovascular diseases, first cause of death in 
Switzerland, are frequently attributable to risk factors already present 
in children and adolescents. The aim of this study was therefore to 
describe the prevalence of cardiovascular disease risk factors in 18-  
to 20-year-old males undergoing medical examination to assess fitness 
for recruitment into the army.
Methods: An exploratory transversal study, approved from the regional 
ethic commission, was conducted during the recruitment days. The 
analysis includes measurement of the anthropometric parameters, 
arterial brachial pressure, central arterial pressure and arterial 
stiffness (= pulse wave velocity in m/s). Moreover, a structured 
questionnaire addressing smoking behavior, sedentariness and 
familial cardiovascular risk factors, as well as blood analysis for 
determination of glycaemia, lipids and Vitamin D metabolism values 
was performed.
Results: In the period between 1/4/2014-31/12/2016, 1045 voluntary 
were included in our study. Following cardiovascular risk factors were 
present in this young male population: tobacco use (N = 449, 43%), 
body mass index >25.0 Kg/m2 (N = 274, 26%); Abdominal 
circumference > 94.0 cm (N = 117, 11%); Arterial pressure = or >140/90 
mm Hg (N = 83, 8%); 25-OH-vitamina D3 rate = or <50 nmol/L (N = 
201, 19%); total cholesterol = or >5.2 mmol/L (N = 54, 5%); uricaemia 
>500 µmol/L (N = 61, 6%); pulse wave velocity >10m/s (N = 25, 2.5%). 
Conclusion: The results of this study allow us to analyze the 
cardiovascular health of young males living in Southern Switzerland. 
These results clearly show that a high number of young male present 
at least one cardiovascular risk factor. 
Figure 1: Confidence range regarding chronic wound.
Conclusions: Our data suggest that many junior house staff in 
internal medicine do not feel confident with chronic wound 
management and wish for more training in this area which they 
consider a frequent problem and a major public health issue. This 
statement of needs, paves the way for a larger study designed to 
confirm these preliminary findings and to identify ways to improve  
the training in chronic wound management. 
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Results: In the specifications for the prototype, we included existing 
EMR or paper functionalities (e.g., task lists, clinical data entry for 
vitals), as well as new functionalities to support team communication 
(e.g., support for handoffs, team chat). After selecting one’s assigned 
patients for the shift, the app provides an overview of patient charts to 
support the handoffs, as well as a multi-patient view of tasks and 
needed materials per room. At the bedside, scanning the patient’s 
identity bracelet opens their chart (identito-vigilance): users can 
validate tasks by one swipe and/or add explanatory notes. Clinical data 
can be entered directly at the bedside, and is integrated in the EMR. 
Finally, an informal team chat can help improve team communication. 
Conclusion: Our prototype was designed to fill a gap in the nursing 
bedside workflow process, and was developed iteratively with nurses 
to provide optimal usability. A proof of concept test will be conducted in 
two wards shortly (internal medicine and surgery) to study the app’s 
efficiency, its integration in the workflow process, and its effect on 
patient safety. Based on this prototype, future mobile support tools can 
also be developed for physicians. 
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How asthma, nose polyps and myorcardial infarction  
finally led to the diagnosis of an eosinophilic  
granulomatosis with polyangiitis
Anne-Katrin Rospert, Patrick Muggensturm 
Innere Medizin, Spital Zollikerberg, Zürich, Switzerland
Background: The eosinophilic granulomatosis with polyangiitis 
(EGPA, formerly Churg-Strauss) is a systemic vasculitis of small and 
medium blood vessels, characterised by asthma, nose polyps and 
serum eosinophilia. The most affected organ is the lung. There are 
three typical phases (prodromal, eosinophilic and vasculitic phase). 
Diagnosis is made by clinical findings and in 40–60% by positive 
antineutrophil cytoplasmatic antibodies (ANCA). 
Case presentation: A 49-year old female presented with chest pain, 
dyspnea and ecg changes, suspicious for an infarction. The patient 
has a 4-month history of cardiac attacks, starting with an infarction 
caused by a spontaneous dissection. There was no significant 
coronary sclerosis in the angiography. Since then, the patient had 3 
more attacks, once leading to reanimation. The last angiography due to 
a non-stemi showed vasospasm of the coronaries, reversible to local 
application of nitroglycerin. Under these circumstances, a single 
coronary etiology seemed implausible. The patient has a history of 
allergic asthma, well controlled until her early 30ties. Lately, the patient 
suffered of poor control and of nose polyps. A recent spirometry 
showed severe obstruction and decreased diffusion capacity with 
partial atelectasis of the left lower lobe in a CT-scan. The biopsy 
showed negative cytology and bacteriology but proliferation of the 
eosinophilic granulocytes, also documented in the blood analysis (with 
elevated total IgE). Repeated vasculitis screening was negative. During 
a systemic steroid therapy, the patient was asymptomatic with normal 
eosinophilic blood count. Two weeks later the patient suffered another 
cardiac attack in combination with elevated eosinophilic granulocytes. 
In synopsis of poorly controlled asthma, nose polyps (prodromal 
phase), elevated IgE, serum eosinophilia (eosinophilic phase) and 
cardiac vasospastic attacks (vasculitic phase), we diagnosed EGPA 
despite negative ANCA screening. We started a systemic therapy with 
steroids and cyclophosphamide. The eosinophilia normalised quickly. 
Follow up showed a well controlled asthma without cardiac symptoms 
and a high quality of life.
Conclusions: The diagnosis of a EGPA can often be missed because 
of diffuse symptoms, differential diagnosis and negative ANCA tests (in 
cardiac involvement up to 40%). Heart involvement is a leading cause 
of mortality in EGPA, the more important it is to think of EGPA with 
patients having cardiac symptoms and a history of asthma. 
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Is total and segmental fat mass equally associated  
with cardiovascular risk factors? The Colaus study
Elisabeth Stamm1, Pedro Manuel Marques-Vidal1,  
Peter Vollenweider1, Gerard Waeber1, Didier Hans2, Olivier Lamy1 
1Service de Médecine Interne, Département de Médecine, CHUV; 
2Centre des Maladies Osseuses (CMO), Département de l’Appareil 
Locomoteur, CHUV, Lausanne, Switzerland
Introduction: Obesity is a risk factor for cardiovascular diseases (CD). 
Adipose tissue is an endocrine organ, due to the secretory activity of 
the visceral fat (VF) that is associated with cardiovascular risk factors 
(CRF). Fat mass (FM) can be evaluated by bioelectrical impedance 
(BIA) and dual x-ray absorptiometry (DXA). DXA measures the total 
FM (TFM) and the segmental FM: gynoid fat (GF), android fat (AF) 
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Detection of atrial fibrillation with a smartphone-App – 
 study design and methods of DETECT AF pro trial
Lorena Salomon1, Fabienne Bulacher1, Noah Pierre Thierry1,  
Lian Krivoshei2, Andrea Seeck3, Stefan Weber4, Nicole König3,  
Marcus Doerr5, Jens Eckstein1 
1Division of Internal Medicine, University Hospital Basel, Basel; 
2Department of Cardiology, Inselspital Bern, Bern, Switzerland; 
3Preventicus®, Jena; 4Department of Internal Medicine, University 
Hospital Regensburg, Regensburg; 5Department of Internal Medicine, 
University Hospital Greifswald, Greifswald, Germany
Introduction: Detection of silent atrial fibrillation (AF) is challenging 
but of pivotal importance particularly in stroke prevention. Recent 
studies confirmed the merits of long-term monitoring. Nevertheless, 
currently available diagnostic tools are burdened with disadvantages  
in that they are inconvenient, costly and/or invasive. The prospective 
DETECT AF pro trial aims to verify the accuracy of a new diagnostic 
tool using a smartphone-App (Preventicus® Heartbeats). In a 
predecessor study (DETECT AF) we tested the same App employing 
photoplethysmographic (PPG) signals of a smartphone camera to 
distinguish between AF and sinus rhythm (SR). In that retrospective 
study the App reached a sensitivity and specificity of 95% (Krivoshei 
et al., Europace 2016). 
Study design: Prospective, blinded, multicenter, international study. 
–  Inclusion criteria: Subjects of legal age, with SR or AF, informed 
consent
–  Exclusion criteria: Legally incompetent persons, pacemaker rhythm 
AF Group: Patients with atrial fibrillation at the time of recruitment 
SR Group: Age- and gender-matched patients with sinus rhythm 
Data is blinded to the analysing researcher and will be evaluated and 
monitored externally. 660 subjects will be recruited until February 
2017.
Methods: The subjects place the camera of a smartphone (iPhone 4s, 
Apple, CA, USA) on their index finger for 5 minutes to allow the 
recording of a PPG signal (pulse wave). During this recording the 
finger is illuminated by the integrated LED-light. A single lead ECG is 
recorded (Kardia, AliveCor, USA) as a reference. Person-related data 
including comorbidities and medication are collected. The pulse wave 
curve data are coded with the patient´s ID and analysed by 
Preventicus® in a blinded fashion; files of the patients will be assigned 
to SR or AF. The ECG will be analysed by cardiologists other than the 
researcher in a blinded fashion and assigned to SR or AF as well. 
Results will then be aggregated, unblinded and merged under 
monitoring. Primary target parameters are the App’s sensitivity and 
specificity for detecting AF compared to a standard ECG interpreted by 
a cardiologist. Secondary target parameters include the proportion of 
non-evaluable recordings in the overall study. 
Conclusion: The DETECT AF pro trial provides clinical level evidence 
evaluating an App for automatic detection of AF with a smartphone 
camera. Data will be available for the SSGIM Meeting. 
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Bedside mobility app: improving the bedside  
workflow process
Katherine Blondon1,2, Pascal Ducloux3, Pierre-André Berret4, 
Jean-Yves Wojtasikiewicz5, Frederic Ehrler6 
1Direction Médicale; 2Département de Médecine Interne Générale, 
Réhabilitation et Gériatrie; 3Direction des Soins; 4Département des 
Spécialités de Médecine; 5Département de Chirurgie; 6Service des 
Sciences de l’Information Médicale, Hôpitaux Universitaires de 
Genève, Genève, Switzerland
Introduction: Clinical documentation in the electronic medical records 
(EMR) at the bedside is suboptimal due to lack of adapted tools. The 
current tools used at the bedside in our hospital are paper supports 
(task list printouts or personal notes) and portable computers on 
wheels (COWs). Although the printouts can guide tasks and the 
personal notes can support handoffs, they are a potential source of 
error (e.g., prescriptions made after printing, transcription errors in 
delayed data entry from annotations). COWs facilitate data entry (e.g., 
vital signs, or clinical scores) but are not always available (two COWs 
per unit). Our project aims at developing a prototype of a smartphone 
app that can optimize the bedside workflow process to improve the 
efficiency, quality and safety of patient care.
Method: After studying the bedside work process of nursing teams, an 
interprofessional team elaborated a design for a smartphone 
application with nurses from internal medicine and surgery. The 
iterative development process also included a usability test in a lab 
with twelve nurses.
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The patient is always right – an unusual cause  
of low back pain in an immunocompetent woman
Matthias von Rotz1, Karin Grimm1, Christian Arranto2,  
Felix Burkhalter3, Stefan Erb4, Marten Trendelenburg1,  
Tobias Breidthardt1 
1Division of Internal Medicine, Basel University Hospital; 2Clinic of 
Hematology, Universität Basel; 3Clinic of Transplant Immunology and 
Nephrology; 4Clinic of Infectious Diseases and Hospital Epidemiology, 
Basel University Hospital, Basel, Switzerland
Background: Low back pain is very common and usually does  
not require extensive medical work-up. However, serious medical 
conditions can also cause low back pain and might be challenging  
to diagnose.
Case: A 38 year old woman attended our hospital because of 
worsening low back pain since 14 days. She had a history of chronic 
back pain after an accident 17 years ago, which so far had been 
tolerable under opioid treatment. She had no neurological symptoms 
but fever (38.8 °C) and an elevated C-reactive protein (CRP) at 
65.2mg/l and a creatinine at 129 umol/l. Spondylodiscitis was 
suspected, but could not be confirmed by two serial magnetic 
resonance imaging (MRI) scans 10 days apart, that only showed 
erosive transformation of the vertebral endplates L5/S1 (type Modic I). 
and VF. The aim of this study was to determine which method of FM 
measurement (TFM by BIA or DXA, GF, AF and VF) is best correlated 
with CRF: blood pressure (BP), cholesterol, blood glucose and other 
specific biological markers.
Methods: OsteoLaus, a sub-study of the cross-sectional population-
based CoLaus, includes 1’500 women aged 50 to 80 years. BIA, 
systolic and diastolic BP (SBP, DBP) and biological markers (total 
cholesterol and subclasses, triglycerides, blood glucose, insulin, 
high-sensitivity CRP, ALAT, uric acid, leptin, adiponectin, afamin) were 
carried out during the CoLaus visit. DXA was performed 6 months 
later in a subgroup of 1158 OsteoLaus women. Spearman correlations 
were computed between FM markers and CRF.
Results: The mean age was 63.2 ± 6.3 y, mean BMI 25.8 ± 3.7. All 
correlations were significant at p <0.001. The correlation for the TFM 
evaluated by BIA and DXA was good (r = 0.704). Overall, the CRF 
parameters were better correlated with VF than with AF, and better  
with AF than with TFM (evaluated by BIA or DXA). Most of the CRF 
parameters were poorly correlated with GF. The correlation between 
SBP and VF, AF and TFM by DXA was 0.290, 0.219 and 0.204. Total 
cholesterol wasn´t correlated with any of the measures. LDL was 
poorly correlated with FM measures. Correlation coefficients between 
HDL and VF, AF and TFM were–0.465, –0.363 and –0.366; between 
triglycerides and VF, AF and TFM 0.453, 0.368 and 0.328. Correlation 
coefficients between insulin and VF, AF and TFM were 0.601, 0.565 
and 0.536; between high-sensitivity CRP and VF, AF and TFM 0.601, 
0.565 and 0.536. Leptin level was highly correlated with all FM 
measures (r from 0.563 to 0.743). Adiponectin level was negatively 
correlated with VF, AF ant TFM measures (–0.229, –0.185, –0.166).
Conclusion: The correlation between the TFM measured by BIA and 
DXA was good. We demonstrated a stronger correlation between the 
VF (higher as the other FM measures) and the various CRF analyzed. 
GF was poorly correlated with the CRF analyzed. This shows an 
association between the role of the VF and the CD. 
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Nightlife Switzerland: prevalence of violence and  
violence-linked injuries in major cities on weekend nights
Julian Jakob, Jacques Cornuz 
Policlinique Médicale Universitaire, Lausanne, Switzerland
Introduction: Observed over a week, 78% of night disturbance, 74% 
of verbal conflicts and 73% of violent acts and violence-linked injuries 
are associated to alcohol consumption, mostly on Friday and Saturday 
nights in neighborhoods with active nightlife. The consumption of 
alcohol and recreational drugs may be linked to the opening hours of 
bars and clubs on Friday and Saturday. Comparing the prevalence of 
violent acts with the amount of clubs different Swiss cities count and 
analyzing the number of violent incidents stratified per hour over a 
week could help establishing recommendations for a safer nightlife. 
This includes advice for teenagers and young adults, their parents, as 
well as public health professionals, medical teams and police corps.
Methods: Literature research concerning years 2014 to 2016 and 
communication with five public health institutions and research groups, 
as well as with three nightlife organizations. Consulting of statistical 
evaluations in cooperation with the Federal Statistics Office concerning 
the type and timeframe of violence-linked injuries and municipal and 
cantonal police reported violence acts. Graphical representation of 
nightlife offer in Switzerland 2016 and number of violent acts (yearly 
from 2009 to 2015) stratified per hour.
Results: Violence-linked injuries incidence increases up to over 
eight-fold on weekend nights compared to nights on workdays. Police 
reported infractions against penal code concerning violence were 
clearly more numerous on Friday and Saturday night compared to the 
other ones. Lausanne leading the list of club offer with 6.2 clubs per 
100 000 inhabitants is also the Swiss city with the highest reported 
infractions against penal code in general and ranging in top-three 
position of increase of violence-linked injuries (8.6-fold increase; 8.8 in 
Lucerne, 8.7 in Geneva) in weekend nights compared to the remaining 
ones.
Conclusion: Cities presenting a broad offer of nightlife activities such 
as clubs are prone to sharp increases in violent act incidence on 
Friday and Saturday nights, be it measured on the amount of 
violence-linked injuries or on the amount of reported infractions 
against penal code. Recommendations for “high-risk” hours on 
weekend nights could be made through the results of this study. Public 
health professionals and policy makers should be aware of the issue 
linked to late-night violent acts, and establish and support the 
corresponding medical resources and safety disposures. 
Figure 1: MRI of the lumbar spine (T2 left, T1 right).
However, our initial evaluation further revealed severe microcytic, 
hyporegenerative anemia (hemoglobin 64 g/l), biopsy-proven 
leucocytoclastic vasculitis of the lower legs, hepatosplenomegaly and 
a nephritic urinary sediment. Looking for a unifying diagnosis, bone 
marrow biopsy was unremarkable without signs for hemolysis or 
deficiency of substrates and kidney biopsy showed focal segmental 
glomerulonephritis. Hepatic work up ruled out infectious hepatitis or 
metabolic disease. Due to the persistent back pain and the patients 
conviction that “the problem is in my back”, we performed a 
18F-fluorodeoxyglucose (FDG) positron emission tomography with 
computed tomography (PET/CT), showing marked lumbar spinal 
inflammation being highly suspicious of spondylodiscitis at L5/S1. 
Figure 2: PET/CT with hypermetabolism in transition L5/S1.
The diagnosis could be confirmed by biopsy demonstrating Candida 
albicans related spondylodiscitis. A treatment with an echinocandin 
(caspofungin) was initiated given intravenously for two weeks followed 
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Conclusion: In our service CIRS participation (and satisfaction!) is 
excellent. While all incidents are analysed, the current challenge is to 
transform these analyses into daily improvements. Major limitations 
include the still complicated organisation, the need to prioritise, as well 
as the lack of personal and financial resources available to analyse the 
more complex incidents. 
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Evaluation of a multicomponent childhood obesity  
counseling program in primary care using the Reach, 
Effectiveness, Adoption, Implementation, and Maintenance 
(RE-AIM) framework 
Mei Sien Lew1, Dagmar L’Allemand2, Damian Meli1,  
Peter Frey1, Beatrice Molinari1, Reto Auer1 
1Berner Institut für Hausarztmedizin BIHAM, Bern;  
2Ostschweizer Kinderspital, St. Gallen, Switzerland
Background: Primary care providers can use behavioral lifestyle 
interventions to effectively treat overweight and obese children, but 
implementing these interventions is challenging. Most childhood 
obesity intervention evaluation studies focus on effectiveness. Few 
studies describe implementation. We evaluated critical components of 
a childhood obesity intervention, so stakeholders could implement it in 
other settings. 
Methods: We evaluated a pilot implementation study of an existing 
structured lifestyle intervention in the Canton of Bern, Switzerland. The 
intervention was aimed at children 6-8 years old, whose BMI was over 
the 90th age-adjusted percentile. It was led by a primary care physician 
and consisted of 10 sessions, spread out over a year-long period. We 
used the Reach, Effectiveness, Adoption, Implementation and 
Maintenance (RE-AIM) evaluation framework to describe the pilot 
implementation study. We stratified description of RE-AIM components 
at the patient- and physician-level. For Reach, at the patient-level, we 
counted the number of children screened for BMI. At the physician-
level, we counted the number of physicians invited to participate in the 
study. For Effectiveness, at the patient-level, we measured change in 
BMI z-score. We determined Adoption at the patient-level by the 
number of children included and, at the physician-level, by the number 
of participating physicians. For Implementation, we counted the 
number of consultations held per patient. For Maintenance, at the 
patient level, we counted at the number of children who discontinued 
the intervention; at physician-level, we counted the physicians who still 
used components of the intervention two years after the study ended.
Results: Reach: 864 children were screened; of these, 65 were 
overweight or obese. A total of 394 physicians were invited to 
participate in the study. Effectiveness: BMI z-score significantly 
decreased (–5.6%, p = 0.01). Adoption: 14 participating physicians 
treated 26 patients. Implementation: the mean number of consultations 
was 8. Maintenance: 9 (35%) children discontinued the intervention;  
6 (50%) physicians we contacted continued to apply at least one 
component of the intervention.
Conclusions: The intervention effectively reduced BMI z-score. The 
RE-AIM framework helped us summarize critical components of the 
implementation study so others could more easily implement the 
program in other settings. 
by oral fluconazole for a total of six months. CRP, haemoglobin, serum 
creatinine, proteinuria and vasculitic skin lesions resolved during the 
treatment. However, the L5/S1 intervertebral disc remained destroyed 
by the Candida infection requiring spinal surgery in the near future.
Conclusion: A frequent problem turned out to have a rare cause. 
Candida spondylodiscitis is a very uncommon cause of low back pain, 
especially in an immunocompetent patient without other risk factors for 
fungal infections. Despite the typical symptoms (fever, back pain), 
apparently normal MRI scans initially misguided our diagnostic work 
up. In specific situations, PET/CT may help to distinguish between 
inflammatory and degenerative disease. 
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2-year results of a critical incident reporting system  
in a service of internal medicine
Vanessa Kraege, Joëlle Servet, Pierre-Alexandre Bart,  
Claudio Sartori, Plamena Tasheva 
Service de médecine Interne, CHUV, Lausanne, Switzerland
Introduction: In 2015 a computer-based critical incident reporting 
system (CIRS), accessible to all staff members, was implemented in 
our hospital. In the service of internal medicine all events are 
addressed to a single CIRS coordinator who sorts them into two 
groups: those to be analysed within the service versus those 
necessitating external interlocutors. The latter are sent to the CIRS 
coordinators of the concerned departments and of other specific 
directorates. Internal events are submitted to different CIRS multi-
professional specialists who may work alone or in groups (fig. 1).
 
Here we report the first summary of this implementation.
Methods: We collected data about the total number of incidents and 
the profession of reporters. We categorised the incidents into 22 
subtypes derived from the OMS classification and examined the 
feedback modalities used for these incidents’ analysis.
Results: Between 2015 and 2016 we collected 1224 reports with a 
constant reporting rate of about 1 report/100 hospitalisation days, 
corresponding to about 1.7 reports a day. All events were analysed and 
categorised (fig. 2). 
Nurses reported most incidents (89%), notably falls, medication 
administration errors and equipment problems. Doctors reported 9%  
of the declared events, mostly related to clinical situations. Clinical-
related incidents increased from 5% in 2015 to 14% in 2016, in contrast 
to other subtypes whose incidence remained stable. There were 2 
main feedback modalities. Recurring incidents such as falls or loss of 
personal items were analysed by the CIRS coordinator, supported by 1 
or 2 staff members. Their analyses and potential solutions were directly 
discussed with the reporter and the involved staff. Incidents with higher 
impact and improvement potential were discussed at monthly 
management committees, CIRS specialist or nurse meetings, so as to 
identify improvement strategies. Selected clinical incidents were 
addressed using the London protocol at morbidity and mortality 
conferences (10 times/year) or published as clinical cases. 
Figure 1
Figure 2
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During the hospitalisation the temperature was repeatedly elevated up 
to 39 °C and the state of the patient declined gradually over the next 
weeks. An empirical trial of antibiotics and the probatory administration 
of steroids had no effect, considerably elevated markers of 
inflammation and fever persisted. Based on the patients history with 
MGUS of the type IgM a lymphoproliferative disorder was discussed. 
18F-FDG PET/CT showed a slightly increased uptake in the spleen and 
an enhancement in the ascending colon. But even with the biopsies of 
the colon the suspicion of a lymphoma could not be confirmed. 
Because of further deterioration of the patient and despite only slightly 
increased glucose uptake in the marginally enlarged spleen, 
splenectomy was performed with immediate disappearance of the 
fever. Histologically the diagnosis of a diffuse large B-cell lymphoma 
(DLBCL) was made and chemotherapeutic treatment was started. 
After twelve days fever recurred and the patient died because of a 
sepsis with staphylococcus aureus.
Conclusion: This case demonstrates the difficulties to find the 
underlying disease of fever of unknown origin. Beside thorough 
history-taking, repeated physical examinations, laboratory tests and 
basic imaging procedures, 18F-FDG PET/CT scan can add important 
clues for further investigations of lymphoproliferative or infectious 
disease. In this case only splenectomy provided finally the diagnosis of 
the lymphoma. The diagnosis of primary splenic diffuse large B-cell 
lymphoma is often made by core-needle biopsy, but splenectomy 
seems to improve survival. 
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Challenging fever – case report of a patient with fever  
of unknown origin
Daniel Lüscher, Felicitas Hitz, Markus Diethelm, Michael Brändle 
Departement Innere Medizin, Kantonsspital St. Gallen, St. Gallen, 
Switzerland
Introduction: Fever of unknown origin (FUO) is still a diagnostic 
challenge. The list of disorders causing FUO is very long. We report 
the case of an 81 year old woman where after numerous investigations 
only splenectomy provided the diagnosis.
Case report: While the female patient presented to the hospital, she 
reported general weakness, fatigue and loss of weight during the last 
month. Past medical history was remarkable for monoclonal 
gammopathy of undetermined significance (MGUS) and chronic 
inflammatory demyelinating polyneuropathy (CIDP). For the latter she 
regularly received intravenous immunoglobulins. At admission no 
outstanding clinical features were registered. Important laboratory 
findings are specified in table 1. Chest radiograph was unremarkable. 
Blood cultures remained without bacterial growth. An abdominal 
ultrasound and CT scan showed no explanation for the clinical 
situation.
Table 1: Laboratory findings at admission.
Parameter Result Normal range
Haemoglobin 89 120–160 g/l
Leukocytes 6.2 4–12 G/l
Thrombocytes 327 150–300 G/l
C-reactive protein 261 <8 mg/l
Erythrocyte sedimentation rate 66 <12 mm/h
Free light chains lambda 23.5 5.7–26.3 mg/l
Free light chains kappa 17.3 3.3–19.4 mg/l
Kappa/lambda ratio 0.74 0.26–1.65
IgM 0.9 0.4–2.4 g/l
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schwierig beeinflussbaren Faktoren (Personalfluktuation, Aufgabe von 
Gewohnheiten), Mitarbeiter erkennen/ korrigieren Fehler aber auch.  
6) Die Häufigkeit von Fehlern korreliert mit der Häufigkeit einer 
Tätigkeit. 7) CIRS hat sich als wertvolles Instrument zur 
kontinuierlichen Verbesserung der Qualität bewährt. 
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Is performance-based functional impairment  
associated with readmission and death?  
Results of a prospective cohort study
Carole Elodie Aubert1, Antoine Folly2, Marco Mancinetti 2,  
Daniel Hayoz2, Jacques Donzé3 
1Department of General Internal Medicine, Inselspital, Bern University 
Hospital, University of Bern, Bern; 2Department of General Internal 
Medicine, Fribourg Cantonal Hospital, Fribourg; 3Department of 
General Internal Medicine, Inselspital, Bern University Hospital, 
University of Bern (2nd affiliations: Division of General Medicine and 
Primary Care, Brigham and Women’s Hospital & Harvard Medical 
School, Boston, Massachusetts, USA), Bern, Switzerland
Introduction: Readmission and death are frequent after a 
hospitalization and difficult to predict. Risk factors are manifolds, and 
we could intuitively consider that patient’s functional impairment may 
be one of those risk factors. However, only few studies assessed the 
association between functional impairment and readmission. Although 
those studies tend to report a significant association between 
functional impairment and readmission, they are often limited by  
a retrospective design, and by the use of subjective self-reported 
functional assessment, such as the Activities of Daily Life (ADL) or the 
Instrumental ADL (IADL). We assessed whether a performance-based 
functional impairment at discharge is associated with readmission and 
death after an acute medical hospitalization.
Methods: We prospectively included patients aged ≥50 years admitted 
to the Department of General Internal Medicine of Fribourg Cantonal 
Hospital. Functional status was assessed shortly before discharge 
using the Timed Up and Go test performed twice in a standard way by 
trained physiotherapists. Functional impairment was defined as a test 
duration ≥15 seconds. In a multivariable logistic regression adjusted 
for potential confounders, we assessed the association of functional 
impairment with unplanned readmission and death, within 6 months 
after discharge.
Results: Table 1 describes the baseline characteristics of the 
population.
Table 1: Baseline characteristics.
Variable TUG test duration 
≥15 seconds  
(n = 129)
TUG test duration 
<15 seconds  
(n = 209)
Age (years), median (IQR) 80 (72–86) 70 (61–79)
Men, n(%) 47 (36.4) 121 (57.9)
Charlson comorbidity index, 
median (IQR)
8 (6-10) 6 (4-8)
Multimorbidity, n(%) 125 (96.9) 177 (84.7)
At least one admission in the last 
6 months, n(%)
49 (38.0) 46 (22.0)
Duration of TUG test (seconds), 
median (IQR)
23 (18–34) 10 (8–12)
Elective admission, n(%) 2 (1.6) 11 (5.3)
Length of stay (days), median 
(IQR)
9 (6–15) 5 (4–9)
Within 6 months after discharge, 107/338 (31.7%) patients had an 
unplanned readmission and 31/338 (9.2%) died. Functional impair-
ment was associated with higher risk of death (adjusted OR 2.44, 
95% CI 1.15–5.18), but not with unplanned readmission (adjusted OR 
1.34, 95% CI 0.84–2.15). We also didn’t find a significant association 
between functional impairment and the total number of unplanned 
readmission (adjusted OR 1.59, 95% CI 0.95–2.67). The most frequent 
causes of readmission were cardiovascular, oncological, and infec-
tious diseases, and were similar regardless of functional status. 
P346
Smoke by any other name: heat-not-burn tobacco  
cigarettes
Reto Auer1,2, Nicolas Concha-Lozano3, Isabelle Jacot-Sadwoski1, 
Jacques Cornuz1, Aurélie Berthet1 
1Policlinique Médicale Universitaire, Lausanne; 2Berner Institut für 
Hausarztmedizin, Bern, 3Institut de Santé au Travail (IST), Lausanne, 
Switzerland
 
P347
10 Jahre informatikbasierte CIRS-Erfassung an einer 
mittelgrossen internistischen Klinik
Philippe Rochat, Beat Frauchiger 
Kantonsspital Frauenfeld, Frauenfeld, Switzerland
Einleitung: Die Erfassung von kritischen Ereignissen (critical 
incidents, CI) mit potentiellem Schaden für Patienten hat sich zur 
Reduktion von Systemfehlern im Qualitätsmanagement in Schweizer 
Spitälern zusehends etabliert. Wir berichten über unsere Erfahrungen 
seit der Umstellung von der Erfassung auf Papierformularen auf ein 
IT-Programm.
Methodik: In unserer 80-Betten-Klinik wechselten wir 2007 nach zwei 
Jahren Erfassung auf Papier auf eine spitalweit eingesetzte, anonyme 
Informatiklösung. Wir analysierten die Meldefrequenz, die CI und die 
daraus getroffenen Massnahmen. Semesterweise fanden klinikinterne 
Konferenzen (Pflege, Ärzte, geladene Gäste) mit Fokussierung auf 
Lösungsansätze statt. Freigeschaltete Meldungen können von MA 
gelesen werden. 
Resultate: Im Jahr nach der Umstellung stieg die Melderate von ca 
60/J. auf 152/J. an, in den Folgejahren war sie um 66–115/J. In den 10 
Jahren wurden 944 CI erfasst. Ca. 65–70% der Meldungen stammen 
von der Pflege, ca. 25–30% von Ärzten und ca 5% von anderen 
Berufsgruppen. Mit 390 Meldungen standen falsche 
Medikamentendosierungen an der Spitze (Abb. 1). Die 115 Meldungen 
bez Gerinnungsmedikamente beinhalteten 86 Probleme bez Liquemin 
(davon 45 bez Liqueminperfusoren). 2016 war bei rund 90% der CI 
Unachtsamkeit mitbeteiligt. In den klinikinternen Konferenzen wurden 
in 82 Themenbereichen 99 Massnahmen erarbeitet und umgesetzt.  
5 Themen wurden insg zwei und 2 Problemkreise drei Mal behandelt, 
zT wegen sich inzwischen veränderten Gegebenheiten, z.T. wegen 
Lösungsansätzen mit weiterem Verbesserungspotential.
Schlussfolgerung: 1) Ein konstruktiver und offener Umgang mit  
CI führte rasch zu einer breiten Akzeptanz mit erfreulichem 
Meldeverhalten. 2) Die Eingabemöglichkeit an jedem PC erhöht  
die Meldefrequenz im Vergleich zum Papierformular. 3) Aus den 
Meldungen und in klinikinternen Konferenzen werden geeignete,  
die Sicherheit erhöhende Massnahmen erarbeitet und umgesetzt.  
4) Bekannte und potentiell als gefährlich eingestufte Fehler  
(Gerinnung) werden eher wahrgenommen/gemeldet. 5) Menschliche 
Unachtsamkeit ist eine häufige Fehlerquelle und gehört zu den 
Abbildung 1: CIRS-Meldungen 2007–2016.
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Conclusions: The majority of HF-patients go back to their GP in the 
30 days following their discharge. Unexpectedly, many refused to book 
an appointment during their hospitalization. Reason remains unclear. 
Further studies should identify reasons of this delay and determine if 
some are modifiable. We also should assess whether a shorter delay 
reduce readmissions: current recommendations about appropriate 
time to follow-up are based on expert opinions and limited literature.
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Medical collaboration during ICU admission decisions:  
a qualitative study of internists’ and ICU physicians’ 
perceptions
Monica Escher, Patricia Hudelson, Mathieu Nendaz,  
Bara Ricou, Thomas Perneger, Stéphane Cullati 
Geneva University Hospitals, Geneva, Switzerland
Background: Intensive care (ICU) admission decisions are complex 
particularly for seriously ill patients. They involve collaboration between 
the referring internists and ICU physicians. Good collaboration is 
associated with patient health-related outcomes and healthcare 
providers’ satisfaction with the decision making. How physicians 
perceive each other roles can influence the quality of collaboration.
Aims: Explore internists’ and ICU physicians’ perceptions of their roles 
and how perceptions relate to experience of collaboration during 
admission decisions.
Methods: In-depth interviews with ICU physicians (n = 12) and 
internists (n = 12) working in a Swiss tertiary care hospital. Interviews 
were analyzed using an inductive thematic approach.
Results: Internists and ICU physicians had the same perception of 
their various respective roles. Both groups of physicians estimated that 
their colleagues usually performed their roles satisfactorily. 
Shortcomings were reported in complex situations involving seriously 
ill patients and gave rise to tensions. Sources of tension related to: 1. 
Imparting information about the patient: ICU physicians complained 
that internists did not provide the relevant information, thus making the 
decision more difficult. Internists complained that ICU physicians did 
not trust them and expected to be convinced of the appropriateness  
of intensive care. 2. Choosing comfort care: ICU physicians felt that 
internists did not take their responsibility and let them make a comfort 
care decision. 3. Misunderstanding about ICU physicians’ expected 
role: Internists reported they sometimes only wanted ICU physicians’ 
advice, whereas ICU physicians assumed the internists wanted the 
patient to be admitted to intensive care.
Conclusion: ICU admission decisions involving seriously ill patients 
can give rise to tensions between internists and ICU physicians. 
Further research should determine if physicians’ dissatisfaction leads 
to inappropriate admission decisions.
Funding: Swiss National Science Foundation, NRP 67 “End-of-life” 
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Medical residents working with vulnerable patients  
improve their psychosocial skills: a Swiss pilot study
Pau Mota, Francis Vu, Jeremie Blaser, Elodie Dory,  
Patrick Bodenmann 
Policlinique Médicale Universitaire, Lausanne, Switzerland
Background: Scientific literature has shown that patients at high risk 
of vulnerability are involved in more encounters perceived as difficult 
by physicians. Physicians involved in difficult encounters denoted 
worse psychosocial orientation practice and physicians who 
experience many of their patients as difficult are more likely to end in 
burnout. This study aims to take advantage of a specific setting, the 
Department of Ambulatory Care at the University of Lausanne, a 
university outpatient primary care clinic, in which medical residents 
frequently work with patients holding high levels of vulnerability. The 
main objective of this study was to assess the medical resident beliefs 
about psychosocial aspects of health care, both, before and after, 
working in a university setting dealing with patients at high 
socioeconomic risk.
Methods: This is a prospective pilot study with a 6 months follow-up. 
To assess medical resident beliefs about psychosocial aspects of 
health care we used the Physician’s Belief Scale (PBS). We compared 
the PBS score of medical residents both before and after having 
worked 6 months in the outpatient clinic. A second wave of medical 
new residents (n = 16) is currently under study (final results are 
expected in march-april 2017), with which we will be able to extend  
the sample size to a total of 27 to perform a similar analysis. 
Table 2: Causes of 6-month unplanned readmissions.
Diagnosis category TUG test duration 
≥15 seconds  
(n = 46)
TUG test duration 
<15 seconds  
(n = 61)
Cardiovascular disease, n (%) 10 (21.7) 12 (19.7)
Infection, n (%)  9 (19.6)  7 (11.5)
Oncological disease, n (%)  7 (15.2) 11 (18.0)
Respiratory disease, n (%)  6 (13.0)  7 (11.5)
Neuropsychiatric disease, n (%)  5 (10.9)  7 (11.5)
Gastro-intestinal disease, n (%)  3 (6.5)  6 (9.8)
Osteoarticular disease, n (%)  2 (4.4)  5 (8.2)
Endocrine or metabolic disease, 
n (%)
 2 (4.4)  3 (4.9)
Other, n(%)  3 (6.6)  5 (8.2)
Conclusions: In this prospective cohort study, functional impairment 
at discharge of an acute medical hospitalization was associated with 
higher risk of death, but not with unplanned readmission within 6 
months after discharge. Objective and simple performance-based 
assessment may represent a better prognostic measure for mortality 
than for readmission. 
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Pushing patients back to the general practitioner  
after hospital: as easy as a rendezvous?
Antoine Garnier, Olivier Lamy, David Gachoud, Gérard Waeber, 
Barbara Poloni 
Internal Medicine Department, University Hospital of Lausanne, 
Lausanne, Switzerland
Introduction: Transition from hospital to home is a frail period for 
discharged patients. Patients go back to their own general practitioner 
(GP) with various delays and sometime too long to prevent a 
potentially avoidable readmission. We aimed to assess the feasibility of 
systematic setting an appointment with the GP at discharge.
Methods: LEAR-HF study focused on the implementation of a 
transition plan for heart failure patients. Setting an appointment was 
part of the plan. We included all patients hospitalized with symptomatic 
heart failure and discharged to home. We excluded patients with 
hemodialysis or absence of written consent. As soon as the discharge 
day was known, a nurse visited the patient to set the appointment with 
the GP. If the appointment can’t be set before discharge, she reminded 
and encouraged the patient during follow-up calls at days 3, 7, and 18. 
Self-reported outcomes were rate and time to book an appointment, 
and time to the first consultation within 30 days after discharge.
Results: We included 147 patients over 13 months, mean age 78.1 
years old (SD 10.7). 30-days readmission rate was 21.4%. The nurse 
could set an appointment for 22% patients (33/147) and only 3% 
before discharge. If done, median time to book the appointment was 
5.0 days after discharge (SD 5.9). 87% of patients reported having 
seen their own GP within 30 days after discharge (129/147). Median 
time to first consultation was 6.0 days (SD 5.4). No association was 
found between outcomes and readmission rate (fig.).
Figure: Kaplan-meier curve for time until first visit to the general practitioner. 
HF-patient discharged to home. There was no difference between 
hospitalizations followed by a readmission (dashed line) or not (solid line, 
p-value 0.978). 
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The role of hepcidin in iron homeostasis in  
inflammation – an exploratory pilot subgroup analysis  
in medical inpatients
Carl Chrobak1, Marten Trendelenburg1, Laura Infanti 2,  
Thomas Zumbrunn3, Balthasar Luzius Hug4 
1Medizin, Universitätsspital Basel; 2Blood Transfusion Centre,  
Swiss Red Cross; 3Clinicial Trial Unit, Universitätsspital Basel,  
Basel; 4Medizin, Luzerner Kantonsspital, Luzern, Switzerland
Introduction: Iron metabolism depends on hepcidin in terms of 
absorption, transmembrane transport in the small intestine and 
recycling of iron in macrophages including iron release and 
sequestration. Especially inflammatory states and diseases including 
infections decrease iron availabilty. The primary aim was to analyze 
the correlation between hepcidin and iron-dependent laboratory 
markers (neutrophil granulocytes, procalcitonin, erythropoietin, IL-6, 
TNF-α, IL-3, hemoglobin, serum transferrin receptor, transferrin, 
transferrin saturation, ferritin, free iron, CRP, GFR, MCH, MCV). 
Methods: Study design: Prospective, cross-sectional, observational, 
exploratory pilot subgroup analysis. Primary endpoint: Correlation of 
hepcidin with neutrophil granulocytes, procalcitonin, erythropoietin, 
IL-6, TNF-α, IL-3, hemoglobin and serum transferrin receptor, 
transferrin, transferrin saturation, ferritin, free iron, CRP, GFR, MCH 
and MCV levels. Inclusion criteria: Age: ≥18, medical inpatient 
(hospitalization >24h), CRP >5 mg/l. Exclusion criteria: History of 
dialysis-dependent chronic kidney disease, use of erythropoiesis-
stimulating agents, pregnancy, history of allogeneic stem cell 
transplantation. Two venous punctures: 1. after admission 2. >=5 days 
of hospitalization. Pearson product-moment correlations for hepcidin 
and the mentioned laboratory parameters (see primary aim) were 
calculated. The cut-off level was set at >/= +/-30% correlation due to 
multiple testing. 
Results: Forty randomly selected medical in-patients with CRP  
>5 mg/l were analyzed. The mean age was 69.5 years (range 54–78), 
50 percent were male. The Pearson correlation showed a positive 
correlation of hepcidin levels with TNF-α and procalcitonin levels 
whereas hemoglobin and GFR (CDK-EPI) showed an inverse 
correlation with hepcidin levels. 
Conclusion: Procalcitonin and TNF-α showed a positive correlation 
with hepcidin levels, which could be well explained by inflammation 
and disease activity. GFR and hemoglobin were inversely correlated to 
hepcidin levels. Hepcidin is renally excreted, which could well explain 
higher hepcidin concentration in decreasing kidney function. 
Interestingly, several other well-known markers of inflammation 
including IL-6 showed a Pearson correlation below 30 percent. The 
correlation of hepcidin with inflammation and its mediators needs 
further study, especially taking into account that the first anti-hepcidin 
drugs are being tested in clinical trials. 
Pearson correlation coefficients for hepcidin and different laboratory 
parameters
  Hepcidin vs. laboratory 
parameter
Pearson correlation 
coefficient
Positive correlation Hepcidin vs. Procalcitonin 0.60
  Hepcidin vs. TNF-α 0.40
Negative correlation Hepcidin vs. GFR –0.82
  Hepcidin vs. Hemoglobin –0.51
  Pearson correlation with hepcidin below +- 0.3: neu-
trophil granulocytes, erythropoietin, IL-6, TNF-α, IL-3, 
serum transferrin receptor (sTfR), transferrin, trans-
ferrin saturation, ferritin, free iron, CRP, GFR, MCH, 
MCV levels.
  ± 1.0 equals full correlation, 0 equals no correlation
Results: All the new medical residents were included (n = 11). Mean 
age 32.4 years (± 3.3 sd). 7 women and 4 men. Mean of years of 
training 5.3 years (± 1.1 sd). After 6 months, we observed a decrease 
on the global PBS score mean from 79.5 to 76.4 (p = 0.47 using a 
Wilcoxon rank sum test). If we analyse by gender group, we observe a 
PBS score decrease for women (from 75.8 to 69.8) and an increase 
for men (from 85.75 to 87.7). Indeed, after six months we observed that 
the differences between genders tended to be significant, which was 
not the case at enrolment (p = 0.10 vs. p = 0.44).
Conclusions: We observe an improvement of the medical residents 
PBS score after 6 months working with patients in socio-economical 
adversity. Even though the observed differences are not statistical 
significant, probably due to the small sample size, we could conclude 
that working with patients in socioeconomical adversity improve the 
medical residents’ beliefs about psychosocial aspects of health care, 
and that there may be gender differences in this improvement. 
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Geriatric palliative care: defining and delineating  
the concept, challenges and strategies
Rachel Voumard1,2, Eve Rubli1,3, Lazare Benaroyo4, Ralf Jox1,2 
1Department of Medicine, Chair of Geriatric Palliative Care, Lausanne 
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Medicine, Service of Geriatric Medicine & Geriatric Rehabilitation, 
Lausanne University Hospital; 4Ethics Unit, Faculty of Biology and 
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Background: The increasing life expectancy and the associated 
changes in end-of-life morbidities forecast major challenges for public 
health. A coherent management strategy based on scientific evidence 
is widely lacking. The University Hospital Lausanne has therefore 
launched a unique Chair of Geriatric Palliative Care (GPC).
Objectives: To define the core concept of GPC and its ethical 
underpinnings, and to delineate its major challenges as well as 
strategies to tackle them.
Methods: We conducted a literature review and theoretical reflections, 
oriented by an ethics of care perspective, to conceptualize the field of 
GPC, identificate the challenges and propose strategies.
Results: GPC is a professional field at the intersection of two closely 
analogous specialties. Geriatric and palliative care are both highly 
multi-professional activities with distinctly patient- and family-centred 
activities aimed at improving quality of life, personal autonomy and 
social participation in the face of death. The synergies that result from 
joining these two specialties may serve as a role model for 
collaboration in the increasingly fragmented medicine of today. As the 
severely ill elderly constitute a highly vulnerable group, their wellbeing 
depends on a notion of care that is multidimensional, oriented toward 
relational autonomy and sustainable. The challenges that GPC faces 
include particularly the care and treatment decisions, both at the 
end-of-life and anticipating the end-of-life. Concrete tools such as 
advance care planning intervention have to be studied in 
methodologically impeccable trials across the different health care 
settings. A second challenge is the coordination of care, improved by 
the cybermedicine, in order to share any relevant information in 
emergency situation. A third approach has to be the sustainable 
enhancement of professional competencies, in particular with regard 
to communication and ethical skills. 
Conclusion: The goal of GPC is to develop and offer evidence-based 
strategies of management for the elderly population with severe and 
life-limiting conditions. For this aim, the promotion of advance care 
planning is a major investment to improve decision process. Moreover, 
the coordination of care management will ensure a better access to 
the patient’s central information by eliciting goals of care. Finally, it is 
central to develop practical wisdom to deliver care that is responsible 
to the patient and family needs. 
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compliance to ESC guidelines were positively associated while being 
discharged home or increasing age were negatively associated with 
polypharmacy. Almost two thirds (2’327, 63.5%) of patients had at least 
one potential DDI. The prevalence of potential DDIs increased from 
19.4% in patients taking less than 5 drugs to 83.7% in patients taking 
15+ drugs. Conversely, the prevalence of patients with at least one 
potential DDI remained stable throughout the study period (66.8% in 
2008 and 59.1% in 2015, p = 0.180) (table 2).
Conclusion: Almost all patients with HF are on polypharmacy.  
The prevalence of patients taking 15+ drugs is increasing, but no 
concomitant increase in DDIs was found. 
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Progress! Medication Reconciliation: a national  
programme to improve medication safety at transitions  
in care 
Andrea Niederhauser, Liat Fishman, Chantal Zimmermann 
Stiftung Patientensicherheit Schweiz, Zürich, Switzerland
Introduction: Poor communication and information loss put patients 
at risk for medication discrepancies at hospital admission and 
discharge. Studies have shown that in up to half of patients the 
medication history at admission contains errors, potentially leading  
to unintended omissions, duplications or incorrect dosages of 
medications in hospital and post-discharge. Medication Reconciliation 
(MedRec) is an effective strategy for reducing such risks and is already 
a routine practice in many countries. The goal of the programme 
progress! Medication Reconciliation is to promote this practice in  
acute care hospitals in Switzerland.
Methods: The programme consisted of two main elements: a 
campaign to raise awareness and a pilot project conducted in eight 
hospitals. The pilot focused on a best possible medication history 
(BPMH) at admission as the basis for a safe prescribing process.  
Each hospital designed and tested its own BPMH process taking into 
account the quality standards for a BPMH as defined by the 
programme. For example, some hospitals conducted the BPMH solely 
with medicine interns, while others involved pharmacy staff such as 
pharmacists and pharmacy assistants. The evaluation focused on the 
practical experiences with these processes.
Results: The evaluation demonstrated that the participating hospitals 
laid the groundwork for further improving their medication process. 
Several challenges to sustainable implementation were identified, 
many of them revolving around the time needed to access and 
compare medication sources for the BPMH and to conduct the other 
steps such as systematically interviewing the patient and documenting 
the medication list. Important conditions of successful implementation 
are institutional support, electronic tools which are integrated into the 
workflow, ensuring continuous training and supervision of frontline staff 
and clearly defining roles and responsibilities while promoting a culture 
of interprofessional collaboration.
Conclusion: Medication Reconciliation is regarded as an important 
patient safety measure, however, at this time there are still many 
obstacles to widespread sustainable implementation. To further 
promote MedRec in Switzerland, tools developed by progress! will be 
made available to all Swiss hospitals and a position paper will be 
published. Researchers in Switzerland are encouraged to further 
investigate effective models for implementing MedRec, such as 
selection criteria for targeting high-risk patients. 
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Evolution of medication in heart failure patients  
hospitalized in a Swiss university hospital
Davy Cabrio1,2, Pedro Marques-Vidal1, Gérard Waeber1 
1Department of Medicine, Internal Medicine, Lausanne University 
Hospital (CHUV); 2Université de Lausanne, Lausanne, Switzerland
Background: Patients with heart failure (HF) patients are frequently 
on polypharmacy (5+ drugs), and subsequently at risk of potentially 
deleterious drug-drug interactions (DDI). Our objective is to study the 
trends and determinants in the number and classes of medicines 
prescribed and in the prevalence of polypharmacy among patients 
hospitalized for HF.
Methods: Retrospective analysis of discharge data in the department 
of Internal Medicine of the Lausanne university hospital between 2008 
and 2015. DDIs were estimated according to the criteria of the Geneva 
university hospitals.
Results: Data from 3’666 hospitalizations (mean age 77.6 ± 12.4 
years, 47.1% women) were analyzed. Almost all patients (3’527, 
96.2%) were on polypharmacy at discharge, and 631 (17.2%) were 
discharged with 15+ drugs. The prevalence of polypharmacy remained 
stable at 96.5% in 2008 and 96.8% in 2015, but the prevalence of 
patients with 15+ drugs increased from 12.2% in 2008 to 21.2% in 
2015 (p = 0.05) (table 1).
Table 1: Polypharmacy.
The most frequently prescribed medications were diuretics (79.0%), 
angiotensin-related drugs (angiotensin II receptor blockers or 
angiotensin-converting-enzyme inhibitors, 62.8%) and ß-blockers 
(58.7%). Increased comorbidities, HF as a comorbidity and 
Table 2: DDI.
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Differences in the course of Italian- and German-speaking 
patients’ outcome after interdisciplinary pain program
Thomas Benz1,2, Felix Angst1, Roberto Brioschi1,  
Susanne Lehmann1, Achim Elfering2, André Aeschlimann1 
1Research Department, RehaClinic, Bad Zurzach; 2Institute of 
Psychology, University of Bern, Bern, Switzerland
Background: Management of chronic pain patients is a challenge in 
primary care. Available evidence shows that perception, coping, and 
treatment of pain varies among different populations and cultural 
regions. In particular, it is unknown how much immigrants in Western 
European countries profit from pain management programs. The aim 
of this study was to quantify state and changes of health state and 
quality of life of immigrant native Italian-speaking patients with 
fibromyalgia or chronic back pain before and after a 4-week, 
interdisciplinary inpatient pain program and to compare the results with 
German-speaking patients. 
Methods: The prospective cohort study with 62 Italian-speaking and 
63 German-speaking patients measured health-related quality of life, 
pain, fear and depression comparing at baseline, after 4 weeks of pain 
program and at 1 year follow-up. Differences between the two groups 
were tested on significance by generalized estimation equations 
(GEE). This method modeled changes of health by multivariate logistic 
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“The Mission Possible Project”: successful reduction  
of overtime in residents through implementation  
of doctor’s assistants and structural changes
Philipp Baumgartner, Simon Frey, Michael Egloff, Jana Efe,  
Jolanda Contartese, Jürg-Hans Beer 
Departement Innere Medizin, Kantonsspital Baden, Baden, 
Switzerland
Introduction: Despite the limitation of resident working hours  
by federal law to 50 hours per week, many hospitals experience 
difficulties to establish these limitations. In a survey by the Swiss 
association of residents and seniors (VSAO), mean weekly working 
hours were 56 hour/week, resulting in an average of 135 extra hours 
per year and resident nationwide. Between 2011 and 2016, the 
Department of Internal Medicine of the KSB implemented a number  
of measures to reduce the work load and the extra hours of residents 
in training. We hypothesized that these measures would result in a 
reduction and eventually complete avoidance of overtime.
Methods: 5 time points over the 5 years of the implementation of 
measures were defined. 2011: baseline, 2013: +0.5 doctor’s assistant/
ward/26pts, 2015: +0.5 resident/ward, 2016: +1 resident as evening 
shift (“clean up doc” at the end of the shift). For each year, daily 
overtime in the same two months (February, March) was collected,  
in 2016 two additional months (September, October) with more 
experienced residents were analysed. Residents worked during the 
time period on regular wards, weekends and absences were not 
included. For subgroup analysis, residents were grouped according to 
in-house experience (0–5, 6–11 and >12 months experience at KSB). 
Results: The average overtime per day was 2.08 ± 0.17h in 2011, 2.25 
± 0.22h in 2013, 1.33 ± 0.19h in 2015, 1.28 ± 0.14h in 2016 and 0.46 ± 
0.70h in mid-2016 (fig. 1, p <0.05). Subgroup analysis revealed the 
largest reduction of overtime provided by the doctors assistant 
(2011–13) in the intermediate experienced group. The positive effect of 
the additional ward resident was found in all groups, the largest effect 
was in the inexperienced groups, while the evening shift (2015–16) 
was most profitable for experienced residents (fig. 2). By mid-2016, the 
average overtime for all residents was further reduced, with most 
being able to almost completely suppress their overtime.
Conclusions: a) 3 specific measures reduced the overtime of 
residents to 0–1h. b) Additional residents on the ward are helpful for 
inexperienced residents. c) At higher training levels, doctor’s assistants 
and evening shift residents are more effective to reduce extra hours, 
underlining the acquired capacity of experienced residents to delegate 
tasks, an essential feature of efficient practice. d) After deduction of the 
costs of extra hours, the additional moderate net costs consisted of  
2 doctors’ assistants.
regression adjusting for sex, education, number of comorbidities and 
the baseline score over both follow-ups for each scale. 
Results: Italian-speaking patients (n = 62) showed higher proportions 
of males, lower educated and less burdened by comorbidities than 
German-speaking patients (n = 63). At baseline, physical and 
psychosocial health, depression and fear of the Italian-speaking 
patients were worse than German-speaking patients, with the 
exception of less pain in the Italian-speaking patients on the SF-36. 
Changes of health showed more improvement in German- than in 
Italian-speaking patients on all scales and at both follow-ups. In GEE, 
the highest differences were observed in SF-36 physical functioning (p 
= 0.036), HADS anxiety (p = 0.031) and HADS depression (p = 0.017). 
On SF-36 bodily pain the difference was not significant (p = 0.142). 
Conclusions: This study detected that short- and midterm outcome of 
Italian-speaking patients was worse than that of German-speaking 
patients, even after adjustment for baseline differences. The reasons 
for that are unclear and may have consequences for future 
management of Italian-speaking patients in interdisciplinary pain 
management programs. This supports the hypothesis that patients 
with migration background may have special needs in therapeutic 
management. A cultural sensitive approach in multidisciplinary and 
subsequent ambulatory management might enhance the positive 
outcome in the short- and mid-term. 
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Life and death: a comparison of ICU physicians’  
and internists’ survival predictions for patients  
assessed for intensive care
Monica Escher1, Bara Ricou1, Mathieu Nendaz1,2, Fabienne Scherer1, 
Stéphane Cullati1, Patricia Hudelson1, Thomas Perneger1 
1Hôpitaux Universitaires de Genève; 2Unité de Développement et de 
Recherche en Éducation Médicale, Faculté de Médecine, Geneva, 
Switzerland
Background: Expected improvement in survival is the main 
justification for admission to the intensive care unit (ICU). To make a 
decision, physicians must estimate the patient’s prognosis whether he 
is cared for on the ward or in the ICU. Contradictory estimations may 
explain the occurrence of disagreements between the referring 
physicians and the ICU physicians about the appropriateness of ICU 
admission. Physicians’ ability to accurately predict survival of a patient 
assessed for intensive care is not known.
Aims: Assess referring internists’ and ICU physicians’ accuracy in 
predicting patient survival on the ward and in the ICU, and determine 
whether the survival estimates correlate with the admission decision 
and with observed survival.
Methods: All consecutive requests for ICU admission made for 
patients hospitalized in the Division of General Internal Medicine of  
the Geneva University Hospitals were identified. The ward and the ICU 
physicians involved were contacted within 12 hours and asked to 
estimate patient survival using predefined categories of probabilities. 
The admission decision and the patient characteristics were collected. 
We used regression models for the analysis.
Results: 201 patients were included, of whom 140 (69.7%) were 
admitted into the ICU. Overall 58 patients (28.9%) died within 28 days. 
Physicians predicted a survival benefit from intensive care for most 
patients. Agreement between internists and ICU physicians was good 
(Spearman rho 0.5). Higher survival ratings by both groups of 
physicians were associated with higher proportions of admitted 
patients, but the admission decision was more strongly influenced by 
the ICU physicians’ estimates. Observed patient survival was strongly 
associated with predicted survival by both physicians. The internists’ 
prediction however was more accurate than the ICU physicians’, 
whether the patient stayed on the ward (areas under the ROC curves 
0.74 vs 0.69) or was admitted into the ICU (area under the ROC curve 
0.76 vs 0.63).
Conclusion: Internists more accurately predict survival for patients 
assessed for admission to intensive care than ICU physicians. 
However, ICU physicians’ estimates more strongly influence the 
admission decision.
Funding: Swiss National Science Foundation, NRP 67 “End-of-life” 
Figure 1: Mean daily overtime in 
hours per resident.
Figure 2: Overtime according to in-house experience.
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Results: Polypharmacy decreased from 45% in 2009 to 41% in 2015, 
while excessive polypharmacy increased from 40% to 46%. In 2015, 
13% of patients received 15+ drugs. age, coming from other health 
care settings, higher Charlson Index, number of comorbidities and 
quartiles of LOS to be significantly and independently associated with 
polypharmacy and excessive polypharmacy. The risk of having at least 
one DDI decreased from 66.9% (95% CI: 64.8–68.9) in 2009 to 59.3% 
(57.6-62.0) in 2015 (p <0.001). Multivariate analysis showed number of 
drugs [Odds ratio and 95% confidence interval: 3.69 (3.32–4.11); 9.39 
(8.34–10.6) and 20.3 (17.1–24.0) for [5–9], [10–14] and 15+ drugs, 
respectively], gastrointestinal disease [3.16 (2.76–3.61)] and cancer 
[1.38 (1.19–1.59)] to be positively associated, and lung [0.82 (0.74–
0.90] and endocrinological [0.63 (0.53–0.74)] diseases to be negatively 
associated with risk of DDI.
Conclusion: Excessive polypharmacy is increasing among hospital 
patients, and is associated with an increased risk of DDI. The 
decrease in the overall risk of DDI could be due to an improved 
management of multidrug therapy.
Keywords: polypharmacy; excessive polypharmacy; drug-drug 
interactions; epidemiology; hospital 
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An almost fatal “Müsli” resulting in a superwarfarin  
intoxication
Thierry M. Nordmann1, Mark G. Filipovic1, Bahador Javaheri1,  
Jolanda Contartese1, Hans Ruedi Schmid1, Daniel Müller2,  
Jürg Hans Beer1 
1Kantonsspital Baden, Baden; 2Universität Zürich, Zürich, Switzerland
Background: Vitamin K antagonists are essential in the management 
of coagulation disorders through inhibition of vitamin K 2,3-epoxide 
reductase (VKOR). Superwarfarins are long-acting, high affinity VKOR 
inhibitors and used as rodenticides. 
Case report: A 50-year-old woman with a schizoaffective disorder 
presented with severe acute neck and abdominal pain. Clinical 
examination showed multiple subcutaneous hematomas at the site of 
insulin injection. Laboratory analyses revealed pathologic coagulation 
assays (INR >6) and severe anemia (Hgb: 5.8 g/dl). With a slightly 
elevated fibrinogen and normal factor V activity, acute liver failure was 
ruled out. A CT scan of the abdomen was performed detecting a 
hemorrhagic ovarian cyst without active bleeding sites. After the 
transfusion of one erythrocyte concentrate, the hemoglobin level 
increased adequately and remained stable. While the administration  
of 1000 IU 4-factor prothrombin concentrate and 30 mg Vit. K stabilized 
initial coagulopathy, a minimum of 30 mg Vit. K daily for another 50 
days was required in order to keep the INR below 1.5 (fig. 1). Although 
repetitively denied by the patient, an intake of long acting warfarin was 
suspected. However, urine toxicological screening using a fast 
immunochromatographic assay and a wide range LC-MS screen for 
xenobiotics did not reveal any agent explaining the patient’s symptoms. 
Furthermore, a subsequent serum LC-MS screen for anticoagulant 
agents was negative. Plasma mixing studies restored abnormal 
prothrombin time ruling out an acquired inhibitor problem. As clinical 
suspicion persisted, the patient’s serum was specifically tested for the 
presence of superwarfarins. A specific LC-MS method identified the 
presence of difenacoum. After being confronted, the patient admitted 
rodenticide ingestion with suicidal intent. A bag with this substance 
ambigously labeled with “Müsli” (intended for mice – and not 
“Birchermüsli”) was meanwhile found in the basement. 
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Practical experience of physicians after a structured 
communication training for the postmortem autopsy 
conversation with relatives: results of a representative survey
Iljas Rosenberg1, Renata Flury2, Burkhard Gierer3, Peter Ballmer1 
1Kantonsspital Winterthur, Departement of Medicine; 2Kantonsspital 
Winterthur, Institut für Pathologie; 3IPW – Psychiatrische Poliklinik, 
Winterthur, Switzerland
Background: Autopsy rate has been declining for decades, in 
Switzerland as well as all over the world. This negative trend might 
create important problems because autopsies ensure valide causes of 
deaths. Moreover medical training of physicians and quality of patients’ 
care rely in part on the possibility to perform autopsies. An important 
obstacle for getting permission to autopsy seems to be the poor 
communication skills of physicians.
Methods: After performing a communication training with physicians in 
the Department of Medicine (DM), the new communication strategy 
was applied for the postmortem autopsy conversation with relatives. 
Moreover, we developed a structured questionnaire to find out the 
practical experience of the participating doctors in regard to their 
conversation skills.
Results: In the period from November 2014 to October 2015 489 
patients died in the DM. 353 questionaires could be evaluated. In 76% 
of all evaluated conversations, the new guide of the communication 
training was applied. In 86% of the cases, the conversation was felt as 
open and relaxed with the relatives. Seven % felt the conversation as 
oppressive and unpleasant and 7% did not answer the question. In 
89% of all evaluated questionnaire the doctors could understand the 
decision of the relatives for performing an autopsy or not.
Conclusion: In summary, the majority of the physicians have 
accepted and used the new guide for optimized conversation skills.  
In most cases, the conversation was perceived as comfortable. We 
suggest, that the medical staff should receive regular training in 
communication skills for a confident and better conversation with 
patients and their relatives. 
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Trends and determinants of polypharmacy and potential 
drug-drug interactions at discharge from hospital,  
2009–2015
Nazanin Abolhassani, Julien Castioni, Pedro-Manuel Marques-Vidal 
Lausanne University Hospital (CHUV), Lausanne, Switzerland
Introduction: Polypharmacy is increasingly common and associated 
with risk of drug-drug interactions (DDIs). We aimed to measure the 
trends and determinants of polypharmacy and DDIs among patients 
discharged from the department of Internal Medicine of the Lausanne 
university hospital.
Methods: Retrospective study including 18’075 adult patients 
discharged between 2009 and 2012. Polypharmacy and excessive 
polypharmacy were defined as [5–9] and 10+ drugs, respectively.  
DDIs were defined according to the criteria of the Geneva University 
Hospital.
Figure 1: Polypharmacy. Figure 1
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performed multivariate regression analysis and Monte-Carlo 
simulations. Normcosts (total costs per case normalized per case 
weight) were used as a proxy for hospital profitability.
Results: Mean normcosts for specialized care cases were 10,773.6 
CHF (SD 10,594.6 CHF) and 10,264.6 CHF (SD 8,052.3 CHF) for 
non-specialized care patients. The independent variable “Specialzed 
care” was a significant predictor of higher normcosts in multivariate 
regression analysis (p <0.01). Monte-Carlo simulations of excluding 
specialized care led to a substantial improvement in hospital 
profitability, with a modeled decrease in normcosts (i.e. increase in 
profitability) by 260 CHF per case. Within specialized care, large 
differences in profitability due to systematic imbalances in DRG-related 
reimbursement could be found, with models implying an increase in 
pneumology care from 1% to 2% of total cases increasing normcosts 
by 190 CHF per case and increases in oncology from 1% to 3% of 
cases decreasing normcosts by 73 CHF per case, as assessed with 
Monte-Carlo simulations.
Conclusions: Specialized care can increase hospital’s financial risk. 
Arbitrage due to imbalances in the DRG system may lead to 
oversupply of some medical services and unmet medical needs on the 
other. DRG systems need to be designed as to incentivize the delivery 
of a mix of care which meets patients needs; supply should follow 
demand. Further, efficiency and quality of care should determine 
hospital profitability, not portfolio engineering. 
P364
Current practice of testing for factor V Leiden  
and Prothrombin G20210A mutation in Lausanne University 
Hospital
Marie Méan, Gérard Waeber, Pedro Marques-Vidal 
Lausanne University Hospital, Division of General Internal Medicine, 
Lausanne, Switzerland
Introduction: The predictive value of factor V Leiden and the 
G20210A prothrombin mutation regarding recurrent venous 
thromboembolism (VTE) is limited and does not influence subsequent 
patient management. Hence, systematic testing for such genetic 
thrombophilia should be avoided, but to which extent such testing is 
practiced in Switzerland is currently unknown. We therefore aimed to 
examine the current practice of factor V Leiden and/or G20210A 
prothrombin mutation testing in a University Hospital. 
Method: We included 2106 adults patients with an acute or prior VTE 
hospitalized in Lausanne university hospital between January 2013 
and December 2015. We assessed the frequency of FV Leiden and/or 
prothrombin G20210A mutation testing, the determinants of FV Leiden 
and/or prothrombin G20210A mutation testing, and the association 
between testing and outcomes.
Results: Overall, FV Leiden and/or prothrombin G20210A mutation 
testing was performed in 67 (3.2%) patients with VTE. On average, 
during the study period, factor V Leiden and/or G20210A prothrombin 
mutation were tested in 22.3 patients with VTE per year. Younger 
patients with a private insurance had a higher likelihood of having 
such testing.
Table 1: Factors associated with thrombophilia testing.
Testing for FV 
Leiden and/
or prothrom-
bin G20210A 
mutation
No  
(N = 2039)
Yes  
(N = 67)
P-value OR (95%CI) P-value
Age, years 68.7 ± 17.2 55.1 ± 16.3 <0.001 NA NA
Age ≥65 years 
(%)
1322 (64.8) 19 (28.4) <0.001 0.19  
(0.11–0.33)
<0.001
Female gender 
(%)
1026 (50.3) 36 (53.7) 0.583 1.26  
(0.77–2.07)
0.362
Swiss national 
(%)
1589 (77.9) 53 (79.1) 0.820 1.50  
(0.81–2.77)
0.201
Coming from 
home (%)
1750 (85.8) 50 (74.6) 0.010 0.48  
(0.27–0.85)
0.011
Private Insu-
rance (%)
197 (9.7) 10 (14.9) 0.154 2.00  
(0.99–4.07)
0.054
NA: not assessable
Patients coming from home were less likely of having FV Leiden and/
or prothrombin G20210A mutation testing. Patients with FV Leiden 
and/or prothrombin G20210A mutation testing had similar length of 
stay compared to VTE without such testing (median: 7.7 versus 9.9 
days, p = 0.319); no statistically significant difference was found 
regarding in-hospital mortality.
Conclusions: 1) This case illustrates the long-acting and high affinity 
anticoagulant effect of superwarfarins, widely available as rodenticides 
occasionally consumed with suicidal intent. 2) Due to the long-acting 
effect of superwarfarin (difenacoum T1/2: 128d), long term and high 
dose vitamin K treatment is essential along with continuous 
prothrombin-time monitoring (fig. 1). 3) Our report emphasizes the 
importance of staying persistent when high clinical suspicion is 
present despite so-called negative test results.
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The minimal clinically important difference (MCID)  
raises the significance of outcome effects above  
the statistical level
Felix Angst1, Jules Angst2, André Aeschlimann3 
1Forschung, RehaClinic, Bad Zurzach; 2Forschung, Psychiatrische 
Uniklinik Burghölzli, Zürich; 3Medizin, RehaClinic, Bad Zurzach, 
Switzerland
Background: In measurement of outcome effects, the patient’s 
subjective perception to feel a change in health defines clinical 
effectiveness irrespective of statistical significance. The aim was to 
illustrate and discuss current and proposed new concepts of effect 
quantification and significance.
Methods: Different methods for determining minimal clinically 
important differences (MCIDs) are reviewed and further developed 
focusing on their characteristics and (dis)advantages.
Results: In controlled studies, empirical score differences between 
verum and placebo become statistically significant if sample sizes are 
sufficiently large. For example, a score difference of 5 points (scale 
0–100) between the verum and the placebo effect becomes 
statistically significant, if the sample sizes are n ≥33 for each of both 
groups at a standard deviation = 10 of the score differences (baseline 
to follow-up). MCIDs by contrast, are defined by patients’ perceptions, 
which led to “anchoring” of effects by the “transition” item, where 
patients rate their change of health between baseline and follow-up in 
an evaluation study. The MCID for improvement by the “mean change 
method” is the difference of the mean change experienced by the 
“slightly better” group minus that of the “almost equal” group. The 
MCID can be expressed as absolute or relative score, as effects size 
(ES), standardized response mean (SRM) and standardized mean 
difference (SMD) (bivariate). It can further be adjusted by multivariate 
regression modeling. In our example of knee osteoarthritis, the MCID 
for pain relief was 8.74 score points, 17.15% of the baseline score, ES 
= 0.407, SRM = 0.413, SMD = 0.469. This is consistent to the range of 
0.30–0.50 for MCIDs reviewed in literature. After adjusting for potential 
confounders, the MCID was 7.09 score points or an increase of 2.9% 
per score point to feel better (logistic regression).
Conclusion: Absolute and relative MCIDs are easy to interpret and 
apply to data of investigative studies. MCIDs expressed as ES/SRM/
SMD reduce bias, which mainly results from dependency on the 
baseline score. Multivariate linear and logistic regression modeling 
further reduces bias by adjustment for possible confounders and 
increase validity. Anchor-based methods use clinical/subjective 
perception to define MCIDs and should be clearly differentiated from 
distribution-based methods that provide statistical effect significance 
only.
Angst F et al. J Clin Epidemiol. 2016; epub 13.12.16. 
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Specialized care can increase hospital’s financial  
risk under DRG-based reimbursement
Tarun Mehra1, Tobias Wekhof2, Dominik Rothenhäusler2,  
Jürg Hodler3, Milo Alan Puhan4, Mehra & Wekhof 
1Klinik und Poliklinik für Innere Medizin, Universitätsspital Zürich;  
2ETH Zürich; 3Ärztliche Direktion, Universitätsspital Zürich; 
4Epidemiology, Biostatistiscs and Prevention Institute,  
Universität Zürich, Zürich, Switzerland
Introduction: Specialized care is rewarded with higher reimbursement 
premiums under DRG based reimbursement. Hospitals, under 
increasing financial pressure, may strive to increase hospital revenues 
by increasing the proportion of specialized care. However, due to a 
higher level of medical risk and more heterogeneous patient 
characteristics, specialized care might also carry a higher financial  
risk and eventually decrease profitability. 
Methods: We obtained the Fallkostenstatistik from the Swiss National 
Statistics Office from 2013. We grouped the cases with the software 
used for hospital planning provided by Canton of Zurich, version 
2013.1. After cleaning the data, 798,975 cases remained. We 
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Objective: As preventive activities are an effective way to reduce the 
burden of chronic diseases, our aim was to document preventive  
care practices of primary care physicians [f1] in Continental Europe 
(Switzerland [cantons of Geneva and Vaud] and France [Alsace, Pays 
de la Loire]).
Methods: This was a cross-sectional questionnaire survey conducted 
in 2015 in a randomly selected sample of 3400 community-based 
PCPs (1000 in Switzerland, 2400 in France). The doctors were asked 
how often they ped the following twelve preventive procedures:  
blood pressure, weight and height measurements, screening for 
dyslipidemia, alcohol screening and brief intervention, screening for 
smoking (and brief intervention), colon and prostate cancer screening, 
and influenza immunization). Response options on the five point Likert 
scale were never, rarely, sometimes, often, always. The PCPs were 
considered to be performing the preventive measure regularly if they 
declared performing it often or always.
Results: 764 participants returned the questionnaire. The proportion 
of PCPs who reported that they performed the preventive procedures 
regularly varied upon the procedure: blood pressure measurement 
(98%), height measurement (52%), screening for smoking and brief 
intervention (93%), annual influenza immunization for at-risk patients 
<65 years (38%), It was also dependent on the country, with 1) higher 
frequencies in Switzerland (vs France) for the following practices: 
height measurement, alcohol screening and refraining from screening 
for prostate cancer, and 2) lower frequencies for the following 
practices: smoking cessation advice or influenza immunization for 
at-risk patients <65 years. 
Conclusions: Whereas some preventive measures now appear to be 
part of primary care routine, others are not applied by the majority of 
physicians. Further studies should explore whether these findings are 
related to miss-knowledge of common guidelines, or other 
implementation barriers in primary care. 
Table 2: Outcome associated with thrombophilia testing.
Testing for FV Leiden and/
or prothrombin G20210A 
mutation
No (N = 2039) Yes (N = 67) P-value
In hospital mortality (5) 142 (7.0) 1 (1.5) 0.085
Length of stay§ 9.9 (3.3–19.9) 7.7 (4.1–14.4) 0.319
§ Median and [interquartile range], between group comparison using Kruskal-
Wallis test
Conclusion: FV Leiden and/or prothrombin G20210A mutation testing 
in hospitalized patients with a prior VTE was unfrequently performed. 
Hence, 22 FV Leiden and/or prothrombin G20210A mutation testing 
were performed per year, which represents roughly 1% of the patients 
with VTE admitted in Lausanne University hospital each year. In the 
majority of cases, the practice of thrombophilia testing for patients with 
VTE in Lausanne University hospital complies with guidelines. 
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Adherence to recommendations for preventive care  
in primary care: a cross-sectional study in Switzerland  
and France
Paul Sebo1, Hubert Maisonneuve1, Bernard Cerutti 2, Jean Pascal 
Fournier3, Cedric Rat3, Nicolas Senn4, Dagmar M. Haller1 
1Unité des Internistes Généralistes et Pédiatres / Université de 
Genève; 2Unité de Développement et de Recherche en Éducation 
Médicale, Faculté de Médecine, Genève, Switzerland; 3Département 
de Médecine Générale, Faculté de Médecine, Université de Nantes, 
Nantes, France; 4Institut Universitaire de Médecine de Famille, 
Lausanne, Switzerland
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Polyglobulie bei Anabolikamissbrauch
Michael Kuhn1, Sylvette Baldesberger2, Stefan Bilz3, Michael Brändle2 
1Allgemeine Innere Medizin/Hausarztmedizin, Kantonsspital St. 
Gallen; 2Allgemeine Innere Medizin/Hausarztmedizin, Kantonsspital 
St.Gallen; 3Endokrinologie und Diabetologie, Kantonsspital St. Gallen, 
St. Gallen, Switzerland
Einleitung: Unterschiedliche Anabolen Androgene Steroide (AAS) 
werden nicht nur im professionellen Bodybuilding sondern zunehmend 
bei ambitionierten Hobbybodybuildern oft in Kombination 
eingenommen.
Fallbeispiel: Wir präsentieren einen Fall von einem 55jährigem Mann, 
der wegen drei Wochen bestehender Kopfschmerzen, vermindertem 
Antrieb sowie wiederholten Schwächeanfällen ohne Bewusstseins- 
störungen durch den Hausarzt zugewiesen wurde. Laborchemisch 
zeigte sich ein Hb von 210 g/l, Hk 0,59 sowie Kreatinin von 132 µmol/. 
Im Somatostatus war das überproportioniert muskulöse 
Erscheinungsbild bei einem BMI 33,3 kg/m2 auffallend. Anamnestisch 
war zu erfahren, dass der Patient wiederholt die letzten Jahre 
verschiedene Anabolika zur Leistungssteigerung einsetzt hatte.  
Unter dreimaligem Aderlass mit je 450 ml war das Hb mit 192 mg/l 
rückläufig. Da der Patient hierunter bereist beschwerdefrei war, 
drängte er auf raschen Austritt. 
Schlussfolgerungen: Polyglobulie ist eine dominante Nebenwirkung 
bei supraphysiologischen Testosteronbehandlungen und im 
Besonderen bei Missbrauch von Anabolika. Sie wird trotz anderer 
offensichtlicher Hinweise oft nicht entdeckt. In randomisierten Studien 
zur Testosteronersatztherapie bei Hypogonadismus konnte gezeigt 
werden, dass das Risiko der Polyglobulie mit steigender Dosierung 
signifikant zunimmt und dies mehrheitlich bei Männern ab dem  
60. Lebensjahr. Dabei tritt initial eine signifikante, dosisspezifische 
Suppression von Hepcidin, einem Peptid in der Regulation der 
Eisenhomöostase, auf. Dies gilt aktuell als ein gesicherter 
pathophysiologischer Mechanismus beim Anstieg des Hämatokrits. 
Ein Problem stellt die Beratung und Behandlung der Betroffenen dar, 
da der Anabolikamissbrauch illegal sowie die Thematik tabuisiert und 
schambesetzt ist. Mit einer modifizierten Form des Motivational 
Interviewing (MI) besteht eine Möglichkeit den Missbrauch so zu 
thematisieren, dass die Gefahr eines Gesprächabbruchs durch den 
Patienten minimiert werden kann. 
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Baseline characteristics of individuals using a new  
online-tool assessing cardiovascular risk factors  
(www.swissheartcoach.ch)
Anja Thomer1, Stéphanie Giezendanner1, Wolfgang Bachmann2, 
Christa Bächtold3, Andreas Zeller1 
1Centre for Primary Health Care; University of Basel, Liestal, 
Switzerland; 2VR Consult, Niederberg, Germany; 3Swissheart 
Foundation, Berne, Switzerland
Background: Controlling the epidemic of CVD requires a multifaceted 
strategy targeting modifiable cardiovascular risk factors. In 2012 the 
Swissheart Foundation – in cooperation with experts in the field – 
started to develop an online programme called www.swissheart-
coach.ch. The project addresses the general population (primary 
prevention) as well as individuals with established CVD (secondary 
prevention). Computer-based education may be used as an effective 
strategy for transferring knowledge and skill development to patients. 
We undertook a survey to characterize the baseline data (e.g. 
cardiovascular risk profile) of the registered users during the first six 
month since launching, potentially indicating the attractiveness and 
use of tool.
Methods and results: The project was launched by advertisement in 
lay press in March 2016 and since then users’ data have been 
systematically collected. From March to September 2016, a total of 
1217 people registered their data on www.swissheartcoach.ch. 
Twenty-eight subjects (0.02%) were excluded from the analysis since 
only data of gender, age and BMI were available. The analysed 
sample’s (n = 1189) mean age is 58.6 years (SD = 12.3) and 46.2% 
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Suspected complications require quick diagnostic steps including 
computed tomography and rapid therapy to avoid life threatening 
conditions after this standard diagnostic procedure to minimize 
morbidity and mortality. 
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An unusual cause of severe recurrent gastroenteritis  
– a case report
Sara Stadelmann1, Isabelle Pache2, Tarek Laswad3, Marc Uhlmann4 
1Urgences; 2Gastroentérologie et Hépatologie; 3Service d’Imagerie 
Médicale, 4Médecine Interne, Hôpital Riviera Chablais, site de 
Monthey, Monthey, Switzerland
Introduction: An 82 years-old man known for ulcerative colitis and 
hypertension was hospitalized for the 5th time in 1 month with the 
same clinical characteristics: acute nausea, vomiting, diarrhea, low 
blood pressure, acute renal failure and leukocytosis. Following each 
episode he recovered quickly, but the day after returning home the 
symptoms reappeared, requiring another hospitalization. Various 
pathologies were considered instigating numerous investigations.  
At this 5th admission, a close look at the patient’s record showed  
that his antihypertensive drug (olmesartan) had systematically been 
suspended at admission. At discharge, as blood pressure raised and 
renal function recovered, he was told to take his usual medication 
again. We did a challenge test with 40 mg olmesartan. After 1h, he 
suffered of nausea, vomiting and diarrhea. The symptoms disappeared 
within 4 hours. C4 complement and C1 esterase inhibitor function were 
normal as well as serum tryptase. We retained the diagnosis of 
visceral angioedema induced by olmesartan.
Method: We searched PubMed, UpToDate and Google Scholar with 
the keywords “angiotensin II receptor blocker” (ARB), “angioedema“, 
“visceral” and “intestinal”. As we retrieved very little literature, we 
extended our search with the key words “angiotensin converting 
enzyme inhibitor“ (ACEI). 
Results: We found sparse literature about ARB-induced intestinal 
angioedema, only case reports. ARBs and ACEIs are responsible for 
similar side effects, sometimes with cross-reactions. ACEI-induced 
visceral angioedema is better described (estimated frequency 
0.1–0.2%). The diagnostic criteria are: timing with medication intake, 
abdominal pain/emesis/diarrhea, normal C1 esterase inhibitor and C4 
levels, CT-scan showing segmental intestinal edema, and absence of 
alternative diagnosis. The pathophysiology is explained by bradykinin 
increase due to ACE inhibition with ACEIs and other less understood 
mechanisms with ARBs. Genetic predisposition, hormonal influence  
or inflammatory pathways may also be involved.
Conclusion: This case report of ARB-induced intestinal angioedema 
reminds us of this rare but potentially life-threatening side effect. 
Delayed diagnosis can lead to unnecessary investigations and 
mistaken treatments. More generally, it reminds us that unexplained 
symptoms may be due to medications. Careful anamnesis, sometimes 
with detailed retrospective medical record study, can be more helpful 
than repetitive blood sampling and extensive imagery. 
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Pulmonary foreign body granulomatosis is an  
important differential diagnosis in patients with intravenous 
drug abuse and suspect radiological examination
Mario Münger1, Regulo Rodriguez2, Tino Schneider3 
1Allgemeine Innere Medizin; 2Pathologie; 3Pneumologie,  
Kantonsspital St.Gallen, St.Gallen, Switzerland
Introduction: Pharmaceutical tablets contain filler agents such as talc, 
microcrystalline cellulose or crospovidone. By intravenous injection of 
such pulverized tablets these filler agents accumulate in the 
pulmonary capillary bed and may cause foreign body granulomas. 
Granulomas can develop in the pulmonary arteries or in the 
interstitium of the lung. After repeated intravenous exposure this 
inflammatory process may lead to interstitial pulmonary fibrosis and 
emphysema.
Case report: A 32-year-old man with a long history of intravenous 
drug abuse (IVDA) was transferred by ambulance to our hospital in an 
overall bad condition, with fever (39 °C), chills and dyspnea. Clinical 
examination revealed crackles in the lower lung fields. Blood tests 
showed increased inflammatory values. The chest X-ray raised strong 
suspicion of miliary tuberculosis. Initially an empiric antibiotic therapy 
with ceftriaxone and clarithromycin was started to treat pneumonia.  
A computed tomography (CT) of the chest showed a micronodular 
pattern. For further diagnostics a flexible bronchoscopy was performed 
for a bronchoalveolar lavage. With the additional hypothesis of a 
foreign body granulomatosis a transbronchial biopsy was taken. This 
were women. Overall, 7.2% reported to be smokers and only 4% to 
suffer from diabetes type 2. From those who know their blood pressure 
(BP) (83.7%), only 6 % have a BP ≥140/90 mm Hg.
Conclusion: Data analysis is ongoing and will be available in more 
details in May 2017. First results suggest that the registered users’ 
cohort is a rather healthy population. Therefore, the potential of 
lifestyle changes in this population might have only a small effect on 
their cardiovascular risk profile as it already seems to be low. Still we 
believe that the implementation of an internet-based educational 
system for lay persons and health care professionals is an innovative 
strategy in Switzerland to foster motivation and know-how regarding 
cardiovascular risk factors and lifestyle changes. 
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Daily business or not – two cases of rare complications 
following bone marrow biopsy
Nicola Frei1, Tobias Silzle2, Christian Bucher3, Markus Diethelm1 
1Allgemeine Innere Medizin / Hausarztmedizin; 2Klinik für Onkologie/
Hämatologie; 3Klinik für Nephrologie und Transplantationsmedizin, 
Kantonsspital St. Gallen, St. Gallen, Switzerland
Introduction: Bone marrow biopsy is a common procedure to 
diagnose several hematological disorders. Although an invasive 
procedure, it is a save intervention with a complication rate of 0.05%. 
Known complications are bleeding, local infection and nerve damage. 
Risk factors for adverse events include myeloproliferative disorder, 
treatment with aspirin (and other putative platelet dysfunction), 
warfarin, obesity or disseminated intravascular coagulation. We 
present 2 cases of serious complications following a bone marrow 
biopsy.
Case report: A 77-year old man was referred for further evaluation of 
a thrombocytosis. Blood tests excluded an iron deficiency in the 
presence of a hyperchrome and macrocytic anemia while treated with 
dual platelet aggregation inhibition in the context of a coronary heart 
disease with stent implantation 4 months ago. To decide the further 
management of the platelet aggregation inhibition therapy in the case 
of a possible myeloproliferative disease a bone marrow biopsy was 
performed. Shortly after the intervention the patient complained of pain 
in the gluteal area. The following computed tomography (fig. 1) with 
angiography showed a pseudoaneurysm of the left superior gluteal 
artery with active hemorrhage and intragluteal hematoma. Dual 
platelet aggregation inhibition was paused and 1 platelet concentrate 
was administred, the patient fully recovered without intervention. In the 
second case, a 40-year old woman on hemodialysis treatment due to 
a chronic glomerulonephritis was evaluated for BMP by reason of 
leukocytosis. As a result of a bleeding from the left internal iliac artery 
with retroperitoneal hematoma causing anemia she was transferred  
to our hospital. Interventional radiologic coiling and substitution of 4 
erythrocyte concentrates was followed by a monitoring of 1 day in the 
intensive care unit. The patient was discharged after 6 days. Aspirin 
300 mg was paused for 2 weeks. The computed tomography depicts 
the way of the biopsy needle (fig. 2).
Conclusion: In general bone marrow biopsy is a safe procedure, 
independent of the examinators experience. Nevertheless in every 
case the indication for this examination is to verify thoroughly and 
paying attention to a technically correct procedure is essential. 
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A trial with prednisone 60 mg daily resulted in an explicit improvement 
of the symptoms with decrease of redness, pain, swelling and 
induration. Since the pain increased again after dose reduction to 30 
mg prednisone daily, we raised prednisone to 50 mg/d. After complete 
recovery a new pacemaker was implanted on the contralateral side 
without any complications. Two months later, prednisone dose could 
be tapered to 20 mg/d. 
Conclusion: After exclusion of bacterial infection, pressure dermatitis 
or postimplantation erythema must be considered in patients with local 
signs of inflammation around the pacemaker pocket. Histological 
examination of the affected skin can contribute to the diagnosis.  
In case of suspected contact hypersensitivity to implant material, 
allergological exploration should be performed (patch testing, in 
selected cases lymphocyte transformation test). Depending on  
the cause, cutaneous reactions are occasionally self-limiting 
(postimplantation erythema) or the pacemaker can translocate 
subpectoral or subcostal (pressure dermatitis). Corticosteroid may 
reduce skin symptoms of contact dermatitis, but recurrence is 
common. In many cases, however, removal of the pacemaker is 
inevitable. Special gold-plated or entirely polytetrafluoroethylene 
coating pacemaker systems are available for reimplantation. In our 
case the early consideration of pacemaker dermatitis eventually could 
have prevented the explantation and reimplantation of the pacemaker. 
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Swimming induced pulmonary edema (SIPE)  
or immersion pulmonary edema is a rare form  
of non-cardiogenic pulmonary edema
Lorenz Bärlocher1, Ruth Gamio-Veis1, Philipp K. Haager2,  
Markus Diethelm1, Michael Brändle1 
1Klinik für Allgemeine Innere Medizin/Hausarztmedizin Kantonsspital 
St. Gallen; 2Klinik für Kardiologie Kantonsspital St. Gallen, St. Gallen, 
Switzerland
Introduction: SIPE is a rare form of non-cardiogenic pulmonary 
edema. The frequency of SIPE is rising because of the increasing 
popularity of endurance sports competitions like triathlons.
Case report: We report on a 66 years old, sporty and healthy patient 
with acute dyspnea and chest pain while swimming in the Lake of 
Constance. Upon arrival of the emergency rescue service peripheral 
oxygen saturation was 85% (with an increase to 92% with 2 l oxygen), 
blood pressure 139/92 mm Hg with a pulse of 71/min. Clinical findings 
were normal except bibasilar crackles on pulmonary auscultation. ECG 
showed negative T waves in I, II, III, aVF and V6 and chest X-ray 
revealed alveolar pulmonary edema (fig. 1a). Echocardiography 
showed a normal left ventricular ejection fraction without underlying 
dyskinesia. Although the symptoms dissolved spontaneously and 
quickly ashore, we performed coronary angiography. We found only 
slight coronary sclerosis with no relevant stenosis. Heart rhythm 
monitoring revealed no rhythm disturbances. Since the alveolar 
pulmonary edema resolved spontaneously on the X-ray (fig. 1b)  
and causes for cardiogenic pulmonary edema were excluded, we 
diagnosed a SIPE.
showed multiple granulomas within the alveolar walls. All granulomas 
contained amorphous birefringent polarizable foreign material. There 
were no signs of malignancy; biopsy and culture were negative for 
tuberculosis. The reason for the elevated inflammatory values was an 
influenza A infection; therapy with oseltamivir was started. The patient 
left the hospital after four days against medical advice.
Figure 1: Chest CT scan: multiple 
pulmonary nodules.
Figure 2: Granuloma with several  
foreign body giant cells]
Conclusion: This case emphasizes the importance of the differential 
diagnosis of pulmonary foreign body granulomatosis in patients with 
IVDA and a suspect chest X-ray. The history of IVDA is crucial and the 
diagnosis is proved with a lung biopsy: amorphous birefringent 
polarizable foreign material in granulomas is pathognomonic. The 
therapy is symptomatic and the cessation of IVDA is mandatory. 
P371
Pacemaker implantation: not every erythema  
is a bacterial infection and needs an explantation
Lorenz Bärlocher1, Joel Dütschler1, Roman Brenner2,  
Markus Diethelm1, Michael Brändle1 
1Klinik für Allgemeine Innere Medizin/Hausarztmedizin Kantonsspital 
St. Gallen; 2Klinik für Kardiologie Kantonsspital St. Gallen, St. Gallen, 
Switzerland
Case report: We report on a 63 year old obese patient with an 
assumed pacemaker pocket infection after pacemaker implantation 
two months ago, due to a sick sinus syndrome with symptomatic 
bradycardia. Locally there was a 20 cm long, very painful erythema 
with hyperthermia and swelling. Repeated echocardiography revealed 
no evidence for vegetation or indirect signs for endocarditis. 
Pacemaker function was correct. We started an empiric antibiotic 
therapy and explanted the pacemaker together with the electrodes. 
Because of negative microbiology (repeated blood cultures, also in an 
antibiotic window; negative serological testing for Coxiella burnetii, 
Bartonella spp., Aspergillus spp., M. pneumonia, Brucella spp., 
Legionella pneumophila, T. whipplei, and Candida spp., negative 
biopsy and negative pacemaker culture) and a nonspecific histology 
(only some neutrophile and eosinophile granulocytes) we supposed 
pacemaker dermatitis (Pacemaker contact dermatitis or 
postimplantations erythema). 
Figure 1: X-ray.
Discussion: SIPE has first described in divers and swimmers 1989. 
Nearly 300 cases have since been published. Incidence and 
prevalence is rising in endurance swimming competitions with a 
reported prevalence of 1.4% in triathletes. Pathophysiology of SIPE is 
not fully understood. It’s presumed to originate from exercise-induced 
elevation of pulmonary capillary pressure causing mechanical stress 
failure of the pulmonary capillaries. Other factors, which favour a SIPE 
are: immersion, elevation of the negative intrathoracic pressure and 
hypothermia. Also cold water, negative static lung load, exertion, fluid 
loading and low vital capacity are postulated risk factors for SIPE.  
In order to diagnose SIPE with typical acute symptoms (dyspnoea, 
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pathogens, while calprotectin was elevated (580 µg/g). Colonoscopy 
showed non-ulcerating pancolitis, and biopsy revealed chronic 
epitheloid, non-caseating granulomatous infiltration with low active 
inflammation, intact crypt architecture and no signs of ulceration. 
Gastroduodenoscopy also revealed diffuse epitheloid granulomatous 
infiltration, one granuloma appearing necrotic, while vascular 
involvement was absent.
haemoptysis) appearing during swimming or shortly after, there must 
be an absence of other causes (laryngospasm, water aspiration) and 
complete disappearance of the alveolar pulmonary edema on the 
chest X-ray within 48h. First treatment measures include leaving water, 
stopping physical exercise and seeking medical care. Therapy is 
supportive with oxygen and possibly diuretics. Prognosis is good 
without any structural or functional lung damage. Patients suffered 
from SIPE are at increased risk of relapse in the same situation. 
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Aortic valve reconstruction with autologous pericardium 
instead of prosthetic replacement: new technique and 
preliminary results of the first 3 cases in Western Switzerland
Mathieu Potin1, François Perret2, Patrick Ruchat2,  
Javier Orrit 2, Gregory Khatchatourov2 
1Unité de Médecine Interne; 2Centre Cardio-Vasculaire,  
Clinique Cecil, Lausanne, Switzerland
Introduction: For more than 10 years, a new technique of aortic valve 
reconstruction (AVR, stenosis as well as insufficiency) has now been 
described in Japan with more than 400 cases reported with a mean 
follow-up of 2–3 years (known as the Ozaki technique, cf. references). 
We report the first 3 cases in Western Switzerland. 
Method: Review of medical records and case report of operated 
patients with the Ozaki technique for aortic valve reconstruction 
between November and December 2016 in a Western Switzerland 
private clinic.
Results: 3 patients have had AVR by the Ozaki technique for: 1. ♂ 46 
years old, indication: congenital unicuspid aortic valve, small aortic 
annulus with high risk of prosthesis-patient mismatch evaluated by 
effective orifice area in relation to body size; 2. ♂ 68 years old, 
indication: 6 weeks post-endocarditis due to Streptococcus mitis oralis 
aortic valvular insufficiency grade IV/IV; 3. ♀ 47 years old, indication: 
aortic valve fibro-elastoma with severe regurgitation of 50–60% and 
relative contra-indication to long-term anticoagulants due to co-
medication interactions. The hospital follow-up was favorable for all 
three, apart from the second case which was complicated by a right 
sided hemothorax reoperated within 12 h but with uneventful recovery 
thereafter, with remarkable results on the early post-operative 
echocardiography follow-up for all 3 cases.
Conclusions: This new surgical technique needs to be known as it 
offers new perspectives and alternatives as to both classic surgical 
techniques (bioprothesis, mechanical valve) and the new transcatheter 
aortic valve implantation (TAVI). The main interest of this technique is 
that the implantation of foreign material is no longer needed and the 
prescription of lifelong anticoagulants or anti-platelets becomes 
unnecessary, with the hope that the use of autologous pericardium will 
prove a durable alternative to biological valves. The only restriction to 
keep in mind is that this technique has no more than a 10 year 
follow-up since the first reported cases and a mean 2 to 3 years 
follow-up on the large series reported in 2014.
References: 
A total of 404 cases of aortic valve reconstruction with glutaraldehyde-treated 
autologous pericardium. Ozaki S, Kawase I, Yamashita H, et al. J Thorac 
Cardiovasc Surg. 2014;147(1):301–6.
Aortic Valve Reconstruction Using Autologous Pericardium for Aortic Stenosis. 
Ozaki S, Kawase I, Yamashita H, et al. Circ J. 2015;79(7):1504–10. 
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Case report: intestinal granulomas in a 22-year old  
Ethiopian woman with abdominal pain
Milos Radosavac1, Petr Hruz2, David Seiffge1, Marius Treusch1,  
Martin Weber1, Thomas Daikeler3, Matthias Matter4, Philip Went4, 
Stefano Bassetti1 
1Division of Internal Medicine, University Hospital Basel; 2Division of 
Gastroenterology and Hepatology, University Hospital Basel; 3Division 
of Rheumatology, University Hospital Basel; 4Department of 
Pathology, University Hospital Basel, Basel, Switzerland
Introduction: We present a rare case of gastrointestinal (GI) 
granulomatous disease in a patient originating from a region with high 
prevalence of tuberculosis (TB) and discuss the diagnostic approach. 
Case presentation: A 22-year old Ethiopian-born female living in 
Switzerland for 5 years presented with a history of abdominal pain, 
bloating, weight loss, intermittent diarrhea and vomiting of two months. 
She reported one episode of pain in the right knee 4 months before 
hospitalisation, but was otherwise healthy and under no medication. 
Clinical examination showed a tender, meteoritic abdomen. Laboratory 
work-up displayed anemia (Hb 111 g/l) and elevated CRP (80 mg/l). 
Stool tests were negative for common parasitic and bacterial 
Figure 1: Biopsy of the colon 
showing epitheloid granuloma.
Figure 2: Necrotic epitheloid 
granuloma in duodenal biopsy.
Computer tomography showed thickened walls of the colon, small 
subpleural and peribronchial nodules of the lung with one enlarged 
hilar lymph node, interpreted as post-bronchitic and unspecific. 
Differential diagnosis included TB of the GI tract, autoimmune, and 
inflammatory bowel disease. Extensive tests for infectious diseases 
and interferon gamma stimulation test in blood were negative, as were 
TB cultures and PCR from biopsy. Rheuma factor, soluble interleukin-2 
receptor and neopterin were elevated, serum angiotensin-converting 
enzyme level was within normal range. Corticosteroid treatment was 
started, under which inflammation markers normalized. Re-
colonoscopy showed a reduction of granulomas, CT scan of the lung 
resolution of nodules. Finally, histology from transbronchial biopsy 
confirmed epitheloid granulomas, and the diagnosis of sarcoidosis  
of the GI tract and lungs was made. Azathioprin was added to the 
treatment regime, under which symptoms of the patient improved.
Conclusion: Differential diagnosis of granulomatous disease is 
challenging in patients at risk for tuberculosis. Sarcoidosis of the GI 
tract is very rare (5–10% of overall cases), and primarily manifests with 
unspecific symptoms. Before establishing immunosuppressive 
treatment, infectious diseases, in particular TB must be excluded. 
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Vocal cord dysfunction: a forgotten differential  
diagnosis in acute dyspnea
Mélanie Salamin1, Katarzyna Keller1, Lars C. Huber1,  
Urs Marbet1, Armin Zink2 
1Innere Medizin; 2Pneumologie, Statdspital Triemli, Zürich, Switzerland
Introduction: Vocal cord dysfunction (VCD) is a clinical phenomenon 
describing an inappropriate episodic adduction of the true vocal folds. 
The prevalence for VCD is unclear but is estimated to be found in up to 
5% of supposed asthmatic patients. Patients typically present 
themselves at the emergency department with acute upper airway 
obstruction. Concomitant psychiatric morbidity, gastroesophageal 
reflux disease and postnasal drip might observed as supplementary 
risk factors. Since internists are not familiar with VCD, diagnosis is 
often delayed and leads to unnecessary costs and treatment including 
intubation and tracheostomy. 
Case report: A 61-year-old female patient with severe dyspnoe attacks 
for many years was considered to suffer from severe and therapy-
resistant asthma culminating in admission to an intensive care unit  
few years ago. Patient history was further remarkable for multiple 
hospitalisations due to asthma attacks, suspicion of Morbus Widal, 
reflux, headache and depression. At presentation, the patient was 
suffering from an acute and severe dyspnoe attack, cough with white 
sputum and sore throat without fever. Arterial blood gas analysis 
(under 12 L supplementary oxygen) showed severe respiratory 
insufficiency (pH 7.44, pCO2 5.37kPa, pO2 6.04 kPa). Chest X-ray 
showed no pulmonary infiltrate. The patient was diagnosed with 
infectious exacerbation of asthmatic disease and antibiotic therapy 
(Ceftriaxon) was initiated. Further workup showed normal lung 
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function, discordant with uncontrolled asthma activity. Subsequent 
detailed history including the use of a VCD screening checklist 
suggested the presence of vocal cord dysfunction. Following logopedic 
intervention and start of proton pump inhibitor therapy the patient was 
dismissed without symptoms. Close follow-up is planned. 
Conclusion: This case report highlights the importance of detailed 
history taking also in patients with longstanding and established 
diagnoses. In addition, awareness of VCD, recognizing patients at risk 
and including this differential diagnosis in patients with severe resistant 
asthma might reduce unnecessary treatments and hospitalisations. 
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Wandering through a rock-garden – case report  
of Tracheobronchopathia Osteochondroplastica
Schirin Elisa Wahl1, Dieter Scholtze2 
1Internal Medicine; 2Division of Pulmonology and Sleep Disorders 
Center, Stadtspital Triemli, Zürich, Switzerland
Chronic cough is a very common symptom in general medicine. 
Sometimes CT and bronchoscopy may reveal an uncommon cause: 
Tracheobronchopathia Osteochondroplastica (TO). We present a case 
of this very rare disease. A 71 year old female patient presented with 
chronic cough for more than a year. She describes waking up from 
cough at night, especially having heavy attacks in the morning with 
some tough mucus. She also experiences being hoarse all day with 
foreign body sensation in the throat. Initial pneumological consultation 
showed bronchial hyperreactiveness, but inhalation therapy brought no 
relief. A trial with a proton pump inhibitor was also unsuccessful. A CT 
scan was performed demonstrating several small lesions adjacent to 
the tracheal wall amounting to the thyroid gland and beneath. 
Bronchoscopy then revealed impressive findings of TO. The entire 
tracheal wall showed multiple firm nodules with intact mucus 
membranes along the cartilaginous rings sparing the Pars 
Membranacea. 
 
P377
Myocarditis associated with campylobacter enteritis
Stephanie Intorp1, Rickli Hans2, Markus Diethelm1,  
Niklas F. Ehl2 
1Medizinische Klinik; 2Kardiologie, Kantonsspital St. Gallen,  
St. Gallen, Switzerland
Introduction: Myocarditis in developed countries is very often 
associated with an infectious etiology, especially viral infections. An 
association with bacterial infections is much less frequent – especially 
the association with campylobacter enteritis is reported only in few 
cases. 
Case report: A 24-year-old, healthy young man was admitted to our 
emergency department because of sudden chest pain, increasing with 
deep inspiration. Apart from transient fever and watery diarrhea for the 
last 3 days the clinical history as well as the actual vital signs were 
unremarkable, no cardiovascular risk factors were known, no drug 
intake. An ECG showed only non-specific findings. Initial blood tests 
showed elevated cardiac and inflammatory markers (Troponin-I 5297 
ng/l (normal value <30 ng/l), C-reactive protein 201 mg/l (normal value 
<8 mg/l)). An echocardiography revealed only mildly reduced left-
ventricular ejection fraction with an infero-lateral hypokinesia (fig. 1). 
While computed tomography coronary angiography could rule out 
coronary artery disease, cardiac magnetic resonance imaging showed 
extensive areas of late gadolinium enhancement in the basal 
segments of the inferolateral wall (fig. 2). Diarrhea as well as chest 
pain ceased during the next days without specific treatment. Stool 
culture revealed campylobacter jejuni (retrospectively due to tartare 
ingestion 5 days before symptom onset). So we were able to make the 
diagnosis of campylobacter-associated myocarditis. 
Figure 1: CT. Figure 2: Bronchoscopy.
Since there is no causative therapy, aware of the benign course of  
the disease, we recommended using antitussive agents to control the 
patient’s chronic cough. TO is a very rare airway disease of unknown 
etiology characterized by accumulation of cartilaginous and osseous 
nodules. It was first described during autopsy by Rokitansky in 1855. 
TO is mostly incidentally detected in CT Scans, during intubation or 
bronchoscopy. Symptoms of patients are usually chronic cough despite 
adequate treatment trials, exertional dyspnea, hoarseness, occasional 
hemoptysis and recurrent pulmonary infections. Diagnosis is 
established via radiology and bronchoscopy demonstrating 
characteristic small submucosal nodules in the trachea sparing the 
posterior wall. It can affect the entire trachea ranging as far as the 
main bronchi, in some cases causing atelectasis. Lesions may be so 
numerous that the bronchscopic aspect may appear as a “rock-garden”. 
Histopathology shows calcification, chondrification or lamellar 
ossification, with possible foci of bone marrow and hematopoesis.  
The underlying etiology and pathology of TO are unclear. Differential 
diagnosis include tracheal neoplasms, calcificating tuberculosis, 
tracheobronchial calcinosis, Wegener granulomatosis and relapsing 
polychondritis. The course of TO is benign with only slow progression. 
Only few of the cases showed or developed more severe airway 
obstruction. Therapy focusses on symptom control using centrally 
acting antitussive agents. 
Figure 2
Figure 1
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aminotransferase (ASAT) 143 U/l, normal alanin aminotrasnferase 
(ALAT) 40 U/l, normal alkaline phosphatase 45 U/l and elevated 
gamma-glutamyl transferase (γGT) 189 U/l. Inflammatory syndrome  
is noted with an elevated C-reactive protein (CRP) 26 mg/l and 
leukocytosis 20.9 g/l. An abdominal ultra-sound and a biliary-tract IRM 
confirmed cholecystitis and gallbladder sludge with liver and spleen 
slighlty enlarged with no other liver or biliary (intra or extra-hepatic) 
lesion. Acute liver failure is however suspected with hypoalbuminemia, 
coagulopathy (V and VII factors decreased), an international 
normalized ratio (INR) at 3.3 and a prothrombin time (TP) at 22%. After 
contact with gastro-enterologist, fulminant hepatitis in an undiagnosed 
Wilson’s disease is suspected and patient is transferred for urgent liver 
biopsy. It is noteworthy that dosage of the G6PD activity was normal 
(16 IE/gHB with normal values between 12.14 IE/gHb). Serum copper 
was high (10.3 microM) and ceruloplasmin was low (0.05g/l). Wilson’s 
disease was further confirmed by liver biopsy. Urgent liver 
transplantion was carried out successfully because of a dramatic 
progression of acute liver failure. Hepatic failure and hemolytic anemia 
should alert physian to look for Wilson’s disease especially in young 
women. 
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Long term relapse of Whipple’s disease:  
a case report and literature review
Dominik Imhoff1, Armin Droll1, Tobias Hoffmann1,  
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Whipple’s disease is an infection caused by the bacteria Tropheryma 
whipplei. It leads to several systemic symptoms such as 
malabsorption, diarrhea, arthralgia, weight loss and fever. The usual 
primary treatment is an intravenous antibiotic (e.g. ceftriaxone) for 2 
weeks followed by a one-year oral treatment with cotrimoxazole. Our 
patient was a 71-year-old woman who has been diagnosed with a long 
term relapse of Whipple’s disease in 2016. She has been successfully 
treated for Whipple’s disease in 1987. In 2016 she presented with 
diarrhea, significant weight loss, fever and newly diagnosed 
rheumatoid arthritis. Diagnosis was based on biopsy samples obtained 
from the stomach and the duodenum showing periodic acid-Schiff-
positive macrophages. A quantitative real-time PCR assay was also 
performed to detect T. whipplei DNA in the biopsy samples. Due to 
ceftriaxone allergy treatment was initiated with meropenem for 2 
weeks. Therapy is currently in progress with cotrimoxazole until May 
2017. Under treatment gastroenterological and rheumatic symptoms 
decreased. As shown in several studies arthralgia vs. diarrhea and 
weight loss is equally frequent in patients suffering from Whipple’s 
disease. Arthritis is often shown as a first symptom. Therefore, we 
hypothesize that T. whipplei infection causes rheumatic disease with 
gastroenterological symptoms. Although incidence of Whipple’s 
disease is very low, studies show IgG against T. whipplei in 70% of a 
healthy population. The bacteria can be found in the lamina propria of 
the gastrointestinal tract in 2–4% of all asymptomatic patients. Several 
host factors, e.g. immunodeficiency seem to be responsible for disease 
onset. 
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Acute Stroke following Amiodarone administration  
in a patient with atrial fibrillation
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Introduction: Guidelines recommend a limit of 48 hours after the 
onset of atrial fibrillation (AF) for cardioversion without anticoagulation. 
Amiodarone is often used for the treatment of AF and it is known to 
cause chemical cardioversion.
Case: In Mai 2016, a previously healthy 65-years-old woman 
presented to her GP with non-specific complaints including 
inappetence and an increasingly deteriorating general condition. The 
patient denied any form of chest pain. The imaging studies showed 
pleura effusions of moderate size on both sides and the patient was 
referred to our emergency department. He was in a stable condition, 
with a blood pressure of 135/102 mm Hg and an abnormal heart 
rhythm (irregular, 150/min). There were no signs of an infection, but 
clinical signs of cardiac congestion. The ECG showed AF with a 
frequency ranging from 150 to 180 bpm. The duration of the AF was 
unknown. The frequency remained above 170 bpm, despite rate-
control with a beta blocker. After injecting Clexane 80 mg i.v, a single 
In an outpatient control 4 weeks later the patient described an 
uneventful course. The echocardiographic findings as well as 
laboratory findings were normalized.
Conclusion: Campylobacter jejuni-enteritis is a rare cause of 
myocarditis; a special feature is the short time interval of one to five 
days between the onset of enteritis and the onset of myocarditis.  
To understand the relation between Campylobacter infection and 
myocarditis, and at least prevent co-accurance, it might be important 
to identify the pathomechanism, which is not known yet. 
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Introduction: Detection of atrial fibrillation (AF) is of pivotal 
importance for stroke prevention. Recent studies confirmed the  
merits of long-term monitoring. Currently available diagnostic tools  
are burdened with disadvantages of inconvenience, costs or 
invasiveness. In a previous study we tested an app that employed 
photoplethysmographic (PPG) signals of a smartphone camera to 
distinguish between AF and sinus rhythm (SR) based on the newly 
developed Preventicus® Heartbeats algorithm. That retrospective study 
has been shown to achieve a sensitivity and specificity of 95%. In the 
WATCH AF study, this algorithm is tested for the first time with PPG 
signals from a smartwatch (Samsung) and a wristband (Wavelet 
health). Our study aims to determine the accuracy of these 
applications compared to an ambulatory ECG system. 
Methods: In this prospective, blind, international, multicenter-study, 
600 subjects are being recruited until March 2017. Subjects must be  
of legal age. SR group is age- and gender-matched with the AF group. 
Pulse wave curves will be recorded for five minutes simultaneously 
with a smartwatch on one and a wristband on the other arm (sides 
randomized). At the same time, an ambulatory ECG system will record 
a synchronous ECG as reference. The pulse wave curve data will be 
analysed in a blinded manner off-line with the Preventicus® Heartbeats 
algorithm and will then be labelled as either SR or AF. Additionally, 
information about cardiovascular risk factors, concomitant disease and 
medication, are collected. Primary target parameters are the app’s 
sensitivity and specificity in correctly detecting AF compared to an 
automatically interpreted ECG. Secondary target parameters include 
the proportion of non-evaluable recordings in the overall study and 
differences between the two devices.
Results: The enrolment is expected to be complete in March 2017. 
Complete trial results are expected for in April 2017.
Conclusion: WATCH AF is the first study to validate PPG signals from 
the wrist to detect AF in a blinded, ECG controlled fashion. 
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A fulminant Wilson’s disease in a case of pretended  
glucose-6-phosphate dehydrogenase deficiency
Corinna Trippini1, Joana Vieira-Barbosa2, Uwe Schiemann1,  
Mathieu Firmann1, Montserrat Fraga2 
1Internal Medicine, HFR, Riaz; 2Gastro-entorology, CHUV, University 
Hospital and University of Lausanne, Lausanne, Switzerland
Wilson’s disease is an autosomal recessive disorder of impaired biliary 
copper excretion that results in the accumulation of copper in various 
organs including liver, cornea and brain. Orthotopic liver 
transplantation is indicated in advanced cases with hepatic 
decompensation or in patients with fulminant Wilson’s disease. We 
describe herein a Wilson’s disease presenting with fulminant hepatic 
insufficiency and hemolytic anemia. A 19-years old female girl from 
Italian Origin, anamnestic known for a Glucose-6-phosphate 
dehydrogenase deficiency (G6PD) and thalassemia minor was 
admitted because of fever since 4 weeks, accompanied by bone pain 
and chills. At the admission, she is hemodinamically stable, icteric, 
with subfebrile temperature. At the physical examination, the Murphy’s 
sign is positive and liver was slightly enlarged. Laboratory tests show a 
Coombs negative haemolytic hypocromic anaemia with hemoglobin  
49 g/l, haptoglobine 0.10 g/l, lactate dehydrogenase (LDH) 816 U/l with 
unexpected elevation of the direct bilirubin 64.2 µmol/l with total 
bilirubin 78.2 µmol/l and slight elevation of liver enzymes (aspartate 
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Liver pain revealing Rendu Osler syndrome:  
in a case report
Amina Abdi 
E.P.S.P Ghoualem, Oran, Algeria
Introduction: Rendu-Osler disease is an inherited multisystem 
angiodysplasia transmitted as an autosomal dominant, which can be 
complicated by vascular visceral malformations, including liver. 
Methods: Patient, 36 years old, mother of 3 children without special 
background, consults for liver pain with sensation of heaviness in the 
right upper quadrant.
Results: The examination reveals a history of repeated spontaneous 
epistaxis, clinical examination purpose, mucocutaneous telangiectasia, 
hepatosplenomegaly. Abdominal ultrasound showed homogeneous 
hepatosplenomegaly, a trunk door permeable, and the existence of 
arteriovenous fistulas hepatic Doppler color and helical computed 
tomography. Upper gastrointestinal endoscopy esophageal varices 
objectified stage I-third lower esophageal without telangiectasia.  
The rendu osler disease is diagnosed in our patient by the criteria  
of Curacao, the staging revealed no other systemic involvement.  
The patient was put under medical treatment and clinical monitoring 
and strict paraclinical, with a family screening.
Conclusions: Hepatic vascular malformations should be sought 
routinely in all patients with the rendu osler syndrome, color Doppler 
ultrasound The test is best suited for the hepatic vascular changes 
during the initial assessment and monitoring of patients. Medical 
treatment is effective for some symptomatic forms, liver transplantation 
should be considered as currently the treatment of choice for severe 
and complicated forms. 
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The Model for End-stage Liver Disease as a predictor  
of short-term mortality in Staphylococcus aureus  
bloodstream infection: a single-centre observational study
Jan A. Roth1, Andreas F. Widmer1, Sarah Tschudin-Sutter1,  
Marc Dangel1, Reno Frei2, Manuel Battegay1, Balthasar L. Hug3 
1Division of Infectious Diseases and Hospital Epidemiology; 2Division 
of Clinical Microbiology, University Hospital Basel, Basel; 3Department 
of Internal Medicine, Cantonal Hospital Lucerne, Lucerne, Switzerland
Introduction: Laboratory-based prediction models may support 
clinical decisions in Staphylococcus aureus bloodstream infections 
(BSIs), which carry a particularly high mortality. Previous studies 
suggest that the laboratory-based Model for End-stage Liver Disease 
(MELD) score is a risk factor for mortality in critically ill patients with 
infections. For S. aureus BSIs, we therefore aimed to assess a 
potential association of the MELD score with mortality. 
Methods: In this single-centre observational study, all consecutive 
patients with a first episode of methicillin-susceptible S. aureus BSI 
occurring between 2001 and 2013 were included. Relevant patient 
data were retrieved from our prospective in-house BSI surveillance. 
We assessed the association of the MELD score at day of BSI onset 
(range ± two days) with 30-day all-cause mortality using uni- and 
multivariable logistic regression analysis. 
Results: 561 patients were included in the final analysis. The MELD 
score at BSI onset was associated with 30-day mortality in S. aureus 
BSIs (odds ratio per 1-point increase, 1.06; 95% confidence interval, 
1.03–1.09; P <0.001). After adjustment for relevant patient and infection 
dose of amiodarone (150 mg) was intravenously given. The AF was 
successfully converted into sinus rhythm. On the following day the 
patient suffered a wake-up stroke with a sudden right-sided motor 
weakness and dysarthria. A gadolinium-enhanced MRI confirmed 
multiple acute cerebellar infarctions in the territory supplied from the 
posterior inferior cerebellar artery, the cortical branches of the basilar 
artery and of the posterior cerebral artery left. Vascular investigations 
showed an acute occlusion of the P1 segment of the left posterior 
cerebral artery. No other intracranial arterial occlusions that could 
suggest an in situ atherothrombotic mechanism or an artery to artery 
embolism were documented. Because of the multiple infarctions in  
the posterior circulation and because of the clear association between 
the neurological deficit and the cardioversion a thromboembolic stroke 
following amiodarone was postulated. M-mode echocardiography 
revealed an enlarged left atrium, suggesting long-standing AF. 
Anticoagulation was started 4 days later. The patient showed a 
complete recovery and was discharged.
Conclusion: Thromboembolic events following electric cardioversion 
are a well described complication. However, thromboembolism by 
pharmacological cardioversion of AF may be underestimated and 
therefore the importance of anticoagulation prior to pharmacological 
cardioversion may not be underestimated. 
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High-intensity interval training as treatment strategy  
for heart failure patients with preserved ejection fraction:  
a protocol proposal for a prospective single-blind  
randomized controlled trial
Elke Thesenvitz1,2, Stefanie Brighenti-Zogg1, Jonas Mundwiler1,  
Benita Janisch1,2, Jörg Daniel Leuppi1,2, Thomas Dieterle1,2 
1Medizinische Universitätsklinik, Kantonsspital Liestal, Liestal; 
2Medizinische Fakultät, Universität Basel, Basel, Switzerland
Background: Chronic heart failure (HF) is a common symptom 
complex characterized by shortness of breath, fatigue, fluid retention 
and severe exercise intolerance. HF with preserved ejection fraction 
(HFpEF) occurs in about 50% of all HF patients. Remodeling and 
fibrosis stimulated by inflammation appear to be main factors for the 
progression of HFpEF. Furthermore, iron deficiency (ID) has been 
recognized to be a common comorbidity in HFpEF. The lack of 
prognostic treatment options in HFpEF urgently calls for new 
therapeutic approaches. While beneficial effects of exercise training 
and iron substitution have been demonstrated in HF with reduced 
ejection fraction, they have not yet been evaluated in HFpEF. 
Therefore, the aim of this study to be discussed is to investigate the 
effect of exercise training in HFpEF patients with optimally adjusted 
iron values. Exercise tolerance measured as peak oxygen uptake 
(VO2peak) will be the primary outcome.
Method: The proposed study will be a prospective single-blind 
randomized controlled trial in a primary care setting including 98 
patients with stable HFpEF. Patients will undergo 3 study visits 
including measurements of disease-specific biomarkers, cardiac and 
arterial vessel structure and function, exercise tolerance, habitual 
physical activity, body composition and quality of life (QoL). After the 
first visit, patients with ID will undergo iron substitution until sufficient 
iron levels are reached (over max. 12 weeks), in order to ensure 
comparable baseline conditions for the training intervention. The study 
measurements will be repeated after 12 weeks in both, initially iron 
deficient and non-iron deficient patients. Patients will then be 
randomized to the intervention or control group, stratified by initial 
iron-deficiency status. The intervention group (n = 49) will attend a 
supervised 12-week high-intensity interval training on a bicycle 
ergometer. The control group (n = 49) will be advised to continue usual 
care. After 12 weeks, the study measurements will be repeated in all 
patients to monitor the effects of the intervention. At 6 months, 1, 2, 
and 3 years after the last study visit, telephone interviews will be 
performed to assess medical outcomes (e.g. hospitalizations, cardiac 
events, death) and QoL.
Outlook: This study is expected to add important knowledge about the 
potential utility of a novel treatment strategy in HFpEF patients, which 
may help to improve both, QoL and functional status. 
Figure 1
PRIMARY AND HOSPITAL CARE – ALLGEMEINE INNERE MEDIZIN 2017;17(SUPPLEMENTUM)
POSTER SGAIM / POSTERS SSMIG 71 S
was given immediately. After 360 minutes, the patient felt dizziness 
with drop of blood pressure (84/54 mm Hg) and tachycardia (107/min). 
The patient recovered after intramuscular injection of 0.3 mg 
adrenaline. One hour after the reaction, blood sample showed an 
elevated tryptase (36.7 µg/l) which normalized several days later, 
consistent with a mast cell-activation in IgE-mediated reaction. Finally, 
the urticaria was treated with monthly injection of 300 mg omalizumab 
with good tolerance without recurrence of urticaria (follow-up 
5 months). 
Discussion: Hypersensitivity reactions to H1-antihistamines are very 
rare and only twelve cases have been reported in literature. Above all, 
cetirizine has been implicated in these reactions. The exact 
mechanisms are speculative, but the piperazinine ring has been 
implicated in some cases of cetirizine hypersensitivity. However, this 
hypothesis remains controversial as prochlorperazine, an antiemetic 
drug containing a piperazinine ring, was well tolerated in another case 
after cetirizine anaphylaxis. Other groups suspected a hypersensitivity 
to side chains of cetirizine. Interestingly, an intolerance reaction to 
cetirizine has also been reported. 
Conclusion: This is the first report of an anaphylactic reaction to 
bilastine. Patients may react to one single or multiple H1-
antihistamines, which is challenging in the treatment of chronic 
urticaria. Prediction of crossreactivity is difficult because the epitope 
has not been identified. Careful assessment of the risk/benefit ratio is 
necessary to avoid potentially harmful provocation tests. Omalizumab 
should be considered as first choice treatment in patients with chronic 
urticaria and H1-antihistamines hypersensitivity. 
characteristics, an increased MELD score remained a strong predictor 
of 30-day mortality (adjusted odds ratio per 1-point increase, 1.05; 95% 
confidence interval, 1.01–1.08; P = 0.005). In time-dependent analysis, 
a MELD score at BSI onset of 10–15 points and >15 points (reference, 
<10 points) was significantly associated with death before day 30 
(P <0.001; fig. 1). 
Conclusions: In our study population, the MELD score at BSI onset 
was an independent predictor of mortality in S. aureus BSIs. The 
MELD score may be part of clinical decision support systems in 
patients with suspected or confirmed BSI. 
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Anaphylactic shock to bilastine
Yann Coattrenec, David Spoerl, Peter Jandus, Thomas Harr 
Service d’Immunologie et Allergologie, Hôpitaux Universitaires  
de Genève, Genève, Switzerland
Introduction: Antihistamines are drugs that antagonize the activity  
of histamine receptors. H1-Antihistamines are firstline treatment for 
chronic urticaria and are used to treat allergic reactions. Anaphylactic 
reactions to antihistamines are very unusual. 
Methods: We describe the case of a 53-year-old woman with history 
of chronic urticaria experiencing urticaria, angioedema and syncope  
to multiple H1-antihistamines (hydroxyzine, cetirizine and 
fexofenadine). In order to proof tolerance with an alternative H1-
antihistamine a double-blind provocation test with bilastine versus 
placebo was performed. 
Results: After a cumulative dose of 37 mg bilastine (90 minutes), the 
patient developed generalized urticaria. Prednisolone 100 mg per os 
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Painless swelling of the forefoot and recurrent  
subcutaneous abscesses of the lower leg – two distinct 
presentations illustrating the spectrum of eumycetoma  
in a non-endemic country
Adrian Schibli1, Daniel Goldenberger2, Andreas Krieg3,  
Anna Hirschmann2, Elisabeth Bruder2, Michael Osthoff4 
1Stadtspital Triemli, Zürich; 2Universitätsspital Basel; 3Universitäts-
Kinderspital beider Basel; 4Klinik für Innere Medizin, Universitätsspital 
Basel, Basel, Switzerland
Introduction: Eumycetoma is a neglected tropical disease that is 
characterized by the triad of painless swelling, sinus formation and 
purulent discharge. This chronic disease causes significant disability  
if diagnosed late. 
Methodology: We report two cases of eumycetoma presenting to  
our hospital, one early presentation with a painful swelling of the left 
forefoot in a 41-year-old man from the Indian subcontinent (Patient 1) 
and one late presentation with recurrent subcutaneous abscesses of 
the left leg extending into the ankle joint in a 21-year-old Eritrean 
migrant (Patient 2). 
Results: Patient 1 had emigrated from India to Switzerland in 1996, 
and his last visit to the Indian subcontinent (Pakistan) was five years 
ago. He presented with a soft tissue mass on his left forefoot, which 
has been steadily growing over three months. Owing to the initial 
suspicion of a soft tissue tumor, the patient underwent complete 
surgical resection. Histopathology revealed fragments of black grains 
and a granulomatous necrotizing inflammatory reaction surrounding 
fungal hyphae (fig. 1). 
Identification of Madurella mycetomatis as the causative organisms 
was established by panfungal polymerase chain reaction (PCR).  
The patient was treated with itraconazole for six months with regular 
therapeutic drug monitoring without evidence of relapse 30 months 
after treatment cessation. Patient 2 had emigrated from Eritrea about 
four months before presentation to our hospital with progressive pain 
and swelling of his left ankle. On examination, a painful fluctuation was 
noted below his medial ankle consistent with a subcutaneous abscess 
(fig. 2), which was drained and sent for culture. 
POSTERTOUR 2: MÉDECINE SPÉCIALISÉE I I / FACHMEDIZIN I I  
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contact with ill persons. A part from fever (38.8 °C), parameters  
(blood pressure, heart rate [HR], saturation) were normal. Physical 
examination revealed tenderness over the right deltoid and lumbar 
area, painful cervical lymphadenopathy and tender vesico-pustular 
lesions over the face, neck, arms, thighs and back; bipolar aphthosis 
was also present. Besides leucocytosis and an elevated CRP (233.5 
mg/l), blood tests (kidney and liver function, common viral serologies 
and a complete immunological panel) were normal. ECG and chest 
X-ray were unremarkable. Biopsy of one skin lesion showed dermal 
neutrophilic infiltrate without vasculitis. We considered a diagnosis of 
acute neutrophilic dermatosis. Pulse methylprednisolone therapy (1 g/
day for 3 days) was introduced. Improvement was dramatic with rapid 
disappearance of pain and fever, resolution of skin lesions and 
normalization of inflammatory parameters. 48 hours after the first pulse 
of methylprednisolone, the patient presented asymptomatic 
bradycardia (HR: 40 BPM) with an HR of 32-38 BPM in the 2 following 
days. ECG showed normal sinus rhythm without AV conduction 
abnormalities. We opted for watchful waiting. The patient was switched 
to oral prednisone (1 mg/kg per day) on day 4. 72 hours after the last 
pulse HR was normalised (>60 BPM). The patient was finally 
discharged at day 10. At 1-month follow-up the patient, still on oral 
steroids, is fine and HR is normal.
Conclusion: In the absence of other drugs or medical conditions that 
could affect HR, and with a Naranjo scale of 7 (probable relation), we 
believe that patient’s bradycardia should be ascribed to pulse 
methylprednisolone. We suggest that HR should be routinely evaluated 
in patients receiving pulse corticosteroids and particularly in those with 
cardiac risk factors. 
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Spinal tuberculosis – almost a forgotten differential  
diagnosis for back pain in the western world
Nebal Abu Hussein1, Silke Böll1, Fabian Franzeck2, Martin 
Krähenbühl1, Nina Khanna2, Cordula Netzer3, Stefano Bassetti1 
1Division of Internal Medicine; 2Infectious Diseases & Hospital Hygiene 
Department; 3Spinal Surgery Department, University Hospital Basel, 
Basel, Switzerland
Extrapulmonary tuberculosis (TB) is rare. Bone TB accounts for about 
10% of all extrapulmonary TB cases. The spine is the most frequently 
affected location. TB treatment becomes challenging because of the 
spread of multi-drug resistant (MDR) TB. A 28 yo patient was referred 
to our hospital for further diagnostic because of a radiological 
diagnosed pulmonary and spinal mass of unknown origin with 
suspected compressive myelopathy. She had been complaining for 
almost nine months of upper back pain during her pregnancy, and 
after giving birth. She was treated with painkillers and physiotherapy, 
later on; she developed ataxic gait and hyperreflexia. The patient 
immigrated from India 2 years ago. She had no known history of or 
exposure to TB. CT-Imaging on admission demonstrated Growth in the 
right upper pulmonary lobe with infiltration of the paravertebral tissue 
on thoracic level 4–6, infiltration of the thoracic vertebral bodies 4–7, 
compression fracture of thoracic vertebral body 5 with high grade that 
was narrowing of the spinal canal. M. tuberculosis was cultured from 
sputum and spinal biopsies. Testing by Genexpert showed a rifampicin 
resistance mutation. Due to the neurocompressive symptoms, we 
began an empiric antituberculosis treatment combination with 
amikacin, linezolid, moxifloxacin, ethambutol, pyrazinamid, cycloserin 
and clofazimine for assumed MDR-TB. 2 weeks later a spinal surgery 
with decompression and stabilisation was performed. The 
postoperative period showed nearly complete recovery of neurological 
symptoms. The final phenotypic resistance testing revealed rifampicin, 
streptomycin, ethambutol and isoniazid resistance, following the 
results we could reduce the TB treatment to 5 substances. The patient 
tolerated the treatment well; the laboratory monitoring showed no sign 
of toxicity. However the follow-up audiological testing disclosed 
impaired hearing in the high frequencies. Consequently, the dosis of 
amikacin was reduced. Finally, the patient has recovered well. In the 
follow-up exams, the patient had a normal gait and no signs of a 
peripheral polyneuropathy. Spinal TB is an uncommon condition, which 
is often overlooked and misdiagnosed because of the rarity in the 
western world. Considering TB as a diagnosis and considering risk 
factors can avoid delays in diagnosis and management and 
subsequently prevent significant neurological complications. 
additionally physicians should be aware of the increasing risk of 
MDR-TB. 
He reported recurrent local infections on his left foot since the age of 
10. Abscess cultures revealed growth of a mold, which was identified 
as Madurella mycetomatis using panfungal PCR. Treatment with 
itraconazole 100mg twice daily was initiated, which resulted in marked 
reduction of pain after four weeks. Unfortunately, the patient was 
transferred to Italy and was lost to follow-up. 
Conclusion: The present cases underscore the importance of 
considering epidemiological clues for eumycetoma in the differential 
diagnosis of painless soft tissue swellings or recurrent subcutaneous 
abscesses of the feet. Physicians in countries currently hosting 
refugees from East and Central Africa or the Indian subcontinent need 
a high index of suspicion for this neglected tropical infection. 
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Fever after treatment with rituximab and bendamustin –  
don’t forget the ticks!
Joëlle Nicoletti, Vineeta Bansal, Reinhard Imoberdorf,  
Jacques Gubler, Urs Karrer 
Departement Medizin, Kantonsspital Winterthur, Winterthur, 
Switzerland
Case report: A 79 year-old patient suffering from follicular lymphoma 
stage IV was referred to our clinic for further evaluation of daily fever 
>39 °C, fatigue, arthralgias, imbalance and weight loss. A recent 
relapse of lymphoma had been treated with rituximab and 
bendamustin. Clinical examination showed cachexia and slightly 
enlarged and indurated cervical, supracalvicular (left) and axillary 
(right) lymph nodes. Laboratory analyses demonstrated anemia 
(Hemoglobin 9.2 g/dL; normal range: 14.4–17.5 g/dL), elevated 
C-reactive protein (CRP 86 mg/L; <5 mg/L) and ferritin (1600 mg/L; 
22–275 mg/L) but normal lactate dehydrogenase (165 U/L; <220 U/L). 
Blood cultures and serologies for an infectious aetiology (Parvovirus 
B19, Brucella, Coxiella) were negative. PET-CT showed increased 
FDG-uptake in bone marrow and lymph nodes and needle biopsy of 
the latter was compatible with recurrent lymphoma. However, broad 
spectrum bacterial PCR (16s rRNA) from blood and lymph node was 
positive for Candidatus Neoehrlichia mikurensis establishing the 
diagnosis of neoehrlichiosis. Whithin a day after initiation of antibiotic 
therapy with doxycyclin fever ceased and the patient recovered quickly. 
He did not recall a tick bite.
Discussion: Candidatus Neoehrlichia mikurensis is a tick-transmitted, 
nonculturable intracellular bacterium recently identified to cause 
prolonged fever in immunocompromised patients particularly after 
rituximab. Additional symptoms include malaise, weight loss, myalgias, 
arthralgias as well as vascular and thromboembolic events. Up to 8% 
of swiss Ixodes ticks are infested with Ca. N. micurensis. Nevertheless, 
neoehrlichiosis remains a rarely identified disease suggesting only 
mild and transient symptoms in immunocompetent hosts. However, 
neoehrlichiosis should be actively searched for using molecular 
diagnostics in immunocompromised patients with fever and/or 
unexplained inflammation since exposure is easily possible in 
Switzerland and treatment with doxycyclin is simple and highly 
effective. 
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Pulse corticosteroids-induced bradycardia
Matteo Coen1, Bérénice Cramer1, Maxime Borgeaud1,  
Aline Gabrielli1, Léa Guibentif1, Peter Jandus2, Jörg Seebach2, 
Jacques Serratrice1 
1Service of Internal Medicine, Department of Internal Medicine, 
Rehabilitation and Geriatrics; 2Service of Immunology and Allergology, 
Department of Internal Medicine Specialties, Geneva University 
Hospitals, Geneva, Switzerland
Introduction: High dose intravenous (pulse) corticosteroid therapy is 
used to treat a vast array of diseases. Pulse corticosteroids-induced 
bradycardia is rare and has been seldom reported.
Methods: We describe the case of a patient with neutrophilic 
dermatosis who developed bradycardia after pulse 
methylprednisolone. We used the Naranjo adverse drug reaction 
probability scale to determining the likelihood of a causal relationship 
between bradycardia and steroid administration.
Results: A 36-year-old woman was admitted to our unit for myalgia 
and fever. Patient’s medical, family, allergy and travel history was 
insignificant. She was taking no drugs or medications and denied 
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IgG4-related disease without IgG4.  
Don’t forget the plasmablasts
Matteo Coen1, Omar Kherad2, Dan Adler3, Nicolas Mach4,  
Angela Pugliesi-Rinaldi4, Jacques Serratrice1 
1Service of Internal Medicine, Department of Internal Medicine, 
Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva; 
2Internal Medicine, La Tour Hospital, Meyrin; 3Service of Pneumology, 
Department of Internal Medicine Specialties; 4Service of Oncology, 
Department of Internal Medicine Specialties, Geneva University 
Hospitals, Geneva, Switzerland
Introduction: IgG4-Related Disease (IgG4-RD) is a rare autoimmune 
disorder. Histologically, it is characterized by the infiltration of IgG4 
plasmablasts in different organs and fibrosis. Different studies suggest 
that IgG4-RD predisposes to the development of certain tumours. 
Methods: We describe the case of a patient with multiple fibrotic 
nodules in which IgG4-RD was suspected. 
Results: A 60 years-old woman was referred to us for a with a 5-year 
history of recurrent pancreatitis without a definite cause despite 
multiple investigations, including biopsies. A thoraco-abdominal CT 
scan performed during the 4th year of follow-up showed multiple 
bilateral basal nodules; needle biopsy concluded to chronic 
pachypleuritis withoutof malignancy. PET/CT scan at 5-month interval 
showed progression of nodules. Transbronchial biopsy was non 
contributive. Another CT scan at 3-months interval showed 
augmentation of lung lesions and s micronodular infiltration of 
omentum. A few days later the patient developed jaundice. Endoscopic 
retrograde cholangiopancreatography (ERCP) visualized stenosis of 
the common bile duct that was treated with stenting; endobiliary brush 
cytology and biopsies were negative for malignancy. The patient was 
referred to our department for further evauation. Patient’s medical  
and family history was insignificant and physical examination 
unremarkable. Kidney and liver function, viral serologies and a 
complete immunological panel including protein electrophoresis and 
immunofixation were normal. Flow cytometry showed abundant 
circulating IgG4-positive plasmablasts suggesting an IgG4-RD. PET/
CT was repeated and showed multiple hypercaptating lesions at 
pancreas and lung. Thoracoscopic wedge resection of two pulmonary 
nodules was performed. Histology was consistent with metastases  
of a moderately differentiated adenocarcinoma with mucinous 
differentiation; immunohistochemistry could not distinguish between 
lung or pancreatic origin. Analysis of the lymphocytic infiltrate showed 
an IgG4/IgG ratio of à 75% compatible with IgG4-RD. The patient, 
actually at the 5th FOLFIRINOX cycle, is asymptomatic without 
radiologic evolution. 
Conclusion: When we encounter a fibrotic disease of unknown 
etiology, IgG4-RD is often evoked but rarely found. Normal serum IgG4 
levels should not preclude diagnosis in a patient with a high clinical 
suspicion of IgG4-RD. Identification and measurement of IgG4 
plasmablasts by flow cytometry can be a useful tool. 
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Neurolisteriosis mimicking progressive multifocal 
leukoencephalopathy in an immunocompromised patient
Alexia Cusini1, Valerie Luyckx2, Hannes Stefan Josef Haller2,  
Claude Nauer3 
1Infektiologie; 2Klinik für Innere Medizin, 3Klinik für Radiologie, 
Kantonsspital Graubünden, Chur, Switzerland
Introduction: A 78 year old man presented to our emergency 
department complaining of severe diarrhea for three days. The patient 
was taking methotrexate and prednisone 50 mg for a remitting 
seronegative, symmetrical synovitis for 14 months. On admission the 
patient was hemodynamically stable and afebrile. His CRP was 
elevated at 173 mg/l, leucocytes were 9200/ul with a lymphocyte count 
of 140 /ul. Fluid replacement was initiated and stool cultures were 
performed. On day 2 the patient developed a fever of 39 °C. Given a 
suspicion of infectious enteritis blood cultures were taken and empiric 
antibiotic therapy with piperacillin/tazobactam was initiated.
Methods: Given intermittent somnolence despite antibiotic therapy, 
although the patient had no headache, focal neurologic signs or signs 
of meningeal irritation, a MRI of the brain and a lumbar puncture were 
performed on day 7 respectively on day 9. 
Results: The blood and stool cultures grew Listeria monocytogenes 
after 24 hours. Antibiotic therapy was deescalated to amoxicillin (2 g IV 
every four hours). The MRI of the brain showed in the right temporal 
lobe a lesion of the white matter that appeared hypointense in T1 and 
hyperintense in T2, typically seen in patients with progressive 
multifocal leukoenzephalopathy (PML).The CSF showed a minimally 
elevated cell count with 8 polymorphonuclear cells / mL. Protein and 
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A rare cause of severe systemic inflammation  
and bilateral femoral head osteonecrosis
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Kantonsspital St. Gallen, Switzerland
Introduction: Femoral head osteonecrosis is a rare disease occurring 
not infrequently bilateral. Superinfections are rare and can be 
associated with risk factors for bacteremia (central lines, urinary tract 
infection, etc.). 
Case report: A 63-year-old female patient with severe pain from 
bilateral femoral head osteonecrosis was admitted for bilateral hip joint 
replacement. Blood analyses are shown here:
Table: Blood analysis
  Result Normal values
Hemoglobin 86 g/l 120–160 g/l
Leucocytes 13.5 G/l 4–10 G/l
Platelets 604 G/l 150–300 G/l
Albumin 18.9 g/l 34–48 g/l
C-reactive Protein 228 mg/l <8 mg/l
Three months earlier the patient was hospitalized in another clinic 
because of an urosepsis with Escherichia coli. At that time, chronic hip 
pain exacerbated and advanced bilateral femoral head osteonecrosis 
was diagnosed radiologically. Two weeks after discharge the patient 
had fever, felt weak and increased inflammatory markers (CRP 168 
mg/l) and a low hemoglobin of 66 g/l (which was 89 g/l at discharge) 
were measured. An upper and lower endoscopy, CT scan and a bone 
marrow aspirate were performed without further diagnostic clues. 
Finally, an 18F-FDG PET/CT Scan showed FDG-uptake in both hips 
what was considered as a consequence of femoral head 
osteonecrosis.
Figure 1: PET-CT Scan.
The implantation of a total hip prosthesis was performed first on the 
right side. As preoperatively planned the femoral head was taken for 
histological and microbiological examinations. Postoperative 
antimicrobial treatment with intravenous amoxicillin/clavulanate was 
started. Histology showed destruction of the femoral head and 
osteomyelitis. A pansensible E. coli was grown. Ten days later, a 
Girdlestone situation was created on the left side. E. coli osteomyelitis 
could also be diagnosed there. Amoxicillin/clavulanate was changed to 
ceftriaxone and after 4 weeks to ciprofloxacin per os. A rapid clinical 
improvement and a slow decrease of the inflammatory markers 
occurred. After 12 weeks, antimicrobial treatment was stopped and 
after an interval of 2 weeks and normal CRP, the implantation of the 
left hip joint was done. One year later, the patient was free of pain and 
had a good function of both prosthesis. 
Conclusion: In patients with femoral head osteonecrosis and elevated 
inflammation markers, superinfection should be considered. It is very 
important to initiate a histological and microbiological examination of 
the femoral head. FDG uptake is unspecific and cannot differentiate 
between neoplasia and inflammation caused by necrosis or infection. 
Only few cases of documented bilateral superinfection of bilateral 
femoral head osteonecrosis were found in the literature. 
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excluded. Sepsis diagnosis was made with both old and new definition. 
For the old definition, at least two of four SIRS criteria had to be 
present. For the new definition, quick SOFA score was done. If this 
was positive, sepsis was confirmed with an at least two point increase 
in SOFA Score. 
Results: 176 patients were included. 29 patients had no sepsis in both 
definitions. While according to the old definition, 144 patients were 
diagnosed to have a sepsis, this was present in only 70 patients 
according to Sepsis 3.0. 67 patients were found to be septic in both 
the old and the new definition. Only three patients were “upgraded”, 
having no sepsis according to the SIRS definition but fulfilled the 
criteria of Sespis 3.0. 
Conclusion: In Non-ICU patients, only about half of the patients  
with Sepsis according to the old definition fulfil criteria of Sepsis 3.0. 
These could have implication for case-weights in the DRG-System. 
Table 1
New (Sepsis 3.0)  
sepsis no Sepsis total
Old Definition sepsis 67  77 144
  no Sepsis  3  29  32
  total 70 106  
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Treatment of Helicobacter pylori unmasking  
Whipple’s disease
Caroline Hochuli1, Gabriela Bösch2, Susann Hasler1,  
Jacques Gubler1 
1Department Medizin, Kantonsspital Winterthur, Winterthur; 
2Department Medizin, Stadtspital Triemli, Zürich, Switzerland
Case: A 54-year old man presented with a 10 year long history of 
twice weekly intermittent fever, arthralgia, soft tissue swelling and 
systemic inflammation. Numerous medical evaluations at different 
institutions including innumerable tests for malignant, infectious or 
autoimmune diseases, including PET/CT scans and bone marrow 
biopsy yielded no conclusive results. Histology of a duodenal biopsy 
had shown no evidence for Tropheryma whippelii (TW) in 2009. The 
only short period the patient reported lack of symptoms was following 
a treatment with amoxicillin, metronidazol and pantoprazol for a 
helicobacter pylori (HP) infection. Triggered by the history of response 
of the symptoms to antibiotics during HP eradication therapy, a new 
search for Whipple’s Disease (WD) was initiated. Again no histological 
signs for TW were found in a duodenal mucosal biopsy. However, PCR 
for TW was positive in duodenal mucosa and in stool. Treatment with 
cotrimoxazol had to be changed to ceftriaxone due to a severe DRESS 
syndrome (drug reaction with eosinophilia and systemic symptoms), 
followed by doxycycline and hydroxychloroquine for an ongoing 12 
months. The medical condition improved dramatically within days of 
starting ceftriaxone treatment: Systemic inflammation and symptoms 
disappeared and physical performance improved rapidly. The patient 
has been free of any symptoms since August 2016.
Discussion: Whipple’s Disease is a rare, systemic infection caused  
by the intracellular bacterium Tropheryma whippelii (TW). Clinical 
presentation may vary greatly and can mimic multiple clinical 
conditions. All organs can be affected. In classical gastrointestinal WD, 
the clinical condition and PAS-positive foamy macrophages in the 
lamina propria of duodenal mucosa lead to the diagnosis. In 
extraintestinal disease, the histological or PCR finding of TW in 
specimens are proof of infection. TW can be a commensal of the 
upper GI-tract, therefore a PCR result in both duodenal mucosa and 
stool leaves a 10% likelihood of false positivity. The diagnosis of a 
TW-associated condition must then be assumed by the clinical 
response to antibiotic therapy. In our patient, careful history taking led 
to a clinical suspicion, the response of a year-long clinical illness to 
antibiotics on two occasions makes us confident to classify our patient 
as having probable, albeit not completely proven TW associated 
systemic infection. 
glucose were normal. The CSF culture showed no growth, but the 
patient was on antibiotic therapy for eight days. The eubacterial  
PCR and the specific PCR for HSV I and II, CMV, EBV and JC were 
negative. Under treatment for listeriosis the patient improved, his 
altered neurological status normalized. A control MRI three weeks later 
showed a clear regression of the temporal lesion, which retrospectively 
was clearly interpreted in line with an encephalitis due to Listeria 
monocytogenes. 
Conclusion: CNS-listeriosis is challenging to diagnose. As described 
here, the symptoms are often atypical, meningeal signs uncommon 
and the CSF findings non-specific. Listeria monocytogenes has a 
predilection for the brainstem and cerebellum; lesions in the temporal 
lobe as in our case have rarely been reported. The clinical course in 
our patient is highly suggestive of cerebral listeriosis which needed a 
prolonged antibiotic therapy of six weeks. Brain imaging and lumbar 
puncture should be considered early in immunosuppressed patients 
with listeria and any neurological symptoms. 
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Involvement of the adaptive immune system  
in metamizole-induced agranulocytosis 
Dolores N. Dina1, Klara K. Eriksson1, Rudin Deborah2,  
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Introduction: Metamizole is an analgesic and antipyretic drug that 
represents an alternative when NSAID and acetaminophen are 
contraindicated. Nevertheless treatment with metamizole can lead to 
life-threatening agranulocytosis in rare cases. To date mechanisms 
underlying metamizole-induced agranulocytosis (MIA) remain 
unknown. A few cases of patients re-exposed to metamizole reacted 
with rapid onset and more severe symptoms are known. This suggests 
that the adaptive immune system could be a key player in the 
pathogenesis of MIA. 
Methods: A clinical cohort has been created including MIA patients, 
metamizole tolerant patients and unexposed healthy donors. PBMC  
of these three groups are being cultured with metamizole and its 
metabolites in vitro. Cellular activation is analyzed by measurement  
of CD69 upregulation and proliferation with flow cytometry. Generation 
of metamizole-reacting T cells lines is performed as well. 
Results: The reactivity of T cells from MIA patients towards 
metamizole or its metabolites has been investigated using capacity of 
T cells to proliferate, to secrete cytokines (TNFα) and to be cytotoxic 
(CD107a) after antigen encounter. So far a T cell response against 
metamizole could not be obviously shown. Indeed the proliferation 
seen in MIA patient was only moderate and did not reach statistical 
significance when compared with control groups. Furthermore, TCL 
generation was not easily achieved and TCL reactivity could not be 
kept in vitro over a long period. T cell response in MIA patients cannot 
be excluded either at this point.
Conclusion: These non-significant results may be due to several 
reasons: a low detection threshold, an inadequate stimulation, a still 
unknown metabolism or a maladjusted protocol to the drug used. 
Furthermore, the time period between the disease outbreak and the  
in vitro analysis was on average of 49.5 months. According to the 
practical experience acquired on delayed type hypersensitivity reaction 
to drugs, the optimal diagnostic window is between 6 weeks and 6 
months after a complete and sustained acute symptoms resolution.  
It is known that the number of specific memory cells in the peripheral 
blood decreases over time. For this reason, 49.5 months appear to  
be too long to allow the detection of memory cells with conventional 
methods. Therefore we cannot conclude that metamizole did not 
induce a T cell response in MIA patients. 
P394
Comparison of new and old definitions for diagnosis  
of sepsis in non-ICU patients
Rein Jan Piso1, Sebastian Stibitz2, Stefanie Jenni2 
1Medizinische Klinik, Infektiologie; 2Medizinische Klinik,  
Kantonsspital Olten, Olten, Switzerland
Background: Definition of Sepsis used to be based on SIRS criteria. 
However, these criteria turned out to be too permissive and diagnosis 
of sepsis did not have impact in prognosis or treatment. The new 
definition (Sepsis 3.0.) is based on organ dysfunction and should more 
reliably select patients with critical infectious situations. 
Methods: Inclusion criteria were hospitalized febrile patients, in whom 
an infectious disease consult was performed. ICU-patients were Figure 1: Intermittent soft tissue swelling.
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Conclusion: Despite higher workload on the countryside, the job 
satisfaction does not essentially differ between city and countryside. In 
the city as well as in rural areas shortage of GPs is considered a 
serious issue. We found significant differences between the linguistic 
regions in Switzerland that should be considered when implementing 
political measures. 
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Use of new oral anticoagulants in an academic  
primary care medicine facility: where are we now?
Yves Jackson, Adriana Keta, Noëlle Junod Perron 
Service de Médecine de Premier Recours, HUG, Genève, Switzerland
Direct oral anticoagulants (NOAC) have become the first alternative  
to vitamin K antagonists (VKA) showing a reduced hemorrhage risk, 
short half-life, lack of food interaction, need for monitoring and minimal 
drug interactions. The only drawback is the limited availability of an 
antidote. Few studies have looked at the adoption of these drugs by 
primary care physicians. 
Objectives: To evaluate the proportion of patients currently receiving 
VKA eligible for NOAC and to facilitate interns uptake of the new 
recommendations. 
Method: The study was conducted within the Division of Primary  
Care Medicine. All patients receiving VKA and followed-up between 
April 2015 and May 2016 were included. Based on the HUG 
recommendations on NOAC, we designed a study file exploring: 
sociodemographic data, indications for anticoagulation, duration of 
follow-up, number of venous and capillary INR checks, proportion of 
therapeutic values, therapeutic adhesion, and the presence or 
absence of contraindications to NOAC. After a pilot test, interns were 
asked to analyze a set of electronic medical records (EMR). 
Results: Each intern spent 2 hours conducting in-depth analysis of 
5-7 EMR. Fifty-seven patients on VKA were identified (men: 71.9%; 
mean age: 63.6, standard deviation: 14.6 years). Indications for 
anticoagulation were: treatment or prevention of thromboembolic 
events (n = 13, 23%), prevention of stroke by non-valvular atrial 
fibrillation (AF) (n = 19, 32.7%), prevention of stroke by valvular AF  
or mechanical valve (n = 17, 30.7%), others (n = 8, 13.6%). In the 35 
(61.4%) patients eligible to NOAC therapy, the average duration of 
VKA treatment was 5.4 (SD: 4.7) years. The previous year’s mean 
number of venous and capillary INR measurements was 9.4 (SD: 10.6) 
and 9.7 (SD 9.5). The percentage of patients with INR within the 
therapeutic range in more than 50% of tests was 38.2%. Therapeutic 
adhesion was evaluated as good in 50%. Only 21.2% had medical 
contraindications and 8.8% pharmacological contraindications. After 
considering all factors, 22 (63%) patients could benefit from a change 
in oral anticoagulation in favor of NOAC. However, only 11% had been 
switched to NOAC during the one-year study period. 
Conclusion: A minority of patients had safe and effective 
anticoagulant therapy. Nearly two-thirds on VKA could theoretically be 
switched to a NOAC while the actual rate of change was low. Next step 
will imply measuring the impact of training on the guidelines adoption. 
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Syrian crisis: an innovative sanitary response  
in the canton of Vaud
Jeremie Blaser1, Ioana Hincu1, Brigitte Pahud-Vermeulen1,  
Mario Gehri2, Joan Carles Suris Granell 2, Eric Masserey3,  
Patrick Bodenmann1 
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Introduction: The Swiss government started a resettlement program, 
in collaboration with the United Nation High Commission on Refugees 
(UNHCR) to facilitate the arrival of particularly vulnerable refugees 
from Syria. As those refugee families don’t follow the usual procedure 
for asylum seekers, a dedicated healthcare program is needed. Around 
1800 persons are expected to arrive in Switzerland between 2016 and 
2017 from the resettlement program. The objectives of the present 
project are: 1) To provide the necessary healthcare for this particularly 
vulnerable population in the canton of Vaud. 2) To gather information 
about this population, in terms of medical conditions, but also from a 
more holistic view of the families, as we know they are selected on 
vulnerability criteria. This can be used as a feedback to the health 
authorities about the specific needs of this population.
Method: An interdisciplinary family consultation was set up for  
those families, staffed with a pediatrician, a general practitioner, an 
interpreter, as well as a nurse practitioner. At the 1st consultation,  
a health assessment is provided to the family at the same time. 
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Written interprofessional communication in the  
follow-up of homebound patients
Julien Le Breton1, Sophie Pautex2, Olivier Perrier-Gros-Claude3, 
Patricia Hudelson1, Noëlle Junod-Perron1 
1Service de Médecine de Premier Recours, Hôpitaux Universitaires  
de Genève, Genève; 2Unité de Gériatrie et de Soins Palliatifs 
Communautaires, Hôpitaux Universitaires de Genève; 3Institution 
Genevoise de Maintien à Domicile, Carouge, Switzerland
Introduction: In the follow-up of homebound, polymorbid patients, 
health professionals in Geneva often use a point-of-care notebook to 
share information with each other (“carnet de liaison”). The aim of the 
study was to analyse how and for what health professionals used such 
notebooks and to explore their perceptions regarding the strengths 
and weaknesses of such written notes for interprofessional 
collaboration.
Methods: We conducted a mixed-method study among health 
professionals caring for homebound patients in the canton of Geneva, 
Switzerland. A sample of notebooks of homebound elderly patients in 
Geneva was first analysed descriptively. Then 6 focus groups 
interviews were conducted with different groups of health professionals 
(doctors, nurses and nursing aides). Focus groups were transcribed 
verbatim and analysed thematically.
Results: The analysis of 11 notebooks revealed that most of the  
time, the intended recipient of written information was unspecified;  
content focused mainly on somatic health and medication; explicit 
interprofessional communication was rare and patients never wrote 
down any information. There were no explicit care plan goals. 
Thirty-one health professionals participated to the focus groups. 
Several themes emerged. Participants felt that the notebook embodied 
the primary care network and was a milestone in the follow-up of 
homebound polymorbid patient. However, in the absence of a shared 
electronic health record, most of them complained about having to 
write the information down at least twice. The fact that the notebook 
was accessible to anyone and was considered the patient’s property 
influenced how and what professionals wrote in the notebook. Lack of 
patient contributions to the notebook was a source of concern.
Conclusions: Our results show that fulfilment of notebook’s primary 
function (i.e. share information and communicate among health 
professionals) is suboptimal. In order to enhance patient-centered, 
written interprofessional communication, more attention should be paid 
to defining and implementing care plan goals. 
P397
Regional variation in primary care in Switzerland?  
Work Force Study 2015
Timon Wartenweiler, Stéphanie Giezendanner, Andreas Zeller 
Universitäres Zentrum für Hausarztmedizin beider Basel, Liestal, 
Switzerland
Introduction: The issue of shortage of General Practitioners (GPs)  
is an important matter of debate. With the Work-Force-Study 2015 the 
current work situation of GPs was assessed. The aim of this study was 
to evaluate whether in primary care regional variation exist in terms  
of working hours, workload, and job satisfaction in Switzerland.
Methods: In 2015 a 7-page survey assessing the work conditions  
was sent to 3554 Swiss GPs. In total, 1299 surveys (response rate of 
36.6%) were available for analysis. The questionnaire was available  
in German (n = 964), French (n = 273) and Italian (n = 62). The study 
population consisted of 26% female GPs and the average age was 55 
years. The data was analysed for potential differences between cities, 
agglomeration, and countryside. For the classifications of these 
categories a definition of the Federal Statistical Office was applied. 
Additionally the data was investigated for potential differences between 
the three linguistic regions in Switzerland. 
Results: GPs on the countryside have more patient contact per week 
compared to their colleagues in the city (36.7 hours vs. 33.3 hours, p = 
0.002). Rural doctors provide essentially (p <0.001) more emergency 
services (38.1 days per year) than in the city (10.1 days per year). 
Country doctors are as satisfied with their workload (p = 0.35) and 
work situation in general (p = 0.415) as their colleagues in the other 
regions. The proportion of GPs who perceive a lack of GPs lies 
between 55.7% and 65.3% without reference to rurality (p = 0.053). In 
the German-speaking part GPs have weekly contact with their patients 
during 33.8 hours whereas in Romandy they have 35.6 hours and in 
Italian-speaking part 35.0 hours (p = 0.045). German-speaking GPs 
see 104.4 patients, French-speaking 83.1 patients and Italian-
speaking 91.1 patients in one week (p <0.001). The proportion of GPs 
being available by phone after working hours for their own patients is 
highest in the Italian-speaking part (89.1%), in the other regions this 
proportion lies by 49.2% (p <0.001).
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layout of the monitoring tool enhances user friendliness and facilitates 
chronic care by means of an EHR. In the near future, the Delphi 
procedure will be extended to an international level aiming at a 
European consensus paper on monitoring of chronic diseases by 
means of EHR. 
IHAMZ: Institut für Hausarztmedizin Zürich (Institute of Primary Care, 
University of Zurich)
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Involvement of a group of simulated patients in a  
patient advisory group to conduct iterative cycles  
of evaluation and adaptation of communication material  
to the public. Results from a pilot project
Regula Cardinaux, Kevin Selby, Jacques Cornuz, Reto Auer 
Policlinique Médicale Universitaire, Lausanne, Switzerland
IIntroduction: Guidelines recommend a participatory approach with 
target populations when developing decision aids and communication 
materials (CM). While focus groups enable patients to comment on 
CM, they are often conducted with final versions of CM, limiting 
opportunities for significant changes. Iterative cycles of evaluation and 
adaptation allow users to shape CM at early stages of development 
and to verify whether changes improve the CM. We aimed to test the 
feasibility and yield of involving a group of simulated patients in a 
patient advisory group to improve CM developed within a statewide 
colorectal cancer (CRC) screening program.
Methods: We invited simulated patients aged 50–69 years involved in 
the teaching of medical students from the University of Lausanne to 
participate in a patient advisory group. Exclusion criteria were personal 
history of CRC. We planned 2h meetings every 3 months and used  
a cyclic approach: we submitted the CM beforehand, collected the 
comments during group discussions, identified specific adaptations  
to be made, adapted the CM, and re-submitted the modified CM to  
the group for further adaptations. Participants received a CHF 
50.– voucher per meeting for their participation.
Results: Out of the 20 eligible simulated patients invited, 5 (25%) 
accepted the invitation. They came to 4 meetings every 3 months over 
a 12-month period. Their comments helped to identify discrepancies 
between the intended and perceived tone of messages in CM, test the 
proposed solutions and readapt based on repeated evaluation. In 
particular, they commented on the overall presentation, the vocabulary, 
formulations, and the character of the message. In addition, they 
suggested developing new CM for people with special needs. All 
participants said they would recommend others to participate in these 
groups and approved the process of implicating patients in the 
development of CM.
Conclusion: The participative approach of having CM be reviewed by 
a patient advisory group improved the CM and helped identify critical 
elements and avoid discrepancies in the CM. The cyclic approach was 
useful to clarify our understanding of the comments of the participants. 
This pilot project highlighted the willingness of participants to be 
implicated in the process of evaluation of medical CM. The method 
should now be rigorously tested in particular with populations with 
special needs. 
Vaccinations are proposed and screening for tuberculosis is planned 
for children systematically. Patients can then be oriented toward 
different medical specialties as needed. A second consultation is 
planned two months later for a clinical follow-up, to pursue the 
vaccination plan, and to discuss the results if tests were performed.  
A shared meeting with the medical team concludes the assessment. 
After this 2nd consultation, a follow-up with a private general 
practitioner and/or pediatrician is organized.
Results: Between July and December 2016, 60 persons have been 
seen for a first medical evaluation, including 32 adults and 28 children. 
The adults had on average complaints concerning 3.1 chapters of the 
ICPC-2 classification (classification of symptoms and medical 
conditions for primary care), and children 1.3. With the use of a 
validated vulnerability scale published by Bodenmann & al: 2 adults 
were identified with 4 axes of vulnerability and 3 with 3 axes. One child 
was identified with 3 axes. 
Conclusion: The interprofessional model of a consultation for Syrian 
migrant families is feasible. It could be implemented in other cantons 
receiving Syrian refugees and could be extended to different refugee 
populations. Medical information about this population can be useful to 
the health authorities. 
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Monitoring of patients with chronic diseases  
in primary care using electronic medical record
Leandra Falck, Marco Zoller, Thomas Rosemann, Corinne Chmiel 
IHAMZ, Institut für Hausarztmedizin Zürich, Universität Zürich 
(Institute of Primary Care, University of Zurich), Zurich, Switzerland
Purpose: Non-communicable diseases account for about 80% of 
health costs in Switzerland. Long term care for patients with chronic 
diseases poses a huge challenge. Deficits exist regarding monitoring 
and structured follow up. Our goal was to develop an evidence based 
and practical tool to help monitor patients with chronic diseases by 
means of an electronic health record (EHR).
Methodology: Five highly prevalent chronic diseases were chosen  
to develop the monitoring tool: Diabetes mellitus type 2, arterial 
hypertension, asthma, osteoarthritis and chronic heart failure. A  
best practice review among international guidelines was performed 
searching for indicators how to monitor each disease. In order to find 
further relevant indicators, this search was complemented by a 
systematic review of primary literature on the subject “monitoring”. 
The resulting two data sets were then combined and evaluated by 
selected experts of each speciality by means of a Delphi procedure 
(fig. 1).
Figure 1: Study flow.
Figure 2: Monitoring tool for 
Type 2 Diabetes mellitus.
Results: This multi-step procedure resulted in a condensed set of 
indicators, divided into sublayers to maximise ergonomics. A cockpit 
serves as an overview of fixed goals and set procedures to facilitate 
disease management. An additional tab contains information on 
non-disease specific indicators, as for example allergies and vital signs 
(fig. 2).
Conclusion: To our knowledge this study represents the first 
scientifically founded recommendation for the standardised long term 
monitoring of chronically ill patients in general practice. The ergonomic 
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for discontinuation were organizational (40.9%) and financial aspects 
(18.1%) and the general practitioner refusing to hand over treatment 
responsibility (18.1%). Development of HbA1c, BP, LDL-cholesterol 
and PACIC showed some significant positive effects in favor of 
practices originally randomized to the intervention group and practices 
continuing to treat patients according to the CCM. 
Conclusions: Diabetes care according to the CCM including the 
involvement of practice nurses is a reasonable tool to improve care 
also in the long-term. CCM-training of the whole team is essential to 
overcome organizational challenges. Continuous team education, 
technical decision support, as well as recognition of the importance of 
these new structures by health care policy might improve the long term 
clinical effect of the team approach. 
TRIAL REGISTRATION: The study protocol was published in 
Cardiovascular Diabetology in 2010, registration number: 
ISRCTN05947538.
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Vulnerable patients in an academic community health  
centre in Geneva: health needs, services utilization  
and impact of nurses front-line consultation
Yves Jackson1,2, Antoine Fernandez3, Gilles Hourton1,  
CAMSCO Nurses 
1Service de Médecine de Premier Recours, HUG; 2Institut de Santé 
Globale, Université de Genève, Genève; 3Université de Genève, 
Geneva, Switzerland
Introduction: The community health centre (CAMSCO) of the  
Geneva University Hospital (HUG) is a unique academic structure in 
Switzerland, serving as a walk-in clinic for patients with socioeconomic 
vulnerability and as a port of entry into the public healthcare system. 
Nurses conduct first-line comprehensive assessment and do triage 
and orientation. We aimed at characterizing patients health needs, 
health services utilization and the impact of front-line nurses 
consultation. 
Methods: We included all patients consulting in August 2016 and 
extracted data from their health records. 
Results: The 483 patients were mostly female (60.9%), aged 40.1 
(SD: 11.9) years old. Only 1.5% were insured in Switzerland and 8.1% 
were homeless. They originated from Europe (17.4%), Asia (23.2%), 
Latin America (39.5%) and Africa (19.9%). It was the first contact ever 
with HUG in 26.7%, whereas 47.3% had consulted CAMSCO in the 
previous year. The mean number of HUG consultation in the previous 
year was 2.8 (SD: 5.4). Patients entailed 553 consultations and had  
an average of 1.5 (SD: 0.7, range: 1-6) health complains. Women chief 
complains were sexual or reproductive (38.5%) and osteoarticular 
(9.1%) whereas men had mainly dental (14.6%) and skin (11.4%) 
complains. Mental health problems were frequent secondary 
complains. Access to prescription medicines was the main reason  
for consulting in 10.5% of the whole cohort. Seventeen (3.1%) 
consultations were triaged as urgent and required referral to the 
emergency room and 22.6% necessitated a complementary 
consultation by the intern on site. Nurses could manage 21.5%  
cases alone. Main referral destinations were division of primary care 
medicine (22.6%), gynecology and obstetrics (16.6%) and dentists 
(8.5%). On a 5-point Likert scale assessing subjective case 
complexity, average score was 2.2 (SD: 1) points. On average, 
consultations lasted 21 (SD: 14) minutes. 
Conclusion: CAMSCO acts as an advanced primary care health post 
in the community with a high patients turnover. Its activity highlights 
hidden healthcare needs of very diverse populations in urban context 
in Switzerland. Front-line nurses solve a consequent share of cases 
and patients showed overall limited health services utilization. Yet, 
given the variety of health problems severity and nature, effective 
referral processes with secondary structures is required. Access to 
dental healthcare and to medicines represents major challenges in this 
vulnerable group of population. 
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4-year-long-term follow-up in diabetes patients after 
implementation of the Chronic Care Model in primary care 
Corinne Chmiel1, Irina Giewer1, Anja Frei2, Thomas Rosemann1 
1Institut für Hausarztmedizin der Universität Zürich; 2Institut für 
Epidemiologie, Biostatistik und Prävention der Universität Zürich, 
Zürich, Switzerland
Introduction: Implementing the Chronic Care Model (CCM) via 
involvement of specially trained practice nurses improves 
cardiovascular risk profile as well as perception of care among type 2 
diabetes patients in small primary care practices (PCP) on the short 
term. Little is known on the long term effects of this intervention. 
Methods: Cross-sectional survey among the participants of the cluster 
randomized controlled CARAT trial (30 PCPs, 303 diabetes patients) 
three years after its completion. 
Outcomes: proportion of patients still treated according to CCM, 
possible reasons for discontinuation, glycosylated hemoglobin 
(HbA1c), blood pressure (BP), LDL-cholesterol, and accordance to 
CCM (assessed by PACIC (Patient Assessment of Chronic Illness 
Care)).
Results: 40.9% of practices (40.7% of patients) continued using the 
CCM. PCPs originally randomized to the intervention arm were 
significantly more likely to still using the CCM (p <0.001). Main reasons 
Figure 1: Implementation of the Chronic Care Models over 4 years.
CARAT = Chronic CARe for diabetes trial, n = number of primary care practices, 
Pat = patients, CCM = Chronic Care Model
Figure 2: Study Population and Drop-Outs.
CARAT = Chronic CARe for diabetes trial, n = number of primary care practices, 
x = number of patients, Pat = patients, CCM = Chronic Care Model,  
PCP = primary care practice 
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Case report: A 52-year old woman with marked persistent 
eosinophilia, cough and fever episodes every two to three weeks was 
admitted to our hospital for further evaluation. The chest x-ray showed 
an enlarged heart. Blood tests showed a severely elevated blood 
eosinophilia of 75% (absolute 11 G/l) (fig. 2). Abdominal ultrasound, 
gastroscopy and colonoscopy showed no organ manifestation. Results 
for HIV, parasites and a rheumatological screening were all negative. 
The transthoracic echocardiography and CT scan of chest (fig. 1) 
showed a large pericardial effusion. After puncture (700 ml) just three 
days later the pericardial effusion filled up again. The cytological 
examination showed no malignant cells but also lots of eosinophils, as 
did the investigations of the lung (broncho-alveolar lavage and biopsy). 
A bone marrow punction showed a slight hypercellularic blood forming 
bone marrow with overcome of eosinophils as can be seen in an early 
phase of an eosinophilic leukaemia or an idiopathic hypereosinophilic 
syndrome. The genetic results showed no positive results for 
associated myeloproliferative neoplasms. The idiopathic 
hypereosinophilic syndrome is an exclusion diagnosis and we assume 
in our case, because we found no other reason, that´s the most likely 
diagnosis. Because of the large pericardial effusion and marked 
persistent eosinophilia and pulmonary involvement we started with an 
immunosuppressive medication (prednisolone). Just ten days after the 
eosinophilic blood count normalized (fig. 2) and under the therapy 
echocardiographically no pericardial effusion was seen anymore. 
Conclusion: Marked persistent eosinophilia is a diagnostic dilemma 
and identifying the cause is a challenging problem. A systematical 
approach can help to detect organ involvement and thus prevent of 
ongoing severe organ damage. 
P404
Mst1 expression in serum is an independent  
prognostic marker in breast cancer patients
Xiaoyan Lin1, Fengfeng Cai1, Su Chen2, Rongrong Cui1,  
Xin Pan3, Ewelina Biskup1,4 
1Breast Cancer Unit, University Hospital Yangpu, Shanghai; 2School of 
Forensic Sciences, Xi’an Jiao Tong University Health Science Center, 
Xi’an, Xian; 3Central Laboratory, Yangpu Hospital, Tongji University 
School of Medicine, Shanghai, China; 4Innere Medizin, 
Universitätsspital Basel, Basel, Switzerland
Backgroud: Mammalian sterile20-like kinase 1 (Mst1) is a major 
inhibitor of cell proliferation, involved in apoptosis, oncogenesis, and 
organ growth via its ubiquitously encoded serine threonine kinase. 
Mst1 has tumor-suppressor function in human breast cancer. Mst1 
deletion or mutation is associated with tumorigenesis, whereas Mst1 
overexpression leads to tumor cell apoptosis and decreases 
tumoriproliferation. Breast cancer is the most common cancer in 
women worldwide and second most common cancer overall. Still, 
there is a limited choice of prognostic factors and individualized 
treatment strategies.
Methods: We measured Mst1 levels in patients’ plasma in order to 
elucidate their correlation with the overall and disease free survival 
(OS, DFS). ELISA was used as an efficient and effective method to 
quantify Mst1-concentration in the serum of breast cancer patients. 
Blood samples were prospectively collected for 12 months at the 
Department of Breast Surgery, Yangpu Hospital. 98 women were 
included and completed the follow up of 98 months. Blood samples 
were taken prior to any surgical or antitumor treatment. Distribution of 
tumor grades and receptor status were representative. The majority of 
the patients presented with carcinoma of a ductal type with luminal 
subtype, grade 2. 
Results: Average Mst1-level was 1.8 µg/mL and was used to 
discriminate Mst1-positive vs. Mst1-negative breast cancers. Patients 
with positive expression of Mst1 had a significantly better overall and 
disease free survival (P <0.0001) (fig. 1A, B). Univariate Cox analysis 
indicated that Mst1 positivity had a significant difference in overall 
survival in breast cancer patients (P = 0.010). In multivariate Cox 
analysis, Mst1 positivity maintained significance as an independent 
prognostic factor in breast cancer (P = 0.002).
Figure 1A
Conclusion: We were able to demonstrate that Mst1-positive patients 
had a significantly better overall and disease free survival and that 
Mst1 is an independent prognostic factor in breast cancer. Our 
methodological concept facilitates a direct translation into clinic, as it is 
easy, feasible, exact and much less biased than immunohistological 
estimations. Also, the sampling (plasma) is incomparably more 
attractive for daily routine and patients’ comfort. We suggest a novel 
way to assess Mst1-levels in breast cancer patients, which can be 
used to predict prognosis and therapy response, and may present 
potential opportunities in breast cancer therapy. 
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Large pericardial effusion and pulmonary involvement  
in a patient with eosinophilia – two severe symptoms  
of a rare disease
Sylvette Baldesberger 
Allgemeine Innere Medizin, Kantonsspital St. Gallen, St. Gallen, 
Switzerland
Introduction: Blood eosinophilia and tissue eosinophilia can be 
caused by numerous diseases that include infectious, allergic, 
neoplastic, primary hematologic disorders and other reasons like 
medications. To identify the cause is a challenging problem. The 
identification of organ involvement by eosinophils is important to 
prevent severe and life-threatening complications. 
Figure 1B
P406
Early readmissions after medical rehabilitation
Michel Kossovsky, Jean-Luc Reny, Christine Cedraschi,  
Christophe Luthy, Anne-Françoise Allaz 
General Internal Medicine, Rehabilitation and Geriatrics,  
Geneva University Hospitals, Genève, Switzerland
Introduction: Early readmissions (occuring within 30 days after 
discharge), are frequent and costly events. They have been 
investigated in several settings, but data after medical rehabilitation are 
scarce. Levels of comorbidity and functional impairment have been 
suggested to be associated with early readmissions. Since 2014 
rehabilitation structures in Switzerland are requested to collect both 
comorbidity measured by the Cumulative Illness Rating Scale (CIRS) 
that assesses on a 4 level scale the severity of the diseases affecting 
14 organic systems; and functional impairment measured by 
Functional Independence Measure (FIM scale) for the building of a 
national tariff structure. We took this opportunity to examine whether 
these validated scales are, actually, related with early readmissions.
Methods: Data concerning patients admitted in two medical 
rehabilitation services were extracted from the information system of 
the Geneva University Hospitals. Only patients discharged towards 
Figure 1: Large pericardial 
effusion in CT scan.
Figure 2: Count of Eosinophils in peripheral 
blood.
Figure 1: Early readmissions 
dynamics.
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Results: Of 257 participants, 136 were nurses (52.9%), 112 physicians 
(43.6%) and 9 were from other fields such as psychologists (3.5%) (fig. 
1). 142 assessments (55%) were obtained, anonymised and analysed. 
Of the three items evaluated all were highly accepted (fig. 2). The 
evaluations’ qualitative analysis permitted the extraction of the 
following main four themes: 1/ the course could be longer and might 
be offered periodically as continuous training (refresh courses); 2/ the 
high quality/fidelity of the simulated patients: 3/ the particularly 
adapted scenarios (timeframe and contents) which were transferable 
to the participants day-to-day reality and 4/ the development of 
interprofessionnalism as a strong new skill. 
Conclusions: Interprofessional training in “breaking bad news” with 
simulated patients gives high satisfaction to pairs of physicians and 
nurses. However, few have the opportunity to attend, depending on the 
number of sessions. Larger resources could improve attendance rates. 
Further research is needed to measure the efficacy of this training on 
participants’ skills improvement and patient’s satisfaction.
P408
Hypercalcemia – an uncommon summation of causes
Ellen Haag, Markus Diethelm, Michael Brändle 
General Internal Medicine, Kantonsspital St. Gallen, St. Gallen, 
Switzerland
Introduction: Hypervitaminosis D and milk alkali Syndrome both are 
rare causes of hypercalcemia. We present a case with severe 
hypercalcemia due to these two causes in combination. 
Case report: A 52 year old mental coach presented with a right-sided 
paroxysmal headache since 3 days, global muscle weakness, great 
thirst and polyuria. He denied taking any medication. Blood tests 
showed severe hypercalcemia with suppressed parathyroid hormone, 
very high 25-OH and elevated 1,25-OH-vitamin D3 levels and acute 
kidney injury. Computed tomography of the chest and abdominal 
sonography were unremarkable, free light chains in serum were 
normal. No evidence was found for a parathyroid-independent 
extrarenal calcitriol production like a granulomatous disease or 
malignancy. Intravenous saline hydration was started. After two days 
we added Torasemid 5 mg/d for 5 days. Because of the slow 
regression of calcium we applied intravenous Pamidronate (Aredia)  
60 mg once. Interrogated again the patient specified the substances 
he took with a view to purification and encouraging health. He took 
every day four capsules of WLS Vitamin D3 containing 50.000 units of 
vitamin D3 for at least two weeks. For the same duration he consumed 
2 teaspoons/day of alkaline supplements (Basenpulver Herbamed) 
against overacidification. Although he denied eating large amounts of 
milk products we witnessed him consuming up to 4–6 yoghurts a day 
during hospitalisation. Following hospitalization, serum calcium and 
renal function normalized slowly but hypervitaminosis D persisted very 
long. More than 3 months later 25-OH vitamin D3 level was still above 
418 nmol/l. 
Conclusion: Hypercalcemia with consecutive kidney injury due to 
vitamin D intoxication is rare because very high doses are necessary. 
Consumption of large doses of vitamin D (50,000 IU/d) for 8 weeks in 
their own home were included. Any new hospital admission occurring 
within 30 days in any of the structures of the Geneva University 
Hospitals after discharge was considered as an event. If patients were 
hospitalized several times during the observation period, only the first 
stay was considered. Survival analysis methods were used for 
describing readmission dynamics and assessing which variables were 
associated with the failure events.
Results: During the years 2014 and 2015, 3374 patients were included 
in the analysis. Among them 424 (11.2%) were readmitted within  
30 days, of which half of them being readmitted within 13 days. 
The risk of readmission was at its peak 9 days after discharge of the 
index stay, decreasing steadily after. 
Table: Variables associated with early readmissions.
Variable Hazard Ratio 95% CI
Age (per additional year) 0.99 0.98–1.01
Sex (M vs. W) 1.08 0.76–1.54
CIRS scale at admission of index stay  
(per additional point)
1.03 1.01–1.06
FIM scale evolution during index stay  
(per additional point)
0.99 0.99–1.01
Comorbidity was the only variable significantly associated with an 
increased risk of early readmission.
Discussion: The dynamics of early readmissions in medical 
rehabilitation was not different from the one observed in general 
internal medicine. In this study, we did not make a distinction between 
planned and unplanned readmissions. However, people returning 
home after medical rehabilitation are rarely planned for additional 
investigations or procedures. Comorbidity was the only dimension 
associated with early readmissions. The distinction between avoidable 
and unavoidable readmissions should be further investigated as the 
former may be related with quality of care. 
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Interprofessionnal training in “Breaking bad news”  
with simulated patients: participants’ satisfaction 
Julien Castioni1, Jean-Baptiste Oboni1, Francine Viret2,  
Serge Gallant3, Fabienne Teike-Lüthi3 
1Internal Medicine, CHUV, University Hospital and University of 
Lausanne; 2School of Medicine, University of Lausanne; 3Formation 
Center, CHUV, University Hospital and University of Lausanne, 
Lausanne, Switzerland
Background: Breaking bad news is a stressful situation for patients, 
their family and also caregivers. This difficult task needs many skills 
such as communication and interprofessionalism. These two skills are 
increasingly taught in Swiss University. However, only a few practical 
courses exist for physicians and nurses during postgraduate and 
practice years. A program has been tested for five years at Lausanne 
University Hospital. It gives caregivers the opportunity to practice 
breaking bad news in pair, namely physician and nurse, with simulated 
patients. We aimed to assess the satisfaction of the participants. 
Methods: From 2011 to 2016, 35 practical courses were given to 3–11 
participants each. Physicians (including students in practical years) 
and nurses participated after achieving a 1.5 hour theoretical course. 
Each four hours practical course contains two to three 15 minutes long 
scenarios, with simulated patients. These are replayed up to twice and 
feedback is given. All participants received a questionnaire with 14 
items and the possibility to add comments. Three items of applicability/
transferability, personal achievement and tailored/personalised 
teaching were evaluated . We regrouped the free comments into four 
main themes. 
Figure 1
Figure 2
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longitudinally follow health status and disease risk factors in a Swiss 
rural cohort, evaluating all health related research and practice 
disciplines to assure development of new implementable and 
successful preventive strategies for healthy aging. 
Methods: Small villages of rural regions in Switzerland with low 
migration rates have been selected for this longitudinal prospective 
study. All residents (age ≥6 years, no upper age limit) are eligible. 
Target enrolment number per village is 300. Examinations and 
measurements encompass medical history, anthropometry, cardiac 
and vascular health, pulmonary function, physical performance, 
nutritional, mental and emotional status, biochemical and molecular 
analyses. Follow-up examinations (identical to baseline) will be 
performed after 5 and 10 years, and in 10-year intervals thereafter. 
Results: In the first participating village, more than 300 participants 
have been enrolled so far. Enrollment will start in a second 
participating village in 2017. 
Conclusions: This study will allow to: (1) identify “hidden” 
(asymptomatic and/or unrecognized) health problems which enhance 
risk for chronic diseases; (2) identify barriers to accessing health care 
and adapting health behaviours; (3) evaluate efficacy of present 
preventive strategies and recommendations; (4) evaluate knowledge 
and attitude towards ongoing health programs and public health 
recommendations; (5) monitor change and progress towards the 
national health objectives; (6) formulate new preventive strategies and 
recommendations based on the findings and knowledge base of the 
last 10 years; (7) formulate models for successful prevention of chronic 
diseases and for healthy aging. 
P411
Summertime swimming in the lake of Zurich suddenly  
turning into shortness of breath and hemoptysis
Carole Guillet, Thomas Bregenzer 
Klinik für Innere Medizin, Spital Lachen, Lachen, Switzerland
Case report: A 66 year old male presented with acute onset of 
shortness of breath NYHA IV, coughing and hemoptysis. Spending a 
summer afternoon together with his wife and grandchildren at the lake 
of Zurich, the symptoms began after having swum about 200 meters. 
Ambient and water temperatures were around 20.0 °C. He had no 
relevant past medical or allergic history. He denied submersion injury 
or aspiration. His initial oxygen saturation was 89% with normal blood 
pressure. A respiratory examination showed bilateral crackles. 
Laboratory findings included a normal arterial blood gas analysis and 
electrolytes, a pro-NT-BNP within normal limits and a slightly elevated 
troponin1 of 84 ng/l (<57 ng/l). Resting ECG did not show any signs of 
acute ischemia and echocardiography showed normal ejection fraction 
with normal wall motility. A thoracic computed tomography scan 
showed bilateral ground glass opacities in the peripheral lungs. We 
initiated treatment with furosemide intravenously. Symptoms of 
pulmonary edema resolved within 24 hours. We diagnosed swimming 
induced pulmonary edema (SIPE) because of typical clinical 
manifestation and complete remission of symptoms after very short 
duration. Slightly elevated troponin was interpreted secondary to 
possible elevated pulmonary arterial resistance during SIPE with 
normal ECG and returned to baseline within two days. 
Discussion: The etiology of acute pulmonary edema is interpreted as 
fluid movement into the alveoli secondary to alteration in one or more 
of Starling’s forces. The exact mechanisms of SIPE, however, remain 
unclear. It has been hypothesized that immersion elevates cardiac 
output for a given oxygen consumption and increases preload and 
thus leads to capillary leakage.
Conclusion: In the setting of acute onset of dyspnea and coughing 
after swimming exercise and without notable co-morbidities, SIPE is an 
important differential diagnosis. Risk factors for developing SIPE have 
been identified as exposure to cold water, arterial hypertension, 
overhydrating, female gender and previous episodes of SIPE. SIPE is 
frequently a self-limiting condition, prognosis is good with supportive 
treatment only. 
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Effectiveness of lipid-lowering therapy in a  
hematopoietic stem cell transplant cohort
Melanie Premstaller1, Melanie Perren2, Sabine Gerull3,  
Jakob Passweg3, Jörg Halter3, Anne B. Taegtmeyer2 
1Medical University Clinic, Kantonsspital Baselland, Liestal; 
2Department of Clinical Pharmacology and Toxicology; 3Department  
of Hematology, University Hospital Basel, Basel, Switzerland
Introduction: Hyperlipidemia is frequently observed in patients after 
hematopoietic stem cell transplantation (HSCT), but is often 
undertreated. With a growing appreciation of the elevated incidence  
young men did not change their calcium levels significantly. Therefore, 
we assume that the ingestion of Basenpulver and milk products 
(resulting in a milk alkali syndrome) enhanced the hypercalcemia. It is 
alarming that over the counter vitamin products which are supposed  
to benefit health are sold with no recommendation of exact daily or 
maximum dosage and no warning for intoxication symptoms. Patients 
do not consider vitamins or food supplements as medication. 
Therefore they often do not specify them when asked and do not fear 
side effects. Thus, it is very important to ask patients specifically for 
vitamins or food supplements. 
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Drug rechallenging and an unlucky acute generalized 
exanthematous pustulosis manifestation
Eliana Tadini, Stojan Todorov, Mireille Nsangu, Véronique Erard, 
Matieu Firmann 
Internal Medicine, HFR, Riaz, Switzerland
Drugs sides effects especially antibiotics side effects are often 
misdiagnosed and classified as allergy. Drug allergy is reported in 
20–40% of patients in the USA but close to 95% is not a real allergy. 
The most recent guidelines stress about reintroduction of antibiotics in 
patients with possible but not confirmed past drug reaction. Penicillin 
allergy histories are more likely to be rechallenged with the same or 
similar medication in the future, especially if Penicillin is the preferred 
therapy. Antibiotic reintroduction challenging is crucial even if adverse 
events may happen. Acute Generalized Exenthematous Pustulosis 
(AGEP) is a rare severe T-cell mediated drug reaction with an 
incidence of 1–5 par million/year. AGEP is characterized by acute 
formation of sterile pustules on erythematous background, fever and 
neutrophilia. We reported a case of a 68 years old male patient 
hospitalized for a dermohypodermatitis with a reported unspecific 
cutaneous rash after Amoxicillin administration in 1980. 
Amoxicillin+clavulanic acid was the preferred antibiotic to treat the 
recent infection. Forty-eight hours after first dose administration, the 
patient quickly developed a diffuse erythema with several follicular 
pustules suspected for AGEP with diagnostic score at 8 (EuroSCAR) 
(Image 1 and 2). Causative drug was immediately removed and 
antibiotic change was provided. None of systemic omplications of 
AGEP had been observed. Cutaneous test had been done 6 weeks 
later and confirmed Amoxicillin allergy. Our unlucky experience must 
not discourage antibiotics rechallenging. Penicillin allergy encompass 
different hypersensitivity reactions. Past history with antibiotics should 
be interpreted carefully in order to give opportunity to rechallenge 
patients with antibiotics. 
Figure 1 Figure 2
P410
Protocol of the Swiss Longitudinal Cohort Study  
(SWICOS) in rural Switzerland
Andreas W. Schoenenberger1, Franco Muggli2, Paolo M. Suter3, 
Augusto Gallino4, Gianfranco Parati5, Georg Ehret6, Renate 
Schoenenberger-Berzins7, Therese J. Resink8, Paul Erne8 
1Department of Geriatrics, Inselspital, Bern University Hospital, and 
University of Bern, Bern; 2Outpatient Medical Clinic, Vezia (Lugano); 
3Department of Medicine, Outpatient Clinic, University Hospital of 
Zürich, Zürich; 4Department of Internal Medicine, Hospital San 
Giovanni, Bellinzona, Switzerland; 5Department of Cardiology, San 
Luca Hospital, Istituto Auxologico Italiano, Milano, Italy; 6Division of 
Cardiology, University of Geneva, Geneva; 7Department of Cardiology, 
Inselspital, Bern University Hospital, Bern; 8Laboratory of Signal 
Transduction, Department of Biomedicine, Basel University Hospital 
and University of Basel, Basel, Switzerland
Introduction: Increased longevity and consequent major changes in 
demographics and population lifestyles necessitate new approaches to 
reduce the burden of aging-related diseases (including CVD) and 
maintain an optimal quality of life. This study aims to examine and 
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Median age at first transplantation was 60 (IQR 48.8–64.3) and 47 
(IQR 36.7–56.1) years for autologous and allogeneic patients, 66 and 
64% were males respectively. Median follow-up time was 6.3 in the 
autologous and 9.8 years in the allogeneic group with a maximum 
follow-up time of 26.1 and 35.0 years and median time to initiation of 
lipid-lowering treatment was 1.2 years in the autologous and 4.1 years 
in the allogeneic group (p <0.001) with a maximum delay of 16.5 and 
32.4 years, respectively. A highly significant reduction of TC, LDL-C 
and TG-levels was observed, while no change in HDL-C-levels 
occurred (fig.). No difference in terms of the amount of reduction was 
found when autologous and allogeneic HSCTs were compared. 
Statins accounted for the great majority of drugs used (85.2 %) with 
atorvastatin being the most commonly prescribed (Table).
Conclusion: Lipid-lowering therapy leads to a significant reduction of 
TC, LDL-C and TG levels irrespective of the type of transplantation. 
Therapy was started significantly later among patients who received 
an allogenic transplantation. 
of cardiovascular complications in these patients, the use and 
effectiveness of lipid-lowering therapy is of great interest.
Methods: A retrospective, single center cohort study with a total  
of 1196 patients (>16 years) who underwent a first autologous or 
allogeneic HSCT at the University Hospital Basel from 1973 to 2013 
and survived >100 days after was performed. Patients were grouped 
according to the type of their first HSCT (autologous or allogeneic) and 
follow up was censored if a subsequent HSCT of the other type was 
performed. For the examination of the effectiveness of the therapy, 
total cholesterol (TC), LDL-cholesterol (LDL-C), HDL-cholesterol 
(HDL-C) and triglyceride (TG) values before and a minimum of 30 days 
after start of treatment were analyzed. The frequencies of prescriptions 
of different drugs were further examined.
Results: A total of 223 patients (18.7 %) received any kind of lipid 
lowering therapy at any time point during the follow-up time, 33 of 
which (14.8 %) were already treated at baseline. 53 patients (23.8%) 
underwent at least one autologous, 170 (76.2%) at least one 
allogeneic HSCT (11 and 16 of them more than one, respectively). 
Figure 1: Lipid values before and after therapy. Table: Drug Prescriptions.
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The relation of bloodpressure and target organ  
damage in the Swiss hypertension cohort study
Benita Janisch1,2, Stéphanie Giezendanner3, Katja Henny-Fullin1,2, 
Daniel Buess1,2, Anja Handschin2, Andreas Zeller3, Jörg Daniel 
Leuppi1,2, Thomas Dieterle1,2 
1Universität Basel, Basel; 2Kantonsspital Liestal, Liestal;  
3Zentrum für Hausarztmedizin beider Basel, Basel, Switzerland
Introduction: Arterial hypertension is widely spread. Previous studies 
have shown an association between elevated blood pressure and 
target organ damage (TOD). The aim was to analyze differences 
between TOD groups regarding systolic and diastolic office blood 
pressure (SOBP, DOBP) across follow up. Further, patients who 
developed symptomatic TOD during study period were compared with 
patients not developing TOD focusing on blood parameters at baseline 
(BL).
Methods: The Swiss Hypertension Cohort Study was a prospective 
observational study recruiting patients in primary care between 2006 
and 2013. Patients eligible had to be ≥18 years old. TOD was defined 
as myocardial infarction, coronary artery disease, revascularization, 
stroke/TIA, heart failure, arterial obstructive disease, stenosis of the 
carotid arteries, a glomerular filtration rate ≤30 ml/min and retinopathy. 
Asymptomatic TOD was defined as left ventricular hypertrophy in the 
ECG or echocardiographic, chronic kidney disease with GFR 30–60 
ml/min, microalbuminuria (30–300 mg/24h), an elevated fasting blood 
glucose level (>6.9 mmol/l) or postprandial blood glucose >11 mmol/l 
or HbA1c>7% or carotid stenosis.
Results: The mean age of the cohort at BL (n = 1004) was 64 years 
(SD = 13.22), 55.6% were male. At baseline 49% (n = 489) had no 
TOD, 30% (n = 300) had asymptomatic TOD and 21% (n = 214) had 
symptomatic TOD. During study period, 32 patients developed a new 
symptomatic TOD. We found that DOBP significantly differed across 
hypertensive TOD groups at various time points indicating lower DOBP 
with increasing TOD (see fig. 1).
Figure 1: DOBP over follow up and TOD categories.
This effect was less pronounced in SOBP where lower SOBP was only 
observed in the group of symptomatic TOD at BL (see fig. 2).
Further, patients who developed a symptomatic TOD during study 
period had lower HDL cholesterol (median = 1.2 vs 1.36 mmol/l, p = 
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Characteristics and outcome of migrant patients  
without a stable resident status starting hemodialysis  
in a Swiss university hospital center
Amalie Frandsen1, Ernandez Thomas2, Patrick Saudan2,  
Pierre-Yves Martin2 
1Université de Genève; 2Hôpitaux Universitaires de Genève, Genève, 
Switzerland
Background: Migrants without permanent resident status is a 
vulnerable population in regards of medical care. They frequently 
present with chronic medical conditions, including Chronic Kidney 
Disease (CKD). In this work, we analyzed the characteristics and the 
outcome of migrant patients starting chronic hemodialysis in our 
center.
Methods: Migrant patients without a stable resident status in 
Switzerland were retrospectively identified among patients who started 
hemodialysis between 2000 and 2014 in the hemodialysis center of 
the University Hospital of Geneva. Demographic and medical data 
were recorded by reviewing their medical records.
Results: Among 594 patients starting hemodialysis, we identified  
29 migrant patients (4.9%, 1.93 patients per year) of whom 15 came 
from Africa, 2 from South America, and the 12 others from Eurasia. 
Eighteen were asylum seekers, 3 had a tourist visa, and 8 were 
undocumented. Compared to the local Swiss resident, migrant patient 
were younger (mean age 44 vs. 52 years), more of femal gender (55% 
vs. 45%) and had less cardiovascular comorbidities. Two thirds of the 
patients had vascular and diabetic causes for End Stage Renal 
Disease and 34% were smokers. Seven patients were already 
hemodialyzed before arriving in Switzerland. Seventeen obtained a 
permanent resident status, 5 are still waiting for regularization, 4 left 
Switzerland and 2 were lost to follow-up. Among the 22 patients who 
stayed in Switzerland, 2 died while on hemodialysis, 11 were 
transplanted of whom one died accidentally after being transplanted 
and 9 were still on hemodialysis. Mean time from first dialysis in our 
country to transplantation was 268 ± 126 weeks.
Conclusions: In our center, nearly 2 migrant patients per year start 
hemodialysis without a permanent resident status in Switzerland. They 
are significantly younger and more often women, and had less 
cardiovascular comorbidities than our permanent Swiss resident 
patients. Sixty-six percent obtained a permanent resident status and 
38% received a renal transplant. 
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Anti-GBM antibody (Goodpasture’s) disease
Robert Schorn1, Christian Clarenbach2, Christine Rüegg2,  
Thomas Bregenzer1 
1Klinik für Innere Medizin, Spital Lachen, Lachen; 2Klinik für 
Pneumologie, Universitätsspital Zürich, Zürich, Switzerland
Introduction: Anti-glomerular basement membrane (GBM) antibody 
disease is rare, with an estimated incidence of 0.5 to 0.9 cases per 
million per year in Caucasian populations. The disease is caused by 
autoimmunity to the NC1 domain of the α-3-chain of type IV collagen 
and leads to rapidly progressive (crescentic) glomerulonephritis and 
pulmonary haemorrhage. The prognosis of untreated anti-GBM 
antibody disease is extremely poor. 
Case report: A 55-year-old male smoker was admitted with pulmonary 
haemorrhage since 6 weeks. X-ray showed diffuse pulmonary 
infiltrates, CT scan demonstrated multiple nodules as well as ground 
glass opacities, and the performed bronchoscopy verified alveolar 
haemorrhage. Renal workup showed a moderate insufficiency and 
glomerular haematuria. Together with demonstration of anti-GMB-
antibodies the diagnosis of anti-GBM antibody (Goodpasture’s) 
disease was made. The patient was transferred to a tertiary care 
hospital. The patient was treated with steroids, cyclophosphamide,  
and plasma exchange. Pulmonary haemorrhage improved rapidly  
and glomerular filtration rate (GFR) returned to normal. Due to 
thrombocytopenia kidney biopsy was refused. 
Discussion: Pulmonary haemorrhage and rapidly progressive 
(crescentic) glomerulonephritis are clinical hallmarks of anti-GBM 
disease. Anti-GBM antibodies are almost present and the antibodies 
level correlates with the severity of nephritis. Although X-ray and 
CT-scan can demonstrate pulmonary involvement, an increased 
uptake of inhaled carbon monoxide (DLCO) is the most sensitive 
indicator of recent pulmonary haemorrhage. Patients with lung 
pulmonary haemorrhage are often current smokers. Kidney biopsy, 
0.012), higher creatinine (median = 82.0 vs 77.75 p = 0.049), higher 
uric acid (median 434 vs 338 umol/l, p = 0.005) and lower DOBP 
(median 78 vs 86 mm Hg, p <0.001) at BL compared to patients 
without or asymptomatic TOD.
Conclusions: Results indicate that a low DOBP is a predictor of TOD. 
This could be the case because of decreased coronary perfusion 
during diastole. Further analyses are needed to disentangle the effect 
of confounding parameters such as age and pharmacological blood 
pressure therapy. Several studies suggest that a too low DBP is 
associated with elevated morbidity and higher rates of TOD. 
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A 48-year-old woman was admitted with acute right sided, colicky type 
of flank- and abdominal pain and acute oliguric renal failure 6 days 
after uneventful, laparoscopic Hyster- and Salpingectomy including 
peritoneal resection of endometriosis. Upon admission she was 
afebrile with a normal blood pressure of 143/89 mm Hg and a heart 
rate of 109/min. Blood and urine tests showed an elevated creatinine 
of 381 µmol/l, a CRP of 35 mg/l, a hematuria of non- glomerular origin, 
unselective glomerular proteinuria and significant leucocyturia. A 
complete blood count and electrolytes were within normal limits. Due 
to her past medical history of symptomatic kidney stones, imaging 
studies were performed (Ultrasound, CT), showing no sign for urinary 
tract obstruction including nephrolithiasis or urolithiasis. A pre-renal 
cause of acute renal failure seemed unlikely as volume status and 
blood pressure were normal and fractional excretion of sodium was 
>1%. She had taken Ibuprofen as a postoperative analgesic but 
stopped 3 days prior to admission. Due to suspected urinary tract 
infection treatment with ceftriaxone was initiated but stopped after 
urine cultures came back negative. As creatinine further increased and 
the patient became anuric a renal biopsy was performed which 
showed normal kidney tissue. Shortly before initiating hemodialysis on 
day 4 normal urine production resumed and creatinine values dropped 
to a normal value of 67µmol/l within the next 4 days. In the context of 
this patient’s abdominal surgery, the above mentioned normal 
investigations and the spontaneous recovery of renal function we 
postulated that reflex anuria (RA) was the most likely cause of this 
patient’s acute renal failure. RA is a rare phenomenon of an acute 
functional but not structural renal impairment from both kidneys as a 
reaction to irritation or trauma to one kidney, its ureter or severely 
painful stimuli to other organs. The pathogenesis is not entirely 
understood. Various different reflex mechanisms are described in the 
literature leading to an intrarenal arteriole or ureteral spasm causing 
colicky type of flank pain which was also present in our patient. The 
therapy of RA is to eliminate painful stimuli which we also successfully 
implemented in our patient. In conclusion in patients with unexplained 
anuric renal failure, particularly after urogenital or gynaecological 
surgery, RA should be kept as a differential diagnosis. 
Figure 2: SOBP over follow up and TOD categories.
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tumors. Tumor induced osteomalacia in mCRPC is rare but may be 
underdiagnosed and should be considered in severe and sustained 
hypophosphatemia. Although clinical studies are lacking, several lines 
of evidence suggest that TIO may be associated with aggressive 
mCRPC behavior. FGF23 excess and severe hypophosphatemia may 
both contribute to a poor prognosis in affected patients. FGF23 
receptor inhibitor treatment is under preclinical/clinical development 
and may be an approach to control TIO and the underlying malignant 
disease in the future. 
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Introduction: Nowadays bariatric surgery is an established treatment 
of morbid obesity. Since 2006 the number of interventions in 
Switzerland quintupled to more than 5000 operations in 2015. 
Long-term follow-up of these patients is critical and includes 
continuous assessment of nutritional status.
Case report: A 48-year-old women presented with progressive loss of 
vision and hemeralopia for 6 months. Her past medical history was 
remarkable for Roux-en-Y-gastric bypass (RYGB) 19 years ago and 
adjustable gastric banding 8 years ago. Due to psychiatric comorbidity, 
follow-up after surgery remained difficult and adherence to vitamin 
supplementation was insufficient. Ophthalmological examination 
revealed a clearly reduced visual acuity (OD 0.25, OS 0.16), bilateral 
papilledema (OD Frisén grade 3, OS grade 4), complete loss of color 
vision and severe xerophthalmia. Headaches and symptoms/signs of 
elevated intracranial pressure were absent, other differential diagnoses 
of papilledema (e.g. inflammatory, circulatory or neoplastic) were 
excluded by MR-imaging and lumbar puncture. However, laboratory 
analyses demonstrated severe deficiency of vitamin A (<0.07 µmol/L 
[reference range 1.05–2.45]), 25-OH vitamin D (36 nmol/L [75–220]), 
vitamin E (4.1 µmol/L [11.6–46.4]) and zinc (7.2 µmol/L [9.0–26.0]). 
Oral substitution with vitamin A 25’000 IU, vitamin E 400 IU, and 
vitamin D 800 U per day was initiated together with multivitamin and 
trace element supplementation. 8 weeks later ophthalmological follow 
up showed remarkable improvement of vision (OD 1.0, OS 0.64), 
hemeralopia, xerophthalmia, color vision and partial improvement of 
papilledema. 
Comment and conclusions: Vitamin A is an important co-factor for 
corneal and conjunctival development, retinal phototransduction, 
prevention of xerophthalmia and function of the central nervous 
system. Commonly, hypervitaminosis A is associated with 
pseudotumor cerebri-like syndromes with papilledema, but 
hypovitaminosis A as a contributing factor has been also described. 
Intestinal resorption of lipophilic retinol is regulated by several factors: 
Exocrine pancreatic function, bile salt secretion, intestinal 
postabsorptive mechanisms and retinol-binding protein whose 
synthesis is zinc-dependent. Bypassing the proximal small intestine in 
RYGB leads to malabsorption syndromes which can be severe and 
develop insidiously as shown in our Patient. 
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Introduction: Diabetic retinopathy is a serious and frequent 
degenerative complication of diabetes responsible for blindness and 
low vision throughout the world, which is why screening should be 
systematic and early. Our study aims to specify the frequency of 
diabetic retinopathy (RD) And its epidemiological and clinical profile in 
diabetic patients followed in an Internal Medicine department.
Methods: This is a retrospective study involving 200 diabetics, 
followed by the internal medicine department E.P.S.P.Ghoualem 
(Oran). All patients underwent complete ophthalmologic examination. 
Results: Diabetic retinopathy was objectified in 30% of cases. There 
were 10 men and 50 women. The mean age was 57.5 years and the 
mean duration of diabetes was 9.15 years. The mean HbA1c is 10.8%. 
Retinopathy was classified as minimal in 14%, moderate in 10%, 
severe in 2%, and proliferating in 4% of cases. 10 patients have 
nephropathy among whom 4 patients have RD. Dyslipidemia is present 
in 60% of cases. Our patients with retinopathy were under oral 
antidiabetics (ADO) in 30% of cases, insulin in 60% and 10% in ADO 
+ insulin therapy. Diabetes was type 2 in 81.4%, type 1 in 9.5%. 
Diabetic retinopathy was asymptomatic in 82% of cases, visual 
unless contraindicated, shows linear deposition of IgG along the GBM. 
Plasmapheresis removes circulating anti-GBM antibodies and is 
accompanied by corticosteroids as well as cyclophosphamide. The risk 
of recurrence is low. 
Conclusion: Anti-GBM antibody (Goodpasture’s) disease is a rare 
and life-threatening disease. Concurrent treatment with 
plasmapheresis and immunosuppression is recommended. 
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Background: Since discovery of HbA1c in the late 60ies and its 
implementation into clinical practice in the 70ies and 80ies of the last 
century, this parameter has become a hallmark of diabetes care. 
However, this test has limitations, and we conducted a questionnaire 
with key questions about laboratory test. 
Methods: A survey using a questionnaire with five open questions 
was conducted: 1. HbA1c shows mean glucose values of what time 
period? 2. What exactly is measured by the test? 3. What is a normal 
value for HbA1c (diabetics)? 4. What circumstances may lead to false 
low HbA1c values? 5. What circumstances may lead to false elevated 
HbA1c values? 
Results: 53 physicians participated (28 residents, 4 students and 20 
senior physicians), all working in a department of internal medicine in 
hospitals of Switzerland. For question one, two and three, correct 
answers where given in 85, 85 and 55 % respectively. However, for 
question four and five concerning limitations of the parameters, correct 
answers where given only in 11 and 19 % respectively. With exception 
of question 1 (HbA1c shows mean glucose values of what time 
period?), no differences between junior and senior physicians were 
present. 
Conclusion: Our survey shows a considerable lack of knowledge 
about limitations of a widely used laboratory test. This might reflect our 
general inadequate high confidence in laboratory tests. 
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Introduction: Concurrent hypophosphatemia and hypocalcemia are 
well known adverse events in treatment with denosumab, which is 
widely used in metastatic bone disease. Fibroblast growth factor  
23 (FGF23) mediated tumor induced osteomalacia (TIO) is a rare 
paraneoplastic syndrome, leading to severe hypophosphatemia. Here, 
we present a patient with advanced prostate cancer, who developed 
hypocalcemia and severe, sustained hypophosphatemia after initiation 
of denosumab therapy, primarily masking the cause of phosphate (Ph) 
wasting, which in particular was due to FGF23 induced TIO. 
Case report: A 79-year old man with bone and lymph node 
metastases from castration-resistant prostate cancer (mCRPC) 
presented with severe hypophosphatemia (0.2 mmol/L, normal range 
0.8–1.5 mmol/L) and hypocalcemia (1.5 mmol/L, normal range 2.2–2.6 
mmol/L). Treatment with abiraterone/prednisone and denosumab had 
been initiated three weeks earlier. Renal function was normal, 
parathyroid hormone (PTH) levels were elevated and levels of 25-OH 
and 1,25-(OH)2 vitamin D3 were normal with oral calcium (Ca) and 
vitamin D3 supplementation. Inadequately high renal Ph excretion 
without additional urinary electrolyte wasting was detected (Ph 
excretion fraction 24%). Treatment with high parenteral doses of Ca, 
Ph, oral 25-OH and 1,25-(OH)2 vitamin D3 normalized serum Ca- and 
PTH levels within one month. However, severe hypophosphatemia due 
to urinary Ph loss persisted despite high doses of Ph supplementation 
(6.9 g/d). Additional work-up revealed an elevated serum level of 
FGF23 (4 times above upper limit of normal). Ph and calcitriol 
supplementation was continued until the patient died from progressive 
prostate cancer 13 months later. 
Conclusion: Denosumab induced hypophosphatemia was initially 
suspected in this patient with mCRPC. FGF23 induced 
hypophosphatemia is an uncommon but potentially life-threatening 
paraneoplastic syndrome most commonly found in mesenchymal 
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own limited experience seem to indicate that there is a place for 
GLP-agonists in this situation. Further studies will be necessary to 
elucidate the mode of action and to determine the validity of the 
approach in clinical practice. 
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Prolactinoma, an often missed cause of hypogonadism  
in man
Madleen Schmidt, Reinhard Imoberdorf, Cornelia Keller 
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Introduction: Prolactinomas are the most frequent type of pituitary 
adenomas. Hyperprolactinaemia in man induces central 
hypogonadism, but decreased libido as initial symptom is often 
dismissed and diagnosis delayed until symptoms as headache, visual 
impairment or hypopituitarysm appear. The occurrence of sudden 
headache, diplopia, visual field defects, nausea and vomiting should 
suggest pituitary apoplexy as a result of an unrecognized pituitary 
adenomas.
Case report: A 43-year-old male suffering from recurring vomiting, 
nausea and diplopia when looking upwards since several days 
presented in our emergency service. He reported long-standing loss  
of appetite paradoxically accompanied by weight gain, diffuse 
symmetrical face and neck swelling and episodic headaches for 
several months with currently increasing frequency. He referred 
testosterone deficiency since 2006 treated with Nebido (Testosterone) 
every 4 weeks. In the physical examination he had ptosis, incomplete 
oculomotor palsy on the right, bitemporal hemianopsy and slight 
edematous swelling of the skin. Laboratory testing revealed severe 
hypoosmolar hyponatremia (119 mmol/l) due to hypocortisolism (<40 
nmol/L; 101–536 nmol/l), central hypothyroidism (fT4 <5.2 pmol/L; 
9.0–19.1 pmol/L) and hyperprolactinemia (4807 mU/L; 45–230 mU/L). 
MRI showed subacute bleeding in a cystic intra- and suprasellar 
pituitary adenoma (2.3×1,9×1.4 cm) with infiltration of the cavernous 
sinus, elevation of the chiasm and optic nerve and affection of the 
oculomotor nerve on the right consistent with hemorrhagic apoplexy of 
a macroprolactinoma. We initiated substitution with Hydrocortison and 
Levothyroxin and started dopaminagonist therapy with Cabergolin. 
Furthermore, sellary pressure was released by transphenoidal surgery. 
Sodium concentration increased rapidly, Prolactin dropped and four 
weeks later, ptosis and incomplete oculomotor palsy completely 
resolved. Testosterone withdrawel failed, therefore it was reintroduced 
by transdermal application. 
Conclusion: Particulary in men with unexplained gonadal dysfunction, 
prolactin should be measured. In patients suffering from sudden 
headache, vomiting and diplopia pituitary apoplexy should be 
considered. In case of a hypoosmolar hyponatraemia, which simulates 
SIADH (syndrome of inappropriate antidiuresis) cortisol determination 
should be carried out. 
blurring occurred in 17.6% (8) and visual acuity decreased in 0.4%. 
The treatment was based on hygiene-dietetic rules, the intensification 
of antidiabetic treatment and optimization of insulin therapy aiming at  
a glycemic balance with glycemic objectives adapted to each case.  
20 patients required laser photocoagulation.
Conclusion: Diabetic retinopathy increases with the duration and 
poor setting of diabetes. Optimal glycemic control and regular 
ophthalmologic examination are important therapeutic weapons in 
reducing the incidence of diabetic retinopathy. 
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Introduction: Severe postprandial hypoglycemia is a well-known if 
rare phenomenon in patients after gastrectomy for any indication. 
Since bariatric surgery is the most effective available treatment to 
achieve sustained weight loss in obese patients the number of 
procedures is increasing and more patients suffer from adverse effects 
including postprandial hypoglycemia. Pathogenesis is not fully 
understood; presently treatment is based on dietary advice and a 
variety of compounds. In 2013 Abrahamsson published case reports  
of patients suffering from significant postprandial hypoglycemia treated 
with liraglutide, a GLP-1 agonist. We present two cases responding to 
once-weekly GLP-1 agonists exenatide slow release and dulaglutide.
Methods and results: Case 1: A 51-year-old patient suffers from 
gastrointestinal stroma tumor (GIST) first diagnosed 12 years ago. In 
two steps she underwent gastrectomy and esophagojejunostomy.  
The GIST is controlled with Imatinib. For the past 9 years she suffered 
from daily hypoglycemic events including several instances of 
unconsciousness and seizures. Treatment with dulaglutide led to 
cessation of symptoms. We used continuous glucose measurement 
(CGMS, images 1 and 2) before and after the intervention to 
demonstrate the effect of the drug. Case 2: A 42-year-old, man with 
obesity stage III (BMI 41.6 kg/m2) had Roux-en-Y gastric bypass 
surgery six years earlier. Ever since he suffered from multiple 
neuroglycopenic episodes including several times hypoglycemia 
induced seizures. Dietary education and a trial with 
hydrochlorothiazide did not improve his situation. We started him on 
exenatide slow release. There was no further event while on the drug. 
CGMS to document hypoglycemia off the drug could not be written, 
the patient did not want to discontinue the treatment for this purpose.
Discussion: Bariatric interventions lead to increasing numbers of 
patients with the uncommon but potentially debilitating complication  
of severe postprandial hypoglycemia. Excessive incretin answer to 
glucose stimuli is thought to be partially responsible. Treatment with 
GLP-1 is therefore counterintuitive. Published case reports and our 
Figure 1
Figure 2
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Aim: The aim of the study was to verify a correlation between the 
measured temperatures and the number of registered accesses by the 
emergency department, over a long period of observation.
Methods: We prospectively collected the number of emergency 
department visits and mean daytime atmospheric temperature for the 
summer months (July to August) from 2004 to 2015 in Bellinzona 
Regional Hospital and from 2000 to 2015 in Mendrisio Regional 
Hospital, both in Switzerland.
Results: In Bellinzona 1710 ± 168 (mean ± SD) monthly visits with a 
mean temperature of 31.6° ± 1.3 °C were observed. No association 
between temperature and number of visits per month was identified  
(r = 0.31; p = 0.07). In Mendrisio mean number of monthly visits was 
1409 ± 196 with a temperature of 31.9° ± 1.8 °C. No association 
between temperature and number of visits was found (r = 0.21;  
p = 0.15).
Conclusions: The study conducted over a long period it seems not to 
confirm our initial remarks which they showed a match between the 
peaks of maximum temperature registered and the activity by the 
emergency department . Increase of the number of consultations 
seems associated P74 only with short periods of exceptionally high 
temperatures as was july 2015.
1 Lepori M, et al. Swiss Medical Forum 2015 suppl 3 P74.
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Introduction: Typical clinical manifestations of Immunoglobulin light 
chain (AL) amyloidosis include nephrotic-range proteinuria, restrictive 
cardiomyopathy and hepatomegaly. We present a rare manifestation 
with vascular amyloid deposition and necrotizing myopathy and 
suggest a link between these histopathological alterations.
Case report: A 72-year-old man is admitted to the department of 
general internal medicine with an eight months history of proximal 
muscle weakness, progressive dysphagia, and weight loss of 10 kg  
in absence of night sweat or fever. Monoclonal gammopathy of 
undetermined significance was diagnosed 15 years ago; follow-ups 
were stopped after 4 years. On physical examination macroglossia  
and proximal tetraparesis (M4) are noted. Laboratory evaluation 
reveals elevated liver enzymes, creatinine, creatine kinase (CK),  
and a nephrotic-range proteinuria. An M-gradient IgG lambda is 
demonstrated by electrophoresis/immunofixation (21 g/l), together with 
elevated free light chains (FLC) lambda (512 mg/l) and normal FLC 
kappa (17.10 mg/l, ratio 0.03). Bone marrow biopsy demonstrates 
20–30% infiltration with clonal plasma cells. Cardiac magnetic 
resonance imaging (MRI) reveals global left ventricular late gadolinium 
enhancement. Brain natriuretic peptide and highly sensitive troponin I 
are moderately elevated (481 ng/l and 91 ng/l (ref. <30 ng/l)). 
Electroneuromyography of the deltoid muscle and MRI of the thighs 
are suggestive of myopathy. Endoscopic swallowing evaluation reveals 
severe oropharyngeal dysphagia. All remaining CRAB-criteria are 
negative. No amyloid is detectable in the periumbilical subcutaneous 
fat. A vastus medialis muscle biopsy confirms vascular AL amyloidosis 
and necrotizing myopathy. Other common causes for necrotizing 
myopathy such as anti-SRP syndrome, preceding infectious disease or 
statins are absent. A nerve biopsy shows no amyloidosis. Weekly 
dose-reduced bortezomib, cyclophosphamide, and low dose 
dexamethasone are started to prevent further organ damage.
Conclusion: We hypothesize that in analogy to nervous system and 
kidney, vascular amyloid deposition might facilitate myopathy through 
blood supply impairment. Two negative biopsies highlight the focal 
nature of the disease. A negative biopsy must never exclude 
amyloidosis. Amyloidosis should be suspected in patients with a 
monoclonal plasma cell disorder presenting with proximal muscle 
weakness, macroglossia, dysphagia, and elevated CK. 
P423
Patients with diabetes and chronic kidney disease:  
an interdisciplinary program to support medication  
adherence (PANDIA IRIS STUDY)
Jennifer Celio1,2, Dina Duarte Vaquinhas Nobre3, Faiza Lamine3, 
Menno Pruijm3, Grégoire Wuerzner3, Carole Clair4, Michel Burnier3, 
Olivier Bugnon1,5, Anne Zanchi3,6, Marie Paule Schneider1,5 
1Community Pharmacy, School of Pharmaceutical Sciences, 
University of Geneva, University of Lausanne, Geneva; 2Community 
Pharmacy, Department of Ambulatory Care & Community Medicine, 
University of Lausanne; 3Department of Nephrology and Hypertension, 
Lausanne University Hospital; 4Departement of General Medicine, 
Research and Development, University of Lausanne; 5Department of 
Ambulatory Care & Community Medicine, Community Pharmacy, 
University of Lausanne; 6Department of Endocrinology, Diabetes and 
Metabolism, Lausanne University Hospital, Lausanne, Switzerland
Introduction: Despite effective treatments, 30% of diabetic patients 
(type 2) develop kidney disease over time. A diabetes-kidney 
interdisciplinary program was set up by the Lausanne University 
Hospital (CHUV) and the PMU (Policlinique Médicale Universitaire).  
A novel medication adherence program is part of this approach. The 
purpose of the study is to assess the impact of the medication 
adherence program on the long term medication adherence and 
clinical outcomes of patients with diabetes and chronic kidney disease. 
Design: One-center, prospective, randomized study (6- vs. 12- month 
intervention). 
Intervention: usual medical consultations (every 2–3 months) will be 
preceded by a 20 minutes interview with a pharmacist. The interview is 
semi-structured with a motivational feedback based on the adherence 
data. Adherence will be measured using electronic pillbox (gold 
standard). A report of the interview will be sent to the physician(s) and 
the nurse(s). Group A (n = 35) will benefit from this program during  
12 months and group B (n = 35) during 6 months. At the end of the 
intervention, the interviews will be interrupted but the medication 
adherence will continue to be monitored electronically (tot. = 24 
months). 
Inclusion criteria: Patients of either gender aged ≥18 years; type 2 
diabetes; chronic kidney disease (estimated MDRD-eGFR ≤60 ml/
min/1.73 m2 or albumin/creatinin >30 mg/mmol); complete exams 
performed within the previous 6 months. 
Outcomes: Electronic medication adherence (longitudinal data) 
during 24 months; ADVANCE score (Action in Diabetes and Vascular 
Disease: Preterax and Diamicron MR Controlled Evaluation) and 
UKPDS score (United Kingdom Prospective Diabetes Study) at 
baseline, 6 months and 12 months post-intervention; patients’ 
satisfaction. 
Results: The inclusions started in April 2016. Currently, 13 patients are 
included in the program; 10 refused to participate. The reasons for 
refusal are: the use of the pillbox, perceived as too complicated (n = 5); 
too many appointments (n = 2); complex social and economic situation 
& difficult to change pharmacy (n = 1); not interested unless paid (n = 
1); no time (n = 1); refuses any study (n = 1). 
Conclusion: Pilot phase shows that the study is feasible; 
Pharmacists, physicians and nurses involved in the program are 
showing interest and are pro-active in the inclusion process. 
The abstract was presented at the Forum Managed Care (Bern, 
15.06.2016) 
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Background: In 2015, during the most hot period of the heat wave, we 
have observed an increased trend in the number of consultation  
by the emergency department of Public Hospitals of Southern 
Switzerland, compared to previous years (2013 e 2014) [1]. However 
this hypothesis has been verified based on a short period of time (12 
days). We therefore decided to study the phenomen on several months 
and over a period of more than 10 years excluding the two hospital 
sites where the activity could be influenced by the flow of a large 
number of tourists.
POSTERTOUR 3: MÉDECINE SPECIALISÉE V / FACHMEDIZIN V
PRIMARY AND HOSPITAL CARE – ALLGEMEINE INNERE MEDIZIN 2017;17(SUPPLEMENTUM)
POSTER SGAIM / POSTERS SSMIG 86 S
Conclusion: The diagnosis of dermatomyositis must lead to 
systematic and repeated screening for an associated cancer or 
hematologic malignancy to initiate an adapted chemotherapy. 
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Modern first-line treatment of metastatic  
germ-cell cancer
Jörg Beyer1, Sophia Sanders2, Lisa Roth2, Christian Fankhauser2, 
Thomas Hermanns2 
1Onkologie; 2Urologie, UniversitätsSpital Zürich, Zürich, Switzerland
Introduction: The treatment of metastatic germ-cell cancer (GCC) is 
based on the prognostic classification of the international group 
“IGCCCG” that was published in 1997 based on treatments delivered 
between 1975 and 1990. Many diagnostic and therapeutic advances 
have occurred since then.
Methods: We retrospectively reviewed charts of 1163 patients with 
GCC who were treated at the University Hospital Zurich between 1991 
and 2016 for whom electronic files were available. Overall 204 patients 
who received cisplatin plus etoposide based first-line combination 
chemotherapy were identified and analyzed.
Results: Median follow-up time was 4.7 years (range 0.3 to 22.4 
years). Patients belonged to the good risk (n = 127), intermediate risk 
(n = 39) or poor risk (n = 38) groups according to the IGCCCG 
classification. The progression-free survival (PFS) probability was 71% 
and the overall survival (OS) probability was 88% at 5 years for the 
entire patient cohort. PFS at 5 years differed in the three prognostic 
groups according to the IGCCCG score: 83% (good risk), 69% 
(intermediate risk) and 30% (poor risk), p <0.001. However, OS at  
5 years was not different among good risk and intermediate risk 
patients (94% vs 91%, p = 0.62), but differed to poor risk patients 
(65%, p <0.001). OS, but not PFS seems better than predicted by the 
published IGCCCG score, particularly in the intermediate and poor 
risk groups, which may be explained by better salvage treatment.
Conclusions: The overall survival of patients with GCC has improved. 
An update of the IGCCCG score that is currently used for prognostic 
classification is urgently needed. 
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Chronic diarrhea at advanced age – a rare case of  
chronic myelomonocytic leukaemia manifested as colitis
Sigrid Platzer, Raphael Jeker, Karin Hohloch, Thomas Fehr 
Department Medizin, Kantonsspital Graubünden, Chur, Switzerland
Introduction: Chronic myelomonocytic leukemia (CMML) is a rare 
malign disorder in stem cells which can be diagnosed by a 
monocytosis in peripheral blood and by dysplasia in bone marrow 
overlapped with myeloproliferative neoplasms. Most patients are in the 
seventies and show extramedullary manifestations in lymphoreticular 
organs, but also in brain, testes and ovaries. In only 5.7–13% is the 
gastrointestinal tract involved [1]. The here described patient presents 
a even more rare case of CMML which started as chronic diarrhea and 
ended up in being a leukemic colitis.
Case report: A 83 year old male was presented with a 1-month-history 
of chronic diarrhea, no fever but an abnormal weight loss of  
14 kg. With stool and blood cultures infections could be excluded as 
root causes for diarrhea. The colonoscopy (fig. 1) showed an ulcerous 
colitis with inflamed tissue; medical treatment with NSAIDs as potential 
explanation could be excluded and CT scan did not show any signs for 
ischemia. 
P426
Small molecule screen for inhibitors of adipogenesis  
as a strategy to accelerate hematopoietic recovery
Vasco Campos1, Benjamin Rappaz2, Josefine Tratwal1,  
Yannick Yersin1, Stephan Isringhausen3, Cesar Nombela-Arrieta3, 
Gerardo Turcatti 2, Olaia Naveiras1,4 
1Laboratory of Regenerative Hematopoiesis, Institute of 
Bionengineering; 2Biomolecular Screening Facility, EPFL, Lausanne; 
3Department of Experimental Hematology, Universitätsspital Zürich, 
Zurich; 4Hematology Service, Department of Oncology, CHUV, 
Lausanne, Switzerland
Background: Worldwide, more than 50.000 Hematopoietic Stem Cell 
Transplantations (HSCT) are performed annually, although the 
mortality rate still is close to 50% after allogeneic transplantation. Forty 
percent of these fatalities relate to the patients being severely immune 
compromised during the post-ablation period, before the graft has fully 
reconstituted the hematopoietic system. Reducing the time of 
engraftment is therefore critical to increasing the chance of survival  
in these patients. Preventing bone marrow (BM) adipocyte formation  
in the post-transplant period has been demonstrated to accelerate 
hematopoietic stem cell (HSC) engraftment and subsequent 
hematopoietic recovery in mice. 
Methods: In order to uncover novel modifiers of BM adipocyte 
differentiation, we performed a high-throughput label-free in vitro 
screening on the BM-derived mesenchymal stromal cell (MSC) line, 
OP9. This cell line was demonstrated to be both a useful model to 
efficiently differentiate into adipocytes as well as to support 
hematopoiesis in vitro. Using Digital Holographic Microscopy (DHM), 
we screened the Prestwick library of FDA-approved drugs, the Swiss 
Chemical and the Natural Product collections for inhibitors of 
adipocytic differentiation based on real-time lipid accumulation. We 
have validated this novel method with existing adipogenesis 
quantification techniques, simultaneously quantifying cell confluency 
and toxicity thanks to a an in-house developed Cell Profiler plugin. Hits 
have been validated via dose-response curves and counterscreens 
including hematotoxic assays and functional in vitro and in vivo assays. 
Results: From the initial more than 4000 compounds around 1% 
rendered as validated hits that inhibited OP9 adipocytic differentiation. 
These compounds were also non-toxic to the stroma, did not affect cell 
number and had a strong potency (EC50 <1 uM). From these 
compounds, 15 were permissive for primary murine hematopoietic 
stem and progenitor cell (HSPC) expansion and are currently being 
tested in primary HSPC/MSC co-cultures and in murine HSC 
transplantation. Of note, MarrowQuant and whole mount confocal 
microscopy techniques have been developed to measure in vivo BM 
adipogenesis in this context.
Conclusion: All current clinical approaches to enhance hematopoiesis 
target the HSC itself. Here we propose targeting BM adipogenesis as 
an alternative pharmacological strategy to improving hematopoietic 
recovery beyond current G-CSF standard. 
P427
Paraneoplastic dermatomyositis revealing  
non-Hodgkin lymphoma
Ines Kechaou, Imen Boukhris, Samira Azzabi, Eya Cherif,  
Lamia Ben Hassine, Anis Hariz, Narjess Khalfallah 
Service de Médecine Interne B, Hôpital Charles Nicolle, Tunis, Tunisia
Introduction: Dermatopolymyositis is an inflammatory disorder of 
unknown origin. Twenty to thirty percent cases of this disease is 
associated with a cancer. The most involved organs are the ovary,  
the breast, digestive tract and the nasopharynx. The association to 
hematologic malignancies is rare. We report the case of a 
dermatomyositis revealing non Hodgkin lymphoma.
Case report: A 55 year-old woman without pathologic history 
presented a typical dermatomyositis diagnosed with the presence  
of eyelid heliotrope erythema, gottron’s papules in the right hand, 
periungueal erythema and muscular weakness in the pelvic and 
scapular belt. The muscular dysfunction was confirmed by 
electromyography and biopsy. On the first examination, no evidence  
of malignancy was seen. Otorhinolaryngeal examination, CT scan, 
colposcopy, fibroscopy and mammography were normal. A treatment 
by corticosteroids was started relayed by methotrexate due to severity 
of the dermatomyositis. Secondary, the patient received intravenous 
immune globulines because of corticoid resistance. The outcome was 
favorable. Six months later, appeared a febrile pancytopenia. The CT 
scan showed disseminated hepatic nodules associated with 
intraperitoneal effusion leading to an exploratory laparotomy. The 
hepatic biopsy revealed a large B cell lymphoma CD20+ on 
immunochemistry. The patient presented a septic shock two days after 
laparotomy leading to death.
Figure 1: Sigmoid colon, inflammation 
and ulcera.
A first therapy approach with steroids and mesalazin against 
inflammatory bowel disease brought no improvement. A full blood 
exam stated leukocytosis, monocytosis, thrombocytopenia and anemia 
which lead to a bone-marrow puncture. All signs were pointing to 
CMML and genetic analyses were performed to complete the 
diagnosis along the WHO definition. However, the patient didn’t show 
any typical CMML-symptoms. Progressive symptoms with hemorrhagic 
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derivatives, only resulting in a slight improvement of the pain. Finally 
the patient was referred for a local radiation which brought relief. The 
matter of pathogenesis and therapy of HPO is not completely resolved. 
A symptomatic therapeutic attempt with NSAID failed in this case. The 
most efficacious therapeutic option for HPO is the treatment of the 
cancer disease, so the immunotherapy with Nivolumab was continued 
after radiation of the metastasis.
Conclusion: Lung cancer patients present with hypertrophic 
pulmonary osteoarthropathy in up to 17%. It may occur either in 
patients with advanced disease or in early stages, sometimes even 
before the tumor is diagnosed. It is crucial to be aware of the 
combination of digital clubbing, painful joints and periostitis as a 
potential paraneoplastic syndrome. 
P431
Sclerosing mesenteritis – a rare disease mimicking  
malignancy
Till-Simon Lichtneger1, Tobias Hoffmann1, Matthias S. Matter2,  
Michael Huguenin2, Armin Droll1 
1Medicine, Hospital Dornach, Dornach; 2Institute for Pathology, 
University Hospital Basel, Basel, Switzerland
In March 2016, a 74-year-old woman presented herself at our 
emergency department with coughing, abdominal pain, emesis and 
bloody diarrhea for several days. She reported weight loss of 20kg 
during the last 8 months. Her body mass index was 12.2 kg/m2. She 
complained of recurring abdominal pain and diarrhea for a longer time. 
However, several gastrointestinal endoscopic examinations did not 
explain her complaints. The patient has been treated for a large cell 
lung cancer several years ago and was since then in complete 
remission. Furthermore, she had a history of alcohol- and 
benzodiazepine abuse and she continued smoking. She was known to 
have an alcoholic liver cirrhosis with a stage Child A. At admission, the 
patient was in a reduced general condition, hypotensive, the oxygen 
saturation was not measurable and her mental status was seriously 
altered. A CT-scan of the lung and abdomen was performed, showing 
bilateral infiltrates suggestive for pneumonia and massive non-specific 
intraabdominal calcifications. A bronchoscopy demonstrated a purulent 
bronchitis and S. aureus was isolated. Appropriate antibiotic therapy 
was initiated and infection parameters decreased, but the general 
condition remained poor. Unexpectedly, the patient died after 13 days. 
At autopsy a purulent pneumonia was found and interpreted as the 
most probable cause of death. In addition, the mesenterium showed 
extensive calcifications, fibrosis and chronic inflammation. After 
exclusion of a neoplasia and a IgG4-associated disease as well as in 
correlation with the clinical patient history a Sclerosing Mesenteritis 
was diagnosed. Sclerosing Mesenteritis is an idiopathic primary 
inflammatory and fibrotic process that affects the mesentery. Its 
etiology remains unclear, although several mechanisms have been 
suggested such as previous abdominal surgery or trauma, 
autoimmunity, paraneoplastic syndrome, ischemic injury, and infection. 
Furthermore, there seems to be a strong association with nicotine 
abuse. Patients affected often present with anorexia, nausea, diarrhea, 
weight loss and fever. A standard therapy is not established, mostly 
prednisone is used, but experience is limited.
Conclusion: Sclerosing Mesenteritis may mimic malignancy or 
infection. It should be considered in the differential diagnosis of 
abdominal tumors. 
stool, abdominal pains and free air in abdomen made a subtotal 
colectomy necessary. The histopathological report confirmed the 
CMML diagnosis by infiltration of immature mono- and leukocytes in 
connective tissue of mucosa [fig. 2].
Figure 2: Mucosa, infiltration by  
immature monocytes.
Results: CMML is a rare form of leukemia and manifests usually with 
symptoms like fatigue, weight loss, fever and night sweats. Chronic 
diarrhea as primary manifestation is untypical and very rarely 
described in literature [2]. Nevertheless, leukemic infiltration should be 
considered as part of differential diagnosis, when all other common 
causes have been ruled out.
Conclusion: Complex cases with atypical symptoms demand a close 
collaboration of medical disciplines to identify non obvious causes for 
seldom diseases.
1  McCullough KB, Kristen B. Chronic Myelomonocytic Leukemia: a Genetic and 
Clinical Update. Curr Hematol Malig Rep. 2015;10(3):292–302.
2  LoSavio AD, Bunnag AP, Rubin DT. Colonic infiltration with chronic 
myelomonocytic leukemia. Nat Clin Pract Gastroenterol Hepatol. 
2007;4(4):229–33. 
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Digital clubbing, painful joint swelling and periostitis  
in a patient with lung cancer – a paraneoplastic syndrome 
known as hypertrophic pulmonary osteoarthropathy or  
Pierre Marie Bamberger syndrome. A case report
Christina Müller, Susanna Crivelli, Philippe Rochat, Beat Frauchiger 
Department of Internal Medicine, Kantonsspital Frauenfeld, 
Frauenfeld, Switzerland
Introduction: Hypertrophic pulmonary osteoarthropathy (HPO), also 
known as the Pierre Marie Bamberger syndrome, is defined by painful 
swollen joints, digital clubbing and periostitis. It is a paraneoplastic 
syndrome with an incidence ranging from 0.64 to 17% in patients with 
lung cancer. But it can also be associated with extrapulmonary 
malignancies and various other diseases. The primary form of 
hypertrophic pulmonary osteoarthropathy is less common. We present 
the case of a lung cancer patient with disabling pain of the right lower 
leg caused by a soft tissue metastasis and a HPO.
Case description: A 58-year-old woman with an adenocarcinoma of 
the lung, AJCC stage IV, presented with enduring pain in the right 
lower leg for two months. The therapeutic regimen had just been 
switched to Nivolumab because of tumor progression on first-line 
chemotherapy. The clinical examination revealed digital clubbing of 
hands and feet, discrete swelling of the right ankle and severe 
tenderness on palpation of the right ankle and the right proximal fibula.
Figure 2: MRI Periostitis.
Figure 1: Digital Clubbing.
The X-ray of the right lower leg was unsuspicious. The Magnetic 
Resonance Imaging of the region showed a tumor in the lateral origin 
of the soleus muscle as well as a periostitis of the distal lower leg.
Based on the patient’s history, the clinical presentation and the 
radiologic findings we diagnosed a soft tissue metastasis of the lung 
cancer in the proximal soleus muscle and a hypertrophic pulmonary 
osteoarthropathy. We administered cortisone and morphine 
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compare groups. A multivariate Cox model was used to adjust for age, 
Glasgow coma scale, pre-stroke and post-stroke Barthel indices, sex, 
impaired swallow test, motor deficit, diabetes, and inclusion year. The 
predictive values of UI assessed at maximal deficit or seven days after 
stroke were compared using receiver-operating curves. 
Results: 4477 patients were followed for one year after their first 
stroke. UI and IUC were present in 43.9% and 31.2% of patients. UI 
and IUC were both associated with one-year mortality in unadjusted 
(HR 6.84; 95%CI: 5.98–7.83 and HR 5.30; 95%CI: 4.70–5.98) and 
adjusted analysis (aHR 1.78; 95%CI: 1.46–2.19 and aHR 1.84; 95%CI: 
1.54–2.19). Stroke patients with UI and IUC had twice the mortality 
rate compared to patients with only UI (HR 10.24; 95%CI: 8.72–12.03 
versus HR 4.70; 95%CI: 3.88–5.70, p <0.001). UI assessed after one 
week performed slightly better for predicting one year mortality than  
UI assessed at maximal neurologic deficit. Limitations of this study 
include the lack of a standardized definition of UI and the lack of 
information regarding the indication for urinary catheterization. 
Conclusion: IUC in the post-stroke period is associated with death, 
especially among UI patients. 
P432
The intimate relationship between Foley catheters, urinary 
incontinence, and death after a new-onset stroke
Gregor John1,2, Steve Primmaz2, Siobhan Crichton3, Charles Wolfe3 
1Hôpital Neuchâtelois, La Chaux-de-Fonds; 2Hôpitaux Universitaires 
de Genève, Genève, Switzerland; 3King’s College London, London, 
United Kingdom
Introduction: Urinary incontinence (UI) increases mortality after 
new-onset stroke. However, this association might be confounded by 
frequent indwelling urinary catheters (IUC) in this population. The aim 
of the present study was to explore the relationship between IUC, UI 
and death in the post-stroke period. We also explore the best time to 
assess UI (at the time of maximal neurological defect, or one week 
after the stroke) to predict one-year mortality. 
Methods: We included all patients with a first-onset stroke recorded 
between 1995 and 2011 in the prospective South London Stroke 
Register. The patients were followed for one year. The unadjusted 
impact of UI and IUC on time to death was analysed using Kaplan-
Meier survival analysis and unweighted two-sided logrank test to 
P433
Spontaneous intracranial hypotension
Pik Ki Chan1, Carlo Serra2, Christoph David Stettler1 
1Internal Medicine, Spital Lachen, Lachen; 2Neurosurgery,  
University Hospital Zurich, Zürich, Switzerland
Introduction: We describe a case of spontaneous intracranial 
hypotension with a fluctuating disease course over several weeks. 
Definitive diagnosis could only be made with repeated magnetic 
resonance imaging (MRI).
Case report: A 25-year old woman presented with acute headache 
that had begun after strenuous exercising but without notable trauma. 
She reported the pain to vanish in a horizontal position and to reoccur 
within seconds when being upright. She also reported repeated 
vomiting. Neurological examination and cranial computed tomography 
(CT) were normal. Brain MRI showed no clear signs of intracranial 
hypotension which was suspected due to the orthostatic nature of the 
headache (fig. 1). MRI of the cervical spine showed T1 isointensity in 
the epidural space from C2-C4 which was interpreted as an epidural 
hematoma. The patient was referred to the neurosurgical department 
at the University Hospital in Zurich. Repeated spinal MRI showed no 
focal cerebrospinal fluid leak (CSF). The patient improved 
spontaneously and was discharged with the presumptive diagnosis  
of spontaneous intracranial hypotension. Three days later she 
represented with severe headache, neck stiffness and right sided 
peripheral facial palsy. Repeated brain MRI showed diffuse 
pachymeningeal contrast enhancement as a typical sign of intracranial 
hypotension (fig. 2). CT myelography showed a CSF leak at L5/S1. 
Application of an epidural blood patch resulted in prompt resolution of 
the headache and the facial palsy. 
Discussion and conclusion: Spontaneous intracranial hypotension 
refers to the occurrence of a CSF leak leading to CSF hypovolemia 
and hypotension without a preceding causative event. Orthostatic 
headache is the prototypical manifestation. Diagnosis is made by MRI 
[1]. The acronym SEEPS (for Subdural fluid collections, Enhancement 
of the pachymeninges, Engorgement of the venous structures, 
Pituitary enlargement, and Sagging of the brain) recalls the typical 
findings [2]. It is frequently misdiagnosed because the neurological 
examination is usually normal. Our case is notable because initial 
brain MRI was negative. It stresses the importance of the history of 
present illness as the most important diagnostic tool. Confronting a 
specific and persisting symptom clinicians must refrain from excluding 
a diagnosis prematurely and consider repeated testing.
References: 
1 Mokri B. Neurol Clin. 2014;32(2):397–422.
2 Schievink WI. JAMA. 2006;295(19):2286–96. 
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Complementary and alternative medicine use by forced 
migrants living in the canton of Vaud: a pilot survey
Laura Walthert1, Patrick Bodenmann2, Bernard Burnand3,  
Pierre-Yves Rodondi3 
1Ecole de Médecine; 2Policlinique Médicale Universitaire; 3Institut 
Universitaire de Médecine Sociale et Préventive CHUV, Lausanne, 
Switzerland
Introduction: Complementary and alternative medicine (CAM) is used 
by about a third of the population in different countries. In Switzerland 
nearly half of the population used CAM at least once during their life, 
and the most frequently types of CAM used were homeopathy, 
osteopathy and acupuncture. Among migrants, studies in the US and 
in Asia showed the same prevalence of CAM use as the native 
population of a country. However the type of CAM used varied 
according to ethnicity. Some studies showed an association between 
self-perceived discrimination and CAM use. The objective of this pilot 
study was to search for the prevalence and type of CAM used by 
forced migrants in the canton of Vaud and to evaluate their self-
perceived discrimination. 
Methods: A cross-sectional study with questionnaires was performed 
among a convenience sample of forced migrants in the canton of 
Vaud, Switzerland. The questionnaire was filled in between August and 
December 2015 using face-to-face interviews, in French, English, 
Arabic and Tigrinya languages. 
Results: In this first study in Switzerland about CAM use and 
self-perceived discrimination among forced migrants, a total of 61 of 
them participated in the study. The mean age of the sample was 27.8 
(IQR: 18–48) and 78.7% were male. Eritrea (55.7%), Kosovo (4.9%) 
and Afghanistan (4.9%) were the most often encountered nationalities. 
The majority (91.7%) declared they trust their physician about their 
healthcare advices. Lifetime prevalence of CAM use was 45.9%. A 
third (31%) of the CAM used was herbal medicine. CAM use during 
the last twelve months was reported by 27.9% of them. Herbal 
medicine use was much more with self-use (70%) than with the 
recommendation of a health professional. Among forced migrants who 
were using CAM, 54.2% informed their physician about their use. 
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first as two or more chronic conditions, and secondly as three or more 
chronic conditions, was estimated and stratified by gender and age 
group. We also examined which group of chronic conditions 
participated most to this multimorbidity. 
Results: Prevalence of two or more chronic conditions, and three or 
more chronic conditions was respectively estimated to 52% and 35%, 
without significant gender difference. Prevalence of two chronic 
conditions by age group was 6.2% for patients below the age of 20, 
19% for those between 21 and 40, 44.8% in the age group between 
41 and 60, 71.8% for those between 61-80 and 85.8% in the above 
80-age group. The most prevalent conditions were cardiovascular 
(42.5%), psychological (28%) and metabolic or endocrine (24%). 
Conclusion: Our study highlighted the high prevalence of 
multimorbidity in a representative sample of patients of all ages in 
family practices in Switzerland. High prevalence of cardiovascular, 
psychological and metabolic conditions was underlined. These new 
elements could help to guide resource allocations and post-graduate 
training. 
P437
Outpatient withdrawal from high-dose benzodiazepine 
dependence – novel approach with interprofessional 
collaboration and electronic monitoring of polypharmacy
Isabelle Arnet1, Kenneth M. Dürsteler2, Johannes Strasser2,  
Kurt E. Hersberger1 
1Pharmaceutical Care Research Group, Universität Basel; 2Division  
of Addictive Disorders, Psychiatric Hospital, Basel, Switzerland
Introduction: There is no well-established protocol for the 
management of high-dose benzodiazepine (BZD) withdrawal. 
Discontinuation of high-dose BZD in dependent patients occurs by 
dose tapering and psychosocial support, and is generally 
unsuccessful. Interventions that increase patients’ autonomy and 
motivation along with individually driven tapering regimens might be 
promising. At the Psychiatric Hospital Basel, agonist substitution - 
usually with the long-acting BZD clonazepam – is initiated during 
hospitalization. We present a novel concept for tapering BZD using the 
case of a 35-year-old unemployed male patient with depression and 
co-dependence on cannabis and lorazepam (20–25 mg/d, Internet 
purchase). Outpatient withdrawal started February 18, 2015.
Methods: Commercially available multidose punch cards (7×4 
cavities) were equipped with a film containing loops of conductive 
wires. A microchip records date and time when a loop is broken i.e., 
when a cavity is emptied. After discharge, our patient consented to get 
his medication in weekly e-punch cards which he picked up from the 
community pharmacy, immediately after his weekly visit with the 
psychotherapist. Withdrawal was centred on the BZD tablets the 
patient would and could intentionally left-over. BZD tablets were 
repacked in portions of daily doses and spread over all cavities. 
Tapering was obtained by reducing the mg-content of the cavities by 
the amount equivalent to leftovers, which determined the rate of dose 
reduction. Physician, psychotherapist and pharmacist exchanged 
weekly figures of past week intake which were discussed with the 
patient during the following psychosocial session in order to determine 
dosage changes for the next punch card.
Results: Over the 28-week monitoring period, dispense of daily 
clonazepam was reduced from 8 mg to 2 mg, and of daily lorazepam 
from 7.5 mg to 5 mg. Amount taken was always less and ended at 
daily clonazepam 1.5 mg (80% reduction). No withdrawal symptoms 
occurred. Cannabis abstinence was reached at week 16. For physician 
and pharmacist, extra-time consumption was within usual practice. 
Satisfaction was given for all participants.
Conclusion: Successful withdrawal from high-dose BZD resulted from 
collaboration between different healthcare professionals, use of 
electronic monitoring with graphical feedback, and empowerment of 
the patient who dictated the speed of tapering. 
P438
Inappropriate use of arthroscopic meniscal surgery in 
degenerative knee disease: an observational study from 
Switzerland
Leander Muheim1, Oliver Senn1, Mathias Früh2, Oliver Reich2, 
Thomas Rosemann1, Stefan Neuner-Jehle1 
1Institut für Hausarztmedizin Zürich, Universitätsspital Zürich; 
2Department of Health Sciences, Helsana Group, Zürich, Switzerland
Background: Current evidence suggests that arthroscopic knee 
surgery has no added benefit compared to non-surgical management 
in degenerative meniscal disease. Yet in many countries arthroscopic 
partial meniscectomy (APM) remains among the most frequently 
performed surgeries. We quantify and characterize the current use of 
Self-perceived discrimination was reported by 36.7% of forced 
migrants, with 70% of them reporting discrimination because of their 
national origins. CAM users reported significantly more discrimination 
than non-users (44.4% versus 30.3%, p = 0.027). 
Conclusion: Forced migrants used complementary and alternative 
medicine for a half of them during their life and for a third during the 
last twelve months, especially herbal medicine. A half informed their 
physician about their CAM use. Self-perceived discrimination was 
reported by a third of forced migrants and it was associated with CAM 
use. 
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Cold and pale – rare and unusual: a case report  
of hypothenar-hammer syndrome
Ashley Kilchenmann, Ewelina Biskup 
Universitätsspital Basel, Basel, Switzerland
Introduction: Hypothenar-Hammer-Syndrome (HHS) is a rare 
disease, primarily affecting young men, presenting with painful, cold 
and pale digiti IV and V. Repetitive, blunt trauma to Guyon’s canal 
leads to thrombus formation, subsequent occlusion of hand arteries 
and ischemic necrosis. Local anatomy of the ulnar artery (superficial 
palmar arc) makes it susceptible to injury. Angiography is the 
diagnostic gold standard. Management of choice is intra-arterial lysis; 
operative approach is rarely required. 
Case report: A 30-year-old male presented in our ER with sharp pain, 
pallor, numbness and temperature loss in left fingers IV and V, which 
began 5 hours prior, after using his hand as a hammer whilst tiling 
floors. Patient’s medical and family history was unremarkable, 
especially no Raynauds-, cardiac, rheumatic, vascular or coagulation 
disorders were known. He regularly consumed alcohol, tobacco and 
cannabis. Clinical examination showed skin marbling, hypothermia  
and dysaesthesia of the hypothenar, digits IV and V, with prolonged 
capillary refill and pathological Allen-test. Segmental pulse 
oscillography showed a pathological flow volume diagram of digits 
III–V. Primary Raynaud’s seemed unlikely due to isolated occurrence 
in digits IV and V, as were secondary Raynaud’s aetiologies e.g. 
arteriosclerosis, diabetes or lupus. Normal differential blood count 
spoke against myleproliferative neoplasia. Cardiac arterial emboli, 
cryoglobulinaemia, thoracic-outlet-syndrome, CREST and paradoxical 
embolism were ruled out. CT-angiography revealed distal thrombotic 
occlusion with no aneurysm of the ulnar artery at the pisiform bone, 
and no stenosis further proximally. HHS was diagnosed. We 
commenced pulse-spray arterial lysis and systemic anticoagulation 
with i.v. heparin. Control angiography at 24h showed regular perfusion 
of the ulnar interdigital arteries, with persistent partial thrombosis of 
the distal ulnar artery up to the superficial palmar arc. Anticoagulation 
was converted to phenprocoumon and combined with an antiplatelet 
agent (aspirin). Clinical and radiological examination at week 12 
revealed normal results.
Summary: HHS is an important differential diagnosis in patients 
presenting with unspecific Raynaud’s-signs, ischemic pain and 
hypothermia of the ulnar palm and fingers. Significant delay of 
diagnosis and therapy are associated with high morbidity. It thus 
remains imperative to draw physicians’ attention to the disease’s 
presentation and treatment options. 
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Prevalence of multimorbidity in Swiss family practices:  
a cross-sectional study within the Swiss Sentinel  
Surveillance System (Sentinella)
Sophie Excoffier1, Alexandra A N’Goran2, Anouk Déruaz-Luyet2,  
Lilli Herzig2, Dagmar M Haller1 
1Primary Care Unit, Faculty of Medicine, University of Geneva, 
Geneva; 2Institute of Family Medicine, Lausanne University Hospital, 
Lausanne, Switzerland
Introduction: Multimorbidity, commonly defined as two or three or 
more chronic conditions within one person, is a growing challenge in 
view of the aging of the population. Management of multimorbidity is 
frequently the responsibility of the family practitioner, increasing the 
complexity of health care. Estimation of its prevalence differs 
significantly between studies according to different methodologies and 
definitions of multimorbidity. We estimated prevalence of multimorbidity 
in a national and representative sample of patients from family 
medicine practices using the Sentinella network. 
Methods: We used data from 2904 patients of all ages, attending 118 
family practitioners from the Sentinella network from September to 
November 2015. Recorded data included date of birth, gender and a 
list of 75 chronic conditions derived from International Classification for 
Primary Care version 2 (ICPC-2). Prevalence of multimorbidity, defined 
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(GP) office lead to a better patient experience also in domains not 
affected by renovation known as perceptual bias. The aim for this study 
was to assess 1) how long a perceptual bias lasts and 2) if this bias 
can be reproduced in a second renovation.
Methods: We conducted this study in a GP office with 2 GPs in 
Switzerland that was renovated twice within 3 years (fig. 1: left before, 
right after). 
knee arthroscopies in Switzerland, assessing a distinctively non-
traumatic patient group. 
Methods and results: We assessed claims of a non-accident 
insurance plan of a major Swiss health insurance company (Helsana 
group) for surgery rates of APM, arthroscopic debridement and lavage 
in patients over the age of 40, comparing years 2012 and 2015. Claims 
were analyzed for prevalence of osteoarthritis, associated 
interventions and insurance status. Surgery rates for Switzerland were 
calculated using weighted projections. In all, 648,708 and 647,808 
patients were examined in 2012 and 2015 respectively. The incidence 
of APM, debridement and lavage was 2,520 in 2012 and 2,282 in 2015 
in non-traumatic patients aged over 40, consisting mostly of APM 
(95.6%). Osteoarthritis was diagnosed in 24.6% of inpatients. In all  
of Switzerland, APM was performed an estimated 9,958 and 10,203 
times in middle-aged (40–64) and 5,854 and 4,815 times in elderly 
(≥65), non-traumatic patients in 2012 and 2015, respectively. This 
translates into a surgery rate of 209 per 105 person-years for all ages. 
Supplementary private hospital insurance and chronic diseases were 
associated with a higher risk for surgery. High deductible class and 
use of pain medication were associated with a reduced risk for 
surgery.
Interpretation: APM is widely-used in non-traumatic patients in 
Switzerland, although it provides no significant benefit according to 
current evidence. Surgery rates did not change in non-traumatic 
middle-aged patients between 2012 and 2015. Accordingly, the 
potential of inappropriate use of APM in non-traumatic patients in 
Switzerland is high and current practice needs to be changed. 
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Performances of a brief assessment tool for the  
early diagnosis of geriatric syndromes in family medicine
Yolanda Mueller1, Stéfanie Monod2,3, Isabella Locatelli 4,  
Jacques Cornuz5, Nicolas Senn6 
1Institut Universitaire de Médecine de Famille; 2Service de la Santé 
Publique, Etat de Vaud; 3Département de Gériatrie; 4Institut de 
Médecine Sociale et Préventive, Université de Lausanne; 5Policlinique 
Médicale Universitaire; 6Institute of Family Medicine, Lausanne 
University Hospital, Lausanne, Switzerland
Introduction: Although early detection of geriatric syndromes has 
been shown to limit functional decline, it is rarely implemented in family 
medicine because of lack of training and lack of time for a full geriatric 
assessment. The AGE project (active geriatric evaluation) aimed at 
developing and validating a brief assessment tool (BAT) for family 
physicians (FP) to detect geriatric syndromes. This study aimed to 
estimate diagnostic performance of the BAT compared to a 
comprehensive geriatric assessment.
Methods: Prospective diagnostic study conducted inone university 
primary care clinic and three private practices, canton of Vaud, 
Switzerland. Eligible patients were aged at least 70 years old, routinely 
followed in one of the recruitment sites, able to provide informed 
consent and without previous geriatric assessment. FPs performed the 
BAT, followed by a comprehensive (2 hours) geriatric evaluation 
performed within the next two months. Both the BAT and the full 
geriatric assessment targeted the following eight syndromes: cognitive 
impairment, mood disorder, urinary incontinence, visual impairment, 
hearing loss, undernutrition, osteoporosis, gait and balance 
impairment.
Results: Out of 85 patients, 53 (62.4%) were included at the university 
clinic and 32 (37.7%) in private practices. Mean age was 78 years (SD 
6) and 46/85 (54.1%) were females. Prevalence of each syndrome 
ranged between 30.0% (malnutrition and cognitive impairment) and 
71.0% (visual impairment). Patients suffered from a median number of 
3 syndromes (IQR 2 to 4). Negative predictive values (NPV) ranged 
between 73.5% (95%CI 61.4% – 83.5%) and 84.1% (95%CI 69.9% – 
93.4%), apart from visual impairment with a NPV of 50.0%. Median 
time to perform the BAT was 20 min (range 5–60). 
Conclusions: The BAT performed well to screen elderly patients for 
geriatric syndromes when compared to a full geriatric assessment, 
and was feasible in routine practice. 
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Interior renovation of a primary care office leads  
to a biased patient experience for about 1 year
Jérôme Gauthey1, Raphaël Tièche2, Sven Streit3 
1Spitalzentrum Biel, Bienne; 2Primary Care Office, Grenchen; 3Institute 
of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
Introduction: Measuring patient experience is key to assess quality  
of care. But in a previous study we found patient experience can be 
biased: a renovation of the interior design of a general practitioner 
We assessed patient experience at baseline (before the first 
renovation) and after 2 months (follow-up 1, FUP1) in a previous study 
and extended FUP for this study to 14 months (FUP2) after the first 
and 3 months (FUP3) after a second renovation. Each time, we invited 
a consecutive sample of 180 patients presenting for a routine 
consultation to participate anonymously in a paper survey. Patients 
graded patient experience in 4 domains on a 6-point Likert-scale: 
appearance of the office; qualities of medical assistants and GPs; and 
general satisfaction. We compared crude mean scores of each domain 
from baseline until FUP3. In a multivariate regression model, we 
adjusted for patient’s age, gender and for how long patients had been 
their GP.
Results: The response rate for all consecutive samples of patients 
was 84–94%. At baseline, patients aged 60.9 (17.7) years, 52% 
females, and 67% were with their GP for >5 years.
Figure 1
Figure 2
Figure 2 shows crude mean scores per domain of patient experience. 
After a first renovation, we found a regression to the baseline level of 
patient experience at FUP2 except for appearance of the office (p 
<0.001). After a second renovation (FUP3), patient experience 
improved in appearance of the office (p = 0.008), qualities of the GP  
(p = 0.008), and general satisfaction (p = 0.014). Qualities of the 
medical assistant showed a trend of improvement (p = 0.068).  
The multivariate model did not change results.
Conclusions: Interior renovation of a GP practice causes a perceptual 
bias for >1 year that positively influences patient experience also in 
domains that are not affected by a renovation.  
We could reproduce this bias in a second renovation strengthening 
evidence for causality. This implies, to restrict measurement of patient 
experience to at least one year after interior renovation in primary care 
and therefore avoid biased estimates when measuring patient 
experience. 
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Interprofessional collaboration between physicians  
and community pharmacists – where are barriers  
and facilitators?
Sandra Unfer-Grauwiler1, Andreas Zeller2, Kurt E. Hersberger1, 
Isabelle Arnet1 
1Pharmaceutical Care Research Group, University of Basel; 2Centre 
for Primary Health Care, University of Basel, Basel, Switzerland
Introduction: Today, one profession can no longer hold all knowledge 
and skills that is needed for safe and quality care. Although the 
Federal Office of Public Health published in 2013 concrete examples  
of interprofessional collaboration, many mistake it for interdisciplinary 
work. Because different professionals can hardly work together if they 
do not learn together, Swiss research programs will be launched in 
2017 for projects in interprofessional teaching in medicine curriculum. 
Simultaneously, a political proposal (so called Postulat Humbel) 
requested in 2012 to demonstrate which new role community 
pharmacies could play to guarantee access to high quality care. In this 
context, we aimed at searching literature for barriers and facilitators to 
physician-pharmacist collaboration in primary care.
Methods: A pragmatic literature search was performed in PubMed 
and google scholar on Jan 1st 2017 with variations of the terms: 
interprofession* OR collaborati* AND physician* AND pharmac* AND 
“primary care” AND barrier* and the restriction “-education”. We present 
the key messages of the 156 retrieved articles which may be pertinent 
for Switzerland.
Results: Individual, contextual and exchange factors influence 
interprofessional relationship. Some issues seem predisposed such as 
medication review, medication dose adjustment, repeat dispensing, 
therapeutic substitution and medication adherence. Management of 
patients with abuse potential could be expanded. Physician-
pharmacist collaboration in primary care is highly facilitated by 
reciprocal trust in capabilities and knowing each other, co-location or 
geographical proximity, and regular face-to-face contact. Beside lack  
of motivation and willingness, lack of time and remuneration are  
often cited as barriers to the implementation of interprofessional 
collaboration. Technical difficulties may hinder information sharing,  
and confidentiality remains a topic of concern. The current main barrier 
seems the poor acceptance of the new pharmacists’ role and their 
provision of additional services. Adding diagnosis to prescriptions 
could represent a first step in shared decision making. Prescribing by 
pharmacists represents a clear hurdle.
Conclusion: The literature contains many articles on physician-
pharmacist collaboration, but implementation is still in its early stages. 
However, the Swiss Federal Council is evaluating how community 
pharmacists could play a more important role in primary care in future. 
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The life threatening side of otitis media –  
a case report of pneumococcal meningitis
Ashley Kilchenmann, Ewelina Biskup 
Universitätsspital Basel, Basel, Switzerland
Introduction: Acute otitis media (AOM) is a common infection, mainly 
affecting children, typically presenting with unilateral otalgia and 
decreased hearing. Otoscopic examination is the diagnostic standard. 
Streptococcus pneumonia is the most frequent bacterial cause. 
Complications such as mastoiditis, facial paralysis, labyrinthitis and 
meningitis develop in less than 0.5% cases in adults. Therapy of 
choice is amoxicillin.
Case report: A 55-year-old female was referred to our ER after having 
been found in her home with an altered, confused mental status. 
Recently, she had been complaining of ear pain. At admission, she 
was restless, septic, with a GCS of 6, requiring intubation. Orientating 
cranial CT showed opacification of the left mastoid air cells, as well as 
intracranial air entrapment and cerebral edema. During the CT, the 
patient suffered a seizure, which was successfully terminated with 
midazolam. With a high clinical suspicion of otogenous bacterial 
meningitis, empirical antibiotic therapy with tazobactam was 
commenced. In left ear otoscopy otitis media was diagnosed. Lumbar 
puncture revealed a high intracranial pressure (>50 mm Hg), liquor 
was positive for pneumococcal antigen. The antigen was also detected 
in the urine, confirming the diagnosis of pneumococcal meningitis. 
Antibiotic therapy was converted to empirically ceftriaxon and 
vancomycin, then ceftriaxone only (as per antibiogram). A surgical 
exploration of the mastoid was performed, revealing purulent 
secretion. A tympanostomy tube was temporarily inserted. In the 
control CT scan signs of high intracranial pressure were persistent. 
Neurovascular ultrasound showed an increased blood flow in the 
medial cerebral artery, which we interpreted as indirect signs of 
vasospasms. A therapy with nimodipine was installed. Within 12 days  
a vast clinical improvement was observed. The patient suffered no 
neurologic deficits, was spatially and temporally orientated and 
independently mobile so that discharge to a neurorehabilitation was 
feasible. 
Summary: Despite AOM being generalised as a trivial infection, delay 
in diagnosis and therapy can be lethal. Pneumococcal meningitis is a 
rare, life threatening complication, occurring in only 4% of invasive 
pneumococcal infections, with a case-fatality rate of up to 25%. 
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Concordance in the perception of complaints  
between general practitioners and their multimorbid  
patients: a cross-sectional study in Swiss primary care
Stefan Neuner-Jehle, Daniela Daniela Grossmann Maissen,  
Stefan Zechmann, Thomas Rosemann, Oliver Senn 
Institut für Hausarztmedizin, Universität und Universitätsspital Zürich, 
Zürich, Switzerland
Background: Multiple chronic health conditions (multimorbidity) is 
inevitably leading to multiple treatment procedures, unless health 
conditions are prioritized along patients’ needs and preferences. Thus, 
for improving healthcare, it is crucial for GPs to know what condition 
the patient is suffering most. The aim of our study was to investigate to 
what degree GPs perceive the subjectively most important complaint 
(MIC) of their multimorbid patients, and therefore to assess the 
GP-patient concordance in regard to MIC’s. 
Methods: Cross-sectional analysis based on a cluster-RCT among 46 
GPs and 334 multimorbid patients (≥60 years taking ≥5 drugs for at 
least 6 months) in Northern Switzerland recruited between March 2015 
and July 2016. Intervention group GPs (n = 20) were asked to list the 
four MIC of the patient, and patients (n = 128) were asked to list their 
MIC. MIC’s were classified using the ICPC-2 coding system on chapter 
and component level. We defined as concordance if the ICPC-2 code 
of patient’s MIC was identical with one of the MIC codes on GP’s list. 
We classified concordance into full, moderate and low, depending on 
the patient’s MIC code ranked first, second or third/fourth on GP’s list. 
We defined as discordance if the patient’s MIC code was not listed on 
GP’s list. Complaints frequencies were measured in the whole study 
sample (n = 334). Statistics included descriptive measures using the 
statistical software R, version 3.2. 
Results: Mean age of patients was 76.9 (SD 8.1) years, 38% male, 
taking 7.9 (SD 2.6) drugs on long-term. The most frequent complaints 
were pain, weakness / tiredness, shortness of breath and dizziness 
(fig. 1). Patient-GP concordance of the MIC was given in 101/128 
Figure 1
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Autoimmune limbic encephalitis with anti-LGI1  
antibodies, a treatable cause of behavior and  
memory disorder: a case report
Stéphanie Pillet, Vincianne Rey-Bataillard, Nicolas Garin 
Hôpital Riviera Chablais, site de Monthey, Monthey, Switzerland
Introduction: A 79 year-old healthy man was hospitalized with 
progressive memory impairment, confusion and abnormal perioral 
movements. Brain magnetic resonance imaging (MRI) revealed left 
amygdalo-hippocampal swelling with contrast enhancement. 
Electroencephalography (EEG) revealed paroxystic electrical activity 
without clinical correlate. Antiepileptic treatment did not alter the 
symptoms. A repeated MRI showed a second similar lesion located in 
the right hippocampus. Cerebrospinal fluid (CSF) was clear with one 
leukocyte pro microliter and normal proteinorachia. Antibodies with 
anti-LGI1 specificity were positive in the blood and CSF. A diagnosis of 
autoimmune limbic encephalitis with anti-LGI1 antibodies was made, 
and treatment consisting of high dose methylprednisolone bolus 
followed by 0.6 mg/kg of prednisone orally and 2 g /kg of 
immunoglobulins intravenously was administered, with dramatic 
improvement of symptoms. A thorough investigation for the presence 
of neoplasia was negative.
(78.9%) on the ICPC-2 chapter level, while 86/128 (67.2%) were full, 
8/128 (6.3%) moderate and 7/128 (5.5%) low concordance. If the 
MIC’s were classified on ICPC-2 component levels, concordance was 
given in 83/128 (64.8%), whereby 72/128 (56.3%) were full, 6/128 
(4.7%) moderate and 5/128 (3.9%) low concordance (fig. 2). In 27/128 
(21.1%) there was discordance (chapter level). 
Figure 2
Conclusion: A majority of GPs perceives the MIC of the multimorbid 
patient correctly, but there is room for improvement: 21% of family 
physicians do not list the MIC of the patient at all in a four-part list. 
Thus, directly addressing patient’s complaint as part of the encounter 
might help for better coping with multimorbidity and improving the 
quality of care for multimorbid patients. 
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Diversity in the clinic: analysis of transcultural  
consultations requested by primary care physicians
Julieta Norambuena1, Asmaa Dhina1, Melissa Dominicé Dao1,2 
1Université de Genève, Faculté de Médecine de Genève; 2Médecine 
Communautaire, de Premier Recours et des Urgences, Service de 
Médecine de Premier Recours, HUG, Genève, Switzerland
Introduction: Because of current geopolitical contexts and migratory 
fluxes, primary care physicians (PCP) encounter an increasing amount 
of culturally diverse patients in their practice. This cultural diversity 
impacts the consultation and requires additional expertise. At the 
Geneva University Hospitals, a transcultural consultation is available 
for all health care professionals, providing cultural evaluation of 
referred patients, and issuing clinical recommendations. The aim  
of this research was to understand the type of clinical difficulties 
encountered by PCP caring for culturally diverse patients and their 
relevance for cultural competence training of PCP.
Methods: We conducted a retrospective analysis of all transcultural 
consultations requested by PCP between 2006 and 2015. We included 
situations for which a cultural evaluation was completed and excluded 
those for which only telephone advice was given. We analyzed 
consultation request intake forms and consultation reports issued to 
the PCP. We analyzed patient and provider characteristics, motives of 
consultation requests, issues identified by the cultural evaluation and 
recommendations made to PCP.
Results: 32 consultations were included in the analysis. The main 
reasons for consultation were clarification of patient’s socio-cultural 
context and exploration of patient’s explanatory model of illness. The 
main issues identified by the cultural evaluation were the high level of 
socioeconomic vulnerability interfering with health care management, 
divergent explanatory models between patient and PCP, necessity to 
refer to mental health care, and linguistic barriers to optimal 
communication. Recommendations included integration of additional 
professionals and modifications of clinical management.
Conclusion: PCP confronted with culturally diverse patient population 
need additional knowledge and skills. Useful competencies include 
understanding the impact of socio-economic vulnerability on illness 
self-management, tools to explore patient models of illness and the 
impact of culture on the expression of distress. 
Figure 1: T2. Figure 2: T2*FLAIR.
Methods: We searched PubMed° for relevant articles using the 
keywords “limbic encephalitis”, “LGI1 antibody”, and “faciobrachial 
dystonic seizure”
Results: Limbic encephalitis is a subacute disease, with progressive 
memory impairment and confusion, with or without faciobrachial 
dyskinesia. Men in the 7th decade are mostly affected. The EEG is 
pathological in more than 50% of patients. MRI shows hypocampic 
hypersignal in T2 or T2 FLAIR. The diagnosis is confirmed by isolation 
of anti-VGKC antibodies above 400 pmol/L, with anti-LGI1 specificity, 
in the CSF and serum. A neoplasia is associated in 10 to 20% of cases. 
Administration of corticosteroids for 4 to 6 months, along with 
immunoglobulins or plasmapheresis, leads to rapid clinical 
improvement. Relapses are rare and generally respond to Rituximab 
administration. Atrophy or sclerosis of the hippocampus can occur in 
case of delayed treatment. 
Conclusion: Autoimmune limbic encephalitis with anti Lgi1 antibodies 
should be evoked in patients with subacute memory and behavioral 
troubles, in particular when associated with faciobrachial dyskinesia. 
Though the etiology is rarely paraneoplastic, assessment for the 
presence of cancer is warranted. Timely treatment with corticosteroids 
and immunoglobulins leads generally to remission of the symptoms. 
For these reasons, awareness of its semiology and early diagnosis are 
important in order to start specific treatment as soon as possible. 
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Securing an adequate follow-up in patients with  
discrepancies between the preliminary and final radiology 
report in the emergency department
Gert Krummrey, Wolf E. Hautz, Aristomenis K. Exadaktylos 
Universitäres Notfallzentrum, Inselspital Bern, Bern, Switzerland
Introduction: In the setting of an emergency department (ED), 
preliminary radiological findings are often reported via telephone. The 
final report can be different, especially after being reviewed by a senior 
radiologist. If those additional findings aren’t adequately communicated, 
they are prone to be lost to follow-up with possibly detrimental results 
e.g. in the case of suspect pulmonary lesions. In larger departments, 
validating hundreds of reports per day can be strenuous, therefore an 
automated process is desirable. 
Methods: Diagnoses and radiology reports are usually recorded in an 
unstructured manner. We used natural language processing (NLP) and 
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options, but before considering a randomized controlled trial, we 
wanted to confirm the burden related to cramps in a primary care 
setting as well as the feasibility of such a study.
Objective: The objective of this study was to prospectively explore the 
cramps’ frequency, duration, severity and related sleep disturbance. 
Methods: We planned to enroll 600 patients in 30 practices, between 
march 2014 and September 2015. Questionnaires and daily log were 
distributed to patient to prospectively obtain information about 
demographics, cramp frequency, severity, sleep disturbance, and 
treatment. A research assistant realized 3 telephone interview during 
the the study. 
Results: We included only 102 people in 14 practices, among them, 
86 (86%), reported cramps during the 2 weeks of the study. Overall 
cramp frequency was 2,26/week, overall duration was 5 minutes. 
Overall severity was 4,17 on analog numerical scale from 0 to 10, 
overall sleep disturbance was quoted 5,28 on analog numerical scale 
from 0 to 10. Overall Pittsburgh sleep quality index was 7, while  
28 patients reported a score >8 and 46 reported a score >5. 
Conclusions: These results confirmed the severe pain and sleep 
disturbance already showed in previous studies but questioned the 
feasibility of a randomized controlled trial in our setting. 
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Exploration of social and psychological difficulties  
related to acne by the general practitioner:  
a systematic review
Axelle Massuyeau, Michael Moeri, Dagmar M. Haller,  
Hubert Maisonneuve 
Unité des Internistes Généralistes et Pédiatres / Université de 
Genève, Genève, Switzerland
Introduction: Acne vulgaris is a chronic inflammatory disease of the 
skin affecting a very large proportion of the general population. It can 
have a considerable negative impact on patients’ mental health and 
quality of life and has been associated with high rates of depression, 
anxiety and suicide. Acne patients must be screened for psychosocial 
distress in primary care. The aim of this systematic review was to study 
how general practitioners explore the psychological, psychosocial and 
psychiatric distress caused by or linked to acne vulgaris in their 
ambulatory practice.
Methods: We searched Pubmed, Medline, Cochrane, Embase, 
Psycinfo and Cinahl from inception until February 3rd 2016. We 
included literature reviews, observational studies, interventional 
studies and review articles. All non-pediatric acne patients with no 
treatment susceptible of causing psychological distress, including 
isoretinoin, and suffering from psychosocial distress due to acne were 
considered. Data extraction included study, population, context and 
intervention characteristics, and relevant subjective and objective 
outcomes. A narrative synthesis was performed.
Results: Our search resulted in five relevant articles. Many quality  
of life and mental health assessment tools were described, but no 
information was given on their use in general practice. One Australian 
study specifically explored psychological intervention in primary care. 
Overall, our results suggested that psychological aspects are 
neglected in the therapy of acne patients, without any supportive 
quantitative data.
Conclusion: Very little data is available on the exploration of 
psychosocial suffering in acne patients in primary care. No adequate 
acne-specific tool has been validated for psychosocial screening in 
general practice. Research should be undertaken to assess how 
general practitioners explore psychosocial suffering caused by acne. 
We suggest maximising awareness on this issue amongst general 
practitioners, validating a straightforward and ergonomic tool to do so 
and assessing its clinical use in primary care. 
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Access to electronic records of general practitioners  
and specialists in rural central Switzerland for spatial  
analyses
Ingrid Tanner1,2, Christoph Merlo1, Stefan Essig1,3 
1Institute of Primary and Community Care Luzern; 2Department of 
Health Sciences and Health Policy, University of Lucerne, Luzern; 
3Swiss Paraplegic Research, Nottwil, Switzerland
Background: For many countries, the geographic distribution of 
general practitioners (GPs) and specialists remains insistently unequal 
despite the notable increases in overall supply. How physicians are 
distributed and how their patient populations differ in healthcare 
utilization dependent on geographical and demographic factors are 
aspects requiring great consideration during healthcare planning. 
Therefore, we asked, is there a maldistribution of physicians in Central 
named entity recognition (NER) to find expressions denoting ICD-10 
entities. In order not to miss possible pathological findings we also 
searched for keywords, such as “tumor”, “nodule”, “infiltrate” in the 
radiology report. A suspected mismatch would then prompt a manual 
comparison of clinical diagnoses and the final report. To validate this 
approach we used a random sample of cases. 
Results: The validation of the algorithm itself to match ICD-10 codes 
to free text fields was done using a set of diagnoses which were 
manually encoded by two independent observers. The matching-
results were found to be sufficient on a 3-digit code level (ICD-10 main 
diagnosis group). It was noted, however that the variability in phrasing, 
spelling, naming and abbreviating entities was rather large. Also a 
difference in jargon was found between clinical diagnoses and 
radiological reports. It was therefore necessary to define a thesaurus, 
a list of abbreviations and additional text parsing rules to improve 
entity recognition. We are currently adapting the methodology as to 
reduce the number of false positive mismatch warnings. 
Conclusions: Text mining and named entity recognition are 
challenging for a number of reasons, including multiple names and 
abbreviations for a given diagnosis as well as simple typos. Using the 
methods described we were successful in automating the process to 
avoid overlooking findings which are contained in the final written 
radiology report only and to secure an adequate follow-up. It has to be 
stated that we could only identify a small number in which those 
discrepancies had a clinical impact. Nevertheless we plan to improve 
the algorithm to allow for deployment in the near future. 
P447
Abdominal pain and very high alkaline phosphatase  
level – is there a coherence?
Arno Peng, Raphael Jeker 
Innere Medizin, Kantonsspital Graubünden, Chur, Switzerland
Introduction: Little is known about a coherence of intestinal 
angioedema, very high alkaline phosphatase and asymptomatic factor 
V Leiden Mutation. 
Case report: A 22-years old professional endurance sportswoman 
was presenting several time with sudden abdominal pain, nausea and 
vomitus over a period of almost 2 years. An asymptomatic factor V 
Leiden Mutation was known and the only daily taken drug was an oral 
anticonception (Desogestrel). In the physical examination we founded 
an epigastrical pain on pressure without peritonism. The blood results 
showed a very high level of alkaline phosphatase (3500 U/l) with 
normal inflammation parameters and gamma-GT. In a computer-
tomography we documented edematous thickened ileum terminals and 
colon ascendens. A stenosis of the terminal Ileum, with a normal 
mucosa was found in the colonoscopy. In a MRI which was performed 
a day after, the stenosis and the edematous tissue was disappeared. 
Therefore an intestinal angioedema was proven. We did not find any 
infection (EBV, CMV, Leishmania, Yersinia) or porphyria. The C1-
Esterase and tryptase levels were normal. We stopped Desogestrel 
and the patient was asymptomatical and two months later alkaline 
phosphatase was 135 U/l. 
Discussion: The clinical signs can be explained with an intestinal 
angioedema. High levels of alkaline phosphatase are known as 
transient benign hyperphosphatasemia in children but not in adults 
and especially not in coherence with angioedema. As we know there  
is no coherence known with angioedema, transient benign 
hyperphosphatasemia factor V-Leiden Mutation and desogestrel.  
We consider that there is a coherence and the patient therefore was 
without any symptoms after stopping the intake of daily desogestrel. 
Conclusion: This case shows that a very high alkaline phosphatase 
without signs of a liver disease or osteomalacia also in adults should 
be considered as transient benign hyperphosphatasemia. Also there 
might be coherence with intestinal angioedema, factor V-Leiden 
Mutation and desogestrel. Further research is needed. 
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Sleep disturbance related to nocturnal leg cramps  
in Geneva: a prospective observational study with  
a feasibility perspective
Hubert Maisonneuve1, Paul Sebo1, Bernard Cerutti2,  
Dagmar M Haller1 
1Unité des Internistes Généralistes et Pédiatres / Université de 
Genève; 2Unité de Développement et de Recherche en Éducation 
Médicale, Faculté de Médecine, Genève, Switzerland
Introduction: Cramps are involuntary painful muscle contractions. 
They affect almost one in two people over 60 in primary care. In 
declarative retrospective study, cramps were shown to cause severe 
pain and sleep disturbance. Studies are needed to assess therapeutic 
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Which factors influence the use of Electronic Health  
Record (EHR) during the first ten minutes of the clinical 
encounter?
Cédric Lanier1, Bernard Cerutti2, Melissa Dominicé Dao2,3,  
Patricia Hudelson2,3, Noëlle Junod Perron2,3 
1Primary Care Unit, Faculty of Medicine, University of Geneva; 
2Faculté de Médecine de Genève; 3Geneva University Hospitals, 
Geneva, Switzerland
Introduction: The Electronic Health Record (EHR) is used in about 
12–55% of clinical encounters, especially at the beginning. Several 
factors related to physician, patient, consultation or spatial 
characteristics may influence the use of the EHR. However no studies 
have specifically assessed the relative importance of each of these 
factors for EHR use during clinical encounters. The aim of the study 
was to identify the physician, patient and consultation characteristics 
that influenced EHR use by primary care physicians during the first ten 
minutes of the consultation. 
Methods: A cross-sectional study was conducted at the Division of 
Primary Care at the Geneva University Hospitals. Seventeen residents 
at the end of their training as general internists provided 6–8 self-
videotaped clinical encounters. Use of the EHR was defined by use  
of the keyboard and/or the screen during the first 10 minutes of the 
clinical encounter. The influence on EHR use of patients’ 
characteristics (sex and age and language spoken), physicians’ 
characteristics (sex, age, self-perceptions regarding EHR use) and 
consultation characteristics (new-follow-up, content of consultation, 
language used) were evaluated using multivariate analyses.
Results: A total of 142 videotaped consultations were included. Both 
addressing biomedical content (p = .0178) and having little clinical 
experience (p = .0213) increased the use of the EHR. There was also 
weak evidence that being a male MD (p = .1010) or conducting a new 
consultation rather than a follow-up (p = .0967) could also increase the 
amount of EHR use. There was no evidence that physicians’ self-
perceptions regarding the use of computer, or patients’ characteristics 
influenced their EHR use.
Conclusion: The results suggest that only a few elements regarding 
the physicians or the consultation characteristics were associated with 
EHR use during consultations. Because lack of clinical experience 
seemed linked to increased use of the EHR, training on how to use the 
EHR in a patient-centered manner should take place early in medical 
training in order to minimize the negative impact of EHR use on the 
physician-patient relationship. 
Switzerland and if so, does it influence healthcare accessibility in rural 
areas? 
Methods: Data was provided from the Physicians Association’s and 
MedKey, a patient data trust center. Physicians were asked prior to 
analysis for access to their patient’s electronic health records. They 
were given 3 options to choose from, (1) full access to anonymized 
electronic records for all research going further, (2) only allow access 
to records for this research project, and (3) no access to records. For 
this analysis responses one and two were treated as a yes and option 
three as no. Using the Eurostat’s degree of urbanization, physicians 
were designated into regions (urban, suburban, rural) dependent on 
population density. The physicians’ locations will be geocoded, at the 
street level, and paired with their patient population, at the zip code 
level. Analyses will be performed to estimate travel time and distance 
between physicians and their patients, and to examine the 
associations between physician’s distributions by the degree of 
urbanization and patient characteristics.
Results: From the data provided, 938 letters for consent to utilize 
electronic records were sent to practicing physicians working in Central 
Switzerland. 183/342 (54%) urban physicians responded, 141 (41%) of 
them give access to the records. 236/433 (55%) suburban physicians 
responded, 173 (40%) of them give access. 95/163 (58%) rural 
physicians replied, 87 (53%) of them give access. Of the respondents 
345 (67%) were GPs and 169 (33%) were specialists. Yes responses 
by Cantons, 222 were from Lucerne, 65 Zug, 52 Schwyz, 24 
Nidwalden, 18 Obwalden, and 17 from Uri.
Conclusions: From the gathered data, a spatial analysis will 
investigate the distribution, provision and utilization of primary care 
and specialty care in Central Switzerland. Generalizability will be 
limited due to varying response, however, rural physicians were more 
willing to give access to their data than urban or suburban physicians. 
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Cryptoccocal infection as a sign of severe underlying 
immunodeficiency
Lisa-Marie Schleithoff1, Patrick Hakman1, Sabine Majer2,  
Beat Frauchiger1 
1Department of Internal Medicine, Kantonsspital Frauenfeld, 
Frauenfeld; 2Department of Infectious Diseases, Kantonsspital 
Münsterlingen, Münsterlingen, Switzerland
Introduction: Cryptococcosis is an AIDS-defining opportunistic 
infection and a sign of severe immunosuppression. With wide access 
to antiretroviral therapy Cryptococcosis has become a rare disease in 
high-income countries like Switzerland. But incidence is still high in 
countries with high prevalence of HIV/AIDS. 
Case: A 33-year old Kenyan man was admitted to our hospital 
because of episodes of recurrent vomiting and syncope. He reported 
reduced appetite, unintentional weight loss, night sweats, malaise and 
intermitting fever. During the past 10 days, he suffered from position-
dependent headache. At the emergency department the patient had 
two epileptic seizures. On clinical examination the patient was skinny, 
vital signs were normal. The laboratory diagnostics showed a 
microcytic, hypochromic anaemia (Hb 116 g/l) and leucopenia  
(3.8 G/l, lymphopenia 0.3 G/l). The cranial computed tomography was 
unremarkable and the cerebrospinal fluid (CSF) showed a total cell 
count of only 2 cells/µl with a slightly increased protein (0.49 g/l). The 
patient was admitted to the intensive care unit and an anticonvulsive 
therapy with Levetiracetam was started. The subsequent magnetic 
resonance imaging scan of the neurocranium was unremarkable with 
no signs of increased intracranial pressure. Surprisingly, the 
cytopathological examination of the CSF showed Cryptoccocus 
neoformans, cryptoccal antigen was positive in the CSF and all blood 
cultures grew Cryptoccocus neoformans. An antifungal therapy with 
Amphotericin B and Flucytosin was started. In the meanwhile the HIV 
screening test was positive. The patient was transferred to a 
neurological intensive care unit. Due to repeatedly elevated 
cerebrospinal pressure >25 cmH2O, a continuous ventricle drainage 
was placed. Despite highest intensive care, the patient developed a 
fulminant cerebral oedema with compression of the CSF spaces and 
transtentorial herniation as well as a herniation through the foramen 
magnum. Nine days after the admission the patient died. 
Conclusions: This case shows a fatal central nervous system 
infection due to Cryptoccocus neoformans in a patient with unknown 
HIV. Cryptococcosis is often fatal, even if treated, and early recognition 
is mandatory. 
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trunk, buttocks, thighs and wrists were present. Besides an elevated 
CRP, blood tests comprising common viral serologies and a complete 
immunological panel were normal. Dermoscopy allowed identification 
of Sarcoptes scabiei and a diagnosis of scabies was made. Because 
of incomplete response to previous treatment, an additional cycle of 
ivermectin (2 doses 10 days apart) was prescribed. Arthralgias briefly 
worsened with the first of these 2 doses. The patient was discharged 
at day 7. At 1-month follow-up skin lesions had totally regressed and 
arthralgias disappeared.
Conclusion: In the absence of other drugs or medical conditions 
that could explain patient’s symptoms, arthralgias were ascribed to  
a post-ivermectin Mazzotti-like reaction. Although hardly reported in 
scabies, it is likely that such reaction developed because of high 
parasitic load from long mistreated scabies. Clinicians should be aware 
of this potential complication particularly when treating crusted or 
long-standing scabies. 
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A rare form of granulocytic meningitis
Joëlle Nicoletti, Dorothea Horschik, Livia Kammerlander,  
Jacques Gubler 
Department Medizin, Kantonsspital Winterthur, Winterthur, Switzerland
Introduction: Granulocytic meningitis is a rare form of central nervous 
system (CNS) inflammation of various infectious, autoimmune and 
other causes. Exclusion of opportunistic infections, especially in 
patients with autoimmune diseases treated with immunosuppressive 
agents, can be a challenge. Brain biopsy is often needed for definite 
diagnosis.
Case report: A 60-year-old woman was referred for evaluation  
of weight loss (10 kg in 3y), increasing confusion and anemia. A 
seronegative, anerosive rheumatoid arthritis (RA) had been diagnosed 
a year earlier and was treated with leflunomide. The occurrence of 
memory loss and dysarthria had been ascribed to an atypical cerebral 
hemorrhage due to amyloid angiopathy a few months earlier. The 
patient’s cognitive functions deteriorated rapidly and she started 
having fluctuating motoric neurological deficits. The cerebrospinal fluid 
(CSF) was slightly xanthochromic, showed a lymphocytic pleocytosis 
(37 Ly /39 cells/µl) and an elevated protein (1087 mg/l). The MRI  
(fig. 1) revealed leptomeningeal thickening with contrast enhancement 
as well as progredient subarachnoidal and parenchymatous micro-
hemorrhages. Biopsies of meninges and brain confirmed the diagnosis 
of a granulomatous inflammation and amyloid angiopathy (fig. 2). 
Search for infectious causes by culture and PCR was negative. 
Therapy with leflunomide was stopped, intravenous pulse 
corticosteroid therapy was given for 5 days followed by oral 
prednisolone tappered over several months. Additionally, two doses of 
1000 mg each of Rituximab were applied. Over 6 months, the ESR fell 
to normal, the anemia resolved and the cognitive impairment improved 
slowly albeit incompletely.
Discussion: Rheumatoid leptomeningitis (RLM) is a rare neurological 
complication of rheumatoid arthritis (RA). It usually occurs in patients 
with longstanding RA but can also be found early in disease or even 
as the presenting manifestation. Symptoms may include behavioral 
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When your dog suddenly barks silently
Isabelle Marcaccini, Vineeta Bansal Zweifel, Susann Hasler,  
Anne Miller, Urs Karrer, Peter Ballmer, Jacques Gubler 
Departement Medizin, Kantonspital Winterthur, Winterthur, Switzerland
Case description: A 59-year-old patient was admitted due to acute 
onset of dizziness, vomiting and bilateral hearing loss. A week earlier, 
his illness started with influenza-like symptoms, followed by severe 
nausea, protracted emesis, progressive dizziness, vertigo and 
unstable gait. Almost complete bilateral hearing loss occurred the day 
before admission. The patient lived alone with numerous small animals 
(goats, cats, dogs), he consumed alcohol excessively. On examination, 
he had a temperature of 38.2 °C, looked ill with signs of severe 
vestibulo-cochlear failure (unsteady gait with drift to left, Weber and 
Rinne-testing was not heard, bilateral positive head impulse test and 
spontaneous left-beating nystagmus) but no neck stiffness. Blood  
tests showed leucocytosis of 20.7 G/l with marked left shift, 
thrombocytopenia of 43 G/l, and C-reactive protein of 85 mg/l. 
Cerebrospinal fluid (CSF) analysis revealed a polynuclear pleocytosis 
of 493/µl, with a lactate of 3.3 mmol/l (N <2.0). Treatment with 
ceftriaxone, amoxicillin and aciclovir was started. A cerebral MRI 
disclosed multiple small subacute supratentorial ischemic lesions.  
The echocardiography demonstrated an apical akinesia as sequela  
of a myocardial infarction and a thrombus within the apex. Coronary 
angiography was normal without coronary stenosis. Cultures of blood 
and CSF were negative. However, broad-spectrum PCR of the CSF 
was positive for Capnocytophaga canimorsus. The patient was treated 
with i.v. Ceftriaxone for 10 d, recovered slowly of his neurologic deficits 
over 6 months but at the end needed a cochlear implant for persisting 
deafness.
Discussion: Capnocytophaga canimorsus, a slow growing gram 
negative rod, is part of the commensal oral flora of dogs and cats. It 
can cause severe septic infection, especially in immunocompromised 
patients (i.e. asplenia, liver cirrhosis, excessive alcohol consumption). 
C. canimorsus infection activates the blood coagulation cascade; 
thromboembolic myocardial infarction has been described in patients 
with C. canimorsus sepsis and normal coronary arteries. Meningitis 
due to C. canimorsus goes along with a high rate of sensorineuronal 
hearing loss. Our patient with typical risk factors of dog and cat 
exposure, combined with excessive alcohol consumption, sufferred 
from two classical complications of systemic C. canimorsus infection, 
notably meningitis with bilateral hearing loss and thromboembolic 
cardiac involvement despite normal coronary arteries. 
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Ivermectin-associated athralgias. Blame it on the mite?
Matteo Coen1, Julia Christine Hermes-Laufer1, Vincent Poffet1,  
Arnaud Naville1, Aurélie Hsieh2, Axel Finckh3, Ilias Lazarou3, 
Sébastien Piotton3, Emmanuel Laffitte2, Mathieu Nendaz1,4 
1Service of Internal Medicine, Department of Internal Medicine, 
Rehabilitation and Geriatrics; 2Service of Dermatology and 
Venereology, Department of Internal Medicine Specialties; 3Service of 
Rheumatology, Department of Internal Medicine Specialties, Geneva 
University Hospitals; 4Unit of Development and Research in Medical 
Education (UDREM), University of Geneva, Faculty of Medicine, 
Geneva, Switzerland
Introduction: Ivermectin is used to treat a variety of parasitoses. 
Post-treatment side effects, or Mazzotti reaction (i.e. fever, headache, 
chills, arthralgia, rash, eosinophilia, anorexia) may occur due to 
antigen release from dying parasites. Common in onchocerciasis, 
Mazzotti reaction in scabies has been described only once in a patient 
with crusted form. (Ito T., 2013).
Methods: We describe the case of a patient who developed 
polyarthralgias after oral ivermectin for scabies.
Results: A 46-year-old woman developed a pustular rash after 
swimming in a lake 4 months before hospitalisation. The rash 
appeared on her buttocks and progressively extended to the trunk, 
arms, and legs. The initial differential diagnosis included cercarial 
dermatitis, toxidermia, and autoimmune disease. Skin biopsy showed 
features of parasitosis but no parasites were seen. Oral and topical 
steroids and antihistamines were tried without success. One month 
before hospitalisation, empiric ivermectin treatment (2 doses of 200 
ug/kg at 2-week interval) was administrated with slight clinical 
improvement. Two days after the second dose, the patient developed 
serious polyarthralgias requiring hospitalisation. Pain relief was 
obtained with paracetamol and opioids. Patient’s past medical, family, 
allergy and travel history was insignificant. Parameters were normal. 
Physical examination revealed painful and tender elbow, wrists, knees 
and ankles. Itchy erythematous, papular and vesicular lesions on the 
Figure 1: Histo-1_
LeptomeningitisCR.
Figure 3: MRI_
LeptomeningitisCR.
Figure 2: Histo-2_
LeptomeningitisCR.
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Atypical presentation of pneumocystis pneumonia in  
a tofacitinib treated patient with rheumatoid arthritis
Ian Pirker1, Jacqueline Krane-Nuber1, Thomas Neumann2 
1Allgemeine Innere Medizin, Kantonsspital St. Gallen; 2Klinik für 
Rheumatologie, Kantonsspital St. Gallen, St. Gallen, Switzerland
Introduction: Pneumocystis pneumonia (PCP) is a potentially 
life-threatening opportunistic infection in immunocompromised 
individuals. HIV-negative PCP patients, particularly those with 
inflammatory rheumatologic diseases, rapidly develop fulminate 
pneumonia with severe respiratory failure. As a diagnostic pitfall, in  
the early stages of PCP in these patients, respiratory symptoms are 
nonspecific and nonsevere. We report the case of a patient with 
rheumatoid arthritis (RA) treated with tofacitinib, who developed severe 
PCP with atypical clinical presentation. 
Case report: A 78-year old male patient with RA treated with 
tofacitinib, an oral JAK inihibitor (a non-biologic targeted synthetic 
DMARD), methotrexate (MTX) and low dose corticosteroids 
(Prednisolon 5 mg daily) was admitted with arthralgia, nausea  
and confusion. Laboratory findings revealed hypercalcemia  
3.12 mmol/l albumin-corrected with normal PTH and elevated 
1,25-dihydroxyvitamin D3 (162 ng/l). Therapy of hypercalcemia was 
initiated at admission with intravenous sodium chloride solution 
(0.9%). For further investigation of hypercalcemia we performed a  
CT scan, that showed bilateral interstitial pneumonic infiltrates.
changes, changes of consciousness, focal neurologic signs and 
seizures, headache, weakness and weight loss. Since RLM can 
develop regardless of systemic disease activity, it should be 
considered in any patient with RA and unexplained neurologic 
symptoms. Brain and meningeal biopsy are needed for diagnosis, 
allowing also to exclude opportunistic infections. Therapy consists of 
corticosteroids followed by immunsuppressive agents. Recent case 
reports show that the historically poor prognosis of RLM can thus be 
improved. 
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Adult-onset Still’s disease
Samy Hassan1, Benjamin Niedergassel1, Christoph Etter1,  
Franziska Häfner1, Ariana Gaspert2, Rolf Streuli1, Christine Manser1 
1Klinik für Innere Medizin, See-Spital Horgen, Horgen; 2Institut für 
klinische Pathologie, Universitätsspital Zürich, Zurich, Switzerland
Introduction: Adult-onset Still’s disease (AOSD) is a rare systemic 
inflammatory disease that occurs in less than 1 in every 100.000 
people per year. Its classic symptoms consist of a triad of high spiking 
fever, joint-pain and a salmon-colored bumpy rash. It is a diagnosis of 
exclusion and symptoms may be unspecific and lead to a challenging 
search for a diagnosis. 
Case: A 51-year-old male patient was admitted to our unit due to fever 
of unknown origin since three months, following a cold with a sore 
throat. He reported having episodes of exceptionally high fever spikes, 
predominantly at night. Patient history showed that he had been 
suffering from joint pain in his distal and proximal phalanges in both 
hands for over 1.5 years and his right hip for approximately 4 years. 
Joint pain was manageable with the use of mefenamic acid. He had 
not travelled outside of Switzerland or Austria for the past 9 years and 
worked in the recycling industry, as well as the fire department and 
denied contact with toxic substances. On admission blood work-up 
showed signs of inflammation, procalcitonin was negative, increased 
GOT, GPT, GGT, AP and markedly increased ferritin. Compared to a 
blood sample 4 months ago, we saw a substantial decrease in renal 
function, mixed proteinuria and an elevated erythrocyte sedimentation 
rate. Abdominal ultrasound and CT-scan only showed splenomegaly. 
Infectious diseases, hematological malignancies and immunological 
disorders were ruled out. AOSD was diagnosed with Yamaguchi’s 
diagnostic criteria, of which the patient fulfilled three major (fever 
spikes, joint pain, leukocytosis) and four minor criteria (sore throat, 
elevated liver enzymes, negative tests for rheumatoid factor and 
antinuclear antibody, splenomegaly). Kidney biopsy showed acute 
interstitial nephritis, most likely drug-related (mefenamic acid) and  
no signs of vasculitis. The patient was started on 1000 mg 
methylprednisolone i.v. daily for three days and subsequently 50 mg 
prednisolone orally per day. Symptoms improved shortly after therapy 
was started. 
Conclusion: AOSD is a rare disorder that should be considered in 
patients with fever of unknown origin. The distinctive salmon-colored 
bumpy rash might be a give-away symptom, but as seen in this case, 
is not obligatory. Infectious, hematological and immunological causes 
need to be ruled out beforehand and the diagnosis can be made with 
Yamaguchi’s criteria, which are 96.2% sensitive and 92.1% specific for 
AOSD. 
Figure 1: Renal histology 1.
Figure 2: Renal histology 2.
Figure 1: CT scan: bilateral  
pneumonic infiltrates.
We started an antibiotic therapy with ceftriaxone and clarithromycin. 
The patient developed respiratory failure with need for non-invasive 
ventilation/ high flow oxygen therapy on ICU. Bronchoalveloar lavage 
revealed a positive pneumocystis jiroveci PCR and adequate therapy 
with trimethoprim/sulfamethoxazole (TMP/SMX) and prednisone was 
initiated. After seven days intensive care, the patient was referred to 
the normal ward. Treatment with TPM/SMX had to be stopped because 
of severe hyponatremia and acute status of confusion. As second line 
therapy we initiated clindamycin and primaquine. Four days later we 
stopped the therapy due to thrombozytopenia. The patient recovered 
respiratorilly after 17 days of antibiotic therapy. Hypercalcemia resolved 
under adequate therapy of PCP and was – after exclusion of other 
possible causes – probably fungal associated. 
Conclusion: PCP should be considered in RA patients on Tofacitinib 
treatment. The diagnosis can be challenging because of atypical 
clinical presentation. Hypercalcemia in conjunction with a pulmonary 
infection should raise the clinical suspicion of PCP. Considering the 
potentially fatal courses of PCP and with the rise of new biological and 
non-biological DMARDs it is important to evaluate carefully the need 
for PCP prophylaxis. 
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A rare reason for genito-oral ulcerations
Gabriela Jermann, Madeleine Rothen, Daniel Ernst,  
Armin Stucki 
Spital Thun, Thun, Switzerland
Introduction: Behcet disease (BD) is an inflammatory multisystem 
disease of unknown origin. The clinical presentation is heterogenous, 
leading to delayed diagnosis. However, the main characteristic sign is 
a bipolar aphthosis. The prevalence is high in countries along the silk 
road (from Japan over the middle east to the Mediterranean countries). 
BD is rare in western Europe. However, an increase of case reports in 
our geographic region during the last years indicates the importance  
of knowing and recognizing the clinical symptoms of BD. Because of 
the lack of universally accepted diagnostic criteria, the mainstay of 
diagnosis is the clinical presentation and the exclusion of differential 
diagnosis. 
Case description: We describe the case of a 20 years old male 
Swiss. He presented with oral and genital aphthosis. Because of oral 
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ALA is vital, considering the curable nature of this disease and 
potentially fatal outcome of untreated abscess. In our patient, the 
presence of liver hemangioma was tricky, potentially leading to 
erroneous diagnosis. Travel history represents a key moment in the 
diagnostic process. 
P460
From acute otitis media to acute kidney injury –  
a clinical case
Christoph Ryser, Claudia Buser 
Allgemeine Innere Medizin, Luzerner Kantonsspital, Luzern, 
Switzerland
Introduction: Granulomatosis with polyangiitis (GPA; Wegener’s)  
is a rare and potentially lethal systemic necrotizing granulomatous 
vasculitis of the small- and medium-sized arteries and veins, 
classically involving the upper and lower respiratory tracts with 
frequent involvement of the kidneys. Prevalence of otologic 
manifestations at beginning of disease varies from 19 to 61%; most 
frequent findings there are chronic otitis media, followed by serous 
otitis media and sensorineural hearing loss.
Case report: A 53-years old woman was evaluated in hospital for 
abdominal pain after returning from a journey to India, and a 4 weeks 
previously diagnosed and treated right sided acute otitis media with 
perforation and affection of the inner ear with persistent otalgia, 
otorrhoea, hearing loss and tinnitus. Clinical and sonographic 
abdominal examinations were inconclusive. Laboratory findings 
showed elevated inflammatory parameters. After an observation period 
of 4 days with spontaneous regression of abdominal pain, patient 
newly presented fever additionally to aggravation of otitis symptoms, 
slight dyspnoea and biltateral conjunctivitis. Unenhanced CT-scan 
showed acute mastoiditis and affection of inner ear on the right side  
as well as bilateral pulmonary nodules. Furthermore development of a 
rapid progressive renal failure with active urine sediment was noticed. 
Evidence of proteinase 3 antineutrophilic cytoplasmatic antibodies 
(PR3-ANCA), in combination with histological findings of focal 
segmental extracapillary proliferative glomerulonephritis in kidney 
biopsy, finally led to diagnosis of a granulomatosis with polyangiitis. 
Under immunosuppressive therapy with high-dose corticosteroids and 
cyclophosphamide patient showed a rapid improvement of symptoms 
and sings, induced to renal, pulmonal, abdominal, conjunctival and ear 
affections of vasculitis.
Conclusion: Occasionally otologic manifestations presents as the first 
signs of GPA, which makes diagnosis more difficult and delayed. 
Therefore, in cases of atypical inflammatory states of the ear or 
treatment failures GPA should be considered as a differential 
diagnosis. Histologic diagnosis from the middle ear is usually difficult 
(small specimens, lack of typical histologic findings), so that 
determination of ANCAs are helpful in making diagnosis, especially  
in ear limited disease. Early diagnosis and appropriate treatment is 
important to prevent progression of disease to an irreversible state. 
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Septic encephalopathy or bacterial meningo- 
encephalitis in a patient with Parkinson’s disease?
Danijela Grgic1, Urs Karrer2, Peter E Ballmer1, Alexandra Furrer3 
1Departement Medizin, Kantonsspital Winterthur; 2Infektiologie; 
3Pathologie, Kantonspital Winterthur, Winterthur, Switzerland
A 85 year old caucasian woman known for Parkinson’s disease and 
atrial fibrillation treated with rivaroxaban was admitted to our hospital 
with nausea, vomiting and elevated blood pressure since one day.  
Her blood pressure was 151/99 mm Hg, the heart rate 104 beats/min., 
the temperature 39 °C and the oxyganation 96% with 2l O2/min. She 
was oriented, had no neck stiffness and her long standing symptoms 
of Parkinson’s disease, e.g. tremor, rigor and orofacial dyskinesia  
had considerably worsened.Laboratory analyses showed 
thrombocytopenia and inflammation (Leucocytes 12.8×109/l, CRP 
11 mg/L). However, chest X-ray and urine analysis did not identify an 
infectious focus. Empiric antibiotic therapy with amoxicillin/clavulanic 
acid was initiated and the patient satisfyingly recovered. After blood 
cultures were positive for Listeria monocytogenes treatment was 
adapted to amoxicillin and gentamicin. Due to anticoagulation lumbar 
puncture for CSF-analysis was not performed. On day 11 of 
hospitalisation the patient developed severe abdominal pain. CT-scan 
showed no abdominal pathology but pleural effusions. Two days later, 
the patient developed progressive dyspnea and somnolence and died 
one day later. The autopsy showed pneumonia and fresh pulmonary 
embolism. Morover subacute to chronic meningo-encephalitis was 
seen by the pathologist. Listeria monocytogenes (Lm) is an ubiquitous 
pain, intake of food and fluids was limited and the patient dehydrated. 
Two weeks before, the patient had already consulted several other 
physicians and was prescribed several symptomatic treatments 
without improvement of symptoms. The former medical history was 
unremarkable. Infectious causes and Crohn’s disease were excluded 
by serologies and endoscopic and histologic investigations. Therefore, 
the suspicion of a first episode of BD was raised. After starting a 
therapy with prednison and colchicin, the patient recovered quickly. 
After hospitalization, the patient was seen in the rheumatological 
outpatient clinic. To underpin the diagnosis, HLA B51 was tested to  
be positive. 
Conclusion: Our case is a classical example that the diagnosis of BD 
is difficult and needs a high clinical suspicion. The diagnosis of BD is 
difficult, hard to prove and can often be confirmed only at the long run 
after excluding many other possible diagnosis. Our patient was of 
western European origin, an ethnology that typically is rarely affected 
by BD. Our case report shows, that BD may occur as well in patients 
of western European origin. BD in our western population is probably 
more frequently then assumed. Therefor thinking of BD is those 
symptoms is not an orphan diagnosis. 
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Amebic liver abscess in a man with liver hemangioma
Corinna Trippini, Stojan Todorov, Véronique Erard,  
Mathieu Firmann, Jérome Burnand, Uwe Schiemann 
Internal Medicine, HFR, Riaz, Switzerland
Entamoeba histolytica is a protozoan parasite that colonizes the large 
intestine of humans causing amoebiasis. It remains a significant cause 
of morbidity and mortality in developing countries and is responsible 
for up to 100,000 deaths worldwide each year. The clinical outcome of 
an E. histolytica exposure varies greatly and can present as diarrhea, 
dysentery or invasive amoebiasis. Amoebic liver abscess is the most 
common manifestation of extra-intestinal amoebiasis. We report the 
case of a man known for hemangioma, with superimposed amebic 
liver abscess. A 51-year-old male patient with a history of 3 weeks 
abdominal discomfort with epigastric heaviness, abdominal bloating, 
weight lost and the last 2 days fever up to 39 °C. He spent one week  
in India 4 months before. Clinical examinations show normal blood 
pressure (108/66 mm Hg), low-grade fever (37.3 °C) while the 
abdominal exam is insignificant. Laboratory tests show increased 
C-reactive protein (221 mg/l) and leukocytosis (15.0 G/l) without 
eosinophilia. Liver and pancreatic enzyme levels are normal. Urinary, 
stool and blood cultures are negatives. Antibody tests for 
Campylobacter Yersinia and Salmonella are negative. Abdominal 
ultrasound shows several hemangioma (V, VI and VII segments) and a 
new lesion at hepatic dome entering in differential diagnosis between 
abscess and hemangioma. An abdominal MRI confirms the presence 
of several hemangioma and shows an abscess of 4.5 cm in diameter, 
hard to drain, because of the diaphragmatic proximity (fig. 1). Two 
different antibody tests (ELISA at 1.43, IFAT at 320) confirm the 
diagnosis of amoebiasis. Under the treatment of 14 days of 
Metronidazole, followed by a week of paromomycine the patient fully 
recovers. A control MRI 6 months later shows a complete regression of 
the liver abscess, confirming ALA (fig. 2). Amoebic liver abscess (ALA) 
is an uncommon but potentially life-threatening complication of 
infection with the protozoan parasite E. histolytica. Complications 
involve rupture of the abscess causing spreading into the peritoneum, 
pleural space or pericardium. Recognition of variable presentation of 
Figure 1
Figure 2
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meningitis with a more gradual onset, less nuchal rigidity and more 
prominent movement disorders. Invasive Lm-infection is an important 
but rare disease with an incidence of 0.5–1 case/100’000 inhabitants 
and year (50–100 cases / year in Switzerland). Lm is inherently 
resistant to cephalosporins. Therefore, amoxicillin should be added  
to the empiric treatment regimen of suspected bacterial meningitis in 
patients with risk factors. 
gram positive rod capable of replication at a broad range of 
temperatures including refrigerated food (at 4 °C). It can be found on 
fruits, vegetables, meet, fish and cheese and may cause febrile 
foodborne enteritis. Immunodeficiency, pregnancy, alcoholism and 
advanced age are risk factors for invasive listeriosis like. The present 
case showed a meningo-encephalitis, only postmortem. The clinical 
presentation is often different to pneumococcal or meningococcal 
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Anticoagulant therapy in the elderly: how to be safe?
Ines Kechaou, Samira Azzabi, Eya Cherif, Imen Boukhris,  
Lamia Ben Hassine, Narjess Khalfallah 
Service de Médecine Interne B, Hôpital Charles Nicolle, Tunis, Tunisia
Background: The management of anticoagulant treatment requires 
great caution in the elderly because of their frequent polypathology 
and polypharmacy. The aim of our study was to investigate the 
particularities of the use of anticoagulants in the elderly.
Methods: Retrospective study included 100 patients aged at least  
65 years old and hospitalized for initiation of anticoagulation, was 
performed in an Internal Medicine Department between 2000 and 
2015.
Results: They were 55 women and 45 men (sex ratio: 0.81), with  
a mean age of 75.7 ± 6.9 years. The indications for anticoagulant 
treatment were venous thromboembolism (VTE) (92%) and atrial 
fibrillation (AF) (8%). The VTE were divided into deep venous 
thromboembolism (DVT) of the inferior members (85%), superficial 
venous thromboembolism (SVT) (9%) and pulmonary embolism  
(PE) (6%). Eight patients had simultaneously two reasons for 
anticoagulation. Low molecular weight heparin (LMWH) was 
prescribed in 80% of patients and unfractionated heparin (UFH) in 
20% of patients. The indication of UFH in our patients was a renal 
failure (creatinine clearance <30 ml/min). Overdose with heparin 
without bleeding was observed in 4 patients (30,7%) exclusively on 
heparin sodium. Heparin-induced thrombocytopenia was observed 
under LMWH in 2 patients (2.5%) and UFH in 4 patients (20%). The 
average length of overlap Sintrom®/heparin was 10.83 days ± 5.8. The 
average duration of treatment with Sintrom® was 17.22 days ± 7.9. The 
dose of Sintrom® initiation was 1 mg in 85% of patients and 2 mg in 
15%. INR <2 was observed in 15% of patients. INR in the target area 
was obtained in 47% of patients with a mean dose of 2.33 mg of 
Sintrom®. An overdose under Sintrom® was noted in 38% of patients: 
average INR at 4.7. Seven patients had bleeding events. An overdose 
was noted in 4 among them. Fever, infection, inflammatory syndrome, 
hypoalbuminemia, hypoprotidemia and malnutrition were associated 
with a greater risk of overdose in our patients. Gastroduodenal ulcer 
disease, past medical history of gastrointestinal bleeding and renal 
failure <60 ml/mn were risk factors of bleeding in our patients.
Conclusion: The use of anticoagulants in the elderly requires a 
comprehensive assessment including comorbidities, geriatric settings 
and social environment. 
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Risk factors of falls in the elderly: about 40 Tunisian  
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Service de Médecine Interne B, Hôpital Charles Nicolle, Tunis, Tunisia
Background: Falls are common health problem in the elderly. Its origin 
is often multifactorial. The aim of our work was to identify risk factors of 
falls in elderly people, to study the contribution of clinical functional 
test to discriminate between fallers and no fallers, in order  
to establish preventive measures.
Methods: Retrospective study was conducted between September 
2014 and January 2016 including 80 patients (65 years and over), 
followed at an Internal Medicine Department. Based on the presence 
or absence of a notion of falling in the previous year according to data 
from the anamnesis, we divided patients into 2 groups: case group  
(40 fallers) and control group (40 non-fallers). Risk factors of falls were 
screened by anamnesis and clinical examination. Timed up and go 
test, stop walking when talking and the unipodal stance test were 
realized in all patients after falls. Frailty was determined by SEGA 
score (Short Emergency Geriatric Assessment) after falls.
Results: The average age of faller’s patients was 75.7 years old with a 
clear female predominance (30 W/ 10 M). The average number of 
contributing factors of falls was significantly more common among 
fallers (4) compared to non-fallers (2.8) (p <0.05). Risk factors of falls 
identified in our study were: flat feet, knee osteoarthritis, osteoporosis, 
glaucoma, walking and balance disorders, nocturia and fraility. 
Otherwise, because of the low number of patients in our study, fallers 
and non-fallers were comparable in terms of average age, life style, 
polypathology of polypharmacy, urinary incontinence and loss of 
autonomy. Some clinical functional test allowed discriminating between 
fallers and non-fallers: Timed up and go test, stop walking when talking 
and the unipodal stance test.
Conclusion: A global care in the elderly, systematic screening for fall 
risk factors by all practitioners and establishing a “consultation falls” 
would prevent bad consequences of falls and improves the quality of 
life. 
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Impact of T-cell depletion on outcome of patients  
undergoing allogeneic hematopoietic cell transplantation 
(HSCT) for myelodysplastic syndrome (MDS)
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Anne-Claire Mamez2, Caroline Stephan2, Juan Felipe Rodriguez 
Morales2, Karolina Polchlopeck-Blasiak2, Yordanka Tirefort2,  
Stavroula Masouridi-Levrat2, Yves Chalandon2 
1Faculté de Biologie et Médecine, Université de Lausanne, Lausanne; 
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Introduction: MDS is a clonal haematological disorder and HSCT is 
the only curative option. In the transplant unit of Geneva University 
Hospital, we use partially T-cell depleted graft (TDEP) to reduce 
graft-versus host disease (GvHD). Here, we compared 3-years overall 
survival (OS), progression free survival (PFS), GvHD-free/relapse-free 
survival (GRFS), relapse incidence (RI) and transplantation-related 
mortality (TRM) between TDEP patients and non TDEP ones 
allografted for MDS. We also evaluated the impact of TDEP on acute 
and chronic GvHD.
Patients and methods: We analyzed 62 consecutive patients (44% 
were female, median age of 48 (range: 18–70) allografted for MDS 
(median EBMT risk score of 3, median disease risk index of 
intermediate risk) over a 19-year period (1998 to 2016) with MAC 
conditioning for 66% and RIC for 34%. Median time from diagnosis to 
HSCT was 7.5 months (range: 3–86). PBSC (90%) or BM (10%) grafts 
were from identical siblings (45%), MUD (42%) or MMUD (13%). T-cell 
depletion was performed for 52% of patients. Median follow-up was 
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revealed median values of 2 (IQR 0–3), 90% (IQR 90–100%), 4 (IQR 
3–5) and 15 (IQR 11–20), respectively. In univariate and multivariate 
analyses with a median follow-up of 12 months (IQR 3–36), a FEV1  
of 50-79% vs. particular lower FEV1 of <50% and an impaired KPS 
<90% was significantly associated with a higher risk for all-cause 
death – independent of age, conditioning regimes and donor type 
Conclusions: Taken into account the changes in practices, supportive 
care and management of comorbidities, in our cohort, a reduced 
pretransplant lung function and impaired performance status remain 
independent predictors of mortality in HSCT. 
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Haploidentical hematopoietic bone marrow  
transplantation with consecutive living kidney  
transplantion from the same donor in a sickle cell  
disease patient with end-stage renal failure
Eva Knüppel1, Michael Medinger1, Gregor Stehle1, Laura Infanti1,  
Jörg Halter1, Felix Burkhalter2, Edin Mujagic3, Dominik Heim1,  
Jakob Passweg1 
1Hämatologie; 2Clinic for Transplantimmunology and Nephrology; 
3Department of Vascular and Transplant Surgery, Universitätsspital 
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Introduction: Homozygous Sickle cell disease (SCD) patients 
suffering from end-stage renal disease (ESRD) show a variable 
outcome after kidney transplantation. We present a case of a 27-year 
old patient with severe SCD and ESRD who underwent haploidentical 
bone marrow transplantation (BMT) with consecutive living kidney 
transplantion (LKT).
Methods: The patient suffered from multiple complications of SCD 
including stroke with secondary hemorrhage, symptomatic epilepsy, 
ESRD and uncontrolled hypertension. The rationale for BMT was 
uncontrollable iron overload. A reduced intensity conditioning regimen 
was used with (fludarabine, cyclophosphamide and 2Gy of TBI, 
dose-adjusted to ESRD). Graft-versus-host disease (GvHD) 
prophylaxis consisted of post-transplant high-dose cyclophosphamide, 
cyclosporine A (CyA) and mycophenolate mofetil (MMF). The donor 
was her 56-year old mother with HbS trait, the stem cell source was 
bone marrow, the cell dose 4.74×108 nucleated cells/kg. During 
conditioning daily hemodialysis was performed to keep drug levels 
stable. Neutrophil engraftment occurred on day +26, chimerism at day 
+19 was 98%. HbS increased from 1.3% pre-HSCT to 40.0% 6 months 
after HSCT. Hemoglobin values increased from 70 g/L pre-HSCT  
to 110 g/L post-HSCT and reticulocytes from 16 G/L to 124 G/L. 
Erythropoietin levels increased from 2.3 IU/L pre-HSCT to 178 IU/L  
6 months after HSCT. During the follow-up, the patient did not show 
any sign of acute GvHD or vaso-occlusive crisis, hemolysis or sickling. 
Relevant complications were disease-related (therapy resistant 
hypertension and epileptic seizure due to former brain damage).  
On day +151 a LKT from the same donor was performed. The initial 
immunosuppressive treatment with MMF was continued, CyA was 
switched to tacrolimus and steroids were added for 3 months. The 
post-transplant period was uneventful. Currently, 12 months after 
haploidentical BMT and 6 months after LKT there are no signs of 
GvHD, the blood chimerism is 100%, the kidney allograft function is 
very good (GFR 73 ml/min/1.73 m2) and immunosuppression is 
withdrawn. Iron overload is being corrected by regular phlebotomies. 
The patient no longer requires antihypertensive medication and there 
is evidence of vascular remodeling.
Conclusions: This is the first report of a successful haploidentical 
BMT followed by kidney transplantation from the same donor in a 
patient with SCD. 
4.6 years (range: 0–15). There was no significant difference between 
TDEP and non-TDEP for patient characteristics. OS, PFS were 
estimated using the Kaplan-Meier method. Cumulative incidence 
estimates of TRM and GvHD were calculated with RI defined as 
competitive events by the Fine and Gray method.
Results: 3-years OS for all patients was 42 ± 14%, PFS 40 ± 14%, 
GRFS 26 ± 12%, RI 37 ± 13% and TRM 25 ± 12%. 3-years OS for 
TDEP patients and for non TDEP ones was not different (48 ± 18% 
and 34 ± 21% respectively, p-value 0.317) (Graph). Similarly, there 
was not difference between TDEP and non TDEP patients for 3-years 
PFS (48 ± 18% and 28 ± 20%, p-value 0.321), 3-years GFRS (32 ± 17 
vs 19 ± 17, p-value 0.111) (Graph), 3-years RI (36 ± 18% and 37 ± 
20%, p-value 0.622) and 3-years TRM (26 ± 16% and 23 ± 18%, 
p-value 0.933). Finally, TDEP had no significant impact on 3-years 
grade 2-4 aGVHD when compared to the non TDEP (26 ± 18% and 31 
± 16%, p-value 0.656). It had not either on 3-years cGVHD (26 ± 18% 
and 28 ± 34%, p-value 0.637).
Conclusions: Our study shows that TDEP is feasible on patients 
undergoing HSCT for MDS and does not make the outcomes worse 
compared to non TDEP (OS, PFS, RI and TRM). Unexpectedly, TDEP 
does not significantly reduce the incidence of acute or chronic GVHD. 
However, the number of patients is small and the period span is long. 
These finding should be confirmed prospectively in larger cohort.
Figure 2
P465
Pretransplant lung function and performance status  
as mortality predictors after allogeneic hematopoetic  
stem cell transplantation: a single-center cohort study
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Medicine and Pulmonary Cell Research, University Hospital Basel, 
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Introduction: Allogeneic hematopoetic stem cell transplantation 
(HSCT) remains associated with a high morbidity and mortality in  
spite of advances in HSCT management. Specifically, pulmonary 
complications account for a substantial proportion of deaths within  
the first 100 days after HSCT. Given the inconsistent association of 
pretransplant lung function parameters on mortality after HSCT and 
the significant changes in HSCT care over the last decades, the aim  
of our study was to estimate the effect of pulmonary function and 
comorbid conditions on mortality in patients undergoing HSCT. 
Material and methods: We retrieved relevant clinical data of all 
consecutive patients at the Hematology division of the Basel University 
Hospital with a transplant for hematological disorders between 2008 
and 2015. We examined the lung function at baseline and 3, 6 and 12 
months after HSCT – including the 1-second forced expiratory volume 
(FEV1 % of predicted), FEV1/VCmax and diffusing capacity for carbon 
monoxide. Additionally, we assessed pretransplant conditions such as 
age, sex, Karnofsky Performance Status (KPS), donor type, and 
various risk scores in HSCT (HCT-CI, European Society for Blood and 
Marrow Transplantation [EBMT], revised Pretransplant Assessment of 
Mortality Score [PAM]). Using uni- and multivariate survival analysis, 
we evaluated potential patient- and transplant-related risk factors for 
all-cause mortality by including the following candidate variables: 
FEV1, KPS, age, conditioning intensity and donor type. 
Results: Within the study period, 429 patients with predominantly 
acute leukemia (64%) or lymphoproliferative disorders (28%) 
underwent myeloablative (n = 330) and non-myeloablative (n = 99) 
HSCT at a median age of 54 years (interquartile range [IQR] 43–61 
years). The analysis of the HCT-CI, KPS, EBMT and PAM score 
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erythroid response according to IWG 2000/2006, reduction in red 
blood cell transfusion and transfusion-independency.
Results: We could identify only two small RCTs. In 2006, Balleari  
et al. performed a small RCT investigating the effect of recombinant 
human EPO (rhEPO) 10’000 IU s.c. 3×/week vs. rhEPO + G-CSF 300 
µg s.c. 2×/week for at least 8 weeks in 30 patients. Erythroid response 
was 73% (11/15) in patients receiving rhEPO + G-CSF compared to 
40% (6/15) receiving rhEPO only after 8 weeks. Nair et al. submitted 
an abstract to the Blood Journal in 2006 of a RCT investigating the 
effect of rhEPO 10’000 IU + G-CSF 150 µg 1x/week vs. rhEPO alone 
for 12 weeks in 68 patients. Erythroid response was 65% in the arm 
with rhEPO + G-CSF compared to 33% with rhEPO alone. 
Furthermore, we identified two relevant trials (NCT00234143, 
NCT01196715), which were terminated early without publishing 
relevant data.
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Veronika Blum1,2, Alexander D. Heini1, Urban Novak1,  
Behrouz Mansouri Taleghani3, Gabriela M. Baerlocher3,  
Kurt Leibundgut4, Katja Seipel5, Yara Banz6, Mario Bargetzi7,  
Thomas Pabst1 
1Department of Medical Oncology, Inselspital Bern, Bern; 2Department 
of Oncology, Kantonsspital Luzern, Luzern; 3Department of 
Hematology; 4Department of Pediatric Hemato-Oncology;5Department 
of Clinical Research, Inselspital Bern; 6Institute of Pathology, 
University of Bern, Bern; 7Department of Hematology, Kantonsspital 
Aarau, Aarau, Switzerland
Introduction: Autologous stem cell transplantation (ASCT) is used  
to consolidate a first remission in good- and intermediate-risk acute 
myeloid leukemia (AML) patients, and peripheral blood stem cells 
(PBSC) are the predominant graft source. Few data exist on the failure 
rate to mobilize a sufficient number of PBSC in AML patients after 
documented achievement of a first complete remission. In addition,  
the efficacy of subsequent PBSC remobilization and the outcome after 
ASCT using remobilized PBSC are unknown in AML patients with 
primary mobilization failure. 
Methods: In this single-center retrospective analysis, we evaluated our 
strategy using a single dose of 35 mg/m2 vinorelbine and filgrastim as 
a rescue procedure to remobilize PBSC of AML patients in first 
complete remission (CR1) following primary mobilization failure after 
two cycles of induction chemotherapy. We aimed to determine the 
survival rates of AML patients successfully remobilized with vinorelbine 
compared to conventionally mobilized patients. 
Results: Between 05/2005 and 01/2015, 69/85 (81%) AML patients  
in CR1 underwent successful collection of PBSC after two cycles of 
induction treatment whereas 16/85 (19%) patients had primary 
mobilization failure. With 37.5% (6/16 patients), the rate of mobilization 
failure was highest in NPM1mut-FLT3wt patients as compared to the 
other genomic subgroups. In 9 of the 16 (56%) patients with primary 
mobilization failure, subsequent treatment with vinorelbine and 
filgrastim mobilized sufficient PBSC to enable these patients to 
proceed to ASCT consolidation whereas the seven patients with failure 
after vinorelbine mobilization ultimately underwent conventional 
chemotherapy consolidation. Finally, we observed that progression 
free and overall survival rates were not different between primary and 
secondary mobilizers nor were hematologic recovery or transplant-
related mortality. 
Conclusion: Our data suggest that vinorelbine remobilization is an 
effective rescue option for AML patients in first remission with primary 
PBSC mobilization failure, thereby enabling such patients to proceed 
to subsequent ASCT consolidation. 
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myelodysplastic syndromes: a systematic review
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Introduction: The myelodysplastic syndromes (MDS) are a group  
of heterogeneous hematopoietic stem cell disorders characterized  
by dysplasia and peripheral cytopenias with a propensity to evolve 
towards acute myeloid leukemia (AML). The treatment of patients with 
lower-risk MDS (IPSS: low or intermediate-1) includes the application 
of hematopoietic growth factors like erythropoiesis stimulating agents 
(ESA) eventually in combination with granulocyte colony stimulating 
factor (G-CSF). However, the evidence on the additional effect of 
G-CSF on erythropoiesis remains unclear. The goal of this systematic 
review is to identify the level of evidence for treatment of anemia by 
EPO + G-CSF in lower-risk MDS patients.
Methods: We performed a systematic literature research by examining 
the Cochrane Library, Embase and PubMed databases. We 
additionally checked ongoing trials and conference abstracts of the 
American Society of Hematology and the European Hematology 
Association. We focused on interventional studies investigating the 
effect of G-CSF combined with ESA in patients with lower-risk MDS. 
Therefore, only randomized controlled trials (RCTs) investigating ESA 
+ G-CSF vs. ESA were considered. Endpoints of interest were the 
Figure 1
Discussion: G-CSF in combination with low-dose ESA seems to 
have a positive effect on the erythroid response in patients with 
low-risk MDS. However, the numbers of RCTs are low and the sizes of 
study populations are small. Moreover, RCTs on EPO-refractory MDS 
patients receiving full-dose (60’000–80’000 IU) are lacking and 
strongly needed in the future. 
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Introduction: Despite remarkable progress in the treatment of 
myeloma, the majority of patients consolidated with ASCT in first 
remission will relapse within a few years. Whereas numerous options 
have become available for relapse treatment, the role of ASCT to 
consolidate a second remission (ASCT2) remains less clear. In 
particular, randomized studies in relapsing myeloma patients are 
lacking comparing the strategy of prolonged administration with one of 
the current doublet or triplet combinations versus the concept involving 
a limited number of such cycles followed by ASCT2. 
Methods: In this retrospective single-center study, we compared these 
two therapeutic options in consecutive myeloma patients with a first 
Table 1
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Conclusions: The results are the first population-based 
epidemiological data analysis from CML patients in Switzerland.  
We found a stable incidence of CML over the years observed and 
importantly, a significant decrease in the mortality rates reflecting the 
high efficacy of TKI treatment. Further survival analyses are planned  
to examine this decline in more detail. Moreover, longitudinal data on 
treatment, side-effects and outcomes is warranted. 
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Introduction: In acute myeloid leukemia (AML), the use of granulocyte 
colony-stimulating factor (G-CSF) to support hematologic recovery in 
induction and consolidation treatment reduces the number of febrile 
episodes as well as the duration of neutropenia and of hospitalization. 
Despite these facts, it is not routinely used partly because of concerns 
of G-CSF possibly promoting the growth of residual leukemic cells. 
However, a number of prospective studies in AML patients have failed 
to demonstrate negative effects on survival rates when G-CSF is used 
to enhance hematologic recovery. In contrast, studies in AML patients 
undergoing autologous stem cell transplantation (ASCT) have not 
been reported so far. Therefore, it is largely unknown whether 
administration of myeloid growth factors after ASCT is safe in AML 
patients. 
Methods: At our center, it was our policy to administer G-CSF after 
ASCT in all AML patients. In June 2015, however, increasing economic 
pressure prompted us to omit G-CSF after ASCT thereby saving the 
costs of G-CSF. In this retrospective study, we assessed the effects of 
changing our strategy from applying G-CSF for hematologic recovery 
after ASCT (in 103 AML patients) to omitting G-CSF (12 patients). 
Results: We found that administering G-CSF shortened the median 
duration until neutrophil recovery was >0.5 G/l and >1.0 G/L after 
ASCT by four days (P = .0001) and five days, respectively(P = .0020), 
whereas no differences were observed for platelet recovery and 
transfusion needs. At least one febrile episode during neutropenia after 
ASCT occurred in patients with (87.7%) and without (100%) G-CSF 
support (P = .1932), but patients with G-CSF tended to have fewer 
bacteremias (38.3% versus 66.6%; P = .0654). The median duration of 
hospitalization was two days longer in patients without G-CSF support 
(25 days versus 23 days; P = .0603). According to the current version 
of the diagnosis-related index of the Swiss in-patient reimbursement 
system, the shorter hospitalization of +G-CSF patients resulted in 
decreased total costs per patient of 3305 CHF (48 Mio U of G-CSF), 
and 3367 CHF (30 Mio U). No differences were observed in disease 
free (P = .0938) and overall survival (P=.7999) rates between +G-CSF 
versus -G-CSF patients. 
Conclusions: Our data suggest that G-CSF support after ASCT is 
safe and associated with shorter time until neutrophil recovery, fewer 
bacteremia episodes, shorter hospitalization, and lower costs. 
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Introduction: T-cell depletion (TCD), obtained by either in vivo 
anti-thymocyte globulin (ATG) administration or ex vivo depletion,  
is a strategy for Graft-versus-Host-Disease (GvHD) prevention after 
allogeneic hematopoietic stem cell transplantation (HSCT) [1–4]. The 
prolonged lymphopenia can result in increased incidence of disease 
relapse1 and infections. 
Patients and methods: We retrospectively evaluated the incidence  
of infectious complications in 236 consecutive patients who underwent 
allogeneic HSCT at our center from September 2010 to December 
relapse after ASCT1 between 2002 and 2015. We assessed the 
survival rates of myeloma patients consolidated with ASCT in second 
remission (ASCT2), and we compared them to myeloma patients 
receiving prolonged reinduction treatment without ASCT2. 
Results: The cohort comprised 108 myeloma patients relapsing after 
melphalan-based high-dose chemotherapy (HDCT) with ASCT1.  
The second remission was consolidated in 68 patients with ASCT2, 
whereas 40 patients were treated without ASCT2. ASCT2 was more 
likely to be performed in myeloma patients with longer remission 
duration after ASCT1 (28.7 vs. 20.7 months) and with better response 
after ASCT1 (CR1 achieved in 66% versus 28%), whereas other 
parameters did not differ. There was no treatment-related mortality 
associated with ASCT2. ASCT2 was associated with longer 
progression-free survival as compared to a strategy omitting ASCT2 
(PFS2: 30.2 months versus 13.4 months; P = .019). Despite a longer 
median follow-up of patients with ASCT2 (39.6 months versus 16.3 
months; P = .012), fewer patients (57%; 39/68 patients) relapsed so  
far after ASCT2 compared to patients (70%; 28/40 patients) relapsing 
after second-line treatment without ASCT2 (P = .045). Overall survival 
(OS) was better for patients with ASCT2, with the median value not yet 
reached, compared with 25.9 months in patients without ASCT2  
(P <.0001). We observed fewer patients (25%; 17 patients) dying of 
myeloma progression in the group with ASCT2 compared with 58% 
(23 patients) in the cohort without ASCT2 (P = .001). 
Conclusion: Our results suggest that consolidating a second 
remission with melphalan-based HDCT with ASCT2 is associated with 
better survival rates in myeloma patients relapsing after first-line 
treatment including HDCT and ASCT1. 
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Background: Chronic myeloid leukemia (CML) is a clonal 
haematopoietic stem cell disorder characterized and diagnosed by the 
presence of the oncogenic BCR-ABL fusion gene. CML is treated with 
specific tyrosine kinase inhibitors (TKIs), a standard therapy since the 
early 2000. This targeted treatment option has completely changed the 
prognosis for CML patients (pts). Based on population data from the 
cancer registry in Switzerland, we aimed to describe epidemiological 
data over different time periods between 1995–2013. 
Methods: A retrospective observational analysis (age, incidence rate, 
mortality rate) was performed on data from pts with CML (ICD-O-3 
code) reported to the Cantonal Cancer Registries between 1995 and 
2013 and aggregated by the National Institute for Epidemiology and 
Cancer Registration. The Swiss Federal Statistical Office provided 
mid-year Population Estimates and the Cause of Death Statistics from 
all persons in Switzerland. Three time periods were defined, 1995–
2000 (pre-TKI era), 2001–2006 (imatinib era) and 2007–2013  
(first and second generation TKI era). 
Results: 1’122 new CML cases were registered, corresponding to an 
extrapolated number of 1’843 new CML cases in the Swiss population 
during 1995-2013. This represents an median annual case number of 
55 males (range 36 to 67) and 42 females (range 27–56) in entire 
Switzerland. Age-adjusted incidence rates of males were around 
40–70% higher compared to females, however, remained stable for 
males and females during the observation period. Age-adjusted 
mortality rates decreased in males and females over the three time 
periods by 50–80% (fig. 1).
Figure 1
PRIMARY AND HOSPITAL CARE – ALLGEMEINE INNERE MEDIZIN 2017;17(SUPPLEMENTUM)
GASTGESELLSCHAFT SGH / SOCIÉTÉ CONVIÉE SSH 102 S
leukaemia-free survival (LFS) in MDS patients with and without 
SIAMs. SIAMs were classified according to Kastner, Davidson and 
Diamond. Autoimmune metabolic disorders, e.g. Diabetes mellitus, 
were excluded. 
Results: 95 patients were diagnosed with MDS and 30 patients were 
identified with SIAMs (35%). SIAMs comprised affections of 
musculoskeletal system (33.3%), vascular system (26.7%), fever of 
unknown origin (23.3%), skin (16.7%), inflammatory bowel diseases 
(13.3%) and others (20%). SIAMs were treated with glucocorticoids 
(40%), Methotrexate (16.7%), biologicals (13.3%) and Cyclosporine 
(3.3%). For patient-based factors, we found a significant difference of 
cardiovascular comorbidities in MDS patients with SIAMs comparted 
to those without SIAMs. Age, gender and other comorbidities as well 
as exposure to chemotherapy were equally distributed. For disease-
based factors, no difference in IPSS/IPSS-R was seen. CMML and 
RAEB-1 were more frequent in SIAM patients, in contrast RCMD was 
more often seen in MDS patients without SIAMs. Finally, the OS, PFS 
and LFS were equal for both groups.
Conclusion: The heterogeneity of MDS and SIAMs challenged our 
investigation. We found an increase of cardiovascular comorbidities in 
MDS patients with SIAMs. However, due to limited patient numbers our 
study allowed us to detect only trends. We are, therefore, interested in 
extending our investigational questions in a broader MDS cohort such 
as the Swiss MDS Registry/Biobank platform. Therefore, we aim to 
include additional MDS patients from this national and potentially 
international collaborators (Düsseldorf MDS Registry). 
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Paraproteinemia after allogeneic hematopoietic stem cell 
transplantation: a transient phenomenon of underexplored 
significance
Corinne Widmer, Urs Schanz, Alexandre Theocharides 
Hämatologie, Universitätsspital Zürich, Zürich, Switzerland
Introduction: The clinical and biological relevance of paraprotein that 
newly arises after allogeneic hematopoietic stem cell transplantation 
(allo-HSCT) in non-myeloma patients is unknown. In healthy subjects, 
the incidence of monoclonal gammopathy of undetermined 
significance (MGUS) ranges from 3–9% and significantly increases 
with age. In these individuals, the absolute risk of progression to 
plasma cell myeloma at 20 years is 5–58%, depending on the MGUS 
subtype. The aim of this study was to investigate the incidence, the 
course and the clinical relevance of paraproteins found after allo-
HSCT.
Methods: We retrospectively analyzed a cohort of 403 non-myeloma 
patients (median age: 48y, range: 18–69y, 57% men, 43% women) 
who underwent allo-HSCT at the Division of Hematology of the 
University Hospital Zurich between January 2004 and December 2014. 
Patients with a MGUS before allo-HSCT were excluded from the study. 
The immunoglobulin subtype and the light chain restriction of 
paraproteins were determined by immunofixation.
Results: The incidence of paraproteinemia after allo-HSCT (56/403 
patients, 14%) was higher than the reported incidence of MGUS in 
age-matched healthy subjects and in contrast to MGUS did not 
correlate with age. The majority of patients carried an IgG paraprotein 
(80%), while IgM paraproteins were detected in 12.5% of patients. 
Rarely, two types of paraproteins were identified simultaneously. In 
most patients (44/56, 79%), the paraprotein appeared transiently 
2015. 100 patients received TCD grafts by in vivo ATG administration 
(ATG group). 17 patients received partially TCD grafts obtained 
through incubation with alemtuzumab in vitro followed on day +1 by an 
add-back of donor T CD3+ cells5 (pTCD group). 60 patients received 
grafts TCD by both methods. 59 patients did not receive any form of 
TCD (No-TCD group). Cumulative incidence estimates of infectious 
complications were calculated and compared using the Gray test. 
GvHD or death from other causes were defined as competitive events 
in the analysis. 
Results: We didn’t observe any significant difference in the 1-year 
cumulative incidence of bacterial infections in patients receiving TCD 
by ATG [45% (95%CI 35%-54.5%)] pTCD [58.8% (95%CI 31.2–
78.5%)] or both [55% (95%CI 41.4–66.7%)] compared with patients 
receiving No TCD [52.5% (95%CI 38.9–64.5%)]. Similarly, the 1-year 
cumulative incidence of viral infections or reactivations was 
comparable in patients receiving No-TCD grafts [80.3% (95%CI 
66.8–88.8%)] compared with patients receiving TCD grafts [ATG: 
82.2% (95%CI 72.9–88.6%); pTCD: 76.5% (95%CI 45.7–91.2%); 
ATG+pTCD: 81.7% (95%CI 68.9–89.6%)]. Finally, no significant impact 
of TCD was observed on 1-year cumulative incidence of fungal 
[No-TCD: 6.8% (95%CI 2.2–15.2%); ATG: 18.1% (95%CI 11.2–26.3%); 
pTCD: 11.8% (95%CI 1.8–31.9%); ATG+pTCD: 18.3% (95%CI 
9.7–29.1%)] and parasitic [No-TCD: 1.7% (95%CI 0.1–8%); ATG: 1% 
(95%CI 0.1%-4.9%); pTCD: 5.9% (95%CI 0.3%-24.2%); ATG+pTCD: 
1.7% (0.1–8.3%)] infections.
Conclusion: The results indicate that the cumulative incidence of 
infections are similar in patients receiving TCD grafts compared to 
those receiving No-TCD graft, suggesting a favorable toxicity profile of 
different TCD strategy in respect of infections. These results should be 
confirmed by similar analysis in large scale, prospective clinical trials. 
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Introduction: Myelodysplastic syndromes (MDS) are heterogeneous 
clonal hematologic disorders affecting the hematopoietic stem cells, 
leading to ineffective hematopoiesis with a propensity to evolve 
towards acute myeloid leukemia. An increased prevalence of systemic 
inflammatory and autoimmune manifestations (SIAMs) has been 
described anecdotally in myeloid malignancies. Here we present an 
interim analysis of a study investigating the differences of disease-  
and patient-based factors as well as outcomes in MDS patients with/
without SIAMs.
Methods: We performed a retrospective study of a patient cohort at 
our institution with newly diagnosed MDS between 01.01.08 and 
31.09.16. Medical records of MDS patients were reviewed. We 
investigated differences between patient- and disease-based factors 
as well as overall-survival (OS), progression-free survival (PFS) and 
Table 1
Table 2
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Table 2: Hypothyroidism.
Hypothyroidism
TSH before HSCT Ul/ml, 
median (IQR)
1.83 
(1.19–2.58)
2.42 (1.85–3.34) 1.56 
(1.15–2.29)
fT4 before HSCT 
mmol/L, median (IQR)
14.6 
(13.35–16.75)
14.15 
(12.83–16.18)
15.1 
(13.4–16.8)
Overt hypothyroisdism n 
(%)
4 (3.85) 4 (16.7) 0
Subclinical 
hypothyroidsm n (%)
20 (19.2) 20 (83.3) 0
TSH max. after HSCT  
U/ml, median (IQR)
2.87  
(1.88–4.4)
5.58 (4.94–6.97) 2.57  
(1.68–3.1)
fT4 after HSCT mmol/L, 
median (IQR)
14.9 
(12.7–16.55)
14 (12.55–
14.95)
15.75 
(14.25–16.85)
Positive TPO Antibodies 
n (%)
5 (4.8) 3 (12.5) 2 (2.5)
Therapy with fT4 after 
HSCT n (%)
13 (12.5) 13 (54.2) 0
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cereana in a patient with acute myeloid leukemia:  
a case report
Craig Kingston1, Michael Medinger2, Florian Banderet-Uglioni3, 
Stefano Bassetti1, Mario Bargetzi4, Christoph Fux5, Veronika Bättig3, 
Jakob Passweg6, Marc Heizmann4 
1Innere Medizin; 2Hämatologie und Innere Medizin; 3Infektiologie, 
Universitätsspital Basel, Basel; 4Hämatologie, 5Infektiologie, 
Kantonsspital Aarau, Aarau; 6Hämatologie, Universitätsspital Basel, 
Basel, Switzerland
Introduction: Sporopachydermia cereana is a rare yeast found in 
necrotic cactus tissue, predominantly in the Americas. Infection in 
humans has only been reported in 4 neutropenic patients with fatal 
course. Here we present a patient with acute myeloid leukemia (AML) 
and S. cereana infection. 
Methods and results: We present the case of a 50 year old female 
patient who was diagnosed with normal karyotype AML in December 
2015. She achieved complete remission after induction chemotherapy. 
During the 2nd induction cycle the patient developed persistent fever in 
neutropenia. Blood cultures showed growth of Sporopachydermia 
cereana, shown to be sensitive to azoles as well as amphotericin B, 
but resistant to caspofungin. Treatment was changed first to liposomal 
amphotericin B, and with the availability of MIC results to voriconazole. 
After a continuous fungemia, Blood cultures turned negative with the 
introduction of amphotericin B. A CT scan of the chest and abdomen 
prior to allo-HSCT after six weeks of treatment with voriconazole 
revealed new multiple necrotic mesenteric lymph nodes. An 
ultrasound-guided biopsy of a node revealed no growth on fungal 
cultures (Saboraud Agar), a Grocott stain revealed no hyphae or 
spores. A panfungal PCR of an ITS (Internal transcribed spacer) 
fragment revealed fungal DNA, which could be confirmed as S. 
cereana. Subsequent CT scans 4 and 6 weeks later revealed a 
regression of the affected abdominal lymph nodes. In the further 
course non-myeolablative conditioning with fludarabine and busulfan 
prior to allo-HSCT using PBSC from her HLA-matched brother was 
performed. The allo-HSCT was performed under voriconazole 
treatment with no further complications and the patient engrafted at 
day 20. Based on the susceptibility pattern, the treatment was 
changed to fluconazole 400 mg daily before discharge. Due to the 
complete radiological regression of the infection in follow-up scans  
and excellent general condition of the patient 5 months after HSCT, 
fluconazole was discontinued. The patient remains in morphological 
complete remission 6 months after HSCT and has a 100% donor 
chimerism.
Conclusions: The first published case of survival of infection with  
S. cereana exemplifies the continual progress made in treating 
infections in the severely immunocompromised patient. Diagnosis via 
ITS sequence-analysis seems reliable but a high index of suspicion is 
required for neutropenic patients who do not respond well to standard 
antimycotic therapy. 
within the first year after allo-HSCT with a median duration of 5.8 
months (range 2.5–43.9 months). Post-allo-HSCT paraproteinemia 
was significantly associated with chronic GvHD, but no association 
was found with other clinical and laboratory parameters. Importantly, 
development of plasma cell myeloma or lymphoma was not observed 
in patients with paraproteinemia arising after allo-HSCT.
Conclusions: Our study reveals a high incidence of transient 
paraproteins after allo-HSCT that unlike MGUS are not related to age 
and follow the expected immunoglobulin subtype distribution. Patients 
with post-allo-HSCT paraproteinemia are not at increased risk of 
developing plasma cell myeloma as observed for MGUS inferring a 
distinct pathogenic mechanism. Skewing of lymphocyte 
subpopulations and alterations in cytokine levels in chronic GvHD may 
explain the expansion of a specific plasma cell subset. 
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Introduction: Hypothyroidism may complicate of allogeneic 
hematopoietic stem cell transplantation (allo-HSCT); risk factors are 
analysed. Methods: We studied 229 patients with AML who underwent 
an allo-HSCT between 2003 and 2013 with different conditioning 
regimens (myeloablative, reduced-intensity, chemotherapy-based, total 
body irradiation-based). Thyroid stimulating hormone (TSH) and free 
thyroxin levels (FT4) were available in 104 patients before and after 
allo-HSCT. 
Results: Median age at transplantation (n = 104) was 47 years [IQR 
40–59], 37 (35.6%) were female and overall mortality was 34.6%  
(n = 36). After a median follow-up period of 47 [IQR 25–84] months, 
overt hypothyroidism (basal TSH >4.49 mIU/l, FT4 <11.6 pmol/l) was 
observed in 4 patients (3.8%) and subclinical hypothyroidism (basal 
TSH >4.49 mIU/l, normal fT4) was observed in 20 patients (19.2%). 
Positive thyreoperoxidase (TPO) antibodies were found in 5 (4.8%) 
patients. A total of 13 patients (12.5%) were treated with thyroid 
hormone replacement. Acute graft versus host disease of any grade 
(aGvHD) occurred in 55 (52.9%) and chronic GvHD of any stage 
(cGvHD) in 74 (71.2%) of the patients. The risk of developing 
hypothyroidism was higher in patients with repeated allo-HSCTs  
(p = 0.024) and with positive TPO antibodies (p = 0.045). Furthermore 
the development of overt hypothyroidism was inversely proportional to 
age (p = 0.043). No correlation was found with GvHD, HLA-mismatch 
and gender.
Conclusions: After allo-HSCT a significant number of patients 
experience thyroid dysfunction including subclinical and overt 
hypothyroidism. Long-term and continuous follow-up for thyroid 
function after HSCT is important to provide timely and appropriate 
treatment. 
Table 1: Baseline characteristics.
  All patients 
(n = 104)
Patients with 
hypothyroidism 
(n = 24)
Patients 
without 
hypothyroidism 
(n = 80)
Age at diagnosis 
(years), median (IQR)
46 (39–58) 45 (39–57) 47 (39–58)
Follow-up period 
(months), median 
(IQR)
47 (25–84) 71.5 (39–87) 42 (24–76)
Donor      
Identical sibling n (%) 54 (51.9) 13 (54.2) 41 (51.3)
Unrelated n (%) 45 (43.3) 8 (33.3) 37 (46.3)
Mismatched related n 
(%)
3 (2.9) 2 (8.3) 1 (1.3)
TBI conditioning      
No TBI n (%) 56 (53.8) 10 (41.7) 46 (57.5)
TBI n (%) 48 (46.2) 14 (58.3) 34 (42.5)
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Results: We found no statistically significant relationships between 
nutrition status and survival rates in any of the indicators considered. 
We did observe a relationship in which patients with the highest BMI 
had the lowest OS (fig. 1), but it was not statistically significant.  
Table 1 shows the impact of BMI, FMI and FFMI on OS and PFS.
Table 1: Results.
 
 
BMI FFMI FMI
<20 20–30 >30 <p10 p10-p90 >p90 <p10 p10-p90 >p90
n 19 99 24 39 76 27 32 66 44
OS 
analysis 
(p)
0.285 0.79 0.72
OS(%) 60 54 46 60 49 57 51 53 56
CI95% (0.34–
0.79)
(0.42–
0.65)
(0.24–
0.66)
(0.43–
0.74)
(0.34–
0.61)
(0.34–
0.75)
(0.31–
0.68)
(0.38–
0.67)
(0.39–
0.70)
PFS 
analysis 
(p)
0.78 0.68 0.133
PFS(%) 45 47 33 43 50 39 38 53 38
CI95% (0.21–
0.66)
(0.35–
0.57)
(0.08–
0.61)
(0.27–
0.58)
(0.38–
0.61)
(0.17–
0.60)
(0.21–
0.53)
(0.38–
0.65)
(0.21–
0.54)
Conclusions: Inconsistent results may show that bioimpedance 
indexes are not ideal for measuring survival in HSCT patients. While 
some larger studies show more conclusive results (1), others are 
inconclusive (2). Retrospective analysis and small population were 
limitations of our study. A prospective analysis should be done in a 
larger population to establish if BMI is a prognostic marker in HSCT. 
Efforts to assist patients in achieving healthy nutritional status before 
HSCT could be beneficial in survival rates and studies measuring the 
results of these efforts may provide more clarity 
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Introduction: Haploidentical stem cell transplantation (haplo-SCT) is 
increasingly performed if a HLA-matched donor is lacking. Data show 
an association of donor specific HLA-antibodies (DSA) with graft 
failure in this setting. DSA occur in up to 14% of recipients, and are oft 
a reason for rejecting the donor, but can be reduced with 
plasmapheresis and immunosuppression. Patients with 
myelodysplastic syndrome (MDS) oft develop alloantibodies because 
of transfusions and underlying immunologic dysregulation. We report 
on a patient with MDS and rapidly developing DSA, who successfully 
underwent haplo-SCT. 
Case report: A 67 year-old man with transfusion dependent anaemia 
and severe thrombocytopenia was diagnosed with MDS RAEB I in 
August 2015. Azacytidin treatment had no effect on transfusion 
requirements. A decision for allo-SCT with BM as preferred stem cell 
source was met, but only his two sons (SM*1982 and GM*1989) were 
identified as possible donors. In July 2016, an antibody screening 
revealed broad HLA-alloimmunisation and anti-c and -E alloantibodies, 
showing incompatibility to SM*1982 (DSA B*50:01, MFI 4600; 
anti-c-and E alloantibodies). RBC incompatibility but no DSA was also 
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We present the case of a 32 year old man from Sicily with 
β-thalassemia (Th). His parents and sister had a β-Th trait. At the age 
of 2 he showed hemoglobin (Hb) of 9 g/dL with HbA1 94.9% and 
HbA2 5.1%, Th minor was diagnosed. At 4 he got EBV-infection with 
symptomatic anemia (Hb 6.4 g/dL) and received first red blood cell 
concentrates (RBCc). HbA2 was 3.9%/ HbF 65% and diagnosis was 
changed to Th intermedia. Later his Hb remained at a level of 9 g/dL 
without transfusions. At 5 transfusions 2–3 RBCc every 3 weeks were 
started with concomitant chelation therapy to prevent from growth 
failure. His ferritin persisted beneath 1000 µg/l and clinically showed 
normal development without endocrine dysfunction, HIV or hepatitis, 
bone disease or pulmonary hypertension. Liver and heart MRI T2* /
SQUID showed a severe iron accumulation in the liver but none in the 
heart. On 10/ 2014 he moved to Switzerland for work, hematologic 
controls were started in our policlinic. The patient showed good clinical 
condition with jaundice and slightly enlarged spleen. The Hb was 9.7 
g/dL (2 days after RBCc), nucleated red blood cells (NRBC) 2/100 
WBC, Platelets120 G/l, Bilirubin 114 µmol/l, Ferritin 886 µg/l, HbA2 
3.1% and HbF 22.2%. A molecular analysis showed two heterozygotic 
mutations in HBB:c 93-21G>A (IVS-I-110) and HBB:c,-137C>G 
(-87C>G). We rated the aggressive transfusion regime as unnecessary 
and proposed its gradual reduction. 
Methods: We aimed to identify the right transfusion regime and the 
need of additional therapy for this patient. RBCc were administered 
when anemia symptoms occurred or NRBC rose. A therapy with 
hydroxyurea was started on 02/2015, likewise antiplatelet therapy.
Results: Transfusion of RBCc could be reduced to 2 RBCc every 6–7 
weeks with even improving quality of life. Hb below 7 g/dL and/or rising 
NRBC triggered transfusion although the patient generally had no 
symptoms of anemia. Last ferritin values varied between 300 to 500 
µg/l, chelation could be consequently reduced. The HbF rose to 43%. 
Conclusion: This compound heterozygocity of two known mutations 
is an unusual combination not previously reported in the literature. 
Both mutations found in mediterranean countries, usually lead to β+Th 
severe/intermedia. This patient was interpreted and managed during 
25 years like a Th major. Therapy changes, prioritizing health status 
were well tolerated without clinical complications avoiding therefore 
unnecessary transfusions. 
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Introduction: Body mass composition (BMC) might have an impact in 
outcomes of patients undergoing bone marrow transplantation. The 
aim of this study was to analyse the relationship between BMC before 
allogeneic hematopoietic stem cell transplantation (HSCT) and 
transplant outcomes in a cohort of patients transplanted between 2012 
and 2014. Another objective was to determine if fat free mass index 
(FFMI) and fat mass index (FMI) have the potential of being more 
accurate indicators than Body Mass Index (BMI) to measure the 
relationship between nutritional status and overall survival (OS)  
and progression free survival (PFS) after HSCT. 
Patients and methods: We realized a retrospective analysis in  
a cohort of 141 patients, aged over 18 years who received a first 
allogenic HSCT between 2012 and 2014. Bioelectrical impedance 
measurements were realized before HSCT to determine FFMI and 
FMI. We looked at the impact of these two indicators and BMI on OS 
and PFS. For FFMI and FMI we divided patients into: >90th percentile, 
between 90th and 10th percentile, and <10th percentile. For BMI we did 
a first analysis dividing patients with WHO BMI classifications <18, 
18–24, and >24 but finding no relationship, we divided patients into: 
BMI <20, BMI between 20 and 30, and BMI >30. For all three 
indicators, we used Kaplan-Meier estimates to see OS and PFS. 
Cumulative incidence estimates of transplant related mortality (TRM) 
were calculated with the Fine and Gray method. Differences between 
curves were determined using Log-rank Mantel-Cox test.
Figure 1: Kaplan-Meier curve for OS based on BMI.
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Introduction: Myelodysplastic syndromes (MDS) are malignant 
hematological disorders with an increasing incidence in the elderly. 
Sequential accumulation of genetic lesions in hematopoietic stem cells 
and clonal selection are responsible for initiation and progression to 
secondary acute myeloid leukemia (sAML). Motivated by increasing 
insights in the heterogeneity of these disorders, the emerging impact 
on healthcare resources, the limitation of available data and the utility 
of longitudinally collected data/samples for translational studies, we 
set out to implement a cooperative research platform.
Methods: The Swiss MDS Study Group was founded in 2015. It is the 
first collaborative research consortium of hemato-oncologists from 
academic and non-academic hospitals in Switzerland. The group aims 
to improve MDS patient management and foster research based on 
the Swiss MDS Registry/Biobank (SMRB) platform. This platform 
enables to collect systematically and standardized data and samples 
from patients treated at different centres in every-day clinical practices. 
All adult patients with MDS, MDS/MPN and sAML diagnosed after 
2008 can be enrolled. Patient-, disease- and management-related data 
is recorded with an electronic Case Report Form. Samples from 
peripheral blood and bone marrow are collected at diagnosis as well 
as before/after treatment. 
Results: The platform was approved by the lead Cantonal Ethics 
Committee in Bern as a multicenter cohort study and the pilot phase 
started at the Inselspital Bern in 10/2015. The first MDS patient was 
enrolled in 01/2016 and data recording started in 06/2016. As for 
01/2017 61 patients have been included of which 35 are in the 
prospective follow-up, the others died and were included 
retrospectively. Five centers signed the agreement and are ready to 
start enrollment in 2017; at least ten additional centers have expressed 
their interest in participating. Six sub-studies are currently running on 
this platform investigating clinical, translational, basic as well as health 
services research aspects in MDS patients.
Conclusions: Increasing insights in the heterogeneity of disease-, 
patient- and management-based factors are revolutionizing the way of 
treating MDS patients and designing studies. The SMRB provides a 
first cooperative research platform in Switzerland that allows to 
perform a variety of research projects dedicated to improve and 
personalize care of MDS patients treated in every-day clinical 
practices. 
present against GM, who was selected for peripheral blood stem cell 
donation instead of BM. An antibody screening for HLA-antibodies 3 
weeks before SCT revealed 49 new specificities and DSA also against 
GM*1989 (B55*01, MFI 12’400). Because of progressive disease, SCT 
was nevertheless carried on. DSA reduction was made with a single 
dose rituximab on day -12 and plasma exchanges from day –9 until 
day –1. On day 0, the B55*01 DSA was negative (MFI 199), with anti-c 
and anti-E alloantibodies still present. A reduced intensity conditioning 
(fludarabine, cyclophosphamide, TBI 200 cGy), post-SCT high dose 
cyclophosphamide, and cyclosporine and mycophenolate as GVHD 
prophylaxis were given. Neutrophils engrafted on day 17. At day 30, 
platelets were >50 x109/l, the absolute reticulocyte count was >30 
x109/l and chimerism was 100% donor type. At day 180, he had 
hyporegenerative anaemia supported with erythropoietin and 
sustained engraftment of neutrophils and platelets. Alloantibodies 
against c, E and HLA- antigens were detected, but the B55*01 DSA 
was negative. 
Discussion: In haplo-SCT, the presence of DSA can be challenging.  
A careful evaluation of donor-recipient compatibility, including HLA- 
and RBC-antibody assessment, is of great relevance, especially in 
HLA mismatched and haplo-SCT. 
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We report the case of a 52-year-old man, referred for an extreme 
hypereosinophilia. He presented fatigue, quick loss of 14 kg and night 
sweats. He was in poor clinical condition. Laboratory data showed the 
following: hemoglobin 105 g/l, leucocytes 114 G/l, platelets 55G/l – 
rapidly evolving to <10 G/l, neutrophils 27 G/l, lymphocytes 3.4 G/l, 
monocytes 2.2 G/l, eosinophils 81 G/l, no basophiles. Peripheral blood 
smear showed dysplastic eosinophils, neutrophils with toxic 
granulations, few dacryocytes. Liver and renal tests were normal, LDH 
310U/l (N 135–225). Troponins were 224 ng/l (N <14) and NT-proBNP 
2056 ng/l (N <172). Bone marrow was hypercellular with marked 
dysplastic eosinophilia, without excess blast or lymphoma and MF-1 
fibrosis. CT-scan disclosed mediastinal and abdominal adenopathies, 
splenomegaly and a renal Bosniak IV lesion highly suspect for 
carcinoma. Hypereosinophilia-related organ damage assessment 
revealed extended cardiac ischemia on MRI study, and multiple 
ischemic brain lesion. High dose methylprednisolone was immediately 
started with modest effect on eosinophil count (decreased to 30 G/l). 
Imatinib and mepolizumab were attempted without success. Extensive 
workup for eosinophilia was negative: inguinal adenopathy showed 
normal lymphoid tissue, peripheral flow cytometry were negative for 
lymphoproliferative disease, JAK-2, BCR-ABL, FIP1L1- PDGFR-alpha, 
PDGRF-beta, FGFR, C-KIT and CALR mutation were absent. Total IgE 
was 4954 kU/l (N 5–50). Tryptase and anti-neutrophil cytoplasmic 
antibodies were negative, like the parasite workup. A paraneoplastic 
origin was suspected, but a surgical resection of the kidney lesion was 
impossible due to the severe thrombocytopenia and bad condition of 
the patient at this time. A PET-CT showed moderate activity of the 
adenopathies (SUVbw max 6.1 g/mL) with hypermetabolic liver 
infiltration (SUVbw max 9.2 g/mL). The kidney lesion was slightly 
hypermetabolic. Eventually, liver biopsy revealed classical Hodgkin’s 
lymphoma. Modified ABVD-regimen chemotherapy was started and 
eosinophilia resumed within two days. Complete response was 
obtained and the patient fully recovered without cardiac or neurologic 
sequelae. Second lecture of the kidney imagery supported benign 
kystic lesion. Bosniak classification is an unperfect diagnostic tool, 
practitioner-dependant. This case reports a diagnostic challenge of 
unusual Hodgkin’s lymphoma presentation with severe 
hypereosinophilia and dramatic response to chemotherapy. 
P481
The Swiss MDS Registry/Biobank: sharing first  
experiences of the pilot phase of a cooperative research 
platform for personalized medicine in haemato-oncology
Nicolas Bonadies1,2, Vera Ulrike Bacher1, Alicia Rovo1, Julia Bohlius3, 
Georg Stüssi4, Matthias Wilk5, Axel Rüfer6, Andreas Holbro7, Nathan 
Cantoni8, Adrian Schmidt9, Catherine Mengis Bay10, Tobias Silzle11, 
Thomas Lehmann12, Sabine Blum13, Swiss MDS Study Group 
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Hospital, University of Bern; 3Institute of Social and Preventive 
Figure 1: Platform for 
personalized medicine in MDS.
Figure 2: Swiss MDS Registry 
and Biobank platform.
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Results: We identified 12’374, 19’726 and 28’235 phosphopeptides 
corresponding to 5’012, 4’927 and 5’524 PPs, respectively. As shown 
in the Venn diagram in figure 1, 827, 333 and 382 unique PPs were 
identified in K562, NB4 and THP1, respectively. These unique PPs 
were further functionally annotated with PANTHER. Binding and 
catalytic activity were the most frequent functions of PPs shared 
across all cell-lines. Channel regulation and antioxidant activities were 
unique for THP1, whereas PPs with translational activity were found in 
NB4 and K562. More mature data will be shown at the meeting.
Conclusions: We were able to detect characteristic PPs of three 
pheno- and genotypically distinct myeloid cell lines. The further use  
of heavy labeled cell lines (SILAC = stable isotop labeling with amino 
acids in cell culture) will give us a more rigid background for 
quantitative comparison. This will allow us to step ahead to functionally 
characterize involved oncogenic pathways and perform network 
analysis. Our post-genomic, diagnostic approach will enable future 
personalized medicine in patients with myeloid neoplasms that are 
refractory to standard treatment. 
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Injectable iron: fast, effective and well tolerated
Ines Kechaou, Imen Boukhris, Samira Azzabi, Eya Cherif,  
Lamia Ben Hassine, Narjess Khalfallah 
Service de Médecine Interne B, Hôpital Charles Nicolle, Tunis, Tunisia
Introduction: Injectable iron is very useful for the treatment of iron 
deficiency anemia in cases of oral iron intolerance, malabsorption or  
in cases requiring rapid correction of iron stores. However, its use was 
not appreciated for several decades because of the history of adverse 
effects formerly reported. The currently available forms of injectable 
iron appear to be well tolerated. The aim of our work is to determine 
the indications, efficacy and tolerance of this treatment during iron 
deficiency anemia in a group of Tunisian patients.
Patients and methods: A retrospective study was conducted in  
a department of internal medicine. We have collected 9 cases of 
intravenous iron intake for iron deficiency anemia in the form of ferric 
saccharose complex (Venofer®) over an 18-month period from 
September 2011 to February 2013. The dose recommended was 
calculated according to the Ganzoni formula.
Results: There were 4 men and 5 women (sex ratio: 0.8). The median 
age was 47.55 years with extremes of 27 to 81 years. Initial 
hemoglobin was 5.7 g / dl with extremes of 3.9 to 7.6 g/dl. The mean 
globular volume was 66.22 fl (59.5–72.5). Ferritin levels were less than 
7 ng/ml in all patients. The indications for treatment with injectable iron 
were malabsorption in 4 cases (celiac disease: 1 case, malabsorption 
post-gastrectomy: 2 cases and esophageal atresia: 1 case). In the 
other five cases, injectable iron was administered in the presence of  
a history of oral intolerance and non-response to iron. One of these 
patients also had anxiety attacks during transfusions. The mean dose 
received of intravenous iron was 310 mg distributed over 4 injections 
(2–7). The mean difference in hemoglobin after one week, after the 
second to third injectable iron cure, was 1.38 g / dl (0.45–2.8). 
Ferritinemia was corrected in all cases. The injectable iron treatment in 
this series had good tolerance in 8 cases: no allergic manifestations, 
no tachycardia, and normal systolic and diastolic blood pressure 
before and after the infusion. Only one case of tachycardia, agitation, 
tremor, and chills was noted in the same patient with transfusion 
intolerance.
Conclusion: Treatment with injectable iron has proved its 
effectiveness in our series as well as in the literature in the treatment 
of iron deficiency. No serious adverse effects were noted and the cures 
were very well tolerated with a correction of the martial reserves. It is, 
however, a series of small numbers. 
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Integrative bioinformatic characterization of oncogenic 
pathways by phosphoproteinomics in myeloid cell lines: 
developping a novel diagnostic pipeline for personalized 
treatment
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Introduction: The myelodysplastic syndromes (MDS) are 
heterogeneous, clonal haematopoietic stem cell disorders caused by 
sequential accumulation of genetic lesions with a propensity to evolve 
towards secondary acute myeloid leukemia (sAML). The aim of our 
project is to build an integrative bioinformatics pipeline to analyze 
proteomic, transcriptomic and genomic data in order to characterize 
involved oncogenic pathways that drive and maintain the neoplastic 
phenotype. Here we show preliminary data on the ongoing 
phosphoproteome characterization in myeloid cell lines.
Methods: We performed a phosphoproteome (PPs) analysis of the 
myeloid cell lines NB4 (promyelocytic), K562 (erythroid) and THP1 
(monocytic) that are characterized by established oncogenic drivers 
PML-RARalpha, BCR-ABL1 and MLL-MLLT3, respectively (table 1). 
Cytogenetic analysis was performed by conventional cytogenetics and 
resequencing of myeloid driver genes by panel sequencing using 
IonTorrent®. PPs were enriched by the TiO2 method and samples 
analyzed in triplicates by high-performance liquid chromatography 
combined with double mass-spectrometry (HPLC-MS2). The raw data 
was analyzed using MaxQuant® and R was employed for further 
processing. Functional classification of PPs was performed with the 
web-based PANTHER analysis tool. 
Table 1
Figure 1 
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Phenotypic assays using zebrafish models  
for elucidation of hematopoietic toxicity
Loïc Sauteur1, Christoph Schürch1, Claudia Lengerke1,2,  
Claudia McGinnis3 
1Department of Biomedicine, Universität Basel; 2Devision of 
Hematology, University Hospital Basel; 3Roche Innovation Center, 
Basel, Switzerland
Hematologic findings are one of the most common side effects 
encountered in preclinical safety testing of new drug candidates.  
The consequences of direct or indirect damage to blood cells and  
their precursors can be potentially life-threatening, and hence, 
hematotoxicity can lead to the termination of a promising drug 
candidate. Current hematotoxicity testing employs in vitro models with 
a cell viability read-out. However, this approach only allows a limited 
read-out and, for example, does not capture effects on later maturation 
stages of blood cell progenitors. Here, we propose the zebrafish as an 
alternative animal model that captures the full range of hematopoietic 
lineages and maturation stages in an in vivo setting. Therefore, we use 
different transgenic zebrafish lines that specifically mark subsets of 
different hematopoietic lineages, flow cytometry, high content 
live-imaging and automated drug administration and image analysis. 
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postulate that the only way to lasting success in poor-risk disease is  
to radically eliminate LICs and accept collateral damage to HSCs that, 
subsequently, can be replaced by transplantation. We aim to create a 
platform for the generation of immunotherapies directed against 
leukemic and HSC antigens, the first of which will be c-Kit (CD117). 
Methods: We will use mouse AML models as well as humanized 
models carrying human AML cell lines and primary human leukemia  
to evaluate safety and efficacy of BiTE antibodies, CAR T-cells and 
monoclonal depleting antibodies. The capacity to eliminate LICs as 
well as bystander effects on healthy hematopoiesis will be assessed. 
Results: We have established mouse leukemia cell line engraftment in 
wild type mice C57BL/6 as well as a human AML cell line (Kasumi-1) 
in NSG immunodeficient mice. We used a human phage display library 
and recombinant soluble mouse cKit protein to identify a novel 
anti-mouse cKit scFv. This scFv was expressed as an IgG and BiTE 
antibody as well as expressed on murine CAR T cells. In vitro and in 
vivo experiments are underway to determine the leukemia cell killing 
potential of the IgG and BiTE antibodies as well as the CAR T cells.
Conclusion: Our goal is to use these immunotherapies to radically 
eliminate both AML-LICs and HSCs by targeting non-tumor-selective 
HSC antigens and to subsequently deal with the life-threatening HSC 
depletion by allogeneic HSC transplantation. 
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A standardized quantification tool for bone marrow  
cellularity in histological sections
Josefine Tratwal1, Chiheb Boussema1, Olivier Burri 2,  
Vasco Campos1, Rossella Sarro3, Carmen Bárcena4,  
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The bone marrow (BM) is the seedbed of our blood, existing as 
hematopoietic/red or adipocytic/yellow marrow heterogeneously 
distributed with skeletal location, age, and physiological condition. 
Patients who undergo chemotherapy or suffer acute BM failure have  
a rapid adipocytic conversion of the marrow (red-to-yellow transition). 
After hematopoietic recovery such as upon hematopoietic stem cell 
transplantation (HSCT) following intensive chemotherapy, functional 
hematopoiesis is restored (yellow-to-red transition). Pathologist 
assessment of BM cellularity in H&E sections constitutes the Gold 
Standard to quantify hematopoietic function. BM failure or aplasia is 
usually defined as BM cellularity <10%. This expertise is not 
accessible to all laboratories, and multi-site standardization of BM 
cellularity quantification is often critical in the clinical and fundamental 
research setting. In our effort to systematically quantify BM 
components in histological sections in an unbiased manner, we 
developed and optimized a semi-automated image analysis tool for 
ImageJ, MarrowQuant. Area of hematopoietic cells, red blood cells, 
bone, and adipocyte ghosts are identified based on color and texture 
variation of H&E stained histological sections. We find that BM 
cellularity quantification correlates directly with scoring by four 
independent clinical pathologists from different countries, while 
quantification of bone and adipocytes compare with microCT 
volumetric measurement. The C57BL6 mouse has become the 
standard model of mammalian hematopoiesis. We have established a 
consistent map of cellularity in BM sections of homeostatic C57BL6 
mice, and observe highly predictable red-to-yellow marrow transitions 
in the caudal tail and tibia. With age, regions of BM adiposity increase 
in the tibia and appear in the femur. Following HSCT, adipogenesis 
inversely correlates with kinetics of hematopoietic recovery. BM 
adipocytes reach maximum expansion 17 days post-transplant and 
hematopoiesis recovers after 25 days consistent with the exit of severe 
neutropenia and recovery of pre-transplant blood counts. We have 
observed that MarrowQuant can offer greater discrimination than 
pathologist evaluation on extreme cellularities (eg. 0–20% and 
80–100%), which could become useful in certain settings. Validation 
on human trephine biopsies is currently ongoing, opening avenues for 
its application in experimental or clinical contexts requiring 
standardized measurements of various BM components. 
We have recently established an in vivo model that allows analysis of 
the potential impact of chemical compounds on the erythroid lineage 
(Lenard et al, 2016). Here, we use Phenylhydrazine to generate a 
haemolytic anemia model and assay the effect of concurrent drug 
treatment on modulation of erythroid regenerative capacity. Now, we 
are applying this procedure to a large size compound library of 
FDA-approved chemicals and optimize the procedure for automated 
drug administration, data acquisition and analysis. We are now one 
step closer in introducing this novel multiplex in vivo model to 
predictive and mechanistic preclinical safety testing, which eventually 
will complement existing in vitro hematopoietic approaches. 
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Dissecting mechanisms of proliferative aging  
in hematopoietic stem cells
Gianluca Spaltro 
University Hospital and University Zurich, Zurich, Switzerland
Hematopoietic stem cells (HSC) sustain lifelong blood production. 
However, at any given time in steady-state, more than 90% of HSCs 
are dormant. Upon need of massive hematopoiesis, for instance upon 
bleeding, inflammation and infection, HSCs can be activated and 
rapidly cycle in order to spin off progenitors for blood production. Tight 
regulation of HSC turnover is crucial, as both over-production (leading 
to myeloproliferative neoplasms and leukemia) and under-production 
(in the worst case aplasia) would endanger survival. To study HSC cell 
cycle kinetics in vivo, our group established an in vivo HSC divisional 
tracking based on CFSE staining and steady-state transplantation. 
Results showed that the HSC pool consists of cells with distinct 
kinetics that can reversibly switch between dormancy and cycling. 
Importantly, HSCs with extensive proliferative history, e.g. during 
inflammation or aging, tend to switch to dormancy. We aim to 
understand how divisional history drives HSC towards quiescence in 
physiological and pathological events. We hypothesize that fast-cycling 
or enhanced turnover with aging might activate an intrinsic program 
that drives HSC toward quiescence. In this scenario, an intrinsic cell 
memory effect to prevent HSC exhaustion might be counterbalanced 
by an extrinsic drive for proliferation. Dysregulation of these pathways 
might cause bone marrow suppression, which in turn impairs recovery 
from infections, or alternatively lead to accumulation of genetic 
alterations and blood malignancies, especially in aged HSCs. To study 
HSC divisional behavior and quiescence in depth, we have recently 
coupled the CFSE tracking assay with Ki-67 intracellular staining. 
Analysis of young and aged mice in steady state and injections of 
cell-cycle activating compounds (e.g. Tpo and PolyI:C) shows that 
aged HSC delay their entry into cell cycle, if compared to their young 
homologues. In addition, time-course experiments suggest that, after 
each cycle, a proportion of cells slows down or enters quiescence, 
arguing in favor of a model where HSC are able to enter quiescence  
to avoid replicative stress and exhaustion. To understand the divisional 
behavior of the HSC compartment might allow to developing means 
for therapeutic intervention in HSC aging and pre-malignant HSC 
alterations. Also, it will be interesting to evaluate if basic findings on 
HSCs might hold true for other somatic stem cells systems. 
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Treatment of AML with immunotherapies 
Renier Myburgh1, Jonathan Kiefer2, Surema Pfister1,  
Antonia Müller1, Maries van den Broek3, Burkhard Becher4,  
Dario Neri2, Markus G Manz1 
1Hematology, University Hospital and University Zurich; 2ETH Zürich; 
3Experimental Immunology; 4Experimental Immunology; Neuro and 
Tumor Immunobiology, University of Zurich, Zurich, Switzerland
Introduction: Immunotherapies such as Bispecific T-cell engaging 
(BiTEs) antibodies and Chimeric Antigen Receptor (CAR) T cells have 
had a major clinical impact in the treatment of B cell neoplacias in 
recent years. BiTe antibodies consist of two antibody fragments 
(scFvs) linked together where one scFv always targets CD3. Binding of 
a BiTe to T cells and target cells results in the formation of an 
immunological synapse, T cell activation and killing of target cells. CAR 
T cells consist of a scFv linked to the signaling machinery of the T-cell 
receptor and costimulatory molecules. CAR T cells bind directly to their 
target cells. Acute Myeloid Leukemia is a clonal disorder of the 
hematopoietic stem/progenitor cells (HSPCs) and contains a 
subpopulation of leukemia-initiating cells (LIC) that can self-renew  
and give rise to a hierarchy of maturing blasts. While the proliferating 
mature blast pool is highly sensitive to chemotherapy, the quiescent 
LICs are relatively resistant and can be a source of relapse. We 
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include enhancement of activation of caspase 3, exacerbation of 
mitochondrial depolarization, and increase of reactive oxygen species 
(ROS) production, when compared with those induced by each drug 
alone. In vivo preliminary results, combined administration of APO866 
with ASA in a laboratory model of human aggressive lymphoma 
significantly decreased tumor burden and prolonged survival over 
single-agent treatment. Our results thus provide a rationale for 
potential combination of APO866 with ASA to assess the effect on 
hematological malignancies. 
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Influence of blast CD56 expression on bone marrow  
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Introduction: Acute myeloid leukemia (AML) is characterised by 
morphological, genetical and immunophenotypical heterogenity with 
substantial therapeutic and prognostic impact. Immunophenotypically 
aberrant CD56 expression on AML blasts is found in 13–29% of cases. 
CD56 (NCAM-1, neural cellular adhesion molecule 1) functions as an 
adhesion molecule, which is expressed physiologically on neuronal 
cells and natural killer (NK) cells. We postulate that CD56 leads to 
enhanced blast adhesion in bone marrow and hence complicates 
bone marrow aspiration. This might result in false low blast frequencies 
in aspiration cytology compared to histology, which bears substantial 
clinical impact, as blast frequencies are decisive for AML diagnosis 
(>20% blasts) and therapy monitoring. The aim of this study was to 
elucidate the effect of blast CD56 expression strength on observed 
discrepancies in blast frequencies between histology and aspiration 
cytology.
Methods: Retrospective analysis of 32 patients with CD56 positive 
and 34 patients with CD56 negative AML at diagnosis or relapse 
analysed in our center. CD56 positive AML were subcategorised 
according to expression strength in CD56 dim (15 cases) and CD56 
bright (17 cases), by re-analysis of flow cytometric data. Selection 
criteria included: definite diagnosis according to WHO 2008 criteria; 
representative material in both aspirate cytology and bone marrow 
histology; complete datasets with information on cytology, histology 
and flow cytometry.
Results: Blast frequencies in the CD56 bright group were significantly 
lower in aspirate cytology (44%) compared to bone marrow histology 
(64%; p = 0.003, fig. 1). No significant differencies were observed for 
the CD56 dim and CD56 neg groups.
Conclusion: AML cases with CD56 bright expressing blasts showed 
lower blast frequencies in bone marrow aspirate compared to histology. 
CD56 expression strength seems to be causative for that discrepancy, 
as CD56 dim expressing cases showed no significant difference 
compared to histology. If confirmed by others, the potential 
underestimation of blast frequencies for CD56 positive cases by 
aspirate cytology should be taken into account in AML protocols in the 
future. Furthermore larger prospective trials, as well as experimental 
data are required to elucidate if enhanced blast adhesion is the 
pathological cause for the reported inferior outcome of CD56 positive 
AML and subsequently might be targeted by novel specific agents. 
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Introduction: It was established that adipocytes in the bone marrow 
have an inhibitory activity on hematopoietic proliferation (Naveiras et 
al., Nature 2009). In osteoporosis, the osteoblastic/adipocytic 
differentiation equilibrium of the bone marrow stroma cells is altered, 
resulting an adipocytic infiltration of the bone marrow. This work 
attempts to establish if there is a correlation between osteoporosis  
and hematopoiesis before and after an adjuvant chemotherapy in the 
context of breast cancer. Osteoporosis is used as an indirect marker  
of the bone marrow adiposity.
Method: The clinical data of patients from the “breast cancer” cohort 
of the CHUV with a bone density exam (± 3 years from the diagnosis) 
were included in this project and classified according to their 
osteoporosis status. The evolution of the blood count was studied 
before and following the first cycle of adjuvant chemotherapy for breast 
cancer in correlation with the presence or absence of osteoporosis 
adjusted for age, toxicity of the chemotherapy and G-CSF treatment.
Results: Blood counts before chemotherapy: Our results, consistent 
with published data, indicate a negative association between t-score 
and neutrophil as well as thrombocyte counts prior to chemotherapy. 
Recovery after 1st cycle of chemotherapy: The evolution of the blood 
counts during the first cycle of chemotherapy was analyzed. The 
average day of leucocyte nadir is 9.9 ± 4.2 days. An increase of one 
point in TBS correlates with a decreased of 0.43 days on the time for 
leucocyte nadir with a p value of 0.0004. Our data thus suggests that 
the healthier the bone, the faster the decrease in total leucocyte after 
the onset of chemotherapy. Data points were insufficient to address the 
rate of recovery. From our analysis, the other significant response 
variable was infection with an odd ratio of 2.08 and a p value of 
0.000989. The analysis suggests that a healthier bone is associated 
with a higher risk of infection. Probable selection and sampling bias 
will be discussed. 
Conclusion: Our data confirmed the association between 
osteoporosis and lower blood count, already shown, in 
postmenopausal healthy cohorts, within a younger breast cancer 
cohort. The result of the blood count following chemotherapy suggests 
that the healthier the bone, the earlier the lowest blood count value. 
Further studies are needed to analyze the recovery after the lowest 
blood count and understand the dynamic behind it. 
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Aspirin sensitizes leukemic/lymphoma cells  
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Leukemic cells are highly prone to become resistant to treatment. 
Polychimiotherapies, by attacking leukemic cells through various 
pathways are aimed at preventing cell resistance development and 
also at maximizing killing effects. For these reasons, the development 
of new cell targeting therapies, i.e. those modifying metabolic 
pathways are most warranted. To this end, we evaluated the effect of 
aspirin (ASA) on enhancing the antitumor activity of APO866, a novel 
NAD lowering drug on a panel of various hematopoietic malignant 
cells. Hematological malignant cells were treated with or without ASA/
APO866 alone or in combination for 96 hours, then cell viability and 
change in oxidative status were monitored using flow cytometry. We 
found that ASA synergistically increases APO866-induced death in 
various leukemia/lymphoma cell lines. ASA displays a potent cytostatic 
effect whilst APO contributes to increase the cytotoxicity. Mechanisms Figure 1
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Aims: Pregnancy and delivery are high-risk conditions for thrombotic 
complications. Women with heritable thrombophilia with or without 
thromboembolism in their medical history are at additional higher risk 
to develop thrombosis and are normally followed-up during pregnancy 
for evaluation of the prothrombotic state. Follow-up is done by clinical 
evaluation and sometimes it includes biological markers of activation 
of coagulation. A disproportional increase would theoretically predict 
high risk for thrombotic events but usefulness of these markers has 
not been validated in an evidence-based setting. Aims of this study 
were: a) to describe changes of biological markers of coagulation 
activation and thrombin generation in each trimester of pregnancy,  
b) to compare two different methods for assessment of thrombin 
generation, c) to check whether heparin prophylaxis in the third 
trimester affects thrombin generation.
Methods: Data on file of 102 consecutive pregnancies with hereditary 
thrombophilia or thrombosis were retrospectively analyzed. Pregnant 
women were routinely followed every 4-6 weeks for thrombotic 
complications during pregnancy. Any thrombotic event or preeclampsia 
or premature delivery were recorded. Thrombin-Antithrombin-Complex 
(TAT), D-Dimers (DD) and endogenous thrombin potential (ETP)  
by a functional chromogenic assay (CAT, calibrated automated 
thrombogram) were assayed routinely once in the middle of each 
trimester using standard methods. 
Results: TAT (4.3 + 2.9, 6.4 + 5.2, 7.7 + 4.3 microg/L) and DD (0.9 + 
1.5, 1.6 + 2.1, 2.0 + 2.3 microg/ml) were increased slightly but 
continuously and statistically significantly from each trimester to the 
other. Women receiving heparin prophylaxis showed the same pattern 
and did not differ from the whole cohort. CAT did not show any 
differences between trimesters. Women in third trimester with or 
without heparin prophylaxis did not differ with respect to DD (2.0 + 2.6 
vs. 2.0 + 1.7 microg/ml), TAT (7.5 + 2.9 vs. 8.2 + 5.9 microg/L), 
CAT-ETP (1696 + 962 vs. 1715+804 AU).
Conclusions: TAT and DD were elevated as pregnancy progressed, 
as expected. CAT-ETP in addition to TAT does not add any value of 
information. TAT and DD do not add any safe value of information with 
respect to the effect of heparin prophylaxis and they might not be 
needed as isolated observation tools. 
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Introduction: Advanced chronic liver disease (ACLD), a condition 
including cirrhosis and fibrosis, is characterized by changes in the 
coagulation system that embrace both hypo- and hypercoagulability.  
In this rebalanced situation, hypercoagulability can contribute, like 
genetic predisposition or environmental factors, to fibrosis progression 
and cirrhosis complications. Common routine hemostasis tests fail  
to reflect bleeding and thrombotic tendencies in ACLD patients. 
Therefore, a better understanding of underlying mechanisms is 
mandatory for setting-up new assays and treatments. Here, we 
assessed the hemostatic changes in 2 different models of ACLD in 
mice.
Methods: 9–15 adult male mice received i.p. 200 mg/kg of 
thioacetamide (TAA) 3×/week for 12 weeks or 1 ml/kg carbon 
tetrachloride (CCl4) and phenobarbital (0.3 g/L in drinking water)  
twice per week for 11 weeks. At the end of the treatment mice were 
sacrificed; blood and organs were harvested for investigation.
Results: We observed a slight increase in body weight in both CCL4/
Phenobarbital (28.0 ± 2.7 vs 24.5 ± 3.9g, P <0.0001)and TAA (23.9 ± 
3.6 vs 21.5 ± 3.9g, P = 0.0025) treated mice compatible with ascites 
development while mortality rate was higher in the CCL4/Phenobarbital 
than in the TAA group (32% vs 13%). In control mice, liver histology 
revealed normal parenchymal architecture without fibrosis. In CCL4/
Phenobarbital treated mice, livers displayed extensive fibrosis with 
both portal-to-portal and portal-to-central bridging. Albeit present, 
fibrosis in the TAA treated group was less extensive. Interestingly, 
occlusive centrilobular vein thrombosis was more prominent in the TAA 
than in the CCL4/Phenobarbital group, where we observed also partial 
periportal thrombosis. Coagulation investigation showed a slight 
decrease of fibrinogen in both CCL4/Phenobarbital and TAA groups 
compared to the controls (1.4 ± 0.1 vs 1.7 ± 0.1 g/L, P = 0.04 and 1.3 ± 
0.1 vs 1.7 ± 0.1 g/L, P = 0.01) and prolonged prothrombin time in both 
CCL4/Phenobarbital and TAA groups compared to the controls (9.3 ± 
0.1 vs 8.9 ± 0.03sec, P = 0.01 and 9.8 ± 0.2 vs 8.9 ± 0.03 sec, P = 
0.007). Factor VIII was highly increased in the CCL4/Phenobarbital 
group compared to the controls (350.4 ± 17.3 vs 194.3 ± 34.8%, P = 
0.002) but not in the TAA group(282.8 ± 32 vs 194.3 ± 34.8%, P = ns).
Conclusion: These data provide the first evaluation of hemostatic 
profile in mice with ACLD. Additional data are needed to further 
characterize the bleeding and thrombotic tendency linked to murine 
ACLD. 
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Objective: We described the frequency and the acute medical 
problems due to recreational drug use in patients presenting to an 
emergency department in Switzerland during 11 months. The results 
were compared with data from previous years. 
Methods: The retrospective study was conducted at the University 
Hospital of Basel, Switzerland, between October 2015 and August 
2016 and within the Euro-DEN project. All cases presenting with 
symptoms/signs consistent with acute toxicity of recreational drug use 
were included. Isolated ethanol intoxications were excluded. Drug tests 
were performed using immunoassays and liquid chromatography-
tandem mass spectrometry (LC-MS/MS). 
Results: During the study period there were 47’769 emergency 
department attendances of which 211 were directly related to acute 
toxicity of substances used recreationally. The mean patient age was 
32 years, 71% were male. Alcohol co-use was reported in 46% of the 
cases, use of more than one recreational drug in 27% of the cases. 
Most presentations were related to cocaine (38%), cannabis (37%), 
and amphetamines/methamphetamines excluding MDMA (12%). A 
drug screening was available in 108 cases (51%). The most commonly 
analytically detected substances were cannabis (23%), cocaine (22%), 
and benzodiazepines (19%). There was one intoxication with a novel 
substance, presenting with hallucinations, chest pain, dyspnea, and 
palpitations after self-reported use of MDMA; using LC-MS/MS 2C-B 
could later be identified. The majority of patients (40%) had impaired 
consciousness (GCS <15) at presentation and/or pre-hospital, 11% 
were unconscious (GCS <8). Other frequent symptoms were 
tachycardia (35%), nausea/vomiting (29%), anxiety (27%), and 
agitation (24%). Most intoxications (55%) were of minor severity and 
there were no fatalities. Severe complications included 4 acute 
myocardial infarctions (cocaine involved in 3 of them), 1 case with 
multiple organ failure (cocaine monointoxication), psychosis (18 
cases), and seizures (14 cases). Most patients (72%) were discharged 
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Methods: Propofol infusion rates required to achieve changing target 
brain concentration (6 à 4 à 5 mg/L) throughout a 15 min operation  
for a virtual male patient (70 kg, 170 cm, 36 y) were obtained with  
the model of Schnider et al. [1] as implemented in the BasePrimea 
pump (Fresenius Kabi, Germany). This subject was then simulated 
10000 times under the estimated TCI dosage scheme, using the 
comprehensive population model with between-subject variability 
developed by Eleveld et al. [2] to describe plasma propofol 
concentrations in 660 patients. Median concentration with 90% 
prediction interval (PI90%) were calculated and compared to the target 
brain concentrations at equilibrium according to the TCI prediction.  
The percentage of virtual patients reaching propofol levels above  
15 mg/L (maximum allowed in TCI) was also estimated.
Results: The figure shows median with PI90% of the Eleveld model  
and TCI predicted concentrations along with the aimed target levels. 
Median (PI90%) concentrations of 5.6 (3.7–8.1), 3.7 (2.6–5.3) and  
home, 10% took their own discharge, 9% were admitted to intensive 
care, 7% to psychiatric care. 
Conclusion: Similar to the previous years, most medical problems 
related to illicit drugs concerned cocaine and cannabis. Symptoms 
mainly included CNS depression, nausea/vomiting, and/or 
sympathomimetic toxicity. Novel psychoactive substances seem to 
either be rarely used or rarely lead to emergency department 
consultations. 
P511
Mechanisms of cytotoxicity in metamizole-associated 
neutropenia
Deborah Rudin, Fabio Bachmann, Manuel Haschke,  
Stephan Krähenbühl 
Division of Clinical Pharmacology & Toxicology,  
University Hospital Basel, Basel, Switzerland
Objective: Metamizole, a non-opioid analgesic prodrug, rarely causes 
potentially life-threatening neutropenia and agranulocytosis. Currently, 
the mechanisms underlying metamizole-induced neutropenia (MIN) 
are only poorly understood. While immunological mechanisms are 
discussed, certain features are compatible with direct metabolic 
toxicity on granulocyte precursors in the bone marrow. Therefore,  
our objective was to investigate possible mechanisms toxicity by  
the main metamizole metabolites 4-methylaminoantipyrine (MAA), 
4-formylaminoantipyrine (FAA), 4-aminoantipyrine (AA), and 
4-acetylaminoantipyrine (AAA) in granulocytes and granulocyte 
precursors.
Methods: We treated HL60 cells (a promyelocytic cell line) and 
isolated human neutrophil granulocytes with different concentrations of 
metamizole metabolites (1 µM to 200 µM) with or without components 
of an oxidative system composed of horseradish peroxidase (HRP) 
and hydrogen peroxide (H2O2). We assessed the adenylate kinase 
release as a marker of cytotoxicity and the cellular ATP content as a 
marker of energy metabolism.
Results: MAA, FAA, AA, and AAA (up to 200 µM) alone were not 
cytotoxic and did not decrease the ATP content in HL60 cells or 
granulocytes. In the presence of HRP, MAA was not toxic for HL60 
cells. H2O2 (100 µM) depleted the ATP content of HL60 cells by >95% 
and showed a minor cytotoxicity. This cytotoxicity was concentration-
dependently increased by MAA and AA, whereas FAA and AAA were 
not cytotoxic under these conditions. In the presence of HRP and 
H2O2, ATP depletion by H2O2 (»90%) and increased cytotoxicity by 
MAA and AA were detectable, but attenuated compared to H2O2 alone. 
In the presence of oligomycin, which depleted the cellular ATP by 
approximately 60%, MMA was not cytotoxic. Determination of the time 
course revealed that ATP depletion was completed between 3 h and 
12 h and that cytotoxicity started at 12 h. In granulocytes, H2O2 
depleted the cellular ATP content by approximately 80% and MAA was 
not cytotoxic.
Conclusion: MAA and AA are cytotoxic only in the presence of H2O2, 
whereas FAA and AAA are not cytotoxic. Cytotoxicity of MAA and AA 
seems to be related to the H2O2-induced cellular ATP depletion, which 
may render cells more sensitive. The ATP depletion must be >90% 
before cytotoxicity is initiated. Granulocyte precursors appear to be 
more sensitive than granulocytes, which corresponds well with the 
clinical observations. 
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Introduction: Propofol is generally administered by open-loop  
Target Controlled Infusion (TCI) devices for anesthesia induction and 
maintenance. The current algorithms driving TCI pumps are based  
on published pharmacokinetic models developed on small groups  
of healthy volunteers. Propofol infusion rates are adjusted aiming to  
a defined target, based on model-predicted plasma or brain 
concentrations. However, there is currently no monitoring of actual 
propofol level, which, if significantly different from the predicted one, 
could lead to important over or under drug exposures with clinical 
consequences for the patients. The aim of this analysis is to evaluate 
whether there is room for a closed-loop control in anesthesia delivery 
to optimize drugs dosages.
Figure 1
Plasma Propofol concentration vs. Time.
4.6 (3.3–6.5) mg/L were calculated when the target levels of 6, 4  
and 5 mg/L, respectively, were achieved according to TCI predictions. 
Furthermore, 12% of the virtual patients were found with 
concentrations exceeding 15 mg/L within the first minute of propofol 
infusion. 
Conclusions: These results show the potential for a closed-loop 
control of blood concentration to improve automated anesthesia 
delivery. A proportional-integral-derivative (PID) controller based on 
real-time propofol measurement to optimize infusion rate is currently 
under development.
References
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Introduction: A significant fraction of the Swiss population is treated 
with anticoagulants. Bleeding complications are frequent, counting  
for about 10% of adverse drug reaction-related hospitalizations. After 
decades of exclusive use of vitamin K antagonists (VKA), direct oral 
anticoagulants (DOACs) are now available and their use is increasing. 
According to the published randomized controlled trials, DOACs are  
at least as effective as VKA, but might be safer. 
Objectives: This study aimed to evaluate whether DOACs are safer 
than VKA by comparing their respective consumption with the number 
of hospitalizations for bleeding complications in an emergency 
department over the past years. 
Methods: We retrospectively collected data from all patients treated 
with DOACs or VKA who were admitted to the Emergencies of CHUV 
for bleeding with externalization (any site) between 2011 and 2015. The 
severity of these hemorrhages was graded. Patient characteristics 
were recorded. The consumption data of DOACs and VKA were 
obtained from Interpharma and The Cooperative of the Swiss 
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Ribavirin impairs the stability of red blood cells according to both in 
vitro experiments and clinical investigations. In a clinical trial, mean life 
expectancy of erythrocytes in hepatitis C patients treated with ribavirin 
was almost three times shorter than in hepatitis C patients without 
ribavirin treatment (46 vs. 112 days) [1]. In diabetes patients, dramatic 
reduction of red blood cells’ life expectancy under ribavirin translates 
into a significant decline of the level of glycated hemoglobin (HbA1c), 
independently from any glycaemia changes. Dissociation between 
glycaemia and HbA1c levels, already reported in the literature [2], 
understandably complicates management of diabetes patients with 
hepatitis C. However, the issue of diabetes follow-up under ribavirin 
has not yet been assessed in a clinical study. A male patient, 64 years 
old, had insulin-dependent type 2 diabetes with a poor therapeutic 
adherence; as a result, his glycaemia and HbA1c levels were 
repeatedly above the targets (glycaemias 10 to 13 mmol/l, HbA1c 
9.3%). He also had chronic viral hepatitis C with Child-Pugh A grade 
cirrhosis. In september 2016, he started antiviral treatment with 
sofosbuvir, daclatasvir and ribavirin. In november 2016, reduction  
of HbA1c to 6.4% (target levels 6.5 to 7.5% in diabetes patients)  
was witnessed, while glycaemic control was still poor (higher than 10 
mmol/l). A new-onset anemia (hemoglobin 98 g/l) was also diagnosed. 
In december 2016, HbA1c went even further below the target values 
(HbA1c 4.7%); at the same time, glycaemias continuously measured 
during 7 days consistently remained above 10 mmol/l. In light of a 
known impact of ribavirin on the turnover of red blood cells, the 
new-onset anemia as well as a published case report [2], low HbA1c 
levels were deemed to result from a side effect of ribavirin treatment, 
rather than from any improvement in glycaemic control. A falsely 
lowered HbA1c can induce the physician to unnecessarily adapt the 
diabetes treatment with subsequent worsening of the glycaemic 
control, leading to potentially serious complications (hyperosmolar 
hyperglycemic state or ketoacidosis, depending on the type of 
diabetes). This observation prompted a retrospective survey to better 
characterize correlation between ribavirin treatment and glycaemic 
markers in patients suffering from both diabetes and hepatitis C 
infection (underway).
References:  
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Introduction: Besides tailored clinical trials in pediatric and adult 
patients on intermittent hemodialysis (HD), individual case reports on 
pharmacokinetic (PK) assessments provide an important source of 
information about drug dialysability and dose adjustments required  
in this vulnerable population. As there is no systematic guidance 
available for such PK studies, we aimed to provide a review of  
current clinician-initiated PK assessment and reporting practices. 
Methods: We performed a systematic review of case reports on 
individual drug PK in HD patients published between 2000 and 2016. 
We evaluated them for their completeness regarding essential 
information on patient, drug and HD therapy related factors that  
may influence PK. We also reviewed the use of PK calculations of 
relevance in HD patients, in particular dialysis clearance CLD, 
off-dialysis clearance CLoff, and amount of drug removed by HD,  
as suggested by available regulatory and methodological 
recommendations for PK assessment in this population. 
Results: A total of 88 papers were retained in this review. The majority 
of case reports concerned non-renally eliminated drugs with Q0 >0.7 
(60%), and 85% of studied drugs were anticancer and anti-infective 
agents. Thirty-one case reports (35%) reported at least 50% of 
Pharmacists for the years 2011 to 2015. Spontaneous reporting of 
bleeding events under DOACs and VKA to Swissmedic was extracted 
from the Vigilyze database. 
Results: A total of 779 admissions for bleeding events were recorded, 
among which 250 in patients treated with DOACs or VKA. Only  
15 cases were associated with DOACs and were compared with a 
sub-sample of 50 among the 235 cases of the VKA group. Patients in 
the VKA group were slightly older (79.3 vs 76.4 years; NS), with higher 
comorbidity Charlson scores (2.16 vs 1.46; NS), and lower renal 
function (44 vs 57 ml/min/1.73 m2 GFR; p = 0.006). They had more 
often drug interactions (pharmacokinetic: p = 0.008; pharmacodynamic 
p = 0.004). The bleeding events did not differ significantly in their 
location, severity and management. The DOACs market share is 
growing with a number of DOACs units sold outpacing the VKA in 
2015. The number of spontaneous reporting of DOACs-associated 
bleeding events to Swissmedic is higher than that of VKA since 2013. 
Conclusion: The results tend to confirm a better safety of DOACs 
compared to VKA. However, VKA are prescribed to patients in less 
good condition and thus more at risk of bleeding, which may 
accentuate the difference in incidence of bleeding events. The 
over-representation of DOACs in the Swissmedic database might be 
due to reporting biases. 
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Introduction: Highly active antiretroviral drugs (ARVs) have 
transformed HIV infection from a deadly disease into a manageable 
chronic condition. As a consequence, HIV-infected individuals live 
longer and become older, affected by age-related comorbities leading 
consequently to polypharmacy and a higher risk of drug-drug 
interactions (DDIs) [1]. There is currently a lack of real-life clinical data 
on the extent of polypharmacy and DDIs. Moreover, the information on 
drug-gene interaction and pharmacogenetics (PGx) are scarce. In that 
context, we aim to describe the prevalence of polypharmacy and 
PGx-labeled drug prescription in the Swiss HIV Cohort Study (SHCS).
Methods: We have initiated a large-scale prospective observational 
study within SHCS at the occasion of patient’s biannual cohort visits 
that implies the systematic documentation of all co-medications, along 
with plasma levels measurements of antiviral drugs and co-
medications at risk of problematic DDIs. Patients are contacted by post 
one week before their SHCS visits and invited to report all their current 
medications in a record form. Drugs with PGx recommendations are 
identified according to the American and European authorities together 
with the evidence-based expert opinions aggregated by the Clinical 
Pharmacogenetics Implementation Consortium (CPIC) [2].
Results: Data available at present from TDM routine service have 
shown that the most prescribed therapeutic classes are central 
nervous system and cardiovascular drugs representing 32% and 20% 
of the prescription, respectively. The proportion of patients receiving at 
least one non-HIV co-medication is of clinical importance, with a high 
prevalence of lipid-lowering agents (7%). On 10’030 prescriptions, 
7.1% and 14.3% had a CPIC label grade A or B, respectively, affecting 
several therapeutic classes. Few drugs (1.2%) are recommended or 
required to be associated with a PGx test according to FDA as well. 
These results are in accordance with previous studies [3, 4]. 
Conclusion: In the growing healthcare challenge of personalized 
medicine and treatment optimization, research efforts must be pursued 
to improve the quality of ARVs prescriptions, especially with regards to 
potential DDIs.
References
1 Marzolini C, et al. J Antimicrob Chemother. 2011;66:2107.
2 CPIC: https://cpicpgx.org/genes-drugs.
3 Relling MV, Evans WE. Nature. 2015;526:343.
4 Frueh FW, et al. Pharmacotherapy. 2008;28:992.
PRIMARY AND HOSPITAL CARE – ALLGEMEINE INNERE MEDIZIN 2017;17(SUPPLEMENTUM)
GASTGESELLSCHAFT SGKPT / SOCIÉTÉ CONVIÉE SSPTC 112 S
P518
Conceptual evaluation of urea rebound in pediatric 
hemodialysis patients by a physiology-based  
pharmacokinetic simulation study
Verena Gotta1, Olivera Marsenic2, Marc Pfister3 
1Pediatric Pharmacology & Pharmacometrics, University of Basel 
Children’s Hospital (UKBB), Basel, Switzerland; 2Pediatric Nephrology, 
Yale-New Have Children’s Hospital and Yale School of Medicine, New 
Haven, CT, United States; 3Pediatric Pharmacology & 
Pharmacometrics, University of Basel Children’s Hospital (UKBB), 
Basel, Switzerland
Introduction: Pediatric hemodialysis (HD) dosing and monitoring 
strategies are mainly derived from adult studies utilizing pre- and 
post-HD urea plasma concentration measurements. Accuracy of such 
HD evaluation approach depends on extent and duration of post-HD 
urea rebound, which occurs due to redistribution of urea from slowly 
perfused (peripheral) to quickly perfused (central) body compartments. 
The goal of this urea kinetic simulation study was to evaluate the 
expected urea rebound in pediatric HD patients.
Methods: Realistic pediatric HD prescription parameters and 
demographics were calculated over body weight (BW)-bands of 5 kg 
from a large registry database (DaVita) with ≥20 patients and >130 HD 
sessions per BW-band. Typical urea concentration-time profiles during 
and after HD sessions were simulated applying published urea kinetic 
data [1, 2] and implementing expected physiologically-based kinetic 
changes in pediatrics (age-, body weight, and gender-dependency  
of total body water [3, 4], cardiac output [5], and fraction of skeletal 
muscle mass [6] as indicator of slowly equilibrating somatic tissue 
mass). Time to regaining equilibrium (TTE) after HD sessions between 
central and peripheral urea concentration was calculated (i.e.at least 
97% of complete equilibrium).
Results: In children up to 25 kg (10 years) predicted TTE was ≤5 min, 
in adolescents up to 35 kg (17 years) ≤10 min. In young adults (19–21 
years, 40–120 kg) TTE was up to 25 min (longest in boys weighing 
>80 kg), while almost 90% of complete equilibrium was predicted to be 
achieved 5 min post-HD.
Conclusion: Results from urea kinetic simulations that take HD 
prescription parameters and physiologic changes in pediatric patients 
into account indicate that time to equilibrium is shorter in pediatric than 
in adult HD patients, with urea rebound occurring mainly within 5-10 
min after HD sessions. This finding can be utilized to design optimal 
sampling time points in urea kinetic studies in pediatric HD patients.
References: 
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Introduction: Drug-drug interactions (DDIs), which can lead to drug 
toxicity or diminished therapeutic effect, can be prevented by the use 
of DDI screening programs. The aim of our study was to evaluate the 
frequency of DDI at hospital admission by using two DDI screening 
programs, and to assess their clinical relevance. 
Methods: Patients admitted to an internal medicine and infectious 
diseases ward at Geneva University Hospitals between March and 
end of May 2016 were interviewed by a pharmacist/clinical 
pharmacologist for medication reconciliation. This was part of the 
national pilot program “Progress: medication safety at transitions in 
care”. The medication list was systematically screened by Lexi-Interact® 
and by the program from the Compendium Suisse des medicaments 
to detect potential DDI. All cases were independently reviewed by 
three pharmacists/clinical pharmacologists to evaluate the clinical 
relevance of detected DDI. 
relevant components in HD patients. CLD was calculated in 33% of 
case reports, of which only 10% used the recovery gold-standard 
method. CLoff was calculated in 31% and the amount of drug removed 
by HD, which is important to calculate appropriate dose adjustments, 
was assessed in only 20%. Nineteen percent of studies simply 
reported a reduction ratio of drug concentrations before and after  
HD session. 
Conclusions: Clinician-initiated PK assessments in HD patients are of 
definite usefulness for the community, but frequently lack important 
information to allow interpretation and translation of results to other 
patients. Additionally, calculations methods to estimate drug 
dialysability are rarely used to characterize PK information of 
relevance in HD patients. Limited PK data collected in a single patient 
could be further leveraged by taking into account published PK 
information in combination with PK modeling. Checklist and guidance 
for easy-to implement PK calculations and pharmacometric modeling 
can be useful to further enhance publication of individualized dosing 
evaluations in pediatric and adult HD patients. 
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Introduction: Ticagrelor is the first drug of a new non-thienopyridine 
oral antiplatelet agents category. Determination of drugs’ affinity for 
P-glycoprotein (P-gp) efflux transporter is essential for estimation of 
drugs oral bioavailability and potential drug-drug interactions. 
Method: In the current study, the intestinal permeability of ticagrelor 
as well as its potential P-gp mediated active transport was assessed. 
To this end, bidirectional transport of ticagrelor was performed using in 
vitro Caco-2 (human epithelial colorectal adenocarcinoma) monolayer 
model in presence and absence of the potent P-gp inhibitor valspodar. 
Results: Ticagrelor presented high influx permeability with an 
apical-basolateral apparent permeability coefficient (Papp) of 6.0Í10–6 
cm/s. On the other hand, mean efflux ratio (ER) of 2.71 was observed 
for ticagrelor describing a higher efflux permeability compared to the 
influx component. Valspodar showed a significant inhibitory effect on 
the efflux of ticagrelor suggesting involvement of P-gp in its oral 
disposition. Co-incubation of the P-gp inhibitor decreased the efflux 
Papp of ticagrelor from 1.60 Í10–5 cm/s to 1.13 Í10–5 cm/s and decreased 
its ER by 70%. Results are presented in following table:
Conclusion: These results suggest a high permeability and a 
moderate active transport of ticagrelor by P-gp across the Caco-2 cell 
monolayer. However, in case of co-administration of ticagrelor with an 
inhibitor of P-gp, a striking impact on pharmacokinetics of ticagrelor 
appears unlikely in clinical conditions and does not seem to cause 
bleeding events in patients. 
Table
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Background and aims: Little is known about the course of the plasma 
concentration and the bioavailability of non-steroidal anti-inflammatory 
drugs (NSAIDs) contained in dermal patches. In order  
to obtain more information about this subject, we determined the 
plasma concentration-time profile of diclofenac epolamine (from a 
commercially available dermal patch) and of etofenamate (from a 
prototype dermal patch) in 24 healthy human subjects. In order to 
calculate the bioavailability, we compared drug exposure following 
patch application to exposure after i.m. application of diclofenac or 
etofenamate in the same subjects.
Methods: Subjects were treated using a parallel design (n = 12 per 
stratum) with a single dermal patch (removed after 12 hours) followed 
by (after 48 hours) 8 consecutive dermal patches every 12 hours to 
reach steady state conditions. The patches contained 10 mg/g 
diclofenac (Flector®; weight 14 g, 140 cm2) or 50 mg/g etofenamate 
(patent EP 1833471; weight 14 g, 140 cm2). The i.m. applications 
contained 75 mg diclofenac (Voltaren®) or 1 g etofenamate 
(Rheumon®). Plasma concentrations were determined using a 
validated LC/MS method. Bioavailability was calculated as the ration  
of the AUCs with dose adjustment.
Results: One subject treated with etofenamate developed an allergic 
contact dermatitis; otherwise the patches were well tolerated. After the 
first patch, Cmax was 0.81 ± 0.38 (95%CI) ng/mL (reached 12 hours 
after patch removal) for diclofenac and 31.3 ± 8.5 ng/mL for 
flufenamate (reached at patch removal), the main metabolite of 
etofenamate. Etofenamate was not detectable. After repetitive dosing, 
trough plasma concentrations after the eighth dose were 1.72 ± 0.72 
(95%CI) ng/mL for diclofenac and 48.7 ± 14.8 ng/mL for flufenamate. 
Cmax for the i.m. applications were 1790 ± 280 (95%CI) ng/ml for 
diclofenac and 5810 ± 1450 ng/ml for etofenamate (measured as 
flufenamate). Bioavailabilities (single dose) relative to i.m. applications 
were 0.22 ± 0.09% (95%CI) for diclofenac and 1.15 ± 0.13% for 
flufenamate.
Conclusions: Etofenamate is rapidly converted to flufenamate and 
has a higher bioavailability (as flufenamate) than diclofenac after 
topical administration. The bioavailability of both drugs is low 
compared to i.m. application. The plasma concentrations reached are 
well below the IC50 values for COX-1 and COX-2 inhibition of these 
drugs, explaining the absence of dose-dependent toxicities after 
dermal application. 
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Introduction: Among the last generation endothelin receptor 
antagonists (ERAs) only Macitentan has shown a reduction in 
morbidity-mortality endpoints in pulmonary arterial hypertension (PAH) 
as compared to placebo. Moreover, compared to the previous ERA 
Bosentan, Macitentan may have higher clinical efficacy due to: (i) 
enhanced safety profile, (ii) less liver toxicity, (iii) reduced drug-drug 
interaction potential and (iv) improved tissue penetration properties  
as well as ER affinity [1]. Therefore, stable PAH patients currently on 
Bosentan may benefit from a switch to Macitentan. Yet, Bosentan 
moderately induces cytochromes CYP3A4 and CYP2C9, both 
enzymes also implicated in the biotransformation of Macitentan into its 
active metabolite. Then, switching from Bosentan to Macitentan may 
yield transiently subtherapeutic drug levels in patients, which have 
never been investigated before. Possible adverse effects may however 
be attenuated in patients under bi-therapy with PDE5-inhibitors. The 
Results: A total of 64 patients were interviewed, 58% were men. The 
mean age was 65 years old. A mean of 7.6 drugs per patient per day 
were taken (range: 0 to 19), including “as needed” medication. The 
most frequently used drugs were paracetamol, acetylsalicylic acid 
(cardiologic indication) and esomeprazole. A total of 132 potential DDI 
were detected by the Compendium software, and 314 potential DDI 
were detected by Lexi-Interact® (no severity filter added). The  
mean number of DDI detected by each software was 2.2 and 5.0 
respectively (range: 0–17 and 0–33 respectively). The majority were 
pharmacodynamic DDI (89.4 and 70.7% respectively). The three 
independent pharmacists/clinical pharmacologists judged a total of  
87 DDI as being clinically relevant, representing approximately one 
third of all detected DDI by Lexi-Interact®.
Conclusion: Admitted patients are potentially subject to DDI as 
detected by DDI screening programs but not all of them are clinically 
relevant, and the different screening programs show variability in their 
performances. 
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Introduction: Hemorrhagic cystitis (HC) is one of the common 
complications of busulfan-cyclophosphamide conditioning regimen 
during allogeneic hematopoietic stem cell transplantation in children. 
In a retrospective analysis, a higher incidence of HC was observed in 
pediatric patients with higher sulfolane levels. We therefore 
hypothesized that sulfolane might increase the activity or expression  
of cytochromes P450 (CYP), which are involved in the first step of  
the metabolism of CY into its urotoxic metabolite acrolein.
Method: Different concentrations of sulfolane ranging from 0.5 to 5 µM 
were incubated with differentiated HepaRG (passage 19) cells seeded 
on 24-well plates at a density of 2×105 cells/cm2 in a medium 
composed of phenol-free Williams medium E supplemented with 2 mM 
GlutamaxTM, 50 µM hydrocortisone hemisuccinate, 5 µg/ml insulin, 
100 UI/ml penicillin and 100 µg/ml streptomycin at 37 °C, 5% CO2. 
Negative and positive controls with rifampicin (10 and 50 µM), 
omeprazole (50 and 100 µM) and phenobarbital (500 and 1000 µM) 
were used. Final concentration of DMSO during the time of induction 
was 0.1% in all conditions. After 72 hours of incubation with medium 
changes every 24 hours CYP activity was assessed by incubating a 
phenotyping cocktail composed of midazolam 5 µM (CYP3A4), 
S-mephenytoin 50 µM (CYP2C19), bupropion 50 µM (CYP2B6), 
flurbiprofen 10 µM (CYP2C9) and phenacetin 10 µM (CYP1A2) in 
phenol red-free Williams medium E. Reactions lasted 3 hours, after 
which incubation media and plated cells were collected for metabolite 
quantification by LC-MS/MS and gene expression analyses by 
RT-qPCR.
Results: HepaRG exposed to different levels of Su showed significant 
differences neither in CYP activity compared to controls, as measured 
by the velocity of metabolite production normalized to the total protein 
content, nor at the level of gene expression. For CYP2B6, induction  
by 2 fold was observed only at the mRNA level but did not exhibit 
increased activity while phenotyping with the probe drug. Known 
inducers of CYPs like phenobarbital, rifampicin, and omeprazole 
exhibited induction. Data from these experiments indicate no 
significant impact of sulfolane on CYP activity and expression in 
HepaRG cells.
Conclusion: The association between sulfolane levels and the 
incidence of HC in pediatric patients receiving busulfan-
cyclophosphamide conditioning regimen prior to hematopoietic stem 
cell transplantation does not seem to involve CYP modulation. 
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Introduction: A large number of commercially available Clinical 
Decision Support Systems (CDSS) exist. Most commonly, they are 
embedded in an electronic prescribing software program and their 
quality is variable. According to the software developer, the embedded 
CDSS used in our hospital has approximately 21’000 “severe” or 
contraindicated drug-drug interactions depicted, based on trade-
names and generic names. Such alerts “pop-up” automatically during 
the prescribing process.
Methods: Automatically generated warnings regarding drug-drug 
combinations which could result in patient harm (“severe”), or which 
were contraindicated according to the drug label were assessed 
prospectively during routine patient care by pharmacologists, 
pharmacists and internists between May 2015 and September 2016. 
Unsatisfactory warnings were recorded in a local electronic 
spreadsheet and reported to the company along with the requested 
alteration every 3–4 months.
Results: During the 16-month period, 137 problematic alerts regarding 
severe or contraindicated drug-drug interactions were identified and 
reported to the company. Of these, 60% were changed by the 
company as requested, within an average of 59 days. The following 
reasons for not adopting the experts’ requests for optimization were 
given: technical difficulty, difference of opinion and inability to 
undertake country-specific changes to the database.
Conclusion: Close co-operation between treating physicians, 
pharmacologists, pharmacists, IT-specialists and the software 
company is needed to tailor a CDSS to a hospital’s needs and quality 
standards. The process is time- and resource-consuming and does not 
achieve complete implementation of local expert’s desired 
customizations. 
SWITCH clinical study has been initiated to examine in 25 PAH 
patients the evolution of plasma levels of drugs and principal active 
metabolites during the switching process from Bosentan to Macitentan. 
A sensitive and accurate mass spectrometry assay was needed to this 
end. 
Methods: A multiplex liquid chromatography-tandem mass 
spectrometry was developed for the quantification in human plasma  
of Bosentan, Desmethylbosentan, Hydroxybosentan, Macitentan, 
Despropylmacitentan, Sildenafil and Tadalafil. Generic plasma protein 
precipitation with methanol was employed. Matrix-matched calibration 
in plasma was established over the respective clinically relevant range 
of concentrations. Stable isotopically-labelled internal standards were 
employed to circumvent matrix-effect and control the method variability. 
Results: Baseline chromatographic separation of the seven analytes 
was achieved in less than 5 min. Optimal multiple reaction monitoring 
traces were applied for their selective detection using triple quadrupole 
MS. The required sensitivity was reached by optimizing electrospray 
ionization source parameters. The developed assay complies with the 
current recommendations of the FDA guidelines on bioanalytical 
methods validation. 
Conclusion: The validated bioanalytical methodology has been found 
suitable for its application to plasma samples collected within the 
frame of the SWITCH clinical study. 
Reference: 
1 Pulido T, et al. N Engl J Med. 2013;369:809–18. 
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